Datasets:
ChatDOC
/
OCRFlux-pubtabnet-cross

Dataset card Data Studio Files Community
1
image_name
stringlengths
68
68
type
stringclasses
2 values
gt_table
stringlengths
116
12.6k
table_fragment_1
stringlengths
43
8.42k
table_fragment_2
stringlengths
39
8.21k
991e8baf4cfe77c5f35a819b82da4220438295ccd21f4489a80fdf97898f5dbc.png
complex
<table><tr><td colspan="2">Initial Experiment Results</td><td colspan="2">Enhanced Results</td></tr><tr><td>Total Length Ratio</td><td>RMSE (m)</td><td>Total Length Ratio</td><td>RMSE (m)</td></tr><tr><td>0.94</td><td>3.2</td><td>0.96</td><td>0.93</td></tr></table>
<table><tr><td colspan="2">Initial Experiment Results</td><td colspan="2">Enhanced Results</td></tr><tr><td>Total Length Ratio</td><td>RMSE (m)</td><td>Total Length Ratio</td><td>RMSE (m)</td></tr></table>
<table><tr><td>0.94</td><td>3.2</td><td>0.96</td><td>0.93</td></tr></table>
4b01d2f9a5dff16bbecc33e5ec35a1bcd29340f37e669562b4b842699a570a1c.png
complex
<table><tr><td></td><td>Acute</td><td>Chronic</td><td>No Pain</td><td><i>p</i> Value</td></tr><tr><td>Total Number (<i>n</i> = 218)</td><td>140 (64)</td><td>33 (15)</td><td>45 (21)</td><td></td></tr><tr><td colspan="4">Age <i>n</i> (%)</td><td rowspan="3">0.897</td></tr><tr><td>19&#8211;25</td><td>97 (69)</td><td>23 (70)</td><td>33 (73)</td></tr><tr><td>26+</td><td>42 (30)</td><td>10 (30)</td><td>12 (27)</td></tr><tr><td colspan="4">Sex <i>n</i> (%)</td><td rowspan="3">0.066</td></tr><tr><td>Male</td><td>50 (36)</td><td>14 (42)</td><td>25 (56)</td></tr><tr><td>Female</td><td>89 (64)</td><td>19 (58)</td><td>20 (44)</td></tr><tr><td colspan="4">Year in program <i>n</i> (%)</td><td rowspan="4">0.490</td></tr><tr><td>First year</td><td>46 (33)</td><td>15 (45)</td><td>18 (40)</td></tr><tr><td>Second year</td><td>52 (37)</td><td>12 (36)</td><td>13 (29)</td></tr><tr><td>Third year</td><td>41 (29)</td><td>6 (18)</td><td>14 (31)</td></tr><tr><td>Pain intensity mean (SD) <sup>1</sup></td><td>5.2 (2.0)</td><td>5.9 (1.7)</td><td>-</td><td>0.035 <sup>2</sup></td></tr><tr><td>Level of pain tolerated mean (SD) <sup>1</sup></td><td>6.1 (1.9)</td><td>6.3 (1.8)</td><td>-</td><td>0.544</td></tr></table>
<table><tr><td></td><td>Acute</td><td>Chronic</td><td>No Pain</td><td>p Value</td></tr><tr><td>Total Number (n = 218)</td><td>140 (64)</td><td>33 (15)</td><td>45 (21)</td><td></td></tr><tr><td colspan="4">Age n (%)</td><td>0.897</td></tr></table>
<table><tr><td>19–25</td><td>97 (69)</td><td>23 (70)</td><td>33 (73)</td><td rowspan="2">0.897</td></tr><tr><td>26+</td><td>42 (30)</td><td>10 (30)</td><td>12 (27)</td></tr><tr><td colspan="4">Sex n (%)</td><td rowspan="3">0.066</td></tr><tr><td>Male</td><td>50 (36)</td><td>14 (42)</td><td>25 (56)</td></tr><tr><td>Female</td><td>89 (64)</td><td>19 (58)</td><td>20 (44)</td></tr><tr><td colspan="4">Year in program n (%)</td><td rowspan="4">0.490</td></tr><tr><td>First year</td><td>46 (33)</td><td>15 (45)</td><td>18 (40)</td></tr><tr><td>Second year</td><td>52 (37)</td><td>12 (36)</td><td>13 (29)</td></tr><tr><td>Third year</td><td>41 (29)</td><td>6 (18)</td><td>14 (31)</td></tr><tr><td>Pain intensity mean (SD) 1</td><td>5.2 (2.0)</td><td>5.9 (1.7)</td><td>-</td><td>0.035 2</td></tr><tr><td>Level of pain tolerated mean (SD) 1</td><td>6.1 (1.9)</td><td>6.3 (1.8)</td><td>-</td><td>0.544</td></tr></table>
aa9cb5a3733d4c0d362cb60d91cb69d1b3c6c801198f7f51a53e82128749f960.png
simple
<table><tr><td> </td><td>White (<i>n</i> = 93,325)</td><td>Black (<i>n</i> = 8,718) </td><td>Hispanic (<i>n</i> = 24,078) </td><td>Asian/Pacific Islander (<i>n</i> = 16,476) </td><td>American Indian (<i>n</i> = 587) </td><td>Total <i>N</i> = 143,184 </td></tr><tr><td>Mean age in years &#177; SD </td><td>61.49 &#177; 13.47</td><td>57.72 &#177; 13.51</td><td>55.13 &#177; 13.35</td><td>55.87 &#177; 12.93 </td><td>57.50 &#177; 12.44 </td><td>59.53 &#177; 13.67 </td></tr><tr><td> Age </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>&lt;45 </td><td>12.1%</td><td>19.4%</td><td>25.5% </td><td>22.6%</td><td>16.5% </td><td>22,944 </td></tr><tr><td>46&#8211;69 </td><td>58.9%</td><td>59.9%</td><td>58.4% </td><td>61.1%</td><td>66.1% </td><td>84,704 </td></tr><tr><td>70+ </td><td>29.0%</td><td>20.7%</td><td>16.0% </td><td>16.2%</td><td>17.4% </td><td>35,536 </td></tr><tr><td>AJCC stage </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Stage 1 </td><td>50.7%</td><td>37.1%</td><td>38.3% </td><td>45.0%</td><td>43.8% </td><td>67,435 </td></tr><tr><td> Stage 2 </td><td>37.1%</td><td>43.4%</td><td>42.8% </td><td>41.6%</td><td>38.3% </td><td>55,782 </td></tr><tr><td> Stage 3 </td><td>9.5%</td><td>14.5%</td><td>15.3% </td><td>10.6%</td><td>13.6% </td><td>15,664 </td></tr><tr><td> Stage 4 </td><td>2.7%</td><td>5.1%</td><td>3.6% </td><td>2.8%</td><td>4.3% </td><td>4,303 </td></tr><tr><td>ER/PR/HER2 subtype </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> ER+/PR+/HER2&#8722;</td><td>61.3%</td><td>44.2%</td><td>52.2% </td><td>56.1%</td><td>56.9% </td><td>83,169 </td></tr><tr><td> ER+/PR+/HER2+ </td><td>8.7%</td><td>8.9% </td><td>10.3% </td><td>11.3%</td><td>9.5% </td><td>13,293 </td></tr><tr><td> ER+/PR&#8722;/HER2&#8722;</td><td>9.7%</td><td>10.1% </td><td>8.7% </td><td>8.0%</td><td>9.7% </td><td>13,363 </td></tr><tr><td> ER+/PR&#8722;/HER2+ </td><td>3.0%</td><td>3.3%</td><td>3.4% </td><td>3.6%</td><td>3.6% </td><td>4,535 </td></tr><tr><td> ER&#8722;/PR+/HER2&#8722;</td><td>0.7%</td><td>1.1%</td><td>1.0% </td><td>0.8%</td><td>0.7% </td><td>1,131 </td></tr><tr><td> ER&#8722;/PR+/HER2+ </td><td>0.3%</td><td>0.6%</td><td>0.6% </td><td>0.4% </td><td>0.2% </td><td>539 </td></tr><tr><td> ER&#8722;/PR&#8722;/HER2&#8722;</td><td>11.2%</td><td>24.5%</td><td>15.9% </td><td>11.0%</td><td>14.0% </td><td>18,299 </td></tr><tr><td> ER&#8722;/PR&#8722;/HER2+ </td><td>5.2%</td><td>7.3%</td><td>7.9% </td><td>8.8%</td><td>5.5% </td><td>8,855 </td></tr><tr><td>Socioeconomic status (SES) </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> SES1-low </td><td>6.6%</td><td>25.4%</td><td>28.0% </td><td>7.2%</td><td>18.4% </td><td>16,424 </td></tr><tr><td> SES2 </td><td>13.8%</td><td>24.9%</td><td>24.4% </td><td>14.3%</td><td>25.7% </td><td>23,383 </td></tr><tr><td> SES3 </td><td>20.2%</td><td>21.8%</td><td>20.1% </td><td>19.3%</td><td>26.1% </td><td>28,953 </td></tr><tr><td> SES4 </td><td>26.1%</td><td>17.6%</td><td>16.2% </td><td>26.9%</td><td>18.7% </td><td>34,332 </td></tr><tr><td> SES5-high </td><td>33.3%</td><td>10.3%</td><td>11.4% </td><td>32.3%</td><td>11.1% </td><td>40,092 </td></tr><tr><td>Tumor grade </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Well differentiated; grade I (low) </td><td>25.6%</td><td>14.5%</td><td>16.9% </td><td>18.3%</td><td>20.3% </td><td>32,367 </td></tr><tr><td> Moderately differentiated; grade II (low) </td><td>43.7%</td><td>35.1%</td><td>40.2% </td><td>43.0%</td><td>42.6% </td><td>60,820 </td></tr><tr><td> Poorly differentiated; grade III (high) </td><td>29.5%</td><td>48.4%</td><td>41.1% </td><td>37.3%</td><td>36.1% </td><td>47,969 </td></tr><tr><td> Undifferentiated; grade IV (high) </td><td>1.3%</td><td>2.0%</td><td>1.8% </td><td>1.3%</td><td>1.0% </td><td>2,028 </td></tr><tr><td>Tumor size (mm) </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> &lt;1&#8211;4.99</td><td>6.3%</td><td>4.8%</td><td>5.0% </td><td>6.7%</td><td>5.6% </td><td>8,650 </td></tr><tr><td> 5.00&#8211;9.99 </td><td>18.7%</td><td>12.0%</td><td>12.6% </td><td>14.5%</td><td>14.3% </td><td>23,968 </td></tr><tr><td> 10.00&#8211;19.99 </td><td>38.6%</td><td>33.0%</td><td>34.2% </td><td>36.1%</td><td>35.8% </td><td>53,306 </td></tr><tr><td> 20.00&#8211;49.99 </td><td>28.7%</td><td>36.9%</td><td>36.6% </td><td>34.0%</td><td>32.9% </td><td>44,623 </td></tr><tr><td> 50.00+ </td><td>7.7%</td><td>13.3%</td><td>11.6% </td><td>8.6%</td><td>11.4% </td><td>12,637 </td></tr></table>
<table><tr><td></td><td>White (n = 93,325)</td><td>Black (n = 8,718)</td><td>Hispanic (n = 24,078)</td><td>Asian/Pacific Islander (n = 16,476)</td><td>American Indian (n = 587)</td><td>Total N = 143,184</td></tr><tr><td>Mean age in years ± SD</td><td>61.49 ± 13.47</td><td>57.72 ± 13.51</td><td>55.13 ± 13.35</td><td>55.87 ± 12.93</td><td>57.50 ± 12.44</td><td>59.53 ± 13.67</td></tr><tr><td>Age</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><45</td><td>12.1%</td><td>19.4%</td><td>25.5%</td><td>22.6%</td><td>16.5%</td><td>22,944</td></tr><tr><td>46–69</td><td>58.9%</td><td>59.9%</td><td>58.4%</td><td>61.1%</td><td>66.1%</td><td>84,704</td></tr><tr><td>70+</td><td>29.0%</td><td>20.7%</td><td>16.0%</td><td>16.2%</td><td>17.4%</td><td>35,536</td></tr><tr><td>AJCC stage</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Stage 1</td><td>50.7%</td><td>37.1%</td><td>38.3%</td><td>45.0%</td><td>43.8%</td><td>67,435</td></tr><tr><td>Stage 2</td><td>37.1%</td><td>43.4%</td><td>42.8%</td><td>41.6%</td><td>38.3%</td><td>55,782</td></tr><tr><td>Stage 3</td><td>9.5%</td><td>14.5%</td><td>15.3%</td><td>10.6%</td><td>13.6%</td><td>15,664</td></tr><tr><td>Stage 4</td><td>2.7%</td><td>5.1%</td><td>3.6%</td><td>2.8%</td><td>4.3%</td><td>4,303</td></tr><tr><td>ER/PR/HER2 subtype</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>ER+/PR+/HER2−</td><td>61.3%</td><td>44.2%</td><td>52.2%</td><td>56.1%</td><td>56.9%</td><td>83,169</td></tr><tr><td>ER+/PR+/HER2+</td><td>8.7%</td><td>8.9%</td><td>10.3%</td><td>11.3%</td><td>9.5%</td><td>13,293</td></tr><tr><td>ER+/PR−/HER2−</td><td>9.7%</td><td>10.1%</td><td>8.7%</td><td>8.0%</td><td>9.7%</td><td>13,363</td></tr><tr><td>ER+/PR−/HER2+</td><td>3.0%</td><td>3.3%</td><td>3.4%</td><td>3.6%</td><td>3.6%</td><td>4,535</td></tr><tr><td>ER−/PR+/HER2−</td><td>0.7%</td><td>1.1%</td><td>1.0%</td><td>0.8%</td><td>0.7%</td><td>1,131</td></tr></table>
<table><tr><td></td><td>White (n = 93,325)</td><td>Black (n = 8,718)</td><td>Hispanic (n = 24,078)</td><td>Asian/Pacific Islander (n = 16,476)</td><td>American Indian (n = 587)</td><td>Total N = 143,184</td></tr><tr><td>ER−/PR+/HER2+</td><td>0.3%</td><td>0.6%</td><td>0.6%</td><td>0.4%</td><td>0.2%</td><td>539</td></tr><tr><td>ER−/PR−/HER2−</td><td>11.2%</td><td>24.5%</td><td>15.9%</td><td>11.0%</td><td>14.0%</td><td>18,299</td></tr><tr><td>ER−/PR−/HER2+</td><td>5.2%</td><td>7.3%</td><td>7.9%</td><td>8.8%</td><td>5.5%</td><td>8,855</td></tr><tr><td>Socioeconomic status (SES)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>SES1-low</td><td>6.6%</td><td>25.4%</td><td>28.0%</td><td>7.2%</td><td>18.4%</td><td>16,424</td></tr><tr><td>SES2</td><td>13.8%</td><td>24.9%</td><td>24.4%</td><td>14.3%</td><td>25.7%</td><td>23,383</td></tr><tr><td>SES3</td><td>20.2%</td><td>21.8%</td><td>20.1%</td><td>19.3%</td><td>26.1%</td><td>28,953</td></tr><tr><td>SES4</td><td>26.1%</td><td>17.6%</td><td>16.2%</td><td>26.9%</td><td>18.7%</td><td>34,332</td></tr><tr><td>SES5-high</td><td>33.3%</td><td>10.3%</td><td>11.4%</td><td>32.3%</td><td>11.1%</td><td>40,092</td></tr><tr><td>Tumor grade</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Well differentiated; grade I (low)</td><td>25.6%</td><td>14.5%</td><td>16.9%</td><td>18.3%</td><td>20.3%</td><td>32,367</td></tr><tr><td>Moderately differentiated; grade II (low)</td><td>43.7%</td><td>35.1%</td><td>40.2%</td><td>43.0%</td><td>42.6%</td><td>60,820</td></tr><tr><td>Poorly differentiated; grade III (high)</td><td>29.5%</td><td>48.4%</td><td>41.1%</td><td>37.3%</td><td>36.1%</td><td>47,969</td></tr><tr><td>Undifferentiated; grade IV (high)</td><td>1.3%</td><td>2.0%</td><td>1.8%</td><td>1.3%</td><td>1.0%</td><td>2,028</td></tr><tr><td>Tumor size (mm)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><1–4.99</td><td>6.3%</td><td>4.8%</td><td>5.0%</td><td>6.7%</td><td>5.6%</td><td>8,650</td></tr><tr><td>5.00–9.99</td><td>18.7%</td><td>12.0%</td><td>12.6%</td><td>14.5%</td><td>14.3%</td><td>23,968</td></tr><tr><td>10.00–19.99</td><td>38.6%</td><td>33.0%</td><td>34.2%</td><td>36.1%</td><td>35.8%</td><td>53,306</td></tr><tr><td>20.00–49.99</td><td>28.7%</td><td>36.9%</td><td>36.6%</td><td>34.0%</td><td>32.9%</td><td>44,623</td></tr><tr><td>50.00+</td><td>7.7%</td><td>13.3%</td><td>11.6%</td><td>8.6%</td><td>11.4%</td><td>12,637</td></tr></table>
67dcc1e5384d5cd26104c79f3a3515f4fe6503364d017a2fc9c8eb37804581c6.png
complex
<table><tr><td>Threshold</td><td>Net benefit</td><td>Point Estimate</td><td>Bootstrap Mean</td><td colspan="2">Bootstrap confidence interval</td></tr><tr><td></td><td>For:</td><td></td><td>(2000 replications)</td><td>2.5<sup>th </sup>percentile</td><td>97.5<sup>th </sup>percentile</td></tr><tr><td>15</td><td>All</td><td>0.1288</td><td>0.1288</td><td>0.0922</td><td>0.1669</td></tr><tr><td></td><td>Base</td><td>0.1288</td><td>0.1290</td><td>0.0922</td><td>0.1669</td></tr><tr><td></td><td>Full</td><td>0.1590</td><td>0.1613</td><td>0.1280</td><td>0.1955</td></tr><tr><td></td><td>Full vs All</td><td>0.0302</td><td>0.0325</td><td>0.0172</td><td>0.0490</td></tr><tr><td></td><td>Full vs Base</td><td>0.0302</td><td>0.0322</td><td>0.0170</td><td>0.0488</td></tr><tr><td>25</td><td>All</td><td>0.0126</td><td>0.0126</td><td>-0.0288</td><td>0.0559</td></tr><tr><td></td><td>Base</td><td>0.0748</td><td>0.0735</td><td>0.0432</td><td>0.1036</td></tr><tr><td></td><td>Full</td><td>0.1167</td><td>0.1214</td><td>0.0919</td><td>0.1522</td></tr><tr><td></td><td>Full vs All</td><td>0.1041</td><td>0.1088</td><td>0.0802</td><td>0.1369</td></tr><tr><td></td><td>Full vs Base</td><td>0.0419</td><td>0.0479</td><td>0.0257</td><td>0.0712</td></tr><tr><td>35</td><td>All</td><td>-0.1393</td><td>-0.1393</td><td>-0.1871</td><td>-0.0894</td></tr><tr><td></td><td>Base</td><td>0.0428</td><td>0.0410</td><td>0.0181</td><td>0.0662</td></tr><tr><td></td><td>Full</td><td>0.0940</td><td>0.0965</td><td>0.0652</td><td>0.1291</td></tr><tr><td></td><td>Full vs All</td><td>0.2333</td><td>0.2358</td><td>0.1990</td><td>0.2712</td></tr><tr><td></td><td>Full vs Base</td><td>0.0511</td><td>0.0555</td><td>0.0293</td><td>0.0836</td></tr><tr><td>60</td><td>All</td><td>-0.8514</td><td>-0.8513</td><td>-0.9291</td><td>-0.7703</td></tr><tr><td></td><td>Base</td><td>0.0149</td><td>0.0159</td><td>-0.0041</td><td>0.0378</td></tr><tr><td></td><td>Full</td><td>0.0547</td><td>0.0569</td><td>0.0331</td><td>0.0838</td></tr><tr><td></td><td>Full vs All</td><td>0.9061</td><td>0.9083</td><td>0.8345</td><td>0.9824</td></tr><tr><td></td><td>Full vs Base</td><td>0.0399</td><td>0.0410</td><td>0.0176</td><td>0.0676</td></tr><tr><td>80</td><td>All</td><td>-2.7027</td><td>-2.7026</td><td>-2.8581</td><td>-2.5405</td></tr><tr><td></td><td>Base</td><td>-0.0149</td><td>-0.0028</td><td>-0.0230</td><td>0.0243</td></tr><tr><td></td><td>Full</td><td>0.0189</td><td>0.0223</td><td>-0.0054</td><td>0.0527</td></tr><tr><td></td><td>Full vs All</td><td>2.7216</td><td>2.7249</td><td>2.5649</td><td>2.8757</td></tr><tr><td></td><td>Full vs Base</td><td>0.0338</td><td>0.0251</td><td>0.0000</td><td>0.0595</td></tr></table>
<table><tr><td>Threshold</td><td>Net benefit</td><td>Point Estimate</td><td>Bootstrap Mean</td><td colspan="2">Bootstrap confidence interval</td></tr><tr><td></td><td>For:</td><td></td><td>(2000 replications)</td><td>2.5th percentile</td><td>97.5th percentile</td></tr><tr><td>15</td><td>All</td><td>0.1288</td><td>0.1288</td><td>0.0922</td><td>0.1669</td></tr><tr><td></td><td>Base</td><td>0.1288</td><td>0.1290</td><td>0.0922</td><td>0.1669</td></tr><tr><td></td><td>Full</td><td>0.1590</td><td>0.1613</td><td>0.1280</td><td>0.1955</td></tr><tr><td></td><td>Full vs All</td><td>0.0302</td><td>0.0325</td><td>0.0172</td><td>0.0490</td></tr></table>
<table><tr><td></td><td>Full vs Base</td><td>0.0302</td><td>0.0322</td><td>0.0170</td><td>0.0488</td></tr><tr><td>25</td><td>All</td><td>0.0126</td><td>0.0126</td><td>-0.0288</td><td>0.0559</td></tr><tr><td></td><td>Base</td><td>0.0748</td><td>0.0735</td><td>0.0432</td><td>0.1036</td></tr><tr><td></td><td>Full</td><td>0.1167</td><td>0.1214</td><td>0.0919</td><td>0.1522</td></tr><tr><td></td><td>Full vs All</td><td>0.1041</td><td>0.1088</td><td>0.0802</td><td>0.1369</td></tr><tr><td></td><td>Full vs Base</td><td>0.0419</td><td>0.0479</td><td>0.0257</td><td>0.0712</td></tr><tr><td>35</td><td>All</td><td>-0.1393</td><td>-0.1393</td><td>-0.1871</td><td>-0.0894</td></tr><tr><td></td><td>Base</td><td>0.0428</td><td>0.0410</td><td>0.0181</td><td>0.0662</td></tr><tr><td></td><td>Full</td><td>0.0940</td><td>0.0965</td><td>0.0652</td><td>0.1291</td></tr><tr><td></td><td>Full vs All</td><td>0.2333</td><td>0.2358</td><td>0.1990</td><td>0.2712</td></tr><tr><td></td><td>Full vs Base</td><td>0.0511</td><td>0.0555</td><td>0.0293</td><td>0.0836</td></tr><tr><td>60</td><td>All</td><td>-0.8514</td><td>-0.8513</td><td>-0.9291</td><td>-0.7703</td></tr><tr><td></td><td>Base</td><td>0.0149</td><td>0.0159</td><td>-0.0041</td><td>0.0378</td></tr><tr><td></td><td>Full</td><td>0.0547</td><td>0.0569</td><td>0.0331</td><td>0.0838</td></tr><tr><td></td><td>Full vs All</td><td>0.9061</td><td>0.9083</td><td>0.8345</td><td>0.9824</td></tr><tr><td></td><td>Full vs Base</td><td>0.0399</td><td>0.0410</td><td>0.0176</td><td>0.0676</td></tr><tr><td>80</td><td>All</td><td>-2.7027</td><td>-2.7026</td><td>-2.8581</td><td>-2.5405</td></tr><tr><td></td><td>Base</td><td>-0.0149</td><td>-0.0028</td><td>-0.0230</td><td>0.0243</td></tr><tr><td></td><td>Full</td><td>0.0189</td><td>0.0223</td><td>-0.0054</td><td>0.0527</td></tr><tr><td></td><td>Full vs All</td><td>2.7216</td><td>2.7249</td><td>2.5649</td><td>2.8757</td></tr><tr><td></td><td>Full vs Base</td><td>0.0338</td><td>0.0251</td><td>0.0000</td><td>0.0595</td></tr></table>
eacaa4f7575a8e04e674c7906e7d1d947a5109abc2d7f2a0b91385ba770e7aa1.png
simple
<table><tr><td></td><td>AIM HI</td><td>CPRT</td></tr><tr><td>Initial didactic training&#8212;lecture material, video examples, case illustrations, and hands-on practice with coaching and discussion</td><td>12 h (over 2 days)</td><td>8 h</td></tr><tr><td>Ongoing consultation/coaching&#8212;occurs while provider delivers intervention to target child and includes video-based feedback<sup>1</sup></td><td>11 1-h sessions over 6 months (9 group, 2 indiv.)</td><td>4 1-h group sessions and 6 individual coaching sessions over 5 months</td></tr><tr><td>Total length of training</td><td>22 h/6 months</td><td>18 h/6 months</td></tr></table>
<table><tr><td></td><td>AIM HI</td><td>CPRT</td></tr><tr><td>Initial didactic training—lecture material, video examples, case illustrations, and hands-on practice with coaching and discussion</td><td>12 h (over 2 days)</td><td>8 h</td></tr><tr><td>Ongoing consultation/coaching—occurs while provider delivers intervention to target child and includes video-based feedback1</td><td>11 1-h sessions over 6 months (9 group, 2 indiv.)</td><td>4 1-h group sessions and 6 individual coaching sessions over 5 months</td></tr></table>
<table><tr><td></td><td>AIM HI</td><td>CPRT</td></tr><tr><td>Total length of training</td><td>22 h/6 months</td><td>18 h/6 months</td></tr></table>
cd648ccf5a84955b30128b0787d84824003da271ffda3815339b1f04bee53665.png
complex
<table><tr><td>Category</td><td>No. of children</td><td>No. of diarrheal episodes</td><td>Total time at risk (years)</td><td>Diarrheal incidence (episodes/child year)</td><td>Unadjusted IRR (95% CI)</td><td>Adjusted IRR* (95% CI)</td><td><i>P</i> value</td></tr><tr><td colspan="8">Study arm</td></tr><tr><td> No intervention</td><td>109</td><td>85</td><td>80.8</td><td>1.05 (0.85&#8211;1.30)</td><td>Ref</td><td>Ref</td><td>&#8211;</td></tr><tr><td> Intervention (without safe storage)</td><td>65</td><td>54</td><td>44.1</td><td>1.22 (0.94&#8211;1.60)</td><td>1.15 (0.75&#8211;1.77)</td><td>1.14 (0.75&#8211;1.77)</td><td>0.530</td></tr><tr><td> Intervention (with safe storage)</td><td>102</td><td>61</td><td>76.8</td><td>0.79 (0.62&#8211;1.02)</td><td>0.77 (0.52&#8211;1.14)</td><td>0.76 (0.51&#8211;1.13)</td><td>0.178</td></tr><tr><td colspan="8">Gender</td></tr><tr><td> Male</td><td>146</td><td>102</td><td>102.7</td><td>0.99 (0.82&#8211;1.20)</td><td>Ref</td><td>Ref</td><td>&#8211;</td></tr><tr><td> Female</td><td>130</td><td>98</td><td>99.0</td><td>0.98 (0.81&#8211;1.21)</td><td>1.00 (0.71&#8211;1.40)</td><td>1.05 (0.74&#8211;1.48)</td><td>0.790</td></tr><tr><td colspan="8">Age of child (months)&#8224;</td></tr><tr><td> 0&#8211;6</td><td>94</td><td>37</td><td>40.9</td><td>0.90 (0.65&#8211;1.25)</td><td>Ref</td><td>Ref</td><td>&#8211;</td></tr><tr><td> 6&#8211;12</td><td>62</td><td>67</td><td>52.4</td><td>1.28 (1.00&#8211;1.62)</td><td>1.32 (0.87&#8211;2.00)</td><td>1.30 (0.85&#8211;1.98)</td><td>0.222</td></tr><tr><td> 12&#8211;18</td><td>58</td><td>44</td><td>59.1</td><td>0.75 (0.55&#8211;1.00)</td><td>0.75 (0.47&#8211;1.21)</td><td>0.74 (0.46&#8211;1.19)</td><td>0.221</td></tr><tr><td> 18&#8211;24</td><td>43</td><td>52</td><td>48.8</td><td>1.06 (0.81&#8211;1.40)</td><td>1.09 (0.69&#8211;1.74)</td><td>1.07 (0.67&#8211;1.70)</td><td>0.783</td></tr></table>
<table><tr><td>Category</td><td>No. of children</td><td>No. of diarrheal episodes</td><td>Total time at risk (years)</td><td>Diarrheal incidence (episodes/child year)</td><td>Unadjusted IRR (95% CI)</td><td>Adjusted IRR* (95% CI)</td><td>P value</td></tr><tr><td colspan="8">Study arm</td></tr><tr><td>No intervention</td><td>109</td><td>85</td><td>80.8</td><td>1.05 (0.85–1.30)</td><td>Ref</td><td>Ref</td><td>–</td></tr><tr><td>Intervention (without safe storage)</td><td>65</td><td>54</td><td>44.1</td><td>1.22 (0.94–1.60)</td><td>1.15 (0.75–1.77)</td><td>1.14 (0.75–1.77)</td><td>0.530</td></tr><tr><td>Intervention (with safe storage)</td><td>102</td><td>61</td><td>76.8</td><td>0.79 (0.62–1.02)</td><td>0.77 (0.52–1.14)</td><td>0.76 (0.51–1.13)</td><td>0.178</td></tr><tr><td colspan="8">Gender</td></tr><tr><td>Male</td><td>146</td><td>102</td><td>102.7</td><td>0.99 (0.82–1.20)</td><td>Ref</td><td>Ref</td><td>–</td></tr><tr><td>Female</td><td>130</td><td>98</td><td>99.0</td><td>0.98 (0.81–1.21)</td><td>1.00 (0.71–1.40)</td><td>1.05 (0.74–1.48)</td><td>0.790</td></tr><tr><td colspan="8">Age of child (months)†</td></tr></table>
<table><tr><td>0–6</td><td>94</td><td>37</td><td>40.9</td><td>0.90 (0.65–1.25)</td><td>Ref</td><td>Ref</td><td>–</td></tr><tr><td>6–12</td><td>62</td><td>67</td><td>52.4</td><td>1.28 (1.00–1.62)</td><td>1.32 (0.87–2.00)</td><td>1.30 (0.85–1.98)</td><td>0.222</td></tr><tr><td>12–18</td><td>58</td><td>44</td><td>59.1</td><td>0.75 (0.55–1.00)</td><td>0.75 (0.47–1.21)</td><td>0.74 (0.46–1.19)</td><td>0.221</td></tr><tr><td>18–24</td><td>43</td><td>52</td><td>48.8</td><td>1.06 (0.81–1.40)</td><td>1.09 (0.69–1.74)</td><td>1.07 (0.67–1.70)</td><td>0.783</td></tr></table>
1f08b1af2f364112dca9e9d4692c9242111e94c506f6bd929f8e8b491cbc8e4b.png
simple
<table><tr><td> Factor</td><td><i>n</i></td><td>2-year locoregional failure-free survival</td><td>95% CI</td><td><i>P</i> value</td></tr><tr><td>Age</td><td></td><td></td><td></td><td>0.005</td></tr><tr><td> Age &#8804;40</td><td>54</td><td>0.86</td><td>0.75&#8211;0.98</td><td></td></tr><tr><td> Age &gt;40</td><td>158</td><td>0.98</td><td>0.95&#8211;1.00</td><td></td></tr><tr><td>Menopausal status</td><td></td><td></td><td></td><td>0.52</td></tr><tr><td> Premenopausal</td><td>129</td><td>0.99</td><td>0.97&#8211;1.00</td><td></td></tr><tr><td> Postmenopausal</td><td>84</td><td>0.97</td><td>0.91&#8211;1.00</td><td></td></tr><tr><td>BMI</td><td></td><td></td><td></td><td>0.31</td></tr><tr><td> BMI &lt;30</td><td>72</td><td>0.95</td><td>0.88&#8211;1.00</td><td></td></tr><tr><td> BMI &#8805;30</td><td>83</td><td>0.97</td><td>0.92&#8211;1.00</td><td></td></tr><tr><td>T stage</td><td></td><td></td><td></td><td>0.03</td></tr><tr><td> Tis, T0&#8211;2</td><td>159</td><td>0.98</td><td>0.95&#8211;1.00</td><td></td></tr><tr><td> T3-4</td><td>47</td><td>0.89</td><td>0.78&#8211;1.00</td><td></td></tr><tr><td>N stage</td><td></td><td></td><td></td><td>0.13</td></tr><tr><td> N0</td><td>77</td><td>1.00</td><td>1.00-1.00</td><td></td></tr><tr><td> N+</td><td>128</td><td>0.94</td><td>0.88&#8211;1.00</td><td></td></tr><tr><td>Grading</td><td></td><td></td><td></td><td>0.27</td></tr><tr><td> G1-2</td><td>80</td><td>1.00</td><td>1.00-1.00</td><td></td></tr><tr><td> G3</td><td>93</td><td>0.93</td><td>0.86&#8211;1.00</td><td></td></tr><tr><td>Tumor subtype</td><td></td><td></td><td></td><td>0.03</td></tr><tr><td> Luminal A</td><td>75</td><td>0.91</td><td>0.83&#8211;0.99</td><td></td></tr><tr><td> Others*</td><td>114</td><td>0.99</td><td>0.97&#8211;1.00</td><td></td></tr><tr><td>Lymphovascular status</td><td></td><td></td><td></td><td>0.02</td></tr><tr><td> LV0</td><td>67</td><td>1.00</td><td>1.00-1.00</td><td></td></tr><tr><td> LV1</td><td>68</td><td>0.90</td><td>0.79&#8211;1.00</td><td></td></tr><tr><td>Type of surgery</td><td></td><td></td><td></td><td>0.59</td></tr><tr><td> Mastectomy</td><td>121</td><td>0.96</td><td>0.91&#8211;1.00</td><td></td></tr><tr><td> BCS</td><td>91</td><td>0.97</td><td>0.92&#8211;1.00</td><td></td></tr><tr><td>Residual tumor status</td><td></td><td></td><td></td><td>0.56</td></tr><tr><td> R0</td><td>163</td><td>0.97</td><td>0.93&#8211;1.00</td><td></td></tr><tr><td> R1</td><td>15</td><td>1.00</td><td>1.00-1.00</td><td></td></tr></table>
<table><tr><td>Factor</td></tr><tr><td>Age</td></tr><tr><td>Age ≤40</td></tr><tr><td>Age >40</td></tr><tr><td>Menopausal status</td></tr><tr><td>Premenopausal</td></tr><tr><td>Postmenopausal</td></tr><tr><td>BMI</td></tr><tr><td>BMI <30</td></tr><tr><td>BMI ≥30</td></tr><tr><td>T stage</td></tr><tr><td>Tis, T0–2</td></tr><tr><td>T3-4</td></tr><tr><td>N stage</td></tr><tr><td>N0</td></tr><tr><td>N+</td></tr><tr><td>Grading</td></tr><tr><td>G1-2</td></tr><tr><td>G3</td></tr><tr><td>Tumor subtype</td></tr><tr><td>Luminal A</td></tr><tr><td>Others*</td></tr><tr><td>Lymphovascular status</td></tr><tr><td>LV0</td></tr><tr><td>LV1</td></tr><tr><td>Type of surgery</td></tr><tr><td>Mastectomy</td></tr><tr><td>BCS</td></tr><tr><td>Residual tumor status</td></tr><tr><td>R0</td></tr><tr><td>R1</td></tr></table>
<table><tr><td>n</td><td>2-year locoregional failure-free survival</td><td>95% CI</td><td>P value</td></tr><tr><td></td><td></td><td></td><td>0.005</td></tr><tr><td>54</td><td>0.86</td><td>0.75–0.98</td><td></td></tr><tr><td>158</td><td>0.98</td><td>0.95–1.00</td><td></td></tr><tr><td></td><td></td><td></td><td>0.52</td></tr><tr><td>129</td><td>0.99</td><td>0.97–1.00</td><td></td></tr><tr><td>84</td><td>0.97</td><td>0.91–1.00</td><td></td></tr><tr><td></td><td></td><td></td><td>0.31</td></tr><tr><td>72</td><td>0.95</td><td>0.88–1.00</td><td></td></tr><tr><td>83</td><td>0.97</td><td>0.92–1.00</td><td></td></tr><tr><td></td><td></td><td></td><td>0.03</td></tr><tr><td>159</td><td>0.98</td><td>0.95–1.00</td><td></td></tr><tr><td>47</td><td>0.89</td><td>0.78–1.00</td><td></td></tr><tr><td></td><td></td><td></td><td>0.13</td></tr><tr><td>77</td><td>1.00</td><td>1.00-1.00</td><td></td></tr><tr><td>128</td><td>0.94</td><td>0.88–1.00</td><td></td></tr><tr><td></td><td></td><td></td><td>0.27</td></tr><tr><td>80</td><td>1.00</td><td>1.00-1.00</td><td></td></tr><tr><td>93</td><td>0.93</td><td>0.86–1.00</td><td></td></tr><tr><td></td><td></td><td></td><td>0.03</td></tr><tr><td>75</td><td>0.91</td><td>0.83–0.99</td><td></td></tr><tr><td>114</td><td>0.99</td><td>0.97–1.00</td><td></td></tr><tr><td></td><td></td><td></td><td>0.02</td></tr><tr><td>67</td><td>1.00</td><td>1.00-1.00</td><td></td></tr><tr><td>68</td><td>0.90</td><td>0.79–1.00</td><td></td></tr><tr><td></td><td></td><td></td><td>0.59</td></tr><tr><td>121</td><td>0.96</td><td>0.91–1.00</td><td></td></tr><tr><td>91</td><td>0.97</td><td>0.92–1.00</td><td></td></tr><tr><td></td><td></td><td></td><td>0.56</td></tr><tr><td>163</td><td>0.97</td><td>0.93–1.00</td><td></td></tr><tr><td>15</td><td>1.00</td><td>1.00-1.00</td><td></td></tr></table>
117e64a393b7efcc8f1e579e134595db30be901b84b27c2cc83f9b3e933ba5ab.png
complex
<table><tr><td>A. Adolescents and adults</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2"><i>Vaccination health states</i></td><td colspan="3"><i>Disease health states</i></td></tr><tr><td></td><td>Local reaction</td><td>Systemic reaction</td><td>Mild cough</td><td>Severe cough</td><td>Pneumonia</td></tr><tr><td>Mean (SD) adolescent utilities for short-term TTO (N = 94)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> 0%</td><td>0.80 (0.32)</td><td>0.68 (0.36)</td><td>0.51 (0.39)</td><td>0.35 (0.38)</td><td>0.35 (0.37)</td></tr><tr><td> 5%</td><td>0.95 (0.14)</td><td>0.92 (0.16)</td><td>0.87 (0.22)</td><td>0.80 (0.28)</td><td>0.80 (0.26)</td></tr><tr><td> 10%</td><td>0.99 (0.03)</td><td>0.99 (0.04)</td><td>0.97 (0.08)</td><td>0.96 (0.11)</td><td>0.96 (0.08)</td></tr><tr><td>Mean (SD) adolescent utilities for long-term TTO (N = 81)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> 0%</td><td>0.96 (0.06)</td><td>0.92 (0.09)</td><td>0.88 (0.10)</td><td>0.82 (0.13)</td><td>0.82 (0.14)</td></tr><tr><td> 5%</td><td>0.97 (0.07)</td><td>0.94 (0.11)</td><td>0.91 (0.12)</td><td>0.85 (0.18)</td><td>0.85 (0.17)</td></tr><tr><td> 10%</td><td>0.99 (0.05)</td><td>0.97 (0.09)</td><td>0.95 (0.11)</td><td>0.91 (0.17)</td><td>0.91 (0.15)</td></tr><tr><td>Mean (SD) adult utilities for short-term TTO (N = 72)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> 0%</td><td>0.91 (0.24)</td><td>0.83 (0.29)</td><td>0.67 (0.38)</td><td>0.58 (0.42)</td><td>0.62 (0.40)</td></tr><tr><td> 5%</td><td>0.97 (0.13)</td><td>0.96 (0.14)</td><td>0.90 (0.22)</td><td>0.88 (0.23)</td><td>0.88 (0.25)</td></tr><tr><td> 10%</td><td>0.99 (0.04)</td><td>0.99 (0.04)</td><td>0.97 (0.07)</td><td>0.97 (0.08)</td><td>0.97 (0.08)</td></tr><tr><td>Mean (SD) adult utilities for long-term TTO (N = 56)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> 0%</td><td>0.99 (0.02)</td><td>0.97 (0.06)</td><td>0.93 (0.09)</td><td>0.88 (0.17)</td><td>0.88 (0.18)</td></tr><tr><td> 5%</td><td>1.0 (0.01)</td><td>0.99 (0.03)</td><td>0.97 (0.05)</td><td>0.94 (0.13)</td><td>0.94 (0.15)</td></tr><tr><td> 10%</td><td>1.0 (0.00)</td><td>1.0 (0.01)</td><td>0.99 (0.02)</td><td>0.97 (0.09)</td><td>0.96 (0.12)</td></tr><tr><td>B. Infants</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2"><i>Infant health states</i></td><td></td><td></td><td></td></tr><tr><td></td><td>Infant respiratory complications</td><td>Infant neurologic complications</td><td></td><td></td><td></td></tr><tr><td>Short-term TTO (N = 166)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> 0%</td><td>0.27 (0.36)</td><td>0.21 (0.33)</td><td></td><td></td><td></td></tr><tr><td> 5%</td><td>0.71 (0.35)</td><td>0.66 (0.36)</td><td></td><td></td><td></td></tr><tr><td> 10%</td><td>0.92 (0.17)</td><td>0.90 (0.19)</td><td></td><td></td><td></td></tr><tr><td>Long-term TTO (N = 147)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> 0%</td><td>0.36 (0.18)</td><td>0.33 (0.19)</td><td></td><td></td><td></td></tr><tr><td> 5%</td><td>0.84 (0.21)</td><td>0.78 (0.26)</td><td></td><td></td><td></td></tr><tr><td> 10%</td><td>0.89 (0.20)</td><td>0.84 (0.27)</td><td></td><td></td><td></td></tr></table>
<table><tr><td>A. Adolescents and adults</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Vaccination health states</td><td colspan="3">Disease health states</td></tr><tr><td></td><td>Local reaction</td><td>Systemic reaction</td><td>Mild cough</td><td>Severe cough</td><td>Pneumonia</td></tr><tr><td>Mean (SD) adolescent utilities for short-term TTO (N = 94)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>0%</td><td>0.80 (0.32)</td><td>0.68 (0.36)</td><td>0.51 (0.39)</td><td>0.35 (0.38)</td><td>0.35 (0.37)</td></tr><tr><td>5%</td><td>0.95 (0.14)</td><td>0.92 (0.16)</td><td>0.87 (0.22)</td><td>0.80 (0.28)</td><td>0.80 (0.26)</td></tr><tr><td>10%</td><td>0.99 (0.03)</td><td>0.99 (0.04)</td><td>0.97 (0.08)</td><td>0.96 (0.11)</td><td>0.96 (0.08)</td></tr></table>
<table><tr><td>Mean (SD) adolescent utilities for long-term TTO (N = 81)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>0%</td><td>0.96 (0.06)</td><td>0.92 (0.09)</td><td>0.88 (0.10)</td><td>0.82 (0.13)</td><td>0.82 (0.14)</td></tr><tr><td>5%</td><td>0.97 (0.07)</td><td>0.94 (0.11)</td><td>0.91 (0.12)</td><td>0.85 (0.18)</td><td>0.85 (0.17)</td></tr><tr><td>10%</td><td>0.99 (0.05)</td><td>0.97 (0.09)</td><td>0.95 (0.11)</td><td>0.91 (0.17)</td><td>0.91 (0.15)</td></tr><tr><td>Mean (SD) adult utilities for short-term TTO (N = 72)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>0%</td><td>0.91 (0.24)</td><td>0.83 (0.29)</td><td>0.67 (0.38)</td><td>0.58 (0.42)</td><td>0.62 (0.40)</td></tr><tr><td>5%</td><td>0.97 (0.13)</td><td>0.96 (0.14)</td><td>0.90 (0.22)</td><td>0.88 (0.23)</td><td>0.88 (0.25)</td></tr><tr><td>10%</td><td>0.99 (0.04)</td><td>0.99 (0.04)</td><td>0.97 (0.07)</td><td>0.97 (0.08)</td><td>0.97 (0.08)</td></tr><tr><td>Mean (SD) adult utilities for long-term TTO (N = 56)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>0%</td><td>0.99 (0.02)</td><td>0.97 (0.06)</td><td>0.93 (0.09)</td><td>0.88 (0.17)</td><td>0.88 (0.18)</td></tr><tr><td>5%</td><td>1.0 (0.01)</td><td>0.99 (0.03)</td><td>0.97 (0.05)</td><td>0.94 (0.13)</td><td>0.94 (0.15)</td></tr><tr><td>10%</td><td>1.0 (0.00)</td><td>1.0 (0.01)</td><td>0.99 (0.02)</td><td>0.97 (0.09)</td><td>0.96 (0.12)</td></tr><tr><td>B. Infants</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Infant health states</td><td></td><td></td><td></td></tr><tr><td></td><td>Infant respiratory complications</td><td>Infant neurologic complications</td><td></td><td></td><td></td></tr><tr><td>Short-term TTO (N = 166)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>0%</td><td>0.27 (0.36)</td><td>0.21 (0.33)</td><td></td><td></td><td></td></tr><tr><td>5%</td><td>0.71 (0.35)</td><td>0.66 (0.36)</td><td></td><td></td><td></td></tr><tr><td>10%</td><td>0.92 (0.17)</td><td>0.90 (0.19)</td><td></td><td></td><td></td></tr><tr><td>Long-term TTO (N = 147)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>0%</td><td>0.36 (0.18)</td><td>0.33 (0.19)</td><td></td><td></td><td></td></tr><tr><td>5%</td><td>0.84 (0.21)</td><td>0.78 (0.26)</td><td></td><td></td><td></td></tr><tr><td>10%</td><td>0.89 (0.20)</td><td>0.84 (0.27)</td><td></td><td></td><td></td></tr></table>
58fd8001be2e18a8a4ce5d31dd911258fdbe052666dad6797f2a39cbdf6608bb.png
simple
<table><tr><td>Compound</td><td>Description</td><td>Applications</td><td>Remarks</td></tr><tr><td>In111-Capromab pendetide (ProstaScint)</td><td>A conjugation between the murine antibody 7E11.C5.3 and <sup>111</sup>Inin the source of <sup>111</sup>InCl<sub>3</sub> by the action of the GYK-DTPA as a chelating agent.</td><td>Indicated for use in immunoscintigraphy, proven prostate carcinoma and patients who have undergone a prostatectomy and have rising prostate specific antigen (PSA) values and equivocal nonevidenced metastasis.</td><td>It is not indicated with patients with a high clinical suspicion of occult metastatic disease or for screening of prostate carcinoma.</td></tr><tr><td>In111-Satumomab pendetide (OncoScint)</td><td>It contains the murine MAb B72.3 which is directed to tumor-associated glycoprotein. It is labeled with <sup>111</sup>InCl<sub>3</sub> by conjugation with the chelating agent, GYK-DTPA.HCl.</td><td>Used for the detection of colorectal and ovarian cancers [35].</td><td>After an incubation time of 30 min, the labeled mixture is suitable for use in the first 8 hours.</td></tr><tr><td>In111-Imciromab pentetate (MyoScint)</td><td>An antibody produced against myosin in the cell culture, and therefore binds to the heavy chain of myosin after in vivo administration.</td><td>Detection of myocardial infarction.</td><td>Contains the Fab fragment of a murine monoclonal antibody that is covalently bound to DTPA giving <sup>111</sup>In -Imciromab pentetate. </td></tr><tr><td>In-111 and Y90-ibritumomab tiuxetan (Zevalin)</td><td><i>Zevalin</i> consists of a murine monoclonal anti-CD20 antibody covalently conjugated to the metal chelator DTPA, which forms a stable complex with <sup>111</sup>Infor imaging and with <sup>90</sup>Y for therapy.</td><td><sup>90</sup>Y-ibritumomab tiuxetan is used for the treatment of some forms of B cell non-Hodgkin's lymphoma, a myeloproliferative disorder of the lymphatic system while its <sup>111</sup>Inderivative is used to scan the predicted distribution of a therapeutic dosage of <sup>90</sup>Y-ibritumomab in the body [36].</td><td>The antibody binds to the CD20 antigen found on the surface of normal and malignant B cells (but not B cell precursors) allowing radiation from the attached isotope (Yetrium-90) and the cytotoxicity induced by the antibody serve to eliminate B cells from the body allowing a new population of healthy B cells to develop from lymphoid stem cells [37]. </td></tr><tr><td>Rituximab</td><td>An earlier version of anti-CD20 antibody and has also been approved under the brand name Rituxan for the treatment of non-Hodgkin's lymphoma (NHL).</td><td>It was approved for the treatment of patients with relapsed or refractory, lowgrade or follicular Bcell NHL, including patients with rituximab refractory follicular NHL.</td><td>In September 2009, ibritumomab received approval from the FDA for an expanded label for the treatment of patients with previously untreated follicular NHL, who achieve a partial or complete response to first-line chemotherapy.</td></tr></table>
<table><tr><td>Compound</td><td>Description</td><td>Applications</td><td>Remarks</td></tr><tr><td>In111-Capromab pendetide (ProstaScint)</td><td>A conjugation between the murine antibody 7E11.C5.3 and 111Inin the source of 111InCl3 by the action of the GYK-DTPA as a chelating agent.</td><td>Indicated for use in immunoscintigraphy, proven prostate carcinoma and patients who have undergone a prostatectomy and have rising prostate specific antigen (PSA) values and equivocal nonevidenced metastasis.</td><td>It is not indicated with patients with a high clinical suspicion of occult metastatic disease or for screening of prostate carcinoma.</td></tr><tr><td>In111-Satumomab pendetide (OncoScint)</td><td>It contains the murine MAb B72.3 which is directed to tumor-associated glycoprotein. It is labeled with 111InCl3 by conjugation with the chelating agent, GYK-DTPA.HCl.</td><td>Used for the detection of colorectal and ovarian cancers [35].</td><td>After an incubation time of 30 min, the labeled mixture is suitable for use in the first 8 hours.</td></tr><tr><td>In111-Imciromab pentetate (MyoScint)</td><td>An antibody produced against myosin in the cell culture, and therefore binds to the heavy chain of myosin after in vivo administration.</td><td>Detection of myocardial infarction.</td><td>Contains the Fab fragment of a murine monoclonal antibody that is covalently bound to DTPA giving 111In -Imciromab pentetate.</td></tr></table>
<table><tr><td>In-111 and Y90-ibritumomab tiuxetan (Zevalin)</td><td>Zevalin consists of a murine monoclonal anti-CD20 antibody covalently conjugated to the metal chelator DTPA, which forms a stable complex with 111Infor imaging and with 90Y for therapy.</td><td>90Y-ibritumomab tiuxetan is used for the treatment of some forms of B cell non-Hodgkin's lymphoma, a myeloproliferative disorder of the lymphatic system while its 111Inderivative is used to scan the predicted distribution of a therapeutic dosage of 90Y-ibritumomab in the body [36].</td><td>The antibody binds to the CD20 antigen found on the surface of normal and malignant B cells (but not B cell precursors) allowing radiation from the attached isotope (Yetrium-90) and the cytotoxicity induced by the antibody serve to eliminate B cells from the body allowing a new population of healthy B cells to develop from lymphoid stem cells [37].</td></tr><tr><td>Rituximab</td><td>An earlier version of anti-CD20 antibody and has also been approved under the brand name Rituxan for the treatment of non-Hodgkin's lymphoma (NHL).</td><td>It was approved for the treatment of patients with relapsed or refractory, lowgrade or follicular Bcell NHL, including patients with rituximab refractory follicular NHL.</td><td>In September 2009, ibritumomab received approval from the FDA for an expanded label for the treatment of patients with previously untreated follicular NHL, who achieve a partial or complete response to first-line chemotherapy.</td></tr></table>
094bf483c5031052e435b64dec8ed5d5eb9d96a388ca93bc9cd95260780b6b9f.png
simple
<table><tr><td>Questions</td><td>Sub-questions</td></tr><tr><td>1. What is the first thing that comes to mind when you hear the phrase &#8220;oral health&#8221;?</td><td>a. <sup>a</sup>What does &#8220;good oral health&#8221; mean to you?i. <sup>b</sup>When you think of your child, would you say that he or she has &#8220;good oral health&#8221;?ii. <sup>b</sup>How would you describe a child who has good oral health?iii. <sup>b</sup>Think about your child&#8217;s friends, how would you describe those that have good oral health?</td></tr><tr><td>2. What comes to mind when you hear the phrase &#8220;poor oral health&#8221;?</td><td>a. <sup>a</sup>When you think of your child, what could be thought of as poor oral health?i. <sup>b</sup>What could be thought as the worst thing for poor oral health?ii. <sup>b</sup>How would you describe a child with poor oral health?b. <sup>a</sup>How much of a problem is this among children in your family?i. <sup>b</sup>How common is it among children in other families who live in this community? Among your friends?ii. <sup>b</sup>How concerned are you about your son or daughter developing dental problems (dental decay)?</td></tr><tr><td>3. As parents, how do you help your child have healthy teeth?</td><td>a. <sup>a</sup>What do you think parents can do (or you as a parent can do) to prevent dental problems in kids (your kids)?b. <sup>a</sup>As a parent, what do you think are the most important ways to help a child have good oral health?c. <sup>b</sup>What activities can you do to improve your child&#8217;s oral health?d. <sup>c</sup>What about diet and oral health?e. <sup>c</sup>What about flouride and oral health?f. <sup>c</sup>What about the experiences of your other children?</td></tr><tr><td>4. Tell me whether you think you can control your child&#8217;s oral health?</td><td>a. <sup>b</sup>Are there oral health problems that you feel you can control?i. <sup>c</sup>What would they be?ii. <sup>c</sup>What steps can you take to control the problem?iii. <sup>c</sup>Yourself?iv. <sup>c</sup>What about other people? Can they do anything to control the problem?b. <sup>b</sup>When you can control an oral health problem, how does you child respond?c. <sup>b</sup>When you dealt with an oral health problem, how successful were you?d. <sup>c</sup>So, you could not control a problem, then what did you do?i. <sup>b</sup>What was your child&#8217;s response?ii. <sup>b</sup>When you think about it now, does the problem still exist?</td></tr><tr><td>5. Other than your family and those who provide care, is there anyone else that you think should or could have an important role in your child&#8217;s oral health?</td><td>a. <sup>b</sup>Why? What do you think they can do to help?i. <sup>c</sup>What about role models in entertainment?ii. <sup>c</sup>What about advertising and media messages?iii. <sup>c</sup>What about public policies?iv. <sup>c</sup>What about insurance?</td></tr><tr><td>6. What concerns do you have about your child&#8217;s future oral health?</td><td>a. <sup>b</sup>As your child grows older, what oral health problems can affect him/her?i. <sup>c</sup>How can poor oral health affect a child&#8217;s social and psychological well-being?ii. <sup>c</sup>How can it affect a person&#8217;s chances of economic success?iii. <sup>c</sup>How can it affect one&#8217;s general health over a lifetime?</td></tr><tr><td>7. Tell me whether you think you can control your child&#8217;s oral health?</td><td>a. <sup>b</sup>Are there oral health problems that you feel you can control?i. <sup>c</sup>What would they be?ii. <sup>c</sup>What steps can you take to control the problem?iii. <sup>c</sup>Yourself?iv. <sup>c</sup>What about other people? Can they do anything to control the problem?b. <sup>b</sup>When you can control an oral health problem, how does you child respond?c. <sup>b</sup>When you can dealt an oral health problem, how successful were you?d. <sup>c</sup>So, you could not control a problem, then what did you do?i. <sup>b</sup>What was your child&#8217;s response?ii. <sup>b</sup>When you think about it now, does the problem still exist?</td></tr><tr><td>8. Other than your family and those who provide care, is there anyone else that you think should or could have an important role in your child&#8217;s oral health?</td><td>a. <sup>b</sup>Why? What do you think they can do to help?i. <sup>c</sup>What about role models in entertainment?ii. <sup>c</sup>What about advertising and media messages?iii. <sup>c</sup>What about public policies?iv. <sup>c</sup>What about insurance?</td></tr><tr><td>9. What concerns do you have about your child&#8217;s future oral health?</td><td>a. <sup>b</sup>As your child grows older, what oral health problems can affect him/her?</td></tr></table>
<table><tr><td>Ques</td><td>Sub-question</td></tr></table>
<table><tr><td>tions</td><td>s</td></tr><tr><td>1. What is the first thing that comes to mind when you hear the phrase “oral health”?</td><td>a. aWhat does “good oral health” mean to you?i. bWhen you think of your child, would you say that he or she has “good oral health”?ii. bHow would you describe a child who has good oral health?iii. bThink about your child’s friends, how would you describe those that have good oral health?</td></tr><tr><td>2. What comes to mind when you hear the phrase “poor oral health”?</td><td>a. aWhen you think of your child, what could be thought of as poor oral health?i. bWhat could be thought as the worst thing for poor oral health?ii. bHow would you describe a child with poor oral health?b. aHow much of a problem is this among children in your family?i. bHow common is it among children in other families who live in this community? Among your friends?ii. bHow concerned are you about your son or daughter developing dental problems (dental decay)?</td></tr><tr><td>3. As parents, how do you help your child have healthy teeth?</td><td>a. aWhat do you think parents can do (or you as a parent can do) to prevent dental problems in kids (your kids)?b. aAs a parent, what do you think are the most important ways to help a child have good oral health?c. bWhat activities can you do to improve your child’s oral health?d. cWhat about diet and oral health?e. cWhat about flouride and oral health?f. cWhat about the experiences of your other children?</td></tr><tr><td>4. Tell me whether you think you can control your child’s oral health?</td><td>a. bAre there oral health problems that you feel you can control?i. cWhat would they be?ii. cWhat steps can you take to control the problem?iii. cYourself?iv. cWhat about other people? Can they do anything to control the problem?b. bWhen you can control an oral health problem, how does you child respond?c. bWhen you dealt with an oral health problem, how successful were you?d. cSo, you could not control a problem, then what did you do?i. bWhat was your child’s response?ii. bWhen you think about it now, does the problem still exist?</td></tr><tr><td>5. Other than your family and those who provide care, is there anyone else that you think should or could have an important role in your child’s oral health?</td><td>a. bWhy? What do you think they can do to help?i. cWhat about role models in entertainment?ii. cWhat about advertising and media messages?iii. cWhat about public policies?iv. cWhat about insurance?</td></tr><tr><td>6. What concerns do you have about your child’s future oral health?</td><td>a. bAs your child grows older, what oral health problems can affect him/her?i. cHow can poor oral health affect a child’s social and psychological well-being?ii. cHow can it affect a person’s chances of economic success?iii. cHow can it affect one’s general health over a lifetime?</td></tr><tr><td>7. Tell me whether you think you can control your child’s oral health?</td><td>a. bAre there oral health problems that you feel you can control?i. cWhat would they be?ii. cWhat steps can you take to control the problem?iii. cYourself?iv. cWhat about other people? Can they do anything to control the problem?b. bWhen you can control an oral health problem, how does you child respond?c. bWhen you can dealt an oral health problem, how successful were you?d. cSo, you could not control a problem, then what did you do?i. bWhat was your child’s response?ii. bWhen you think about it now, does the problem still exist?</td></tr><tr><td>8. Other than your family and those who provide care, is there anyone else that you think should or could have an important role in your child’s oral health?</td><td>a. bWhy? What do you think they can do to help?i. cWhat about role models in entertainment?ii. cWhat about advertising and media messages?iii. cWhat about public policies?iv. cWhat about insurance?</td></tr><tr><td>9. What concerns do you have about your child’s future oral health?</td><td>a. bAs your child grows older, what oral health problems can affect him/her?</td></tr></table>
c4128e50eff6b2e2fbf6800852789b7b18fb486ad303f10dfa734bdf66ec98f9.png
simple
<table><tr><td>Dependent variable</td><td>Explanatory variable</td><td>Beta</td><td>Chi&#8208;square</td><td><i>p</i> value</td><td>OR (95% confidence interval [CI])</td></tr><tr><td></td><td>Female gender</td><td>1.13</td><td>5.18</td><td>.023</td><td>3.08 (95% CI [1.17, 8.11])</td></tr><tr><td>MMP&#8208;13 saliva</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>CAL</td><td>1.27</td><td>4.35</td><td>.037</td><td>3.57 (95% CI [1.08, 11.82])</td></tr></table>
<table><tr><td>Dependent variable</td><td>Explanatory variable</td><td>Beta</td><td>Chi‐square</td><td>p value</td><td>OR (95% confidence interval [CI])</td></tr><tr><td></td><td>Female gender</td><td>1.13</td><td>5.18</td><td>.023</td><td>3.08 (95% CI [1.17, 8.11])</td></tr></table>
<table><tr><td>Dependent variable</td><td>Explanatory variable</td><td>Beta</td><td>Chi‐square</td><td>p value</td><td>OR (95% confidence interval [CI])</td></tr><tr><td>MMP‐13 saliva</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>CAL</td><td>1.27</td><td>4.35</td><td>.037</td><td>3.57 (95% CI [1.08, 11.82])</td></tr></table>
fb47b3a3693827d63e2542d4ee7b1a14eb46585f3e58b871d3f18169dc54463f.png
complex
<table><tr><td>Patient code</td><td>Age (years)</td><td>Sex</td><td>Clinical form</td><td colspan="2">Location of lesion/Code</td></tr><tr><td colspan="4"> </td><td>Cutaneous</td><td>Mucosal</td></tr><tr><td>1</td><td>52</td><td>M</td><td>MCL</td><td>Arm/1MCL-C</td><td>Oral / 1MCL-O</td></tr><tr><td>2</td><td>48</td><td>M</td><td>MCL</td><td>Nostril/2MCL-C</td><td>Oral/2MCL-O</td></tr><tr><td>3</td><td>25</td><td>M</td><td>MCL</td><td>Arm/3MCL-C</td><td>Nasal/3MCL-N</td></tr><tr><td>4</td><td>54</td><td>M</td><td>MCL</td><td>ND</td><td>Oral/4MCL-O</td></tr><tr><td rowspan="2">5</td><td rowspan="2">47</td><td rowspan="2">M</td><td rowspan="2">MCL</td><td rowspan="2">Arm/5MCL-C</td><td>Nasal/5MCL-N</td></tr><tr><td>Oral/5MCL-O</td></tr><tr><td>6</td><td>16</td><td>M</td><td>MCL</td><td>ND</td><td>Nasal/6MCL-N</td></tr><tr><td>7</td><td>50</td><td>M</td><td>MCL</td><td>Face/7MCL-C</td><td>Nasal/7MCL-N</td></tr><tr><td>8</td><td>29</td><td>M</td><td>MCL</td><td>Trunk/8LMC-C</td><td>Nasal/8MCL-N</td></tr><tr><td>9</td><td>55</td><td>M</td><td>MCL</td><td>ND</td><td>Oral/9MCL-O</td></tr><tr><td>10</td><td>42</td><td>M</td><td>MCL</td><td>ND</td><td>Nasal/10MCL-N</td></tr><tr><td>11</td><td>52</td><td>F</td><td>MCL</td><td>Arm/11MCL-C</td><td>Nasal/11MCL-N</td></tr><tr><td>12</td><td>25</td><td>M</td><td>MCL</td><td>Trunk/12MCL-C</td><td>Oral/12MCL-O</td></tr><tr><td>13</td><td>52</td><td>F</td><td>MCL</td><td>ND</td><td>Oral/13MCL-O</td></tr><tr><td>14</td><td>54</td><td>M</td><td>MCL</td><td>Upper lip/14MCL-C</td><td>Nasal/14MCL-N</td></tr><tr><td>15</td><td>69</td><td>M</td><td>MCL</td><td>ND</td><td>Nasal/15MCL-N</td></tr><tr><td>16</td><td>65</td><td>M</td><td>MCL</td><td>ND</td><td>Oral/16MCL-O</td></tr><tr><td>17</td><td>63</td><td>F</td><td>ML</td><td>A</td><td>Nasal/17ML-N</td></tr><tr><td>18</td><td>53</td><td>M</td><td>ML</td><td>A</td><td>Nasal/18ML-N</td></tr><tr><td>19</td><td>66</td><td>F</td><td>ML</td><td>A</td><td>Nasal/19ML-N</td></tr><tr><td>20</td><td>71</td><td>M</td><td>ML</td><td>A</td><td>Nasal/20ML-N</td></tr><tr><td>21</td><td>12</td><td>M</td><td>ML</td><td>A</td><td>Nasal/21ML-N</td></tr><tr><td>22*</td><td>49</td><td>F</td><td>ML</td><td>A</td><td>Nasal/22ML-N</td></tr><tr><td>23*</td><td>69</td><td>M</td><td>ML</td><td>A</td><td>Nasal/23ML-N</td></tr><tr><td>24*</td><td>60</td><td>M</td><td>ML</td><td>A</td><td>Nasal/24ML-N</td></tr><tr><td>25*</td><td>77</td><td>M</td><td>ML</td><td>A</td><td>Nasal/25ML-N</td></tr><tr><td>26*</td><td>72</td><td>M</td><td>ML</td><td>A</td><td>Nasal/26ML-N</td></tr><tr><td>27*</td><td>71</td><td>F</td><td>ML</td><td>A</td><td>Nasal/27ML-N</td></tr><tr><td>28*</td><td>39</td><td>M</td><td>ML</td><td>A</td><td>Nasal/28ML-N</td></tr><tr><td>29*</td><td>63</td><td>M</td><td>ML</td><td>A</td><td>Nasal/29ML-N</td></tr><tr><td>30*</td><td>44</td><td>F</td><td>ML</td><td>A</td><td>Nasal/30ML-N</td></tr><tr><td rowspan="2">31*</td><td rowspan="2">31</td><td rowspan="2">F</td><td rowspan="2">ML</td><td rowspan="2">A</td><td>Nasal/31ML-N1</td></tr><tr><td>Nasal/31ML-N2</td></tr><tr><td rowspan="2">32*</td><td rowspan="2">29</td><td rowspan="2">F</td><td rowspan="2">ML</td><td rowspan="2">A</td><td>Nasal/32ML-N1</td></tr><tr><td>Nasal/32ML-N2</td></tr><tr><td>33*</td><td>72</td><td>F</td><td>ML</td><td>A</td><td>Oral/33LM-O</td></tr><tr><td rowspan="3">34</td><td rowspan="3">49</td><td rowspan="3">M</td><td rowspan="3">DL</td><td>Arm/ 34DL-C1</td><td rowspan="3">Nasal/34DL-N</td></tr><tr><td>Trunk/34DL-C2</td></tr><tr><td>Leg/34DL-C3</td></tr><tr><td>35</td><td>41</td><td>M</td><td>DL</td><td>Nose/35DL-C</td><td>Nasal/35DL-N</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td>Oral/35DL-O</td></tr></table>
<table><tr><td>Patient code</td><td>Age (years)</td><td>Sex</td><td>Clinical form</td><td colspan="2">Location of lesion/Code</td></tr><tr><td colspan="4"></td><td>Cutaneous</td><td>Mucosal</td></tr><tr><td>1</td><td>52</td><td>M</td><td>MCL</td><td>Arm/1MCL-C</td><td>Oral / 1MCL-O</td></tr><tr><td>2</td><td>48</td><td>M</td><td>MCL</td><td>Nostril/2MCL-C</td><td>Oral/2MCL-O</td></tr><tr><td>3</td><td>25</td><td>M</td><td>MCL</td><td>Arm/3MCL-C</td><td>Nasal/3MCL-N</td></tr><tr><td>4</td><td>54</td><td>M</td><td>MCL</td><td>ND</td><td>Oral/4MCL-O</td></tr><tr><td rowspan="2">5</td><td rowspan="2">47</td><td rowspan="2">M</td><td rowspan="2">MCL</td><td rowspan="2">Arm/5MCL-C</td><td>Nasal/5MCL-N</td></tr><tr><td>Oral/5MCL-O</td></tr><tr><td>6</td><td>16</td><td>M</td><td>MCL</td><td>ND</td><td>Nasal/6MCL-N</td></tr><tr><td>7</td><td>50</td><td>M</td><td>MCL</td><td>Face/7MCL-C</td><td>Nasal/7MCL-N</td></tr><tr><td>8</td><td>29</td><td>M</td><td>MCL</td><td>Trunk/8LMC-C</td><td>Nasal/8MCL-N</td></tr><tr><td>9</td><td>55</td><td>M</td><td>MCL</td><td>ND</td><td>Oral/9MCL-O</td></tr><tr><td>10</td><td>42</td><td>M</td><td>MCL</td><td>ND</td><td>Nasal/10MCL-N</td></tr><tr><td>11</td><td>52</td><td>F</td><td>MCL</td><td>Arm/11MCL-C</td><td>Nasal/11MCL-N</td></tr><tr><td>12</td><td>25</td><td>M</td><td>MCL</td><td>Trunk/12MCL-C</td><td>Oral/12MCL-O</td></tr><tr><td>13</td><td>52</td><td>F</td><td>MCL</td><td>ND</td><td>Oral/13MCL-O</td></tr><tr><td>14</td><td>54</td><td>M</td><td>MCL</td><td>Upper lip/14MCL-C</td><td>Nasal/14MCL-N</td></tr><tr><td>15</td><td>69</td><td>M</td><td>MCL</td><td>ND</td><td>Nasal/15MCL-N</td></tr><tr><td>16</td><td>65</td><td>M</td><td>MCL</td><td>ND</td><td>Oral/16MCL-O</td></tr><tr><td>17</td><td>63</td><td>F</td><td>ML</td><td>A</td><td>Nasal/17ML-N</td></tr></table>
<table><tr><td>Patient code</td><td>Age (years)</td><td>Sex</td><td>Clinical form</td><td colspan="2">Location of lesion/Code</td></tr><tr><td colspan="4"></td><td>Cutaneous</td><td>Mucosal</td></tr><tr><td>18</td><td>53</td><td>M</td><td>ML</td><td>A</td><td>Nasal/18ML-N</td></tr><tr><td>19</td><td>66</td><td>F</td><td>ML</td><td>A</td><td>Nasal/19ML-N</td></tr><tr><td>20</td><td>71</td><td>M</td><td>ML</td><td>A</td><td>Nasal/20ML-N</td></tr><tr><td>21</td><td>12</td><td>M</td><td>ML</td><td>A</td><td>Nasal/21ML-N</td></tr><tr><td>22*</td><td>49</td><td>F</td><td>ML</td><td>A</td><td>Nasal/22ML-N</td></tr><tr><td>23*</td><td>69</td><td>M</td><td>ML</td><td>A</td><td>Nasal/23ML-N</td></tr><tr><td>24*</td><td>60</td><td>M</td><td>ML</td><td>A</td><td>Nasal/24ML-N</td></tr><tr><td>25*</td><td>77</td><td>M</td><td>ML</td><td>A</td><td>Nasal/25ML-N</td></tr><tr><td>26*</td><td>72</td><td>M</td><td>ML</td><td>A</td><td>Nasal/26ML-N</td></tr><tr><td>27*</td><td>71</td><td>F</td><td>ML</td><td>A</td><td>Nasal/27ML-N</td></tr><tr><td>28*</td><td>39</td><td>M</td><td>ML</td><td>A</td><td>Nasal/28ML-N</td></tr><tr><td>29*</td><td>63</td><td>M</td><td>ML</td><td>A</td><td>Nasal/29ML-N</td></tr><tr><td>30*</td><td>44</td><td>F</td><td>ML</td><td>A</td><td>Nasal/30ML-N</td></tr><tr><td rowspan="2">31*</td><td rowspan="2">31</td><td rowspan="2">F</td><td rowspan="2">ML</td><td rowspan="2">A</td><td>Nasal/31ML-N1</td></tr><tr><td>Nasal/31ML-N2</td></tr><tr><td rowspan="2">32*</td><td rowspan="2">29</td><td rowspan="2">F</td><td rowspan="2">ML</td><td rowspan="2">A</td><td>Nasal/32ML-N1</td></tr><tr><td>Nasal/32ML-N2</td></tr><tr><td>33*</td><td>72</td><td>F</td><td>ML</td><td>A</td><td>Oral/33LM-O</td></tr><tr><td rowspan="3">34</td><td rowspan="3">49</td><td rowspan="3">M</td><td rowspan="3">DL</td><td>Arm/ 34DL-C1</td><td rowspan="3">Nasal/34DL-N</td></tr><tr><td>Trunk/34DL-C2</td></tr><tr><td>Leg/34DL-C3</td></tr><tr><td>35</td><td>41</td><td>M</td><td>DL</td><td>Nose/35DL-C</td><td>Nasal/35DL-N</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Oral/35DL-O</td></tr></table>
0be0df9a64f01f87cda9b02feff47f61b9e5c41408160eb0a58e04c6f94b754e.png
complex
<table><tr><td></td><td>Tested population</td><td>NGO facilities</td><td>Services for migrants</td><td>DU services</td></tr><tr><td></td><td><i>N</i> = 2949 (%)</td><td><i>N</i> = 1597 (%)</td><td><i>N</i> = 928 (%)</td><td><i>N</i> = 424 (%)</td></tr><tr><td>Median age (IQR)</td><td>33 years (26&#8211;43)</td><td>31 years (25&#8211;41)</td><td>37 years (29&#8211;47)</td><td>35 years (28&#8211;44)</td></tr><tr><td colspan="5">Gender</td></tr><tr><td> Men</td><td>1934 (65.6)</td><td>1123 (70.3)</td><td>531 (57.2)</td><td>280 (66. 0)</td></tr><tr><td> Women</td><td>973 (33)</td><td>445 (27.9)</td><td>391 (42.1)</td><td>137 (32.3)</td></tr><tr><td> Transgender</td><td>32 (1.1)</td><td>23 (1.5)</td><td>4 (0.4)</td><td>5 (1.2)</td></tr><tr><td> Unknown</td><td>10 (0.3)</td><td>6 (0.4)</td><td>2 (0.2)</td><td>2 (0.5)</td></tr><tr><td colspan="5">Origin</td></tr><tr><td> Italian</td><td>1782 (60.4)</td><td>1432 (89.7)</td><td>86 (9.3)</td><td>264 (62.3)</td></tr><tr><td> Foreigners</td><td>1167 (39.6)</td><td>165 (10.3)</td><td>842 (90.7)</td><td>160 (37.7)</td></tr><tr><td colspan="5">Education (yy)</td></tr><tr><td>&#8804; 8</td><td>684 (23.2)</td><td>167 (10.5)</td><td>340 (36.6)</td><td>177 (41.7)</td></tr><tr><td>&gt; 8</td><td>2249 (76.3)</td><td>1421 (88.9)</td><td>583 (62.8)</td><td>245 (57.8)</td></tr><tr><td> Unknown</td><td>16 (0.5)</td><td>9 (0.6)</td><td>5 (0.6)</td><td>2 (0.5)</td></tr><tr><td colspan="5">Occupation</td></tr><tr><td> Employed</td><td>1478 (50.1)</td><td>939 (58.8)</td><td>413 (44.5)</td><td>126 (29.7)</td></tr><tr><td> Occasional employed</td><td>485 (16.4)</td><td>426 (26.7)</td><td>37 (4)</td><td>22 (5.2)</td></tr><tr><td> Unemployed</td><td>968 (32.8)</td><td>223 (14)</td><td>472 (50.9)</td><td>273 (64.4)</td></tr><tr><td> Unknown</td><td>18 (0.6)</td><td>9 (0.6)</td><td>6 (0.6)</td><td>3 (0.7)</td></tr><tr><td colspan="5">Marital status</td></tr><tr><td> Never married</td><td>1895 (64.3)</td><td>1283 (80.3)</td><td>374 (40.3)</td><td>238 (56.1)</td></tr><tr><td> Married/Cohabiting</td><td>694 (23.5)</td><td>206 (12.9)</td><td>378 (40.7)</td><td>110 (25.9)</td></tr><tr><td> Married before</td><td>305 (10.3)</td><td>78 (4.9)</td><td>156 (16.8)</td><td>71 (16.7)</td></tr><tr><td> Unknown</td><td>55 (1.9)</td><td>30 (1.9)</td><td>20 (2.2)</td><td>5 (1.2)</td></tr><tr><td colspan="5">Previous HIV test</td></tr><tr><td> No</td><td>1334 (45.2)</td><td>565 (35.4)</td><td>613 (66.1)</td><td>156 (36.8)</td></tr><tr><td> Yes</td><td>1545 (52.4)</td><td>1016 (63.3)</td><td>283 (30.5)</td><td>246 (58.0)</td></tr><tr><td> Unknown</td><td>70 (2.4)</td><td>16 (1.0)</td><td>32 (3.4)</td><td>22 (5.2)</td></tr><tr><td colspan="5">Previous STI<sup>a</sup></td></tr><tr><td> No</td><td>2406 (81.6)</td><td>1289 (80.7)</td><td>777 (83.7)</td><td>431 (80.4)</td></tr><tr><td> Yes</td><td>392 (13.3)</td><td>257 (16.1)</td><td>90 (9.7)</td><td>45 (10.6)</td></tr><tr><td> Unknown</td><td>151 (5.1)</td><td>52 (3.3)</td><td>61 (6.6)</td><td>38 (9.0)</td></tr></table>
<table><tr><td></td><td>Tested population</td><td>NGO facilities</td><td>Services for migrants</td><td>DU services</td></tr><tr><td></td><td>N = 2949 (%)</td><td>N = 1597 (%)</td><td>N = 928 (%)</td><td>N = 424 (%)</td></tr><tr><td>Median age (IQR)</td><td>33 years (26–43)</td><td>31 years (25–41)</td><td>37 years (29–47)</td><td>35 years (28–44)</td></tr><tr><td colspan="5">Gender</td></tr><tr><td>Men</td><td>1934 (65.6)</td><td>1123 (70.3)</td><td>531 (57.2)</td><td>280 (66. 0)</td></tr><tr><td>Women</td><td>973 (33)</td><td>445 (27.9)</td><td>391 (42.1)</td><td>137 (32.3)</td></tr><tr><td>Transgender</td><td>32 (1.1)</td><td>23 (1.5)</td><td>4 (0.4)</td><td>5 (1.2)</td></tr><tr><td>Unknown</td><td>10 (0.3)</td><td>6 (0.4)</td><td>2 (0.2)</td><td>2 (0.5)</td></tr><tr><td colspan="5">Origin</td></tr><tr><td>Italian</td><td>1782 (60.4)</td><td>1432 (89.7)</td><td>86 (9.3)</td><td>264 (62.3)</td></tr><tr><td>Foreigners</td><td>1167 (39.6)</td><td>165 (10.3)</td><td>842 (90.7)</td><td>160 (37.7)</td></tr><tr><td colspan="5">Education (yy)</td></tr><tr><td>≤ 8</td><td>684 (23.2)</td><td>167 (10.5)</td><td>340 (36.6)</td><td>177 (41.7)</td></tr><tr><td>> 8</td><td>2249 (76.3)</td><td>1421 (88.9)</td><td>583 (62.8)</td><td>245 (57.8)</td></tr><tr><td>Unknown</td><td>16 (0.5)</td><td>9 (0.6)</td><td>5 (0.6)</td><td>2 (0.5)</td></tr><tr><td colspan="5">Occupation</td></tr><tr><td>Employed</td><td>1478 (50.1)</td><td>939 (58.8)</td><td>413 (44.5)</td><td>126 (29.7)</td></tr><tr><td>Occasional employed</td><td>485 (16.4)</td><td>426 (26.7)</td><td>37 (4)</td><td>22 (5.2)</td></tr><tr><td>Unemployed</td><td>968 (32.8)</td><td>223 (14)</td><td>472 (50.9)</td><td>273 (64.4)</td></tr><tr><td>Unknown</td><td>18 (0.6)</td><td>9 (0.6)</td><td>6 (0.6)</td><td>3 (0.7)</td></tr><tr><td colspan="5">Marital status</td></tr><tr><td>Never married</td><td>1895 (64.3)</td><td>1283 (80.3)</td><td>374 (40.3)</td><td>238 (56.1)</td></tr><tr><td>Married/Cohabiting</td><td>694 (23.5)</td><td>206 (12.9)</td><td>378 (40.7)</td><td>110 (25.9)</td></tr><tr><td>Married before</td><td>305 (10.3)</td><td>78 (4.9)</td><td>156 (16.8)</td><td>71 (16.7)</td></tr></table>
<table><tr><td></td><td>Tested population</td><td>NGO facilities</td><td>Services for migrants</td><td>DU services</td></tr><tr><td></td><td>N = 2949 (%)</td><td>N = 1597 (%)</td><td>N = 928 (%)</td><td>N = 424 (%)</td></tr><tr><td>Unknown</td><td>55 (1.9)</td><td>30 (1.9)</td><td>20 (2.2)</td><td>5 (1.2)</td></tr><tr><td colspan="5">Previous HIV test</td></tr><tr><td>No</td><td>1334 (45.2)</td><td>565 (35.4)</td><td>613 (66.1)</td><td>156 (36.8)</td></tr><tr><td>Yes</td><td>1545 (52.4)</td><td>1016 (63.3)</td><td>283 (30.5)</td><td>246 (58.0)</td></tr><tr><td>Unknown</td><td>70 (2.4)</td><td>16 (1.0)</td><td>32 (3.4)</td><td>22 (5.2)</td></tr><tr><td colspan="5">Previous STIa</td></tr><tr><td>No</td><td>2406 (81.6)</td><td>1289 (80.7)</td><td>777 (83.7)</td><td>431 (80.4)</td></tr><tr><td>Yes</td><td>392 (13.3)</td><td>257 (16.1)</td><td>90 (9.7)</td><td>45 (10.6)</td></tr><tr><td>Unknown</td><td>151 (5.1)</td><td>52 (3.3)</td><td>61 (6.6)</td><td>38 (9.0)</td></tr></table>
a22f87e3f822e11bb8ecf5767b9ceeaf40b1807f7427ed3f9eb67f72b4b49e82.png
simple
<table><tr><td>Diagnosis</td><td><i>n</i></td><td>Percent</td></tr><tr><td>Small for gestational age</td><td>11</td><td>26.8</td></tr><tr><td>Disseminated intravascular coagulation</td><td>5</td><td>12.2</td></tr><tr><td>Respiratory distress syndrome</td><td>7</td><td>17.1</td></tr><tr><td>Sepsis</td><td>21</td><td>51.2</td></tr><tr><td>Anemia</td><td>2</td><td>4.9</td></tr><tr><td>Shock</td><td>5</td><td>12.2</td></tr><tr><td>Meconium aspiration syndrome</td><td>2</td><td>4.9</td></tr><tr><td>Hypoxic ischaemic encephalopathy</td><td>19</td><td>46.3</td></tr><tr><td>Acute kidney injury</td><td>7</td><td>17.1</td></tr><tr><td>Meningitis</td><td>2</td><td>4.9</td></tr><tr><td>Pulmonary hemorrhage</td><td>2</td><td>4.9</td></tr><tr><td>Hyperbilirubinemia</td><td>3</td><td>7.3</td></tr><tr><td>Necrotising enterocolitis</td><td>1</td><td>2.4</td></tr><tr><td>Persistent pulmonary hypertension</td><td>3</td><td>7.3</td></tr><tr><td>Intracranial haemorrhage</td><td>1</td><td>2.4</td></tr><tr><td>Congenital heart disease</td><td>6</td><td>14.6</td></tr></table>
<table><tr><td>Diagnosis</td><td>n</td><td>Percent</td></tr><tr><td>Small for gestational age</td><td>11</td><td>26.8</td></tr><tr><td>Disseminated intravascular coagulation</td><td>5</td><td>12.2</td></tr><tr><td>Respiratory distress syndrome</td><td>7</td><td>17.1</td></tr><tr><td>Sepsis</td><td>21</td><td>51.2</td></tr><tr><td>Anemia</td><td>2</td><td>4.9</td></tr><tr><td>Shock</td><td>5</td><td>12.2</td></tr><tr><td>Meconium aspiration syndrome</td><td>2</td><td>4.9</td></tr><tr><td>Hypoxic ischaemic encephalopathy</td><td>19</td><td>46.3</td></tr><tr><td>Acute kidney injury</td><td>7</td><td>17.1</td></tr><tr><td>Meningitis</td><td>2</td><td>4.9</td></tr><tr><td>Pulmonary hemorrhage</td><td>2</td><td>4.9</td></tr><tr><td>Hyperbilirubinemia</td><td>3</td><td>7.3</td></tr><tr><td>Necrotising enterocolitis</td><td>1</td><td>2.4</td></tr><tr><td>Persistent pulmonary hypertension</td><td>3</td><td>7.3</td></tr><tr><td>Intrac</td><td></td><td></td></tr></table>
<table><tr><td>ranial haemorrhage</td><td>1</td><td>2.4</td></tr><tr><td>Congenital heart disease</td><td>6</td><td>14.6</td></tr></table>
5fda7661b1b2c2f18aaa21981d9bf63b7e7f6f8392e142ba9da0d58cf1d73fbf.png
complex
<table><tr><td>Gastric ulcer model</td><td>Treatments (p.o.)</td><td>Dose (g/kg)</td><td><i>n</i></td><td>Ulcer index (mm)</td><td>Inhibition (%)</td></tr><tr><td rowspan="4">Ethanol-induced</td><td>Saline</td><td>&#8211;</td><td>8</td><td>14.37 &#177; 2.88</td><td>&#8211;</td></tr><tr><td>Ranitidine</td><td>0.04</td><td>8</td><td>11.27 &#177; 2.49<sup><i>&#8727;&#8727;</i></sup></td><td>29.01</td></tr><tr><td>AIG</td><td>1.50</td><td>8</td><td>3.11 &#177; 0.47<sup><i>&#8727;&#8727;</i></sup></td><td>80.43</td></tr><tr><td>AIG</td><td>0.75</td><td>8</td><td>4.46 &#177; 0.51<sup><i>&#8727;&#8727;</i></sup></td><td>71.93</td></tr><tr><td rowspan="4">Pylorus ligature-induced</td><td>Saline</td><td>&#8211;</td><td>8</td><td>11.33 &#177; 3.78</td><td>&#8211;</td></tr><tr><td>Ranitidine</td><td>0.03</td><td>8</td><td>3.55 &#177; 0.63<sup><i>&#8727;&#8727;</i></sup></td><td>68.68</td></tr><tr><td>AIG</td><td>1.0</td><td>8</td><td>2.76 &#177; 0.67<sup><i>&#8727;&#8727;</i></sup></td><td>75.63</td></tr><tr><td>AIG</td><td>0.5</td><td>8</td><td>3.36 &#177; 0.78<sup><i>&#8727;&#8727;</i></sup></td><td>70.33</td></tr><tr><td rowspan="4">Acetic acid-induced</td><td>Saline</td><td>&#8211;</td><td>8</td><td>10.26 &#177; 1.52</td><td>&#8211;</td></tr><tr><td>Ranitidine</td><td>0.03</td><td>8</td><td>3.89 &#177; 0.48<sup><i>&#8727;&#8727;</i></sup></td><td>64.37</td></tr><tr><td>AIG</td><td>1.0</td><td>8</td><td>2.84 &#177; 0.53<sup><i>&#8727;&#8727;</i></sup></td><td>72.49</td></tr><tr><td>AIG</td><td>0.5</td><td>8</td><td>3.38 &#177; 0.64<sup><i>&#8727;&#8727;</i></sup></td><td>63.15</td></tr></table>
<table><tr><td>Gastric ulcer model</td><td>Treatments (p.o.)</td><td>Dose (g/kg)</td><td>n</td><td>Ulcer index (mm)</td></tr><tr><td rowspan="4">Ethanol-induced</td><td>Saline</td><td>–</td><td>8</td><td>14.37 ± 2.88</td></tr><tr><td>Ranitidine</td><td>0.04</td><td>8</td><td>11.27 ± 2.49∗∗</td></tr><tr><td>AIG</td><td>1.50</td><td>8</td><td>3.11 ± 0.47∗∗</td></tr><tr><td>AIG</td><td>0.75</td><td>8</td><td>4.46 ± 0.51∗∗</td></tr><tr><td rowspan="4">Pylorus ligature-induced</td><td>Saline</td><td>–</td><td>8</td><td>11.33 ± 3.78</td></tr><tr><td>Ranitidine</td><td>0.03</td><td>8</td><td>3.55 ± 0.63∗∗</td></tr><tr><td>AIG</td><td>1.0</td><td>8</td><td>2.76 ± 0.67∗∗</td></tr><tr><td>AIG</td><td>0.5</td><td>8</td><td>3.36 ± 0.78∗∗</td></tr><tr><td rowspan="4">Acetic acid-induced</td><td>Saline</td><td>–</td><td>8</td><td>10.26 ± 1.52</td></tr><tr><td>Ranitidine</td><td>0.03</td><td>8</td><td>3.89 ± 0.48∗∗</td></tr><tr><td>AIG</td><td>1.0</td><td>8</td><td>2.84 ± 0.53∗∗</td></tr><tr><td>AIG</td><td>0.5</td><td>8</td><td>3.38 ± 0.64∗∗</td></tr></table>
<table><tr><td>Inhibition (%)</td></tr><tr><td>–</td></tr><tr><td>29.01</td></tr><tr><td>80.43</td></tr><tr><td>71.93</td></tr><tr><td>–</td></tr><tr><td>68.68</td></tr><tr><td>75.63</td></tr><tr><td>70.33</td></tr><tr><td>–</td></tr><tr><td>64.37</td></tr><tr><td>72.49</td></tr><tr><td>63.15</td></tr></table>
f94c6b3b3896b385eece9f86ffd5c8672f9e36f0b11f93dffa79fb980fbdc224.png
simple
<table><tr><td>Characteristics</td><td>Total <i>(n = 140)</i></td><td>TB Group <i>(n = 70)</i></td><td>Control Group <i>(n = 70)</i></td><td><i>P </i>value</td></tr><tr><td>Gender: Male</td><td>95 (68%)</td><td>56 (80%)</td><td>39 (56%)</td><td>0.002</td></tr><tr><td>Age, years, mean &#177; SD</td><td>35.7 &#177; 7.6</td><td>34.4 &#177; 6.2</td><td>37.2 &#177; 8.7</td><td>0.028</td></tr><tr><td>Body weight, Kgs, mean &#177; SD</td><td>54.6 &#177; 9.6</td><td>54.7 &#177; 8.7</td><td>54.4 &#177; 10.6</td><td>0.827</td></tr><tr><td>Body mass index, mean &#177; SD</td><td>20.1 &#177; 2.9</td><td>19.7 &#177; 2.4</td><td>20.5 &#177; 3.4</td><td>0.097</td></tr><tr><td>CD4 cell counts, cells/mm<sup>3</sup>, mean &#177; SD</td><td>62 &#177; 74</td><td>61 &#177; 74</td><td>76 &#177; 75</td><td>0.823</td></tr><tr><td>%CD4, median (IQR)</td><td>5 &#177; 5</td><td>6 &#177; 5</td><td>5 &#177; 5</td><td>0.226</td></tr><tr><td>Plasma HIV RNA, copies/ml, median (IQR)</td><td>433,500 (169,000&#8211;750,000)</td><td>505,000 (269,000&#8211;750,000)</td><td>291,000 (94,600&#8211;714,000)</td><td>0.014</td></tr><tr><td>Plasma HIV RNA, Log copies/ml, median (IQR)</td><td>5.6 (5.2&#8211;5.9)</td><td>5.7 (5.4&#8211;5.9)</td><td>5.6 (5.0&#8211;5.9)</td><td>0.004</td></tr><tr><td>ALP, mg/dl, median (IQR)</td><td>98 (71&#8211;142)</td><td>110 (75&#8211;154)</td><td>91 (70&#8211;128)</td><td>0.072</td></tr><tr><td>AST, U/l, median (IQR)</td><td>30 (20&#8211;50)</td><td>36 (27&#8211;60)</td><td>35 (26&#8211;47)</td><td>0.371</td></tr><tr><td>ALT, U/l, median (IQR)</td><td>27 (19&#8211;42)</td><td>27 (18&#8211;51)</td><td>32 (22&#8211;49)</td><td>0.169</td></tr><tr><td>Total bilirubin, mg/dl, median (IQR)</td><td>0.6 (0.4&#8211;0.7)</td><td>0.6 (0.5&#8211;0.8)</td><td>0.5 (0.4&#8211;0.7)</td><td>0.051</td></tr></table>
<table><tr><td>Characteristics</td><td>Total (n = 140)</td><td>TB Group (n = 70)</td><td>Control Group (n = 70)</td><td>P value</td></tr><tr><td>Gender: Male</td><td>95 (68%)</td><td>56 (80%)</td><td>39 (56%)</td><td>0.002</td></tr><tr><td>Age, years, mean ± SD</td><td>35.7 ± 7.6</td><td>34.4 ± 6.2</td><td>37.2 ± 8.7</td><td>0.028</td></tr><tr><td>Body weight, Kgs, mean ± SD</td><td>54.6 ± 9.6</td><td>54.7 ± 8.7</td><td>54.4 ± 10.6</td><td>0.827</td></tr><tr><td>Body mass index, mean ± SD</td><td>20.1 ± 2.9</td><td>19.7 ± 2.4</td><td>20.5 ± 3.4</td><td>0.097</td></tr><tr><td>CD4 cell counts, cells/mm3, mean ± SD</td><td>62 ± 74</td><td>61 ± 74</td><td>76 ± 75</td><td>0.823</td></tr><tr><td>%CD4, median (IQR)</td><td>5 ± 5</td><td>6 ± 5</td><td>5 ± 5</td><td>0.226</td></tr><tr><td>Plasma HIV RNA, copies/ml, median (IQR)</td><td>433,500 (169,000–750,000)</td><td>505,000 (269,000–750,000)</td><td>291,000 (94,600–714,000)</td><td>0.014</td></tr></table>
<table><tr><td>Characteristics</td><td>Total (n = 140)</td><td>TB Group (n = 70)</td><td>Control Group (n = 70)</td><td>P value</td></tr><tr><td>Plasma HIV RNA, Log copies/ml, median (IQR)</td><td>5.6 (5.2–5.9)</td><td>5.7 (5.4–5.9)</td><td>5.6 (5.0–5.9)</td><td>0.004</td></tr><tr><td>ALP, mg/dl, median (IQR)</td><td>98 (71–142)</td><td>110 (75–154)</td><td>91 (70–128)</td><td>0.072</td></tr><tr><td>AST, U/l, median (IQR)</td><td>30 (20–50)</td><td>36 (27–60)</td><td>35 (26–47)</td><td>0.371</td></tr><tr><td>ALT, U/l, median (IQR)</td><td>27 (19–42)</td><td>27 (18–51)</td><td>32 (22–49)</td><td>0.169</td></tr><tr><td>Total bilirubin, mg/dl, median (IQR)</td><td>0.6 (0.4–0.7)</td><td>0.6 (0.5–0.8)</td><td>0.5 (0.4–0.7)</td><td>0.051</td></tr></table>
09646d2365083a3f028efa2b478645049e985d83ef8ef79235d2fa1a3669bc60.png
complex
<table><tr><td colspan="6">Most significant GO Biological Processes</td></tr><tr><td>GO Term</td><td>GO ID</td><td>Changed Genes</td><td>Total Genes in Class</td><td>P-Value</td><td>Fraction</td></tr><tr><td>Cholesterol biosynthesis</td><td>GO:0006695</td><td>12</td><td>20</td><td>7.04E-09</td><td>0.600</td></tr><tr><td>Nuclear mRNA splicing, via spliceosome</td><td>GO:0000398</td><td>29</td><td>110</td><td>9.77E-09</td><td>0.264</td></tr><tr><td>glycolysis</td><td>GO:0006096</td><td>14</td><td>39</td><td>1.16E-07</td><td>0.359</td></tr><tr><td>Protein biosynthesis</td><td>GO:0006412</td><td>38</td><td>247</td><td>8.00E-07</td><td>0.154</td></tr><tr><td>transport</td><td>GO:0006810</td><td>50</td><td>415</td><td>8.94E-07</td><td>0.120</td></tr><tr><td>Protein metabolism</td><td>GO:0019538</td><td>9</td><td>17</td><td>4.90E-06</td><td>0.529</td></tr><tr><td>Protein folding</td><td>GO:0006457</td><td>28</td><td>174</td><td>5.59E-06</td><td>0.161</td></tr><tr><td>Ribosome biogenesis</td><td>GO:0007046</td><td>6</td><td>14</td><td>3.22E-05</td><td>0.429</td></tr><tr><td>metabolism</td><td>GO:0008152</td><td>39</td><td>316</td><td>9.36E-05</td><td>0.123</td></tr><tr><td>tRNA processing</td><td>GO:0008033</td><td>8</td><td>33</td><td>5.32E-04</td><td>0.242</td></tr><tr><td>Regulation of the cyclin dependent protein kinase activity</td><td>GO:0000079</td><td>8</td><td>34</td><td>9.72E-04</td><td>0.235</td></tr><tr><td>Amino acid biosynthesis</td><td>GO:0008652</td><td>6</td><td>22</td><td>1.01E-03</td><td>0.273</td></tr><tr><td>Lipid metabolism</td><td>GO:0006629</td><td>24</td><td>193</td><td>1.02E-03</td><td>0.124</td></tr><tr><td>Regulation of progression through cell cycle</td><td>GO:0000074</td><td>27</td><td>200</td><td>1.14E-03</td><td>0.135</td></tr><tr><td>Cell cycle</td><td>GO:0007049</td><td>41</td><td>338</td><td>1.64E-03</td><td>0.121</td></tr><tr><td>Regulation of translational initiation</td><td>GO:0006446</td><td>7</td><td>22</td><td>1.88E-03</td><td>0.318</td></tr><tr><td colspan="6">Most significant GO Molecular Function.</td></tr><tr><td>GO Term</td><td>GO ID</td><td>Changed Genes</td><td>Total Genes in Class</td><td>P-Value</td><td>Fraction</td></tr><tr><td>Nucleotide binding</td><td>GO:0000166</td><td>173</td><td>1405</td><td>6.92E-11</td><td>0.123</td></tr><tr><td>RNA binding</td><td>GO:0003723</td><td>78</td><td>389</td><td>4.22E-10</td><td>0.201</td></tr><tr><td>Oxidoreductase activity</td><td>GO:0016491</td><td>61</td><td>382</td><td>6.44E-10</td><td>0.160</td></tr><tr><td>ATP binding</td><td>GO:0005524</td><td>123</td><td>1116</td><td>1.20E-09</td><td>0.110</td></tr><tr><td>Unfolded protein binding</td><td>GO:0051082</td><td>28</td><td>143</td><td>2.68E-08</td><td>0.196</td></tr><tr><td>Protein binding</td><td>GO:0005515</td><td>220</td><td>2514</td><td>1.77E-07</td><td>0.088</td></tr><tr><td>Transferase activity</td><td>GO:0016740</td><td>101</td><td>958</td><td>1.86E-07</td><td>0.105</td></tr><tr><td>L-ascorbic acid binding</td><td>GO:0031418</td><td>6</td><td>11</td><td>1.65E-05</td><td>0.545</td></tr><tr><td>Lyase activity</td><td>GO:0016829</td><td>16</td><td>89</td><td>1.37E-04</td><td>0.180</td></tr><tr><td>binding</td><td>GO:0005488</td><td>47</td><td>399</td><td>2.37E-04</td><td>0.118</td></tr><tr><td>ATP-dependent RNA helicase activity</td><td>GO:0004004</td><td>7</td><td>18</td><td>4.61E-04</td><td>0.389</td></tr><tr><td>Isomerase activity</td><td>GO:0016853</td><td>15</td><td>90</td><td>5.54E-04</td><td>0.167</td></tr><tr><td>Ligase activity</td><td>GO:0016874</td><td>27</td><td>184</td><td>5.54E-04</td><td>0.147</td></tr><tr><td>Oxidoreductase activity</td><td>GO:0016702</td><td>6</td><td>18</td><td>6.72E-04</td><td>0.333</td></tr><tr><td>NAD binding</td><td>GO:0051287</td><td>8</td><td>24</td><td>7.05E-04</td><td>0.333</td></tr><tr><td>Catalytic activity</td><td>GO:0003824</td><td>27</td><td>192</td><td>7.40E-04</td><td>0.141</td></tr><tr><td>Transporter activity</td><td>GO:0005215</td><td>29</td><td>281</td><td>1.50E-03</td><td>0.103</td></tr><tr><td>Kinase activity</td><td>GO:0016301</td><td>22</td><td>163</td><td>1.65E-03</td><td>0.135</td></tr><tr><td>tRNA binding</td><td>GO:0000049</td><td>5</td><td>13</td><td>1.87E-03</td><td>0.385</td></tr><tr><td colspan="6">Most significant GO Cellular Component</td></tr><tr><td>GO Term</td><td>GO ID</td><td>Changed genes</td><td>Total genes in class</td><td>P-value</td><td>Fraction</td></tr><tr><td>cytoplasm</td><td>GO:0005737</td><td>114</td><td>895</td><td>5.00E-10</td><td>0.127</td></tr><tr><td>nucleus</td><td>GO:0005634</td><td>281</td><td>2999</td><td>5.00E-10</td><td>0.094</td></tr><tr><td>mitochondrion</td><td>GO:0005739</td><td>70</td><td>528</td><td>1.01E-09</td><td>0.133</td></tr><tr><td>endoplasmic reticulum</td><td>GO:0005783</td><td>49</td><td>405</td><td>2.47E-06</td><td>0.121</td></tr><tr><td>mitochondrial inner membrane presequence translocase complex</td><td>GO:0005744</td><td>5</td><td>11</td><td>2.82E-04</td><td>0.455</td></tr><tr><td>soluble fraction</td><td>GO:0005625</td><td>24</td><td>194</td><td>3.22E-04</td><td>0.124</td></tr><tr><td>nucleolus</td><td>GO:0005730</td><td>12</td><td>59</td><td>1.09E-03</td><td>0.203</td></tr></table>
<table><tr><td colspan="6">Most significant GO Biological Processes</td></tr><tr><td>GO Term</td><td>GO ID</td><td>Changed Genes</td><td>Total Genes in Class</td><td>P-Value</td><td>Fraction</td></tr><tr><td>Cholesterol biosynthesis</td><td>GO:0006695</td><td>12</td><td>20</td><td>7.04E-09</td><td>0.600</td></tr><tr><td>Nuclear mRNA splicing, via spliceosome</td><td>GO:0000398</td><td>29</td><td>110</td><td>9.77E-09</td><td>0.264</td></tr><tr><td>glycolysis</td><td>GO:0006096</td><td>14</td><td>39</td><td>1.16E-07</td><td>0.359</td></tr><tr><td>Protein biosynthesis</td><td>GO:0006412</td><td>38</td><td>247</td><td>8.00E-07</td><td>0.154</td></tr><tr><td>transport</td><td>GO:0006810</td><td>50</td><td>415</td><td>8.94E-07</td><td>0.120</td></tr><tr><td>Protein metabolism</td><td>GO:0019538</td><td>9</td><td>17</td><td>4.90E-06</td><td>0.529</td></tr><tr><td>Protein folding</td><td>GO:0006457</td><td>28</td><td>174</td><td>5.59E-06</td><td>0.161</td></tr><tr><td>Ribosome biogenesis</td><td>GO:0007046</td><td>6</td><td>14</td><td>3.22E-05</td><td>0.429</td></tr><tr><td>metabolism</td><td>GO:0008152</td><td>39</td><td>316</td><td>9.36E-05</td><td>0.123</td></tr><tr><td>tRNA processing</td><td>GO:0008033</td><td>8</td><td>33</td><td>5.32E-04</td><td>0.242</td></tr><tr><td>Regulation of the cyclin dependent protein kinase activity</td><td>GO:0000079</td><td>8</td><td>34</td><td>9.72E-04</td><td>0.235</td></tr><tr><td>Amino acid biosynthesis</td><td>GO:0008652</td><td>6</td><td>22</td><td>1.01E-03</td><td>0.273</td></tr><tr><td>Lipid metabolism</td><td>GO:0006629</td><td>24</td><td>193</td><td>1.02E-03</td><td>0.124</td></tr><tr><td>Regulation of progression through cell cycle</td><td>GO:0000074</td><td>27</td><td>200</td><td>1.14E-03</td><td>0.135</td></tr><tr><td>Cell cycle</td><td>GO:0007049</td><td>41</td><td>338</td><td>1.64E-03</td><td>0.121</td></tr><tr><td>Regulation of translational initiation</td><td>GO:0006446</td><td>7</td><td>22</td><td>1.88E-03</td><td>0.318</td></tr><tr><td colspan="6">Most significant GO Molecular Function.</td></tr><tr><td>GO Term</td><td>GO ID</td><td>Changed Genes</td><td>Total Genes in Class</td><td>P-Value</td><td>Fraction</td></tr><tr><td>Nucleotide binding</td><td>GO:0000166</td><td>173</td><td>1405</td><td>6.92E-11</td><td>0.123</td></tr><tr><td>RNA binding</td><td>GO:0003723</td><td>78</td><td>389</td><td>4.22E-10</td><td>0.201</td></tr><tr><td>Oxidoreductase activity</td><td>GO:0016491</td><td>61</td><td>382</td><td>6.44E-10</td><td>0.160</td></tr><tr><td>ATP binding</td><td>GO:0005524</td><td>123</td><td>1116</td><td>1.20E-09</td><td>0.110</td></tr><tr><td>Unfolded protein binding</td><td>GO:0051082</td><td>28</td><td>143</td><td>2.68E-08</td><td>0.196</td></tr><tr><td>Protein binding</td><td>GO:0005515</td><td>220</td><td>2514</td><td>1.77E-07</td><td>0.088</td></tr><tr><td>Transferase activity</td><td>GO:0016740</td><td>101</td><td>958</td><td>1.86E-07</td><td>0.105</td></tr><tr><td>L-ascorbic acid binding</td><td>GO:0031418</td><td>6</td><td>11</td><td>1.65E-05</td><td>0.545</td></tr><tr><td>Lyase activity</td><td>GO:0016829</td><td>16</td><td>89</td><td>1.37E-04</td><td>0.180</td></tr><tr><td>binding</td><td>GO:0005488</td><td>47</td><td>399</td><td>2.37E-04</td><td>0.118</td></tr><tr><td>ATP-dependent RNA helicase activity</td><td>GO:0004004</td><td>7</td><td>18</td><td>4.61E-04</td><td>0.389</td></tr><tr><td>I</td><td></td><td>15</td><td>90</td><td></td><td>0.16</td></tr></table>
<table><tr><td colspan="6">Most significant GO Biological Processes</td></tr><tr><td>somerase activity</td><td>GO:0016853</td><td></td><td></td><td>5.54E-04</td><td>7</td></tr><tr><td>Ligase activity</td><td>GO:0016874</td><td>27</td><td>184</td><td>5.54E-04</td><td>0.147</td></tr><tr><td>Oxidoreductase activity</td><td>GO:0016702</td><td>6</td><td>18</td><td>6.72E-04</td><td>0.333</td></tr><tr><td>NAD binding</td><td>GO:0051287</td><td>8</td><td>24</td><td>7.05E-04</td><td>0.333</td></tr><tr><td>Catalytic activity</td><td>GO:0003824</td><td>27</td><td>192</td><td>7.40E-04</td><td>0.141</td></tr><tr><td>Transporter activity</td><td>GO:0005215</td><td>29</td><td>281</td><td>1.50E-03</td><td>0.103</td></tr><tr><td>Kinase activity</td><td>GO:0016301</td><td>22</td><td>163</td><td>1.65E-03</td><td>0.135</td></tr><tr><td>tRNA binding</td><td>GO:0000049</td><td>5</td><td>13</td><td>1.87E-03</td><td>0.385</td></tr><tr><td colspan="6">Most significant GO Cellular Component</td></tr><tr><td>GO Term</td><td>GO ID</td><td>Changed genes</td><td>Total genes in class</td><td>P-value</td><td>Fraction</td></tr><tr><td>cytoplasm</td><td>GO:0005737</td><td>114</td><td>895</td><td>5.00E-10</td><td>0.127</td></tr><tr><td>nucleus</td><td>GO:0005634</td><td>281</td><td>2999</td><td>5.00E-10</td><td>0.094</td></tr><tr><td>mitochondrion</td><td>GO:0005739</td><td>70</td><td>528</td><td>1.01E-09</td><td>0.133</td></tr><tr><td>endoplasmic reticulum</td><td>GO:0005783</td><td>49</td><td>405</td><td>2.47E-06</td><td>0.121</td></tr><tr><td>mitochondrial inner membrane presequence translocase complex</td><td>GO:0005744</td><td>5</td><td>11</td><td>2.82E-04</td><td>0.455</td></tr><tr><td>soluble fraction</td><td>GO:0005625</td><td>24</td><td>194</td><td>3.22E-04</td><td>0.124</td></tr><tr><td>nucleolus</td><td>GO:0005730</td><td>12</td><td>59</td><td>1.09E-03</td><td>0.203</td></tr></table>
93b6a0568ab67bdea09f45bc798579fffe9df45946324a28cd2cdd33ae11b378.png
complex
<table><tr><td>Parameters</td><td colspan="2">Vildagliptin (n-29)</td><td>P value*</td><td colspan="2">Placebo (n-29)</td><td>P value*</td><td>P value<sup>+</sup></td></tr><tr><td></td><td>Pre treatment</td><td>Post treatment</td><td></td><td>Pre-treatment</td><td>Post treatment</td></tr><tr><td>Body weight(kg)</td><td>88&#177;11.3</td><td>79&#177;12.6</td><td>0.036</td><td>82 &#177;16.4</td><td>81&#177;12.4</td><td>0.74</td><td>0.04</td></tr><tr><td>BMI(kg/m<sup>2</sup>)</td><td>30.7&#177;4.2</td><td>27.5&#177;5.2</td><td>0.005</td><td>29.6 &#177;0.4</td><td>29.4&#177;0.7</td><td>0.88</td><td>0.028</td></tr><tr><td>TC (mg/dl)</td><td>252.6&#177;24.4</td><td>220.6&#177;20.2</td><td>0.031</td><td>260&#177; 28.5</td><td>262&#177;28.2</td><td>0.62</td><td>0.01</td></tr><tr><td>TG(mg/dl)</td><td>190&#177;24.9</td><td>115&#177;22.9</td><td>0.005</td><td>197&#177;21.2</td><td>199&#177;20.4</td><td>0.88</td><td>0.001</td></tr><tr><td>LDL-C(mg/dl</td><td>160&#177;15.24</td><td>145&#177;13.2</td><td>0.004</td><td>169&#177;12.8</td><td>167&#177;11.2</td><td>0.57</td><td>0.011</td></tr><tr><td>HDL-C(mg/dl)</td><td>29.6&#177;5.8</td><td>45.5&#177;4.9</td><td>0.001</td><td>28.3&#177;6.0</td><td>33&#177;6.2</td><td>0.98</td><td>0.02</td></tr><tr><td>ALT(IU/L)</td><td>78.2&#177;17.2</td><td>48.6&#177;14.8</td><td>0.036</td><td>76&#177;18.9</td><td>72&#177;2.2</td><td>0.76</td><td>0.04</td></tr><tr><td>AST(IU/L)</td><td>63.5&#177;10.5</td><td>41.5&#177; 9.6</td><td>0.002</td><td>61.2&#177;11.1</td><td>58&#177;10.5</td><td>0.81</td><td>0.001</td></tr><tr><td>GGT (IU/L)</td><td>18.5&#177;5.8</td><td>19.7&#177;7.7</td><td>0.62</td><td>19.7&#177;6.43</td><td>20.8&#177;7.5</td><td>0.43</td><td>0.67</td></tr></table>
<table><tr><td>Parameters</td><td colspan="2">Vildagliptin (n-29)</td><td>P value*</td><td colspan="2">Placebo (n-29)</td><td>P value*</td><td>P value+</td></tr><tr><td></td><td>Pre treatment</td><td>Post treatment</td><td></td><td>Pre-treatment</td><td>Post treatment</td><td colspan="2"></td></tr></table>
<table><tr><td>Body weight(kg)</td><td>88±11.3</td><td>79±12.6</td><td>0.036</td><td>82 ±16.4</td><td>81±12.4</td><td>0.74</td><td>0.04</td></tr><tr><td>BMI(kg/m2)</td><td>30.7±4.2</td><td>27.5±5.2</td><td>0.005</td><td>29.6 ±0.4</td><td>29.4±0.7</td><td>0.88</td><td>0.028</td></tr><tr><td>TC (mg/dl)</td><td>252.6±24.4</td><td>220.6±20.2</td><td>0.031</td><td>260± 28.5</td><td>262±28.2</td><td>0.62</td><td>0.01</td></tr><tr><td>TG(mg/dl)</td><td>190±24.9</td><td>115±22.9</td><td>0.005</td><td>197±21.2</td><td>199±20.4</td><td>0.88</td><td>0.001</td></tr><tr><td>LDL-C(mg/dl</td><td>160±15.24</td><td>145±13.2</td><td>0.004</td><td>169±12.8</td><td>167±11.2</td><td>0.57</td><td>0.011</td></tr><tr><td>HDL-C(mg/dl)</td><td>29.6±5.8</td><td>45.5±4.9</td><td>0.001</td><td>28.3±6.0</td><td>33±6.2</td><td>0.98</td><td>0.02</td></tr><tr><td>ALT(IU/L)</td><td>78.2±17.2</td><td>48.6±14.8</td><td>0.036</td><td>76±18.9</td><td>72±2.2</td><td>0.76</td><td>0.04</td></tr><tr><td>AST(IU/L)</td><td>63.5±10.5</td><td>41.5± 9.6</td><td>0.002</td><td>61.2±11.1</td><td>58±10.5</td><td>0.81</td><td>0.001</td></tr><tr><td>GGT (IU/L)</td><td>18.5±5.8</td><td>19.7±7.7</td><td>0.62</td><td>19.7±6.43</td><td>20.8±7.5</td><td>0.43</td><td>0.67</td></tr></table>
380704db9284ab8defc23b6e7acb8a958af471eaf8c870f9ef8e28829c6654a3.png
simple
<table><tr><td>Feature</td><td>Control group (A)</td><td>Study group (B)</td></tr><tr><td>Number of pin-sites</td><td>268</td><td>368</td></tr><tr><td>AO tubular external fixation</td><td>43</td><td>41</td></tr><tr><td>Unilateral rail</td><td>0</td><td>2</td></tr><tr><td>Ilizarov device</td><td>6</td><td>8</td></tr><tr><td>Pin tract infection (patients)<sup>a</sup></td><td>11 (22.5 %)</td><td>2 (4.1 %)</td></tr><tr><td>Pin tract infection (pin-sites)<sup>a</sup></td><td>38 (14.2 %)</td><td>7 (1.9 %)</td></tr></table>
<table><tr><td>Feature</td></tr><tr><td>Number of pin-sites</td></tr><tr><td>AO tubular external fixation</td></tr><tr><td>Unilateral rail</td></tr><tr><td>Ilizarov device</td></tr><tr><td>Pin tract infection (patients)a</td></tr><tr><td>Pin tract infection (pin-sites)a</td></tr></table>
<table><tr><td>Control group (A)</td><td>Study group (B)</td></tr><tr><td>268</td><td>368</td></tr><tr><td>43</td><td>41</td></tr><tr><td>0</td><td>2</td></tr><tr><td>6</td><td>8</td></tr><tr><td>11 (22.5 %)</td><td>2 (4.1 %)</td></tr><tr><td>38 (14.2 %)</td><td>7 (1.9 %)</td></tr></table>
6381676b6a4f28642224e4e0b695e0f88608b6726092f10efb2bd6c784f651a6.png
simple
<table><tr><td>Trials</td><td> </td><td>Intervention (<i>n</i>/<i>N</i>)</td><td>Control (<i>n</i>/<i>N</i>)</td><td>RR (95% CI)</td><td><i>P </i>value</td></tr><tr><td>LWDHW plus enalapril versus enalapril</td><td>1</td><td>34/42</td><td>21/36</td><td>3.04 (1.10, 8.38)</td><td>0.03</td></tr><tr><td>Meta-analysis</td><td>1</td><td>34/42</td><td>21/36</td><td>3.04 (1.10, 8.38)</td><td>0.03</td></tr></table>
<table><tr><td>Trials</td><td></td><td>Intervention (n/N)</td><td>Control (n/N)</td><td>RR (95% CI)</td><td>P value</td></tr><tr><td>LWDHW plus enalapril versus enalapril</td><td>1</td><td>34/42</td><td>21/36</td><td>3.04 (1.10, 8.38)</td><td>0.03</td></tr></table>
<table><tr><td>Meta-analysis</td><td>1</td><td>34/42</td><td>21/36</td><td>3.04 (1.10, 8.38)</td><td>0.03</td></tr></table>
16e67e3aaa3be8153f6dfe75c280e7d80a4e834613f55d4190f026e5012370d5.png
complex
<table><tr><td></td><td colspan="2">Non-hospitalsN = 191</td><td colspan="2">HospitalsN = 34</td><td>Chi-square (p-value)</td></tr><tr><td></td><td>Yesn (%)</td><td>Don't normally stockn (%)</td><td>Yesn (%)</td><td>Don't normally stockn (%)</td><td></td></tr><tr><td>AMT</td><td>17</td><td>18</td><td>2</td><td>13</td><td>23.0 (.0001)</td></tr><tr><td>CQ</td><td>111</td><td>1</td><td>5</td><td>1</td><td>20.4 (.0001)</td></tr><tr><td>Antibiotics</td><td>16</td><td>5</td><td>4</td><td>3</td><td>4.6 (.10)</td></tr><tr><td>SP</td><td>97</td><td>11</td><td>3</td><td>6</td><td>21.0 (.0001)</td></tr><tr><td>Quinine</td><td>17</td><td>25</td><td>5</td><td>9</td><td>7.5 (.023)</td></tr><tr><td>Halofantrine</td><td>24</td><td>28</td><td>3</td><td>14</td><td>15.9 (.0001)</td></tr><tr><td>Others</td><td>46</td><td>5</td><td>5</td><td>1</td><td>1.0 (.60)</td></tr></table>
<table><tr><td></td><td colspan="2">Non-hospitalsN = 191</td><td colspan="2">HospitalsN = 34</td><td>Chi-square (p-value)</td></tr><tr><td></td><td>Yesn (%)</td><td>Don't normally stockn (%)</td><td>Yesn (%)</td><td>Don't normally stockn (%)</td><td></td></tr><tr><td>AMT</td><td>17</td><td>18</td><td>2</td><td>13</td><td>23.0 (.0001)</td></tr><tr><td>CQ</td><td>111</td><td>1</td><td>5</td><td>1</td><td>20.4 (.0001)</td></tr></table>
<table><tr><td></td><td colspan="2">Non-hospitalsN = 191</td><td colspan="2">HospitalsN = 34</td><td>Chi-square (p-value)</td></tr><tr><td>Antibiotics</td><td>16</td><td>5</td><td>4</td><td>3</td><td>4.6 (.10)</td></tr><tr><td>SP</td><td>97</td><td>11</td><td>3</td><td>6</td><td>21.0 (.0001)</td></tr><tr><td>Quinine</td><td>17</td><td>25</td><td>5</td><td>9</td><td>7.5 (.023)</td></tr><tr><td>Halofantrine</td><td>24</td><td>28</td><td>3</td><td>14</td><td>15.9 (.0001)</td></tr><tr><td>Others</td><td>46</td><td>5</td><td>5</td><td>1</td><td>1.0 (.60)</td></tr></table>
ffe74f072a1af365443c483dc9d39e9f1c6152d70a581b6cb9802a45474b4daa.png
simple
<table><tr><td>Isolate</td><td>Collection</td><td>Country</td><td>Yr of entry into collection</td><td>Sequencing technology</td><td>Reference</td></tr><tr><td>NCTC86_Dunne</td><td>NCTC</td><td>England</td><td>1920</td><td>Pacific Biosciences RS II, Illumina</td><td>2</td></tr><tr><td>NCTC86_Meric</td><td>NCTC</td><td>England</td><td>1920</td><td>Illumina MiSeq</td><td>4</td></tr><tr><td>NCTC86</td><td>NCTC</td><td>England</td><td>1920</td><td>Illumina MiSeq</td><td>This study</td></tr><tr><td>CIP61.11</td><td>Centre de Ressources Biologiques de l&#8217;Institut Pasteur</td><td>France</td><td>1961</td><td>Illumina MiSeq</td><td>This study</td></tr><tr><td>ATCC 4157</td><td>ATCC</td><td>United States</td><td>Unknown</td><td>Illumina MiSeq</td><td>This study</td></tr><tr><td>DSM301</td><td>DSMZ</td><td>Germany</td><td>1970</td><td>Illumina MiSeq</td><td>This study</td></tr></table>
<table><tr><td>Isolate</td><td>Collection</td><td>Country</td><td>Yr of entry into collection</td><td>Sequencing technology</td></tr><tr><td>NCTC86_Dunne</td><td>NCTC</td><td>England</td><td>1920</td><td>Pacific Biosciences RS II, Illumina</td></tr><tr><td>NCTC86_Meric</td><td>NCTC</td><td>England</td><td>1920</td><td>Illumina MiSeq</td></tr><tr><td>NCTC86</td><td>NCTC</td><td>England</td><td>1920</td><td>Illumina MiSeq</td></tr><tr><td>CIP61.11</td><td>Centre de Ressources Biologiques de l’Institut Pasteur</td><td>France</td><td>1961</td><td>Illumina MiSeq</td></tr><tr><td>ATCC 4157</td><td>ATCC</td><td>United States</td><td>Unknown</td><td>Illumina MiSeq</td></tr><tr><td>DSM301</td><td>DSMZ</td><td>Germany</td><td>1970</td><td>Illumina MiSeq</td></tr></table>
<table><tr><td>Reference</td></tr><tr><td>2</td></tr><tr><td>4</td></tr><tr><td>This study</td></tr><tr><td>This study</td></tr><tr><td>This study</td></tr><tr><td>This study</td></tr></table>
8fdc3e31cafeac7499b63c876a68382c69f8536d05358fe8114d06e628b98f0b.png
complex
<table><tr><td></td><td colspan="2">Placebo (<i>N </i>= 112)</td><td colspan="2">25 mg/d Neramexane (<i>N </i>= 108)</td><td colspan="2">50 mg/d Neramexane (<i>N </i>= 107)</td><td colspan="2">75 mg/d Neramexane (<i>N </i>= 102)</td></tr><tr><td></td><td><i>n</i></td><td>%</td><td><i>n</i></td><td>%</td><td><i>n</i></td><td>%</td><td><i>n</i></td><td>%</td></tr><tr><td>Any adverse event</td><td>4</td><td>3.6</td><td>7</td><td>6.5</td><td>9</td><td>8.4</td><td>21</td><td>20.6</td></tr><tr><td> Dizziness</td><td>1</td><td>0.9</td><td>2</td><td>1.9</td><td>7</td><td>6.5</td><td>15</td><td>14.7</td></tr><tr><td> Vertigo</td><td>0</td><td>0.0</td><td>1</td><td>0.9</td><td>2</td><td>1.9</td><td>5</td><td>4.9</td></tr><tr><td> Nausea</td><td>0</td><td>0.0</td><td>0</td><td>0.0</td><td>0</td><td>0.0</td><td>2</td><td>2.0</td></tr><tr><td> Fatigue</td><td>0</td><td>0.0</td><td>0</td><td>0.0</td><td>0</td><td>0.0</td><td>3</td><td>2.9</td></tr></table>
<table><tr><td></td><td colspan="2">Placebo (N = 112)</td><td colspan="2">25 mg/d Neramexane (N = 108)</td><td colspan="2">50 mg/d Neramexane (N = 107)</td><td colspan="2">75 mg/d Neramexane (N = 102)</td></tr><tr><td></td><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td></tr></table>
<table><tr><td>Any adverse event</td><td>4</td><td>3.6</td><td>7</td><td>6.5</td><td>9</td><td>8.4</td><td>21</td><td>20.6</td></tr><tr><td>Dizziness</td><td>1</td><td>0.9</td><td>2</td><td>1.9</td><td>7</td><td>6.5</td><td>15</td><td>14.7</td></tr><tr><td>Vertigo</td><td>0</td><td>0.0</td><td>1</td><td>0.9</td><td>2</td><td>1.9</td><td>5</td><td>4.9</td></tr><tr><td>Nausea</td><td>0</td><td>0.0</td><td>0</td><td>0.0</td><td>0</td><td>0.0</td><td>2</td><td>2.0</td></tr><tr><td>Fatigue</td><td>0</td><td>0.0</td><td>0</td><td>0.0</td><td>0</td><td>0.0</td><td>3</td><td>2.9</td></tr></table>
e1f84b58e16d4ed114576f2274a11efc48770c7a3b7f22b5acb889cb8119d05d.png
complex
<table><tr><td colspan="6">Prevalence of elevated CRP (&gt;10 mg/L)</td></tr><tr><td>Group</td><td></td><td>%</td><td>Univariate p-value</td><td>Multivariate OR *</td><td>Multivariate p-value**</td></tr><tr><td>Age</td><td>&lt;50</td><td>14</td><td>0.49</td><td></td><td></td></tr><tr><td></td><td>50&#8211;59</td><td>13</td><td></td><td></td><td></td></tr><tr><td></td><td>60&#8211;69</td><td>13</td><td></td><td></td><td></td></tr><tr><td></td><td>70+</td><td>18</td><td></td><td></td><td></td></tr><tr><td>Sex</td><td>Male</td><td>14</td><td>0.28</td><td></td><td></td></tr><tr><td></td><td>Female</td><td>18</td><td></td><td></td><td></td></tr><tr><td>NIHSS</td><td>&lt;7</td><td>13</td><td>0.015</td><td>(ref)</td><td>0.03</td></tr><tr><td></td><td>7&#8211;13</td><td>25</td><td></td><td>2.15</td><td></td></tr><tr><td></td><td>14+</td><td>21</td><td></td><td>1.89</td><td></td></tr><tr><td>OCSP classification</td><td>LACI</td><td>15</td><td>0.005</td><td></td><td></td></tr><tr><td></td><td>TACI</td><td>26</td><td></td><td></td><td></td></tr><tr><td></td><td>PACI</td><td>10</td><td></td><td></td><td></td></tr><tr><td></td><td>POCI</td><td>19</td><td></td><td></td><td></td></tr><tr><td>Prior Cerebrovascular disease</td><td>No</td><td>16</td><td>0.97</td><td></td><td></td></tr><tr><td></td><td>Yes</td><td>16</td><td></td><td></td><td></td></tr><tr><td>Pre-existing diabetes mellitus</td><td>No</td><td>14</td><td>0.01</td><td>(ref)</td><td>0.04</td></tr><tr><td></td><td>Yes</td><td>27</td><td></td><td>1.96</td><td></td></tr><tr><td>Smoking habits</td><td>Never smoker</td><td>19</td><td>0.29</td><td></td><td></td></tr><tr><td></td><td>Former smoker</td><td>14</td><td></td><td></td><td></td></tr><tr><td></td><td>Current smoker</td><td>12</td><td></td><td></td><td></td></tr><tr><td>Time to hospital</td><td>&lt;3 hours</td><td>13</td><td>0.20</td><td></td><td></td></tr><tr><td></td><td>3&#8211;5.9 hours</td><td>20</td><td></td><td></td><td></td></tr><tr><td></td><td>6&#8211;11.9 hours</td><td>10</td><td></td><td></td><td></td></tr><tr><td></td><td>12&#8211;23.9 hours</td><td>18</td><td></td><td></td><td></td></tr><tr><td></td><td>Woke up with Stroke (&lt;24 hours)</td><td>17</td><td></td><td></td><td></td></tr><tr><td></td><td>Other (&lt;24 hours)</td><td>26</td><td></td><td></td><td></td></tr></table>
<table><tr><td colspan="4">Prevalence of elevated CRP (>10 mg/L)</td></tr><tr><td>Group</td><td></td><td>%</td><td>Univariate p-value</td></tr><tr><td>Age</td><td><50</td><td>14</td><td>0.49</td></tr><tr><td></td><td>50–59</td><td>13</td><td></td></tr><tr><td></td><td>60–69</td><td>13</td><td></td></tr><tr><td></td><td>70+</td><td>18</td><td></td></tr><tr><td>Sex</td><td>Male</td><td>14</td><td>0.28</td></tr><tr><td></td><td>Female</td><td>18</td><td></td></tr><tr><td>NIHSS</td><td><7</td><td>13</td><td>0.015</td></tr><tr><td></td><td>7–13</td><td>25</td><td></td></tr><tr><td></td><td>14+</td><td>21</td><td></td></tr><tr><td>OCSP classification</td><td>LACI</td><td>15</td><td>0.005</td></tr><tr><td></td><td>TACI</td><td>26</td><td></td></tr><tr><td></td><td>PACI</td><td>10</td><td></td></tr><tr><td></td><td>POCI</td><td>19</td><td></td></tr><tr><td>Prior Cerebrovascular disease</td><td>No</td><td>16</td><td>0.97</td></tr><tr><td></td><td>Yes</td><td>16</td><td></td></tr><tr><td>Pre-existing diabetes mellitus</td><td>No</td><td>14</td><td>0.01</td></tr><tr><td></td><td>Yes</td><td>27</td><td></td></tr><tr><td>Smoking habits</td><td>Never smoker</td><td>19</td><td>0.29</td></tr><tr><td></td><td>Former smoker</td><td>14</td><td></td></tr><tr><td></td><td>Current smoker</td><td>12</td><td></td></tr><tr><td>Time to hospital</td><td><3 hours</td><td>13</td><td>0.20</td></tr><tr><td></td><td>3–5.9 hours</td><td>20</td><td></td></tr><tr><td></td><td>6–11.9 hours</td><td>10</td><td></td></tr><tr><td></td><td>12–23.9 hours</td><td>18</td><td></td></tr><tr><td></td><td>Woke up with Stroke (<24 hours)</td><td>17</td><td></td></tr><tr><td></td><td>Other (<24 hours)</td><td>26</td><td></td></tr></table>
<table><tr><td colspan="2">Prevalence of elevated CRP (>10 mg/L)</td></tr><tr><td>Multivariate OR *</td><td>Multivariate p-value**</td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td>(ref)</td><td>0.03</td></tr><tr><td>2.15</td><td></td></tr><tr><td>1.89</td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td>(ref)</td><td>0.04</td></tr><tr><td>1.96</td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>
f9b1af56ad42e58079a2ac526a9004f8e369c969ab59730d6ad6aa68b3c7bf3d.png
complex
<table><tr><td> </td><td colspan="2">Insular cortex</td><td rowspan="2">Posterior cingulate cortex</td></tr><tr><td> </td><td>Right</td><td>Left</td></tr><tr><td>No. of participants</td><td>4</td><td>4</td><td>4</td></tr><tr><td>Peak latency (ms)</td><td>191.0 &#177; 10.6</td><td>184.0 &#177; 4.6</td><td>468.0 &#177; 13.5</td></tr><tr><td>GOF (%)</td><td>95.3 &#177; 2.1</td><td>93.5 &#177; 1.6</td><td>95.8 &#177; 1.5</td></tr><tr><td>Intensity (nA &#183; m)</td><td>25.0 &#177; 2.8</td><td>16.7 &#177; 2.5</td><td>16.4 &#177; 3.3</td></tr><tr><td>Locations*</td><td> </td><td> </td><td> </td></tr><tr><td> x (mm)</td><td>41.8 &#177; 2.7</td><td>&#8722;41.7 &#177; 3.1</td><td>&#8722;8.3 &#177; 2.6</td></tr><tr><td> y (mm)</td><td>&#8722;20.8 &#177; 4.2</td><td>&#8722;26.2 &#177; 6.1</td><td>&#8722;47.3 &#177; 5.0</td></tr><tr><td> z (mm)</td><td>8.9 &#177; 4.2</td><td>3.3 &#177; 7.9</td><td>25.7 &#177; 6.4</td></tr><tr><td>Orientations*</td><td> </td><td> </td><td> </td></tr><tr><td> &#952; (degrees)</td><td>43.6 &#177; 12.9</td><td>34.8 &#177; 5.7</td><td>116.5 &#177; 23.3</td></tr><tr><td> &#966; (degrees)</td><td>82.6 &#177; 9.3</td><td>99.7 &#177; 12.9</td><td>275.6 &#177; 56.1</td></tr></table>
<table><tr><td></td><td colspan="2">Insular cortex</td><td rowspan="2">Posterior cingulate cortex</td></tr><tr><td></td><td>Right</td><td>Left</td></tr><tr><td>No. of participants</td><td>4</td><td>4</td><td>4</td></tr><tr><td>Peak latency (ms)</td><td>191.0 ± 10.6</td><td>184.0 ± 4.6</td><td>468.0 ± 13.5</td></tr></table>
<table><tr><td>GOF (%)</td><td>95.3 ± 2.1</td><td>93.5 ± 1.6</td><td>95.8 ± 1.5</td></tr><tr><td>Intensity (nA · m)</td><td>25.0 ± 2.8</td><td>16.7 ± 2.5</td><td>16.4 ± 3.3</td></tr><tr><td>Locations*</td><td></td><td></td><td></td></tr><tr><td>x (mm)</td><td>41.8 ± 2.7</td><td>−41.7 ± 3.1</td><td>−8.3 ± 2.6</td></tr><tr><td>y (mm)</td><td>−20.8 ± 4.2</td><td>−26.2 ± 6.1</td><td>−47.3 ± 5.0</td></tr><tr><td>z (mm)</td><td>8.9 ± 4.2</td><td>3.3 ± 7.9</td><td>25.7 ± 6.4</td></tr><tr><td>Orientations*</td><td></td><td></td><td></td></tr><tr><td>θ (degrees)</td><td>43.6 ± 12.9</td><td>34.8 ± 5.7</td><td>116.5 ± 23.3</td></tr><tr><td>φ (degrees)</td><td>82.6 ± 9.3</td><td>99.7 ± 12.9</td><td>275.6 ± 56.1</td></tr></table>
12372347dd4830ec385018ef16b672975711a9e7d552437ad880f5300715b3f7.png
simple
<table><tr><td></td><td>Males (n = 196)</td><td>Females (n = 210)</td><td>Total (n = 406)</td></tr><tr><td>Career aspiration</td><td>Mean (SD)</td><td>Mean (SD)</td><td>Mean (SD)</td></tr><tr><td>Private practice (n = 192)</td><td>1.18 (1.44)</td><td>0.61 (0.98)</td><td>0.84 (1.22)</td></tr><tr><td>Hospital career (n = 172)</td><td>2.19 (2.16)</td><td>1.25 (1.41)</td><td>1.72 (1.88)</td></tr><tr><td>Academic career (n = 42)</td><td>6.66 (2.28)</td><td>4.78 (2.49)</td><td>6.24 (2.80)</td></tr><tr><td>Total (n = 406)</td><td>2.51 (2.77)</td><td>1.05 (1.51)</td><td>1.76 (2.33)</td></tr><tr><td>Effect</td><td>F</td><td>P</td><td>Partial eta squared</td></tr><tr><td>Gender</td><td>F(1,400) = 21.77</td><td>0.001</td><td>0.05</td></tr><tr><td>Career aspiration</td><td>F(2,400) = 101.61</td><td>&lt;0.001</td><td>0.34</td></tr><tr><td>Gender &#215; Career aspiration</td><td>F(2,400) = 2.04</td><td>0.131</td><td>0.01</td></tr></table>
<table><tr><td></td><td>Males (n = 196)</td><td>Females (n = 210)</td><td>Total (n = 406)</td></tr><tr><td>Career aspiration</td><td>Mean (SD)</td><td>Mean (SD)</td><td>Mean (SD)</td></tr><tr><td>Private practice (n = 192)</td><td>1.18 (1.44)</td><td>0.61 (0.98)</td><td>0.84 (1.22)</td></tr><tr><td>Hospital career (n = 172)</td><td>2.19 (2.16)</td><td>1.25 (1.41)</td><td>1.72 (1.88)</td></tr><tr><td>Academic career (n = 42)</td><td>6.66 (2.28)</td><td>4.78 (2.49)</td><td>6.24 (2.80)</td></tr><tr><td>Total (n = 406)</td><td>2.51 (2.77)</td><td>1.05 (1.51)</td><td>1.76 (2.33)</td></tr></table>
<table><tr><td></td><td>Males (n = 196)</td><td>Females (n = 210)</td><td>Total (n = 406)</td></tr><tr><td>Career aspiration</td><td>Mean (SD)</td><td>Mean (SD)</td><td>Mean (SD)</td></tr><tr><td>Effect</td><td>F</td><td>P</td><td>Partial eta squared</td></tr><tr><td>Gender</td><td>F(1,400) = 21.77</td><td>0.001</td><td>0.05</td></tr><tr><td>Career aspiration</td><td>F(2,400) = 101.61</td><td><0.001</td><td>0.34</td></tr><tr><td>Gender × Career aspiration</td><td>F(2,400) = 2.04</td><td>0.131</td><td>0.01</td></tr></table>
5398953270c4d87f2c9931e2d94a3ae6a987028ff05c6c0aaa16dbcca2a4c66d.png
simple
<table><tr><td></td><td>Odds ratio</td><td>95% Confidentialinterval</td><td><i>P</i>-value</td></tr><tr><td>Laboratory variables</td><td></td><td></td><td></td></tr><tr><td>Gamma-glutamyltranspeptidase, IU/L</td><td>1.009</td><td>0.953, 1.068</td><td>0.757</td></tr><tr><td>Cumulative dose of medications, mg</td><td></td><td></td><td></td></tr><tr><td>Leflunomide (53 patients)</td><td>1.000</td><td>1.000, 1.000</td><td>0.007</td></tr><tr><td>Prednisolone (89 patients)</td><td>1.000</td><td>1.000, 1.000</td><td>0.547</td></tr></table>
<table><tr><td></td><td>Odds ratio</td><td>95% Confidentialinterval</td><td>P-value</td></tr><tr><td>Laboratory variables</td><td></td><td></td><td></td></tr><tr><td>Gamma-glutamyltranspeptidase, IU/L</td><td>1.009</td><td>0.953, 1.068</td><td>0.757</td></tr></table>
<table><tr><td></td><td>Odds ratio</td><td>95% Confidentialinterval</td><td>P-value</td></tr><tr><td>Cumulative dose of medications, mg</td><td></td><td></td><td></td></tr><tr><td>Leflunomide (53 patients)</td><td>1.000</td><td>1.000, 1.000</td><td>0.007</td></tr><tr><td>Prednisolone (89 patients)</td><td>1.000</td><td>1.000, 1.000</td><td>0.547</td></tr></table>
618c16b01d28d2472741ae491f4bd5b2482cce3c2ca86f8cc8ca1d4f730afc27.png
simple
<table><tr><td>Clinical presentatiton</td><td>No. of patients</td><td>No. of episods</td><td>Time* (median/month)</td><td>Treatment</td></tr><tr><td>Cholangitis</td><td>5</td><td>9</td><td>19.5 (14&#8211;47)</td><td>Medical</td></tr><tr><td> -without real stricture</td><td>3</td><td>3</td><td>28.3</td><td>Medical</td></tr><tr><td> -with real stricture</td><td>2</td><td>6</td><td>15.5</td><td>Endoscopic (dilatation and/or stenting)</td></tr><tr><td>CBD stone</td><td>2</td><td>2</td><td>21.5 (16&#8211;27)</td><td>Endoscopic (stone extraction)</td></tr><tr><td>Total</td><td>7</td><td>11</td><td></td><td></td></tr></table>
<table><tr><td>Clinical present</td><td>No. of patien</td><td>No. of episods</td><td>Time* (median/month</td><td>Treatme</td></tr></table>
<table><tr><td>atiton</td><td>ts</td><td></td><td>)</td><td>nt</td></tr><tr><td>Cholangitis</td><td>5</td><td>9</td><td>19.5 (14–47)</td><td>Medical</td></tr><tr><td>-without real stricture</td><td>3</td><td>3</td><td>28.3</td><td>Medical</td></tr><tr><td>-with real stricture</td><td>2</td><td>6</td><td>15.5</td><td>Endoscopic (dilatation and/or stenting)</td></tr><tr><td>CBD stone</td><td>2</td><td>2</td><td>21.5 (16–27)</td><td>Endoscopic (stone extraction)</td></tr><tr><td>Total</td><td>7</td><td>11</td><td></td><td></td></tr></table>
f4468aef0d2094bef50b01cd4d4737674626fb82c87e5d1a6b0f8f83310754f1.png
complex
<table><tr><td> </td><td colspan="5">Awareness of ESCCAP Heartworm Guidelines</td><td> </td></tr><tr><td> </td><td colspan="5">Number clinics responding (% responding)</td><td> </td></tr><tr><td>Country</td><td>Not aware</td><td>Slightly aware</td><td>Moderately aware</td><td>Quite aware</td><td>Very aware</td><td>Responders</td></tr><tr><td>UK (non-endemic)</td><td>22 (67)</td><td>5 (15)</td><td>3 (9)</td><td>3 (9)</td><td>0 (0)</td><td>33</td></tr><tr><td>Germany (non-endemic)</td><td>40 (40)</td><td>38 (38)</td><td>20 (20)</td><td>3 (3)</td><td>0 (0)</td><td>101</td></tr><tr><td>Netherlands (non-endemic)</td><td>32 (94)</td><td>1 (3)</td><td>1 (3)</td><td>0 (0)</td><td>0 (0)</td><td>34</td></tr><tr><td>France (non-endemic)</td><td>63 (73)</td><td>9 (10)</td><td>10 (12)</td><td>2 (2)</td><td>2 (2)</td><td>86</td></tr><tr><td>France (endemic)</td><td>29 (62)</td><td>9 (19)</td><td>4 (9)</td><td>4 (9)</td><td>1 (2)</td><td>47</td></tr><tr><td>Spain (non-endemic)</td><td>25 (37)</td><td>13 (19)</td><td>22 (32)</td><td>6 (9)</td><td>2 (3)</td><td>68</td></tr><tr><td>Spain (endemic)</td><td>15 (37)</td><td>4 (10)</td><td>10 (24)</td><td>9 (22)</td><td>3 (7)</td><td>41</td></tr><tr><td>Italy (non-endemic)</td><td>35 (52)</td><td>11 (16)</td><td>14 (21)</td><td>5 (7)</td><td>2 (3)</td><td>67</td></tr><tr><td>Italy (endemic)</td><td>56 (52)</td><td>19 (18)</td><td>20 (19)</td><td>8 (7)</td><td>4 (4)</td><td>107</td></tr><tr><td>Total (non-endemic)</td><td>217 (56)</td><td>77 (20)</td><td>70 (18)</td><td>19 (5)</td><td>6 (2)</td><td>389</td></tr><tr><td>Total (endemic)</td><td>100 (51)</td><td>32 (16)</td><td>34 (17)</td><td>21 (11)</td><td>8 (4)</td><td>195</td></tr><tr><td>Total</td><td>317 (54)</td><td>109 (19)</td><td>104 (18)</td><td>40 (7)</td><td>14 (2)</td><td>584</td></tr></table>
<table><tr><td></td><td colspan="5">Awareness of ESCCAP Heartworm Guidelines</td><td></td></tr><tr><td></td><td colspan="5">Number clinics responding (% responding)</td><td></td></tr><tr><td>Country</td><td>Not aware</td><td>Slightly aware</td><td>Moderately aware</td><td>Quite aware</td><td>Very aware</td><td>Responders</td></tr><tr><td>UK (non-endemic)</td><td>22 (67)</td><td>5 (15)</td><td>3 (9)</td><td>3 (9)</td><td>0 (0)</td><td>33</td></tr><tr><td>Germany (non-endemic)</td><td>40 (40)</td><td>38 (38)</td><td>20 (20)</td><td>3 (3)</td><td>0 (0)</td><td>101</td></tr><tr><td>Netherlands (non-endemic)</td><td>32 (94)</td><td>1 (3)</td><td>1 (3)</td><td>0 (0)</td><td>0 (0)</td><td>34</td></tr><tr><td>France (non-endemic)</td><td>63 (73)</td><td>9 (10)</td><td>10 (12)</td><td>2 (2)</td><td>2 (2)</td><td>86</td></tr><tr><td>France (endemic)</td><td>29 (62)</td><td>9 (19)</td><td>4 (9)</td><td>4 (9)</td><td>1 (2)</td><td>47</td></tr><tr><td>Spain (non-endemic)</td><td>25 (37)</td><td>13 (19)</td><td>22 (32)</td><td>6 (9)</td><td>2 (3)</td><td>68</td></tr></table>
<table><tr><td></td><td colspan="5">Awareness of ESCCAP Heartworm Guidelines</td><td></td></tr><tr><td></td><td colspan="5">Number clinics responding (% responding)</td><td></td></tr><tr><td>Country</td><td>Not aware</td><td>Slightly aware</td><td>Moderately aware</td><td>Quite aware</td><td>Very aware</td><td>Responders</td></tr><tr><td>Spain (endemic)</td><td>15 (37)</td><td>4 (10)</td><td>10 (24)</td><td>9 (22)</td><td>3 (7)</td><td>41</td></tr><tr><td>Italy (non-endemic)</td><td>35 (52)</td><td>11 (16)</td><td>14 (21)</td><td>5 (7)</td><td>2 (3)</td><td>67</td></tr><tr><td>Italy (endemic)</td><td>56 (52)</td><td>19 (18)</td><td>20 (19)</td><td>8 (7)</td><td>4 (4)</td><td>107</td></tr><tr><td>Total (non-endemic)</td><td>217 (56)</td><td>77 (20)</td><td>70 (18)</td><td>19 (5)</td><td>6 (2)</td><td>389</td></tr><tr><td>Total (endemic)</td><td>100 (51)</td><td>32 (16)</td><td>34 (17)</td><td>21 (11)</td><td>8 (4)</td><td>195</td></tr><tr><td>Total</td><td>317 (54)</td><td>109 (19)</td><td>104 (18)</td><td>40 (7)</td><td>14 (2)</td><td>584</td></tr></table>
cdd86b7310d60f3433a4ee4a12383e6c5d2c7085adbaa542dd0086b9768e281f.png
simple
<table><tr><td>Type of model or algorithm</td><td>Target product</td><td>Model-based target: knockout gene A or overexpress gene B</td><td>References</td></tr><tr><td>Dynamic flux balance analysis</td><td>Ethanol</td><td>Ethanol production pathway after 20 h</td><td>[163]</td></tr><tr><td>Genome-scale metabolic model</td><td>Prediction of growth rate with respect to photosynthetic quotient for ethanol and butanol production</td><td>Double reaction knock out of hydrolyase and dehydrogenase</td><td>[164]</td></tr><tr><td>In vivo carbon flux analysis</td><td>Homolanthionine</td><td>Deletion of methionine and cysteine biosynthesis repressor protein</td><td>[165]</td></tr><tr><td>Metabolic flux analysis</td><td>Hydrogen production</td><td>Deletion and addition of GAP1 and dehydrogenase, respectively</td><td>[166]</td></tr><tr><td>Metabolic flux analysis</td><td>Astaxanthin synthesis</td><td>&#8211;</td><td>[167]</td></tr><tr><td>Metabolic flux analysis</td><td>Fixed more CO<sub>2</sub> and had a higher biomass yield</td><td>Alternate pathway for isoleucine synthesis (via citramalate synthase, CimA</td><td>[168]</td></tr><tr><td>Metabolic net fluxes</td><td>Hydrogen production</td><td>Disruption of hydrogenase and poly-&#946;-hydroxybutyrate synthase</td><td>[169]</td></tr></table>
<table><tr><td>Type of model or algorithm</td><td>Target product</td><td>Model-based target: knockout gene A or overexpress gene B</td><td>References</td></tr><tr><td>Dynamic flux balance analysis</td><td>Ethanol</td><td>Ethanol production pathway after 20 h</td><td>[163]</td></tr><tr><td>Genome-scale metabolic model</td><td>Prediction of growth rate with respect to photosynthetic quotient for ethanol and butanol production</td><td>Double reaction knock out of hydrolyase and dehydrogenase</td><td>[164]</td></tr><tr><td>In vivo carbon flux analysis</td><td>Homolanthionine</td><td>Deletion of methionine and cysteine biosynthesis repressor protein</td><td>[165]</td></tr><tr><td>Metabolic flux analysis</td><td>Hydrogen production</td><td>Deletion and addition of GAP1 and dehydrogenase, respectively</td><td>[166]</td></tr></table>
<table><tr><td>Type of model or algorithm</td><td>Target product</td><td>Model-based target: knockout gene A or overexpress gene B</td><td>References</td></tr><tr><td>Metabolic flux analysis</td><td>Astaxanthin synthesis</td><td>–</td><td>[167]</td></tr><tr><td>Metabolic flux analysis</td><td>Fixed more CO2 and had a higher biomass yield</td><td>Alternate pathway for isoleucine synthesis (via citramalate synthase, CimA</td><td>[168]</td></tr><tr><td>Metabolic net fluxes</td><td>Hydrogen production</td><td>Disruption of hydrogenase and poly-β-hydroxybutyrate synthase</td><td>[169]</td></tr></table>
fad23e29abf6cdc4ffe204b801328adc3cafc93637dbb245b0e76639af474f88.png
complex
<table><tr><td colspan="2">Severity of stress</td></tr><tr><td><i>n</i> = 85</td><td>%</td></tr><tr><td>Severe</td><td>33</td></tr><tr><td>Moderate</td><td>27</td></tr><tr><td>Extreme</td><td>22</td></tr><tr><td>None/light</td><td>8</td></tr><tr><td>Catastrophic</td><td>6</td></tr></table>
<table><tr><td>Severity of stress</td></tr><tr><td>n = 85</td></tr><tr><td>Severe</td></tr><tr><td>Moderate</td></tr><tr><td>Extreme</td></tr><tr><td>None/light</td></tr><tr><td>Catastrophic</td></tr></table>
<table><tr><td>Severity of stress</td></tr><tr><td>%</td></tr><tr><td>33</td></tr><tr><td>27</td></tr><tr><td>22</td></tr><tr><td>8</td></tr><tr><td>6</td></tr></table>
3083d5f0ce0722431af6d04c1bc0e68b248c0f818055bff9e2770c2759277424.png
complex
<table><tr><td colspan="2"> </td><td><i>N</i></td><td>%</td><td>Age (mean &#177; SD)</td></tr><tr><td rowspan="2">Sex</td><td>Male</td><td>50</td><td>54.0%</td><td rowspan="2">39.60 &#177; 7.32</td></tr><tr><td>Female</td><td>40</td><td>46.0%</td></tr></table>
<table><tr><td colspan="2"></td><td>N</td><td>%</td><td>Age (mean ± SD)</td></tr></table>
<table><tr><td rowspan="2">Sex</td><td>Male</td><td>50</td><td>54.0%</td><td rowspan="2">39.60 ± 7.32</td></tr><tr><td>Female</td><td>40</td><td>46.0%</td></tr></table>
c0003d710a380e3f0be04b76e5a38166bbafa883e1fa7839667c3510290c2410.png
complex
<table><tr><td> </td><td colspan="6">Any first-degree relative</td></tr><tr><td> </td><td colspan="3">History of cancer (any site)</td><td colspan="3">History of head and neck cancer</td></tr><tr><td> </td><td><sup>&#8225;</sup>No</td><td>Yes</td><td>OR (95% CI)<sup>&#8224;</sup></td><td><sup>&#167;</sup>No</td><td>Yes</td><td>OR (95% CI)<sup>&#8224;</sup></td></tr><tr><td> </td><td>Cases/controls</td><td>Cases/controls</td><td> </td><td>Cases/controls</td><td>Cases/controls</td><td> </td></tr><tr><td>Smoking</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Never</td><td>19/563</td><td>27/559</td><td>1.1 (0.6-2.1)</td><td>35/994</td><td>6/51</td><td>2.4 (1.0-7.0)</td></tr><tr><td>Ever</td><td>231/1002</td><td>306/1030</td><td>1.3 (1.1-1.5)</td><td>427/1785</td><td>58/104</td><td>2.7 (1.8-3.4)</td></tr><tr><td>Drinking</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>&#8804;2 glasses/day</td><td>75/961</td><td>75/954</td><td>0.9 (0.6-1.4)</td><td>123/1704</td><td>11/88</td><td>1.9 (1.0-3.5)</td></tr><tr><td>&gt;2 glasses/day</td><td>167/597</td><td>254/631</td><td>1.4 (1.0-1.8)</td><td>329/1066</td><td>52/67</td><td>2.6 (1.2-3.3)</td></tr><tr><td colspan="2">Smoking &amp; drinking</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>NS &amp; D &#8804;2 glasses/day</td><td>16/412</td><td>17/425</td><td>0.9 (0.4-1.9)</td><td>30/740</td><td>1/39</td><td>1.2 (0.3-4.7)</td></tr><tr><td>ES &amp; D &#8804;2 glasses/day</td><td>59/548</td><td>58/526</td><td>0.9 (0.6-1.4)</td><td>93/962</td><td>10/47</td><td>1.6 (1.0-3.9)</td></tr><tr><td>NS &amp; D &gt;2 glasses/day</td><td>3/147</td><td>8/129</td><td>2.7 (0.6-11.6)</td><td>5/248</td><td>4/10</td><td>18.8 (2.9-119.8)</td></tr><tr><td>ES &amp; D &gt;2 glasses/day</td><td>164/449</td><td>246/499</td><td>1.4 (1.0-1.8)</td><td>324/815</td><td>48/57</td><td>2.1 (1.3-2.9)</td></tr></table>
<table><tr><td></td><td colspan="6">Any first-degree relative</td></tr><tr><td></td><td colspan="3">History of cancer (any site)</td><td colspan="3">History of head and neck cancer</td></tr><tr><td></td><td>‡No</td><td>Yes</td><td>OR (95% CI)†</td><td>§No</td><td>Yes</td><td>OR (95% CI)†</td></tr><tr><td></td><td>Cases/controls</td><td>Cases/controls</td><td></td><td>Cases/controls</td><td>Cases/controls</td><td></td></tr><tr><td>Smoking</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Never</td><td>19/563</td><td>27/559</td><td>1.1 (0.6-2.1)</td><td>35/994</td><td>6/51</td><td>2.4 (1.0-7.0)</td></tr><tr><td>Ever</td><td>231/1002</td><td>306/1030</td><td>1.3 (1.1-1.5)</td><td>427/1785</td><td>58/104</td><td>2.7 (1.8-3.4)</td></tr><tr><td>Drinking</td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
<table><tr><td>≤2 glasses/day</td><td>75/961</td><td>75/954</td><td>0.9 (0.6-1.4)</td><td>123/1704</td><td>11/88</td><td>1.9 (1.0-3.5)</td></tr><tr><td>>2 glasses/day</td><td>167/597</td><td>254/631</td><td>1.4 (1.0-1.8)</td><td>329/1066</td><td>52/67</td><td>2.6 (1.2-3.3)</td></tr><tr><td colspan="2">Smoking & drinking</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>NS & D ≤2 glasses/day</td><td>16/412</td><td>17/425</td><td>0.9 (0.4-1.9)</td><td>30/740</td><td>1/39</td><td>1.2 (0.3-4.7)</td></tr><tr><td>ES & D ≤2 glasses/day</td><td>59/548</td><td>58/526</td><td>0.9 (0.6-1.4)</td><td>93/962</td><td>10/47</td><td>1.6 (1.0-3.9)</td></tr><tr><td>NS & D >2 glasses/day</td><td>3/147</td><td>8/129</td><td>2.7 (0.6-11.6)</td><td>5/248</td><td>4/10</td><td>18.8 (2.9-119.8)</td></tr><tr><td>ES & D >2 glasses/day</td><td>164/449</td><td>246/499</td><td>1.4 (1.0-1.8)</td><td>324/815</td><td>48/57</td><td>2.1 (1.3-2.9)</td></tr></table>
c5e9f5e53084f43e43157bbb2a3214b82d5b18ed96eb8b55675c289a2b50134f.png
complex
<table><tr><td rowspan="2">Variable</td><td colspan="3">Univariate analysis</td><td colspan="3">Multivariate analysis</td></tr><tr><td>HR</td><td>95% CI</td><td><i>P</i> value</td><td>HR</td><td>95% CI</td><td><i>P</i> value</td></tr><tr><td>Sex (Female, Male)</td><td>1.2533</td><td>0.7767-2.0222</td><td>0.3550</td><td colspan="3"></td></tr><tr><td>Age (&#8804; 60, &gt; 60)</td><td>0.6990</td><td>0.4635-1.0542</td><td>0.0876</td><td colspan="3"></td></tr><tr><td>Macroscopic types (Ul, Fu, Me)</td><td>1.0699</td><td>0.7665-1.4935</td><td>0.6912</td><td colspan="3"></td></tr><tr><td>Tumor location (Up, Mi, Lo)</td><td>0.9403</td><td>0.6827-1.2950</td><td>0.7061</td><td colspan="3"></td></tr><tr><td>Tumor size (&#8804; 5, &gt; 5)</td><td>2.3524</td><td>0.8957-2.0419</td><td>0.1510</td><td colspan="3"></td></tr><tr><td>pT (T1-2, T3-4)</td><td>1.3584</td><td>0.7046-2.6187</td><td>0.3604</td><td colspan="3"></td></tr><tr><td>pN (N0, N1-3)</td><td>2.0212</td><td>1.3201-3.0947</td><td>0.0012</td><td>1.8234</td><td>1.1259-2.9528</td><td>0.0146</td></tr><tr><td>Grade (G1, G2, G3)</td><td>1.0777</td><td>0.7912-1.4679</td><td>0.6352</td><td colspan="3"></td></tr><tr><td>Stage (I/IIA, IIB/IIIC)</td><td>1.9646</td><td>1.0188-3.7884</td><td>0.0438</td><td>1.3322</td><td>0.6337-2.8008</td><td>0.4493</td></tr><tr><td>ANO1 (Neg, Pos)</td><td>1.9141</td><td>1.2729-2.8782</td><td>0.0018</td><td>1.9031</td><td>1.2653-2.8624</td><td>0.0020</td></tr></table>
<table><tr><td rowspan="2">Variable</td><td colspan="2">Univariate analysis</td></tr><tr><td>HR</td><td>95% CI</td></tr><tr><td>Sex (Female, Male)</td><td>1.2533</td><td>0.7767-2.0222</td></tr><tr><td>Age (≤ 60, > 60)</td><td>0.6990</td><td>0.4635-1.0542</td></tr><tr><td>Macroscopic types (Ul, Fu, Me)</td><td>1.0699</td><td>0.7665-1.4935</td></tr><tr><td>Tumor location (Up, Mi, Lo)</td><td>0.9403</td><td>0.6827-1.2950</td></tr><tr><td>Tumor size (≤ 5, > 5)</td><td>2.3524</td><td>0.8957-2.0419</td></tr><tr><td>pT (T1-2, T3-4)</td><td>1.3584</td><td>0.7046-2.6187</td></tr><tr><td>pN (N0, N1-3)</td><td>2.0212</td><td>1.3201-3.0947</td></tr><tr><td>Grade (G1, G2, G3)</td><td>1.0777</td><td>0.7912-1.4679</td></tr><tr><td>Stage (I/IIA, IIB/IIIC)</td><td>1.9646</td><td>1.0188-3.7884</td></tr><tr><td>ANO1 (Neg, Pos)</td><td>1.9141</td><td>1.2729-2.8782</td></tr></table>
<table><tr><td>Univariate analysis</td><td colspan="3">Multivariate analysis</td></tr><tr><td>P value</td><td>HR</td><td>95% CI</td><td>P value</td></tr><tr><td>0.3550</td><td colspan="3"></td></tr><tr><td>0.0876</td><td colspan="3"></td></tr><tr><td>0.6912</td><td colspan="3"></td></tr><tr><td>0.7061</td><td colspan="3"></td></tr><tr><td>0.1510</td><td colspan="3"></td></tr><tr><td>0.3604</td><td colspan="3"></td></tr><tr><td>0.0012</td><td>1.8234</td><td>1.1259-2.9528</td><td>0.0146</td></tr><tr><td>0.6352</td><td colspan="3"></td></tr><tr><td>0.0438</td><td>1.3322</td><td>0.6337-2.8008</td><td>0.4493</td></tr><tr><td>0.0018</td><td>1.9031</td><td>1.2653-2.8624</td><td>0.0020</td></tr></table>
b3b07a886640a8b58e68ae35592f1e922b79e67902cad97fdee399bf49fac84d.png
complex
<table><tr><td></td><td colspan="2">Pre-VT SC-IAT</td><td colspan="2">Embodiment after first session of VT</td><td colspan="2">Embodiment after second session of VT</td><td colspan="2">Post-VT SC-IAT</td></tr><tr><td></td><td><i>M</i></td><td>SD</td><td><i>M</i></td><td>SD</td><td><i>M</i></td><td>SD</td><td><i>M</i></td><td>SD</td></tr><tr><td>Synch black</td><td>0.01</td><td>0.38</td><td>0.91</td><td>1.32</td><td>1.14</td><td>1.31</td><td>0.05</td><td>0.30</td></tr><tr><td>Synch white</td><td>-0.05</td><td>0.35</td><td>1.32</td><td>1.46</td><td>1.31</td><td>1.68</td><td>-0.01</td><td>0.37</td></tr><tr><td>Asynch black</td><td>0.01</td><td>0.44</td><td>-0.82</td><td>1.51</td><td>-0.39</td><td>1.71</td><td>-0.11</td><td>0.28</td></tr><tr><td>Asynch white</td><td>0.05</td><td>0.35</td><td>-0.93</td><td>1.46</td><td>-0.74</td><td>1.64</td><td>0.10</td><td>0.37</td></tr></table>
<table><tr><td></td><td colspan="2">Pre-VT SC-IAT</td><td colspan="2">Embodiment after first session of VT</td><td colspan="2">Embodiment after second session of VT</td><td colspan="2">Post-VT SC-IAT</td></tr><tr><td></td><td>M</td><td>SD</td><td>M</td><td>SD</td><td>M</td><td>SD</td><td>M</td><td>SD</td></tr><tr><td>Synch black</td><td>0.01</td><td>0.38</td><td>0.91</td><td>1.32</td><td>1.14</td><td>1.31</td><td>0.05</td><td>0.30</td></tr></table>
<table><tr><td></td><td colspan="2">Pre-VT SC-IAT</td><td colspan="2">Embodiment after first session of VT</td><td colspan="2">Embodiment after second session of VT</td><td colspan="2">Post-VT SC-IAT</td></tr><tr><td></td><td>M</td><td>SD</td><td>M</td><td>SD</td><td>M</td><td>SD</td><td>M</td><td>SD</td></tr><tr><td>Synch white</td><td>-0.05</td><td>0.35</td><td>1.32</td><td>1.46</td><td>1.31</td><td>1.68</td><td>-0.01</td><td>0.37</td></tr><tr><td>Asynch black</td><td>0.01</td><td>0.44</td><td>-0.82</td><td>1.51</td><td>-0.39</td><td>1.71</td><td>-0.11</td><td>0.28</td></tr><tr><td>Asynch white</td><td>0.05</td><td>0.35</td><td>-0.93</td><td>1.46</td><td>-0.74</td><td>1.64</td><td>0.10</td><td>0.37</td></tr></table>
73d2272368e805637c8c419454b12ec6b3d9752b8df7b76997ce03bd57032097.png
complex
<table><tr><td rowspan="3">Group</td><td rowspan="3">n</td><td rowspan="3">Age (year)</td><td rowspan="3">Infertility duration (year)</td><td rowspan="3">BMI</td><td colspan="4">Reproductive hormone level</td></tr><tr><td>FSH/IU&#183;L<sup>-1</sup></td><td>LH/IU&#183;L<sup>-1</sup></td><td>E2/pg&#183;mL<sup>-1</sup></td><td>T/mmol&#183;L<sup>-1</sup></td></tr><tr><td>LE group</td><td>52</td><td>26.4&#177;4.2</td><td>3.4&#177;1.1</td><td>22.4&#177;4.5</td><td>7.1&#177;1.5</td><td>5.7&#177;1.1</td><td>57.7&#177;13.5</td><td>1.41&#177;0.5</td></tr><tr><td>CC group</td><td>52</td><td>27.1&#177;4.7</td><td>3.2&#177;0.7</td><td>23.4&#177;1.5</td><td>6.9&#177;1.2</td><td>5.5&#177;0.9</td><td>54.5&#177;12.7</td><td>1.45&#177;0.3</td></tr><tr><td>LE + HMG group</td><td>52</td><td>27.7&#177;5.2</td><td>3.3&#177;1.3</td><td>22.6&#177;2.6</td><td>6.8&#177;1.1</td><td>5.9&#177;1.2</td><td>61.5&#177;15.8</td><td>1.42&#177;0.2</td></tr><tr><td>F</td><td>-</td><td>0.703</td><td>0.311</td><td>0.515</td><td>0.211</td><td>0.163</td><td>1.635</td><td>1.785</td></tr><tr><td>P</td><td>-</td><td>&gt;0.05</td><td>&gt;0.05</td><td>&gt;0.05</td><td>&gt;0.05</td><td>&gt;0.05</td><td>&gt;0.05</td><td>&gt;0.05</td></tr></table>
<table><tr><td rowspan="3">Group</td><td rowspan="3">n</td><td rowspan="3">Age (year)</td><td rowspan="3">Infertility duration (year)</td><td rowspan="3">BMI</td><td colspan="4">Reproductive hormone level</td></tr><tr><td>FSH/IU·L-1</td><td>LH/IU·L-1</td><td>E2/pg·mL-1</td><td>T/mmol·L-1</td></tr><tr><td colspan="4"></td></tr><tr><td>LE group</td><td>52</td><td>26.4±4.2</td><td>3.4±1.1</td><td>22.4±4.5</td><td>7.1±1.5</td><td>5.7±1.1</td><td>57.7±13.5</td><td>1.41±0.5</td></tr><tr><td>CC</td><td></td><td>27.1±4.</td><td>3.</td><td>23.4</td><td>6.9±1.</td><td>5.</td><td>54.5±12</td><td>1.45</td></tr></table>
<table><tr><td rowspan="3">Group</td><td rowspan="3">n</td><td rowspan="3">Age (year)</td><td rowspan="3">Infertility duration (year)</td><td rowspan="3">BMI</td><td colspan="4">Reproductive hormone level</td></tr><tr><td>FSH/IU·L-1</td><td>LH/IU·L-1</td><td>E2/pg·mL-1</td><td>T/mmol·L-1</td></tr><tr><td colspan="4"></td></tr><tr><td> group</td><td>52</td><td>7</td><td>2±0.7</td><td>±1.5</td><td>2</td><td>5±0.9</td><td>.7</td><td>±0.3</td></tr><tr><td>LE + HMG group</td><td>52</td><td>27.7±5.2</td><td>3.3±1.3</td><td>22.6±2.6</td><td>6.8±1.1</td><td>5.9±1.2</td><td>61.5±15.8</td><td>1.42±0.2</td></tr><tr><td>F</td><td>-</td><td>0.703</td><td>0.311</td><td>0.515</td><td>0.211</td><td>0.163</td><td>1.635</td><td>1.785</td></tr><tr><td>P</td><td>-</td><td>>0.05</td><td>>0.05</td><td>>0.05</td><td>>0.05</td><td>>0.05</td><td>>0.05</td><td>>0.05</td></tr></table>
42e3dae8597b8ff4119c06b0fa9007c1381c0894148373c0903d60356aa3643b.png
simple
<table><tr><td></td><td>Input type</td><td>Database update</td><td>Functional Database support</td><td>Multiple organism support</td><td>Limitations for input genes</td><td>Statistics</td></tr><tr><td>GeneSCF v1.1</td><td>List of genes</td><td>Real-time</td><td>KEGG, GO, Reactome and NCG</td><td>Yes</td><td>No upper or lower limit</td><td>FE test <sup>a</sup> &amp; FDR <sup>b</sup></td></tr><tr><td>GeneSCF v1.0</td><td>List of genes</td><td>Manual (preparation needed)</td><td>KEGG, GO, Reactome and NCG</td><td>No (<i>Homo sapiens</i>)</td><td>No upper or lower limit</td><td>FE test &amp; FDR</td></tr><tr><td>GOrilla</td><td>List of genes</td><td>Weekly auto-update</td><td>GO</td><td>Yes</td><td>No upper limit but has lower limit</td><td>FE test &amp; FDR</td></tr><tr><td>DAVID 6.7</td><td>List of genes</td><td>Last known update 2010)</td><td>KEGG, GO, Reactome and Biocarta</td><td>Yes</td><td>Upper limit 3000 and no lower limit</td><td>FE test &amp; FDR</td></tr></table>
<table><tr><td></td><td>Input type</td><td>Database update</td><td>Functional Database support</td><td>Multiple organism support</td><td>Limitations for input genes</td><td>Statistics</td></tr><tr><td>GeneSCF v</td><td>List of g</td><td>R</td><td>KEGG, GO, Reactome a</td><td></td><td>No upper or lower</td><td>FE </td></tr></table>
<table><tr><td>1.1</td><td>enes</td><td>eal-time</td><td>nd NCG</td><td>Yes</td><td> limit</td><td>test a & FDR b</td></tr><tr><td>GeneSCF v1.0</td><td>List of genes</td><td>Manual (preparation needed)</td><td>KEGG, GO, Reactome and NCG</td><td>No (Homo sapiens)</td><td>No upper or lower limit</td><td>FE test & FDR</td></tr><tr><td>GOrilla</td><td>List of genes</td><td>Weekly auto-update</td><td>GO</td><td>Yes</td><td>No upper limit but has lower limit</td><td>FE test & FDR</td></tr><tr><td>DAVID 6.7</td><td>List of genes</td><td>Last known update 2010)</td><td>KEGG, GO, Reactome and Biocarta</td><td>Yes</td><td>Upper limit 3000 and no lower limit</td><td>FE test & FDR</td></tr></table>
fb4326c5de8dcb7a40b870d7d2d857a601e0fa96bc0623091e22c74843293daa.png
complex
<table><tr><td>DHFR</td><td colspan="5">Regions (%)</td><td>Total N (%)</td></tr><tr><td>Repeat Type</td><td>Delhi</td><td>Nadiad</td><td>Panna</td><td>Chennai</td><td>Kamrup</td><td></td></tr><tr><td>Type 1</td><td>54.54</td><td>0</td><td>11.76</td><td>0</td><td>0</td><td>8 (11.26)</td></tr><tr><td>Type 2</td><td>36.34</td><td>100</td><td>76.47</td><td>100</td><td>100</td><td>60 (84.5)</td></tr><tr><td>Type 3</td><td>9.09</td><td>0</td><td>0</td><td>0</td><td>0</td><td>1 (1.4)</td></tr><tr><td>Type 4</td><td>0</td><td>0</td><td>11.76</td><td>0</td><td>0</td><td>2 (2.81)</td></tr><tr><td>Total (N)</td><td>11</td><td>3</td><td>17</td><td>19</td><td>21</td><td>71</td></tr><tr><td colspan="7">DHPS</td></tr><tr><td>Type A</td><td>10</td><td>10</td><td>0</td><td>5</td><td>21.05</td><td>9.27</td></tr><tr><td>Type B</td><td>90</td><td>85</td><td>83.34</td><td>90</td><td>26.31</td><td>75.25</td></tr><tr><td>Type C</td><td>0</td><td>0</td><td>5.55</td><td>5</td><td>0</td><td></td></tr><tr><td>Type D</td><td>0</td><td>5</td><td>5.55</td><td>0</td><td>15.79</td><td>5.15</td></tr><tr><td>Type E</td><td>0</td><td>0</td><td>0</td><td>0</td><td>10.52</td><td>2.06</td></tr><tr><td>Type F</td><td>0</td><td>0</td><td>0</td><td>0</td><td>10.52</td><td>2.06</td></tr><tr><td>Type G</td><td>0</td><td>0</td><td>5.55</td><td>0</td><td>10.52</td><td>3.09</td></tr><tr><td>Type H</td><td>0</td><td>0</td><td>0</td><td>0</td><td>5.26</td><td>1.03</td></tr><tr><td>Total (N)</td><td>20</td><td>20</td><td>18*</td><td>20</td><td>19*</td><td>97</td></tr></table>
<table><tr><td>DHFR</td><td colspan="5">Regions (%)</td><td>Total N (%)</td></tr><tr><td>Repeat Type</td><td>Delhi</td><td>Nadiad</td><td>Panna</td><td>Chennai</td><td>Kamrup</td><td></td></tr><tr><td>Type 1</td><td>54.54</td><td>0</td><td>11.76</td><td>0</td><td>0</td><td>8 (11.26)</td></tr><tr><td>Type 2</td><td>36.34</td><td>100</td><td>76.47</td><td>100</td><td>100</td><td>60 (84.5)</td></tr><tr><td>Type 3</td><td>9.09</td><td>0</td><td>0</td><td>0</td><td>0</td><td>1 (1.4)</td></tr><tr><td>Type 4</td><td>0</td><td>0</td><td>11.76</td><td>0</td><td>0</td><td>2 (2.81)</td></tr><tr><td>Total (N)</td><td>11</td><td>3</td><td>17</td><td>19</td><td>21</td><td>71</td></tr><tr><td colspan="7">DHPS</td></tr><tr><td>Type A</td><td>10</td><td>10</td><td>0</td><td>5</td><td>21.05</td><td>9.27</td></tr><tr><td>Type B</td><td>90</td><td>85</td><td>83.34</td><td>90</td><td>26.31</td><td>75.25</td></tr><tr><td>Type C</td><td>0</td><td>0</td><td>5.55</td><td>5</td><td>0</td><td></td></tr><tr><td>Type D</td><td>0</td><td>5</td><td>5.55</td><td>0</td><td>15.79</td><td>5.15</td></tr><tr><td>Type E</td><td>0</td><td>0</td><td>0</td><td>0</td><td>10.52</td><td>2.06</td></tr><tr><td>Type F</td><td>0</td><td>0</td><td>0</td><td>0</td><td>10.52</td><td>2.06</td></tr><tr><td>Type G</td><td>0</td><td>0</td><td>5.55</td><td>0</td><td>10.52</td><td>3.09</td></tr><tr><td>Type H</td><td>0</td><td>0</td><td>0</td><td>0</td><td>5.26</td><td>1.03</td></tr></table>
<table><tr><td>DHFR</td><td colspan="5">Regions (%)</td><td>Total N (%)</td></tr><tr><td>Repeat Type</td><td>Delhi</td><td>Nadiad</td><td>Panna</td><td>Chennai</td><td>Kamrup</td><td></td></tr><tr><td>Total (N)</td><td>20</td><td>20</td><td>18*</td><td>20</td><td>19*</td><td>97</td></tr></table>
7239276a48784427fd77c047178a18e8bec860617499717089cdaf0d34cfa400.png
simple
<table><tr><td>Items</td><td>Cronbach&#8217;s alpha if items were deleted</td></tr><tr><td>Physical functioning</td><td>0.845</td></tr><tr><td>Mental health</td><td>0.847</td></tr><tr><td>Vitality</td><td>0.849</td></tr><tr><td>Role physical</td><td>0.858</td></tr><tr><td>General health</td><td>0.853</td></tr><tr><td>Bodily pain</td><td>0.857</td></tr><tr><td>Role emotional</td><td>0.862</td></tr><tr><td>Social functioning</td><td>0.856</td></tr><tr><td>Educational rescue policy</td><td>0.871</td></tr><tr><td>Orphan rescue policy</td><td>0.871</td></tr><tr><td>Employment rescue policy</td><td>0.871</td></tr><tr><td>Poverty rescue policy</td><td>0.871</td></tr><tr><td>Social security policy</td><td>0.872</td></tr><tr><td>Legal rescue policy</td><td>0.872</td></tr></table>
<table><tr><td>Items</td></tr><tr><td>Physical functioning</td></tr><tr><td>Mental health</td></tr><tr><td>Vitality</td></tr><tr><td>Role physical</td></tr><tr><td>General health</td></tr><tr><td>Bodily pain</td></tr><tr><td>Role emotional</td></tr><tr><td>Social functioning</td></tr><tr><td>Educational rescue policy</td></tr><tr><td>Orphan rescue policy</td></tr><tr><td>Employment rescue policy</td></tr><tr><td>Poverty rescue policy</td></tr><tr><td>Social security policy</td></tr><tr><td>Legal rescue policy</td></tr></table>
<table><tr><td>Cronbach’s alpha if items were deleted</td></tr><tr><td>0.845</td></tr><tr><td>0.847</td></tr><tr><td>0.849</td></tr><tr><td>0.858</td></tr><tr><td>0.853</td></tr><tr><td>0.857</td></tr><tr><td>0.862</td></tr><tr><td>0.856</td></tr><tr><td>0.871</td></tr><tr><td>0.871</td></tr><tr><td>0.871</td></tr><tr><td>0.871</td></tr><tr><td>0.872</td></tr><tr><td>0.872</td></tr></table>
c18afd04261552ab10312747cee2a43ae0fe83363f72c79a0c45e72f051ee565.png
simple
<table><tr><td>Crude extract<sup>a</sup></td><td>Yield<sup>b</sup>(g)</td><td>Yield<sup>c</sup>(% of pollen sample)</td><td>Appearance</td></tr><tr><td><i>Corn bee pollen extracts</i></td><td> </td><td> </td><td> </td></tr><tr><td>CMEb</td><td>35.29</td><td>8.40</td><td>Dark brown sticky solid</td></tr><tr><td>CDEb</td><td>2.40</td><td>0.57</td><td>Dark brown solid</td></tr><tr><td>CHEb</td><td>18.13</td><td>4.32</td><td>Yellow solid</td></tr><tr><td><i>Floral corn pollen extracts</i></td><td> </td><td> </td><td> </td></tr><tr><td>CMEp</td><td>9.02</td><td>2.15</td><td>Dark brown solid</td></tr><tr><td>CDEp</td><td>4.82</td><td>1.15</td><td>Brown solid</td></tr><tr><td>CHEp</td><td>7.87</td><td>1.87</td><td>Dark green oil/wax</td></tr></table>
<table><tr><td>Crude extracta</td><td>Yieldb(g)</td><td>Yieldc(% of pollen sample)</td><td>Appearance</td></tr><tr><td>Corn bee pollen extracts</td><td></td><td></td><td></td></tr><tr><td>CMEb</td><td>35.29</td><td>8.40</td><td>Dark brown sticky solid</td></tr><tr><td>CDEb</td><td>2.40</td><td>0.57</td><td>Dark brown solid</td></tr><tr><td>CHEb</td><td>18.13</td><td>4.32</td><td>Yellow solid</td></tr><tr><td>Floral corn pollen extracts</td><td></td><td></td><td></td></tr></table>
<table><tr><td>Crude extracta</td><td>Yieldb(g)</td><td>Yieldc(% of pollen sample)</td><td>Appearance</td></tr><tr><td>CMEp</td><td>9.02</td><td>2.15</td><td>Dark brown solid</td></tr><tr><td>CDEp</td><td>4.82</td><td>1.15</td><td>Brown solid</td></tr><tr><td>CHEp</td><td>7.87</td><td>1.87</td><td>Dark green oil/wax</td></tr></table>
190cc89e660dfa4f641ab5861e88e9a0e80418d4f3a1f2c2f1eb6a9c7a9b02c5.png
complex
<table><tr><td>The Job stress Survey (JSS) Items</td><td>Lack of support leaders</td><td>Demanding job tasks</td><td>Time pressure</td><td>Lack of support co-workers</td></tr><tr><td>No participating in decisions</td><td>0.84</td><td><i>0.20</i></td><td><i>0.03</i></td><td><i>0.04</i></td></tr><tr><td>Lack recognition for good work</td><td>0.80</td><td><i>0.14</i></td><td><i>0.03</i></td><td><i>0.28</i></td></tr><tr><td>Poor or inadequate supervision</td><td>0.61</td><td><i>0.28</i></td><td><i>0.13</i></td><td><i>0.18</i></td></tr><tr><td>Difficult working with superior</td><td>0.81</td><td><i>0.16</i></td><td><i>0.17</i></td><td><i>0.19</i></td></tr><tr><td>Inadequate support by supervisor</td><td>0.57</td><td><i>0.24</i></td><td><i>0.19</i></td><td><i>0.25</i></td></tr><tr><td>Difficulty getting along with supervisor</td><td>0.79</td><td><i>0.01</i></td><td><i>0.19</i></td><td><i>0.22</i></td></tr><tr><td>Working overtime</td><td><i>0.16</i></td><td>0.56</td><td><i>0.05</i></td><td><i>0.12</i></td></tr><tr><td>Critical on the spot decisions</td><td><i>0.20</i></td><td>0.73</td><td><i>0.16</i></td><td><i>0.10</i></td></tr><tr><td>Assigned increased responsibility</td><td><i>0.32</i></td><td>0.62</td><td><i>0.19</i></td><td><i>0.11</i></td></tr><tr><td>Assignment of new duties</td><td><i>0.11</i></td><td>0.75</td><td><i>0.24</i></td><td><i>0.03</i></td></tr><tr><td>Perform duties not in job description</td><td><i>0.04</i></td><td>0.67</td><td><i>0.33</i></td><td><i>0.16</i></td></tr><tr><td>Frequent interruptions</td><td><i>0.26</i></td><td><i>0.28</i></td><td>0.53</td><td><i>0.42</i></td></tr><tr><td>Frequent change simple to demanding tasks</td><td><i>0.06</i></td><td><i>0.44</i></td><td>0.61</td><td><i>0.16</i></td></tr><tr><td>Excessive paperwork</td><td><i>0.09</i></td><td><i>0.19</i></td><td>0.79</td><td><i>0.12</i></td></tr><tr><td>Meeting deadline</td><td><i>0.06</i></td><td><i>0.20</i></td><td>0.82</td><td><i>0.14</i></td></tr><tr><td>Insufficient personal time</td><td><i>0.24</i></td><td><i>0.12</i></td><td>0.66</td><td><i>0.04</i></td></tr><tr><td>Fellow workers not doing job</td><td><i>0.26</i></td><td><i>0.21</i></td><td><i>0.01</i></td><td>0.77</td></tr><tr><td>Covering work for others</td><td><i>0.31</i></td><td><i>0.18</i></td><td><i>0.27</i></td><td>0.56</td></tr><tr><td>Poorly motivated co-workers</td><td><i>0.26</i></td><td><i>0.05</i></td><td><i>0.24</i></td><td>0.79</td></tr><tr><td>Sums of squared loadings</td><td>3.9</td><td>2.9</td><td>2.9</td><td>2.1</td></tr><tr><td>% variance</td><td>20.4</td><td>15.3</td><td>15.1</td><td>11.0</td></tr><tr><td colspan="2">The Norwegian Ambulance Stress Survey (NASS)</td><td>Non-Emergency tasks</td><td>Serious operational tasks</td><td>Physical demands</td></tr><tr><td>Hide feelings towards patients and relatives</td><td></td><td>0.83</td><td><i>0.13</i></td><td><i>0.16</i></td></tr><tr><td>Not being able to express own opinion to patients or relatives</td><td></td><td>0.82</td><td><i>0.08</i></td><td><i>0.19</i></td></tr><tr><td>Medical responsibility in the vehicle</td><td></td><td>0.63</td><td><i>0.34</i></td><td><i>0.17</i></td></tr><tr><td>Negative attitude from relatives about the job you are doing</td><td></td><td>0.60</td><td><i>0.29</i></td><td><i>0.07</i></td></tr><tr><td>The cumulative effect of frequently driving chronically ill patients</td><td></td><td>0.54</td><td><i>0.25</i></td><td><i>0.24</i></td></tr><tr><td>Take care of seriously injured and dying patients</td><td></td><td><i>0.52</i></td><td>0.57</td><td><i>0.15</i></td></tr><tr><td>Uncertainty about what you will meet on the scene of accident</td><td></td><td><i>0.51</i></td><td>0.60</td><td><i>0.11</i></td></tr><tr><td>Incident with seriously injured friend or people you know</td><td></td><td><i>0.19</i></td><td>0.73</td><td><i>0.12</i></td></tr><tr><td>Incident with seriously injured children</td><td></td><td><i>0.09</i></td><td>0.83</td><td><i>0.15</i></td></tr><tr><td>Deal with acting-out and threatening patients</td><td></td><td><i>0.18</i></td><td>0.70</td><td><i>0.22</i></td></tr><tr><td>Driving under difficult conditions</td><td></td><td><i>0.34</i></td><td>0.62</td><td><i>0.18</i></td></tr><tr><td>Heavy lifting</td><td></td><td><i>0.22</i></td><td><i>0.12</i></td><td>0.91</td></tr><tr><td>Carrying out the work under difficult conditions</td><td></td><td><i>0.20</i></td><td><i>0.22</i></td><td>0.91</td></tr><tr><td>Working in bent or twisted positions</td><td></td><td><i>0.18</i></td><td><i>0.25</i></td><td>0.87</td></tr><tr><td>Sums of squared loadings</td><td></td><td>3.3</td><td>3.2</td><td>2.7</td></tr><tr><td>% variance</td><td></td><td>23.3</td><td>22.7</td><td>19.3</td></tr></table>
<table><tr><td>The Job stress Survey (JSS) Items</td><td>Lack of support leaders</td><td>Demanding job tasks</td><td>Time pressure</td><td>Lack of support co-workers</td></tr><tr><td>No participating in decisions</td><td>0.84</td><td>0.20</td><td>0.03</td><td>0.04</td></tr><tr><td>Lack recognition for good work</td><td>0.80</td><td>0.14</td><td>0.03</td><td>0.28</td></tr><tr><td>Poor or inadequate supervision</td><td>0.61</td><td>0.28</td><td>0.13</td><td>0.18</td></tr><tr><td>Difficult working with superior</td><td>0.81</td><td>0.16</td><td>0.17</td><td>0.19</td></tr><tr><td>Inadequate support by supervisor</td><td>0.57</td><td>0.24</td><td>0.19</td><td>0.25</td></tr><tr><td>Difficulty getting along with supervisor</td><td>0.79</td><td>0.01</td><td>0.19</td><td>0.22</td></tr><tr><td>Working overtime</td><td>0.16</td><td>0.56</td><td>0.05</td><td>0.12</td></tr><tr><td>Critical on the spot decisions</td><td>0.20</td><td>0.73</td><td>0.16</td><td>0.10</td></tr><tr><td>Assigned increased responsibility</td><td>0.32</td><td>0.62</td><td>0.19</td><td>0.11</td></tr><tr><td>Assignment of new duties</td><td>0.11</td><td>0.75</td><td>0.24</td><td>0.03</td></tr><tr><td>Perform duties not in job description</td><td>0.04</td><td>0.67</td><td>0.33</td><td>0.16</td></tr><tr><td>Frequent interruptions</td><td>0.26</td><td>0.28</td><td>0.53</td><td>0.42</td></tr><tr><td>Frequent change simple to demanding tasks</td><td>0.06</td><td>0.44</td><td>0.61</td><td>0.16</td></tr><tr><td>Excessive paperwork</td><td>0.09</td><td>0.19</td><td>0.79</td><td>0.12</td></tr><tr><td>Meeting deadline</td><td>0.06</td><td>0.20</td><td>0.82</td><td>0.14</td></tr><tr><td>Insufficient personal time</td><td>0.24</td><td>0.12</td><td>0.66</td><td>0.04</td></tr><tr><td>Fellow workers not doing job</td><td>0.26</td><td>0.21</td><td>0.01</td><td>0.77</td></tr><tr><td>Covering work for others</td><td>0.31</td><td>0.18</td><td>0.27</td><td>0.56</td></tr><tr><td>Poorly motivated co-workers</td><td>0.26</td><td>0.05</td><td>0.24</td><td>0.79</td></tr><tr><td>Sums of squared loadings</td><td>3.9</td><td>2.9</td><td>2.9</td><td>2.1</td></tr><tr><td>% va</td><td>20.</td><td>15.3</td><td>15.1</td><td>11.</td></tr></table>
<table><tr><td>riance</td><td>4</td><td></td><td></td><td>0</td></tr><tr><td colspan="2">The Norwegian Ambulance Stress Survey (NASS)</td><td>Non-Emergency tasks</td><td>Serious operational tasks</td><td>Physical demands</td></tr><tr><td>Hide feelings towards patients and relatives</td><td></td><td>0.83</td><td>0.13</td><td>0.16</td></tr><tr><td>Not being able to express own opinion to patients or relatives</td><td></td><td>0.82</td><td>0.08</td><td>0.19</td></tr><tr><td>Medical responsibility in the vehicle</td><td></td><td>0.63</td><td>0.34</td><td>0.17</td></tr><tr><td>Negative attitude from relatives about the job you are doing</td><td></td><td>0.60</td><td>0.29</td><td>0.07</td></tr><tr><td>The cumulative effect of frequently driving chronically ill patients</td><td></td><td>0.54</td><td>0.25</td><td>0.24</td></tr><tr><td>Take care of seriously injured and dying patients</td><td></td><td>0.52</td><td>0.57</td><td>0.15</td></tr><tr><td>Uncertainty about what you will meet on the scene of accident</td><td></td><td>0.51</td><td>0.60</td><td>0.11</td></tr><tr><td>Incident with seriously injured friend or people you know</td><td></td><td>0.19</td><td>0.73</td><td>0.12</td></tr><tr><td>Incident with seriously injured children</td><td></td><td>0.09</td><td>0.83</td><td>0.15</td></tr><tr><td>Deal with acting-out and threatening patients</td><td></td><td>0.18</td><td>0.70</td><td>0.22</td></tr><tr><td>Driving under difficult conditions</td><td></td><td>0.34</td><td>0.62</td><td>0.18</td></tr><tr><td>Heavy lifting</td><td></td><td>0.22</td><td>0.12</td><td>0.91</td></tr><tr><td>Carrying out the work under difficult conditions</td><td></td><td>0.20</td><td>0.22</td><td>0.91</td></tr><tr><td>Working in bent or twisted positions</td><td></td><td>0.18</td><td>0.25</td><td>0.87</td></tr><tr><td>Sums of squared loadings</td><td></td><td>3.3</td><td>3.2</td><td>2.7</td></tr><tr><td>% variance</td><td></td><td>23.3</td><td>22.7</td><td>19.3</td></tr></table>
e97e56c55386a325297274d2706a9fa01c62ef42e4e6a962e6da8dcbf959dadc.png
complex
<table><tr><td></td><td>English 1st Language</td><td>N</td><td>Mean</td><td>SD</td><td>Age</td><td>N</td><td>Mean</td><td>SD</td><td>Student</td><td>N</td><td>Mean</td><td>SD</td></tr><tr><td rowspan="2">Sum 18 Item</td><td>Yes</td><td>229</td><td>37.96</td><td>7.72</td><td>Younger</td><td>133</td><td>38.56</td><td>7.66</td><td>Yes</td><td>114</td><td>38.19</td><td>7.99</td></tr><tr><td>No</td><td>28</td><td>39.57</td><td>9.37</td><td>Older</td><td>123</td><td>37.58</td><td>8.14</td><td>No</td><td>143</td><td>38.09</td><td>7.88</td></tr><tr><td rowspan="2">Sum Production</td><td>Yes</td><td>236</td><td>20.05</td><td>4.56</td><td>Younger</td><td>138</td><td>20.42</td><td>4.54</td><td>Yes</td><td>117</td><td>20.15</td><td>4.65</td></tr><tr><td>No</td><td>29</td><td>20.93</td><td>5.18</td><td>Older</td><td>126</td><td>19.80</td><td>4.71</td><td>No</td><td>148</td><td>20.14</td><td>4.63</td></tr><tr><td rowspan="2">Sum Perception</td><td>Yes</td><td>238</td><td>16.58</td><td>4.37</td><td>Younger</td><td>141</td><td>16.54</td><td>4.29</td><td>Yes</td><td>116</td><td>17.00</td><td>4.55</td></tr><tr><td>No</td><td>29</td><td>17.31</td><td>5.15</td><td>Older</td><td>125</td><td>16.75</td><td>4.63</td><td>No</td><td>151</td><td>16.40</td><td>4.38</td></tr><tr><td rowspan="2">Sum EQ</td><td>Yes</td><td>224</td><td>17.34</td><td>5.72</td><td>Younger</td><td>133</td><td>18.28*</td><td>5.40</td><td>Yes</td><td>112</td><td>17.35</td><td>5.87</td></tr><tr><td>No</td><td>29</td><td>19.28</td><td>5.85</td><td>Older</td><td>119</td><td>16.71*</td><td>6.05</td><td>No</td><td>141</td><td>17.73</td><td>5.68</td></tr></table>
<table><tr><td></td><td>English 1st Language</td><td>N</td><td>Mean</td><td>SD</td><td>Age</td><td>N</td><td>Mean</td><td>SD</td><td>Student</td><td>N</td><td>Mean</td><td>SD</td></tr><tr><td rowspan="2">Sum 18 Item</td><td>Yes</td><td>229</td><td>37.96</td><td>7.72</td><td>Younger</td><td>133</td><td>38.56</td><td>7.66</td><td>Yes</td><td>114</td><td>38.19</td><td>7.99</td></tr><tr><td>No</td><td>28</td><td>39.57</td><td>9.37</td><td>Older</td><td>123</td><td>37.58</td><td>8.14</td><td>No</td><td>143</td><td>38.09</td><td>7.88</td></tr><tr><td rowspan="2">Sum Production</td><td>Yes</td><td>236</td><td>20.05</td><td>4.56</td><td>Younger</td><td>138</td><td>20.42</td><td>4.54</td><td>Yes</td><td>117</td><td>20.15</td><td>4.65</td></tr><tr><td>No</td><td>29</td><td>20.93</td><td>5.18</td><td>Older</td><td>126</td><td>19.80</td><td>4.71</td><td>No</td><td>148</td><td>20.14</td><td>4.63</td></tr><tr><td rowspan="2">Sum Perception</td><td>Yes</td><td>238</td><td>16.58</td><td>4.37</td><td>Younger</td><td>141</td><td>16.54</td><td>4.29</td><td>Yes</td><td>116</td><td>17.00</td><td>4.55</td></tr><tr><td>No</td><td>29</td><td>17.31</td><td>5.15</td><td>Older</td><td>125</td><td>16.75</td><td>4.63</td><td>No</td><td>151</td><td>16.40</td><td>4.38</td></tr><tr><td>Sum EQ</td><td>Yes</td><td>224</td><td>17.34</td><td>5.72</td><td>Younger</td><td>133</td><td>18.28*</td><td>5.40</td><td>Yes</td><td>112</td><td>17.35</td><td>5.87</td></tr></table>
<table><tr><td>Sum EQ</td><td>No</td><td>29</td><td>19.28</td><td>5.85</td><td>Older</td><td>119</td><td>16.71*</td><td>6.05</td><td>No</td><td>141</td><td>17.73</td><td>5.68</td></tr></table>
768489888c11bc3bce26d86ba71a9f0944166ef169145243c0111e948f4ba6e5.png
simple
<table><tr><td>Cut-off</td><td>No of studies</td><td>Co-sensitivity (95 % CI)</td><td>Co-specificity (95 % CI)</td><td>I<sup>2</sup> (95%CI)</td><td>Pooled positive LR</td><td>Pooled negative LR</td></tr><tr><td>1.5 cm</td><td>1</td><td>0.93</td><td>0.16</td><td>&#8211;</td><td>1.1</td><td>0.43</td></tr><tr><td>2 cm</td><td>2</td><td>0.95, 1</td><td>0.41, 0.20</td><td>&#8211;</td><td>1.61, 1.25</td><td>0.12, 0</td></tr><tr><td>2.5 cm</td><td>3</td><td>0.79, 1, 0.84</td><td>0.84, 0.58, 0.66</td><td>&#8211;</td><td>4.93, 2.38, 2.47</td><td>0.25, 0, 0.24</td></tr><tr><td>3 cm</td><td>7</td><td>0.83, (0.56&#8211;0.95)</td><td>0.64, (0.45&#8211;0.79)</td><td>92, (86&#8211;99)</td><td>2.3, (1.5&#8211;3.5)</td><td>0.27, (0.1&#8211;0.74)</td></tr><tr><td>4 cm</td><td>6</td><td>0.56, (0.35&#8211;0.75)</td><td>0.85, (0.69&#8211;0.94)</td><td>94, (89&#8211;99)</td><td>3.8, (2.3&#8211;6.4)</td><td>0.51, (0.35&#8211;0.75)</td></tr><tr><td>5 cm</td><td>6</td><td>0.31, (0.14&#8211;0.57)</td><td>0.92, (0.80&#8211;0.97)</td><td>93, (86&#8211;99)</td><td>4, (1.9&#8211;8.3)</td><td>0.74, (0.56&#8211;0.98)</td></tr><tr><td>6 cm</td><td>6</td><td>0.32, (0.11&#8211;0.63)</td><td>0.92, (0.85&#8211;0.96)</td><td>92, (85&#8211;99)</td><td>4, (1.9&#8211;8.7)</td><td>0.74, (0.51&#8211;1.08)</td></tr></table>
<table><tr><td>Cut-off</td><td>No of studies</td><td>Co-sensitivity (95 % CI)</td><td>Co-specificity (95 % CI)</td><td>I2 (95%CI)</td><td>Pooled positive LR</td><td>Pooled negative LR</td></tr><tr><td>1.5 cm</td><td>1</td><td>0.93</td><td>0.16</td><td>–</td><td>1.1</td><td>0.43</td></tr><tr><td></td><td>2</td><td>0.</td><td>0.41</td><td></td><td>1.61, 1</td><td>0.12, </td></tr></table>
<table><tr><td>2 cm</td><td></td><td>95, 1</td><td>, 0.20</td><td>–</td><td>.25</td><td>0</td></tr><tr><td>2.5 cm</td><td>3</td><td>0.79, 1, 0.84</td><td>0.84, 0.58, 0.66</td><td>–</td><td>4.93, 2.38, 2.47</td><td>0.25, 0, 0.24</td></tr><tr><td>3 cm</td><td>7</td><td>0.83, (0.56–0.95)</td><td>0.64, (0.45–0.79)</td><td>92, (86–99)</td><td>2.3, (1.5–3.5)</td><td>0.27, (0.1–0.74)</td></tr><tr><td>4 cm</td><td>6</td><td>0.56, (0.35–0.75)</td><td>0.85, (0.69–0.94)</td><td>94, (89–99)</td><td>3.8, (2.3–6.4)</td><td>0.51, (0.35–0.75)</td></tr><tr><td>5 cm</td><td>6</td><td>0.31, (0.14–0.57)</td><td>0.92, (0.80–0.97)</td><td>93, (86–99)</td><td>4, (1.9–8.3)</td><td>0.74, (0.56–0.98)</td></tr><tr><td>6 cm</td><td>6</td><td>0.32, (0.11–0.63)</td><td>0.92, (0.85–0.96)</td><td>92, (85–99)</td><td>4, (1.9–8.7)</td><td>0.74, (0.51–1.08)</td></tr></table>
4a457cdd517762d49279d19b5e77dae518b03ed67ae52dcc5668b61a67fcb8f2.png
simple
<table><tr><td> </td><td>Men</td><td>Women</td><td>p-value*</td></tr><tr><td>Number of patients</td><td>289</td><td>284</td><td> </td></tr><tr><td>Number of deaths</td><td>41</td><td>21</td><td> </td></tr><tr><td>Number of admissions</td><td>1924</td><td>3139</td><td> </td></tr><tr><td>Total time of follow-up (person-years)</td><td>3420</td><td>3204</td><td> </td></tr><tr><td>Follow-up time in years (mean, SD)</td><td>11.8 (7.4)</td><td>11.3 (7.4)</td><td>0.37</td></tr><tr><td>Age at first admission in years (mean, SD)</td><td>31.2 (9.9)</td><td>30.2(12.2)</td><td>0.28</td></tr><tr><td>Total number of days admitted (median, 1 and 3 quartile)</td><td>70 (18.0, 214.5)</td><td>111 (25.3, 293.0)</td><td>0.013</td></tr><tr><td>Number of admissions (median, 1 and 3 quartile)</td><td>3 (1,8)</td><td>4 (2,1)</td><td>0.004</td></tr><tr><td>% with personality disorder as only diagnosis (N)</td><td>30.1 (89)</td><td>23.9 (68)</td><td>0.07</td></tr></table>
<table><tr><td></td><td></td><td></td><td>p-valu</td></tr></table>
<table><tr><td></td><td>Men</td><td>Women</td><td>e*</td></tr><tr><td>Number of patients</td><td>289</td><td>284</td><td></td></tr><tr><td>Number of deaths</td><td>41</td><td>21</td><td></td></tr><tr><td>Number of admissions</td><td>1924</td><td>3139</td><td></td></tr><tr><td>Total time of follow-up (person-years)</td><td>3420</td><td>3204</td><td></td></tr><tr><td>Follow-up time in years (mean, SD)</td><td>11.8 (7.4)</td><td>11.3 (7.4)</td><td>0.37</td></tr><tr><td>Age at first admission in years (mean, SD)</td><td>31.2 (9.9)</td><td>30.2(12.2)</td><td>0.28</td></tr><tr><td>Total number of days admitted (median, 1 and 3 quartile)</td><td>70 (18.0, 214.5)</td><td>111 (25.3, 293.0)</td><td>0.013</td></tr><tr><td>Number of admissions (median, 1 and 3 quartile)</td><td>3 (1,8)</td><td>4 (2,1)</td><td>0.004</td></tr><tr><td>% with personality disorder as only diagnosis (N)</td><td>30.1 (89)</td><td>23.9 (68)</td><td>0.07</td></tr></table>
a456d971532e7deb33a4a068b6ccc6ac85b538fdd784f444a8ac6aaa725493de.png
complex
<table><tr><td colspan="2">PBMS</td><td colspan="3">DMT status</td><td colspan="2"> </td></tr><tr><td colspan="2">Domains</td><td>pre-test</td><td>RCT</td><td>pos-</td><td colspan="2">p-value</td></tr><tr><td> </td><td>Sub-domains</td><td>without /with</td><td>without /with</td><td>sible range</td><td>pre</td><td>RCT</td></tr><tr><td colspan="2">1: Attitude</td><td>2.1 / 4.6</td><td>2.4 / 4.1</td><td>0-9</td><td>&lt;.01</td><td>&lt;.01</td></tr><tr><td> </td><td>a: expectations regarding outcomes</td><td>1.4 / 2.0</td><td>1.5 / 1.9</td><td>0-3</td><td>&lt;.01</td><td>&lt;.01</td></tr><tr><td> </td><td>b: values of expected outcomes</td><td>1.4 / 2.2</td><td>1.5 / 2.1</td><td>0-3</td><td>&lt;.01</td><td>&lt;.01</td></tr><tr><td colspan="2">2: Social norm</td><td>1.2 / 1.8</td><td>1.5 / 2.4</td><td>0-9</td><td>.23</td><td>&lt;.01</td></tr><tr><td> </td><td>a: assumed attitudes of important others</td><td>1.2 / 2.0</td><td>1.5 / 2.2</td><td>0-3</td><td>&lt;.01</td><td>&lt;.01</td></tr><tr><td> </td><td>b: motivation to comply with these norms</td><td>1.0 / .9</td><td>1.0 / 1.1</td><td>0-3</td><td>&lt;.01</td><td>.34</td></tr><tr><td colspan="2">3: Control beliefs</td><td>1.6 / 4.7</td><td>2.1 / 4.1</td><td>0-9</td><td>&lt;.01</td><td>&lt;.01</td></tr><tr><td> </td><td>a: assumed facilitators or barriers</td><td>1.0 / 2.1</td><td>1.2 / 1.9</td><td>0-3</td><td>&lt;.01</td><td>&lt;.01</td></tr><tr><td> </td><td>b: perceived power of these factors</td><td>1.4 / 2.2</td><td>1.5 / 2.0</td><td>0-3</td><td>&lt;.01</td><td>&lt;.01</td></tr><tr><td colspan="2">Intention estimate</td><td>4.8 / 11.1</td><td>6.0 / 10.1</td><td>0-27</td><td>&lt;.01</td><td>&lt;.01</td></tr></table>
<table><tr><td colspan="2">PBMS</td><td colspan="3">DMT status</td><td colspan="2"></td></tr><tr><td colspan="2">Domains</td><td>pre-test</td><td>RCT</td><td>pos-</td><td colspan="2">p-value</td></tr><tr><td></td><td></td><td></td><td>without /w</td><td></td><td>pr</td><td>RCT</td></tr></table>
<table><tr><td></td><td>Sub-domains</td><td>without /with</td><td>ith</td><td>sible range</td><td>e</td><td></td></tr><tr><td colspan="2">1: Attitude</td><td>2.1 / 4.6</td><td>2.4 / 4.1</td><td>0-9</td><td><.01</td><td><.01</td></tr><tr><td></td><td>a: expectations regarding outcomes</td><td>1.4 / 2.0</td><td>1.5 / 1.9</td><td>0-3</td><td><.01</td><td><.01</td></tr><tr><td></td><td>b: values of expected outcomes</td><td>1.4 / 2.2</td><td>1.5 / 2.1</td><td>0-3</td><td><.01</td><td><.01</td></tr><tr><td colspan="2">2: Social norm</td><td>1.2 / 1.8</td><td>1.5 / 2.4</td><td>0-9</td><td>.23</td><td><.01</td></tr><tr><td></td><td>a: assumed attitudes of important others</td><td>1.2 / 2.0</td><td>1.5 / 2.2</td><td>0-3</td><td><.01</td><td><.01</td></tr><tr><td></td><td>b: motivation to comply with these norms</td><td>1.0 / .9</td><td>1.0 / 1.1</td><td>0-3</td><td><.01</td><td>.34</td></tr><tr><td colspan="2">3: Control beliefs</td><td>1.6 / 4.7</td><td>2.1 / 4.1</td><td>0-9</td><td><.01</td><td><.01</td></tr><tr><td></td><td>a: assumed facilitators or barriers</td><td>1.0 / 2.1</td><td>1.2 / 1.9</td><td>0-3</td><td><.01</td><td><.01</td></tr><tr><td></td><td>b: perceived power of these factors</td><td>1.4 / 2.2</td><td>1.5 / 2.0</td><td>0-3</td><td><.01</td><td><.01</td></tr><tr><td colspan="2">Intention estimate</td><td>4.8 / 11.1</td><td>6.0 / 10.1</td><td>0-27</td><td><.01</td><td><.01</td></tr></table>
951d0c0551bc13f9e7483fefd1b901b0e6ed8a9ffbbd07f1772e02c06752c2a5.png
simple
<table><tr><td>SNP</td><td>Position</td><td>Alleles<sup>&#8224;</sup></td><td>MAF</td><td>Beta</td><td>s.e.</td><td><i>P</i></td><td><i>P</i><sub><i>emp</i></sub></td></tr><tr><td>rs1333049</td><td>22,115,503</td><td>C/G</td><td>0.421</td><td>0.0119</td><td>0.012</td><td>3.45E-01</td><td>3.44E-01</td></tr></table>
<table><tr><td>SNP</td><td>Position</td><td>Alleles†</td><td>MAF</td><td>Beta</td><td>s.e.</td><td>P</td><td>Pemp</td></tr></table>
<table><tr><td>rs1333049</td><td>22,115,503</td><td>C/G</td><td>0.421</td><td>0.0119</td><td>0.012</td><td>3.45E-01</td><td>3.44E-01</td></tr></table>
60c70fcd5d96f7d3fbd7a86998713df099ed8c97a4d471bcf4ef8c48435b0b5d.png
simple
<table><tr><td>Characteristics</td><td>Yes (%)</td><td>No (%)</td></tr><tr><td>Ever received an introduction into work place ergonomics</td><td>24 (14.7%)</td><td>136 (83.4%)</td></tr><tr><td>Ever experienced work-related musculoskeletal problems</td><td>123 (75.5%)</td><td>40 (24.5%)</td></tr><tr><td>Musculoskeletal problems in the last four weeks (n=123)</td><td>69 (56.1%)</td><td>53 (43.1%)</td></tr><tr><td>Signed off due musculoskeletal problems last year (n=123)</td><td>11 (8.9%)</td><td>112 (91.1%)</td></tr><tr><td>Doing regularly short breaks for stretching exercises</td><td>36 (22.1%)</td><td>124 (76.1%)</td></tr><tr><td>Any known ametropia</td><td>145 (89.0%)</td><td>17 (10.4%)</td></tr><tr><td>Aggravation of ametropia since working in pathology (n=145)</td><td>82 (56.6%)</td><td>58 (40.0%)</td></tr><tr><td>Eye fatigue symptoms in the last month</td><td>90 (55.2%)</td><td>68 (41.7%)</td></tr><tr><td>Ever experienced occupational injuries in pathology</td><td>135 (82.8%)</td><td>28 (17.2%)</td></tr><tr><td>Experienced such injuries in the last year (n=135)</td><td>37 (27.4%)</td><td>95 (70.4%)</td></tr><tr><td>Remaining permanent damages from such injuries (n=135)</td><td>5 (3.7%)</td><td>127 (94.1%)</td></tr><tr><td>Ever experienced intolerance reactions against formalin</td><td>41 (25.2%)</td><td>118 (72.4%)</td></tr><tr><td>Any known allergy</td><td>55 (33.7%)</td><td>105 (64.4%)</td></tr><tr><td>Since working in pathology ever diseased with...</td><td> </td><td> </td></tr><tr><td>Tuberculosis</td><td>2 (1.2%)</td><td>153 (93.9%)</td></tr><tr><td>Positive tuberculin test only</td><td>31 (19.0%)</td><td>119 (73.0%)</td></tr><tr><td>Hepatitis B</td><td>1 (0.6%)</td><td>154 (94.5%)</td></tr><tr><td>Hepatitis C</td><td>0 (0.0%)</td><td>155 (95.1%)</td></tr><tr><td>HIV</td><td>0 (0.0%)</td><td>154 (94.5%)</td></tr><tr><td>Burnout</td><td>14 (8.6%)</td><td>141 (86.5%)</td></tr><tr><td>Depression</td><td>11 (6.7%)</td><td>144 (88.3%)</td></tr><tr><td>Hypertension</td><td>11 (6.7%)</td><td>144 (88.3%)</td></tr><tr><td>Diabetes mellitus type II</td><td>3 (1.8%)</td><td>152 (93.2%)</td></tr><tr><td>Malignancies</td><td>3 (1.8%)</td><td>149 (91.4%)</td></tr><tr><td>Sufficient hepatitis B immunisation</td><td>153 (93.9%)</td><td>9 (5.5%)</td></tr><tr><td>Ever received BCG (tuberculosis) immunisation</td><td>128 (78.5%)</td><td>31 (19.0%)</td></tr><tr><td>Smoking</td><td>17 (10.4%)</td><td>145 (89.0%)</td></tr><tr><td>Cut-resistant gloves available at workplace</td><td>99 (60.7%)</td><td>60 (36.8%)</td></tr><tr><td>Regular personal use of cut-resistant gloves at dissections/autopsies</td><td>39 (23.9%)</td><td>108 (66.3%)</td></tr><tr><td>Extraction of air in the dissection room considered sufficient</td><td>94 (57.7%)</td><td>66 (40.5%)</td></tr></table>
<table><tr><td>Characteristics</td><td>Yes (%)</td><td>No (%)</td></tr><tr><td>Ever received an introduction into work place ergonomics</td><td>24 (14.7%)</td><td>136 (83.4%)</td></tr><tr><td>Ever experienced work-related musculoskeletal problems</td><td>123 (75.5%)</td><td>40 (24.5%)</td></tr><tr><td>Musculoskeletal problems in the last four weeks (n=123)</td><td>69 (56.1%)</td><td>53 (43.1%)</td></tr><tr><td>Signed off due musculoskeletal problems last year (n=123)</td><td>11 (8.9%)</td><td>112 (91.1%)</td></tr><tr><td>Doing regularly short breaks for stretching exercises</td><td>36 (22.1%)</td><td>124 (76.1%)</td></tr><tr><td>Any known ametropia</td><td>145 (89.0%)</td><td>17 (10.4%)</td></tr><tr><td>Aggravation of ametropia since working in pathology (n=145)</td><td>82 (56.6%)</td><td>58 (40.0%)</td></tr><tr><td>Eye fatigue symptoms in the last month</td><td>90 (55.2%)</td><td>68 (41.7%)</td></tr></table>
<table><tr><td>Ever experienced occupational injuries in pathology</td><td>135 (82.8%)</td><td>28 (17.2%)</td></tr><tr><td>Experienced such injuries in the last year (n=135)</td><td>37 (27.4%)</td><td>95 (70.4%)</td></tr><tr><td>Remaining permanent damages from such injuries (n=135)</td><td>5 (3.7%)</td><td>127 (94.1%)</td></tr><tr><td>Ever experienced intolerance reactions against formalin</td><td>41 (25.2%)</td><td>118 (72.4%)</td></tr><tr><td>Any known allergy</td><td>55 (33.7%)</td><td>105 (64.4%)</td></tr><tr><td>Since working in pathology ever diseased with...</td><td></td><td></td></tr><tr><td>Tuberculosis</td><td>2 (1.2%)</td><td>153 (93.9%)</td></tr><tr><td>Positive tuberculin test only</td><td>31 (19.0%)</td><td>119 (73.0%)</td></tr><tr><td>Hepatitis B</td><td>1 (0.6%)</td><td>154 (94.5%)</td></tr><tr><td>Hepatitis C</td><td>0 (0.0%)</td><td>155 (95.1%)</td></tr><tr><td>HIV</td><td>0 (0.0%)</td><td>154 (94.5%)</td></tr><tr><td>Burnout</td><td>14 (8.6%)</td><td>141 (86.5%)</td></tr><tr><td>Depression</td><td>11 (6.7%)</td><td>144 (88.3%)</td></tr><tr><td>Hypertension</td><td>11 (6.7%)</td><td>144 (88.3%)</td></tr><tr><td>Diabetes mellitus type II</td><td>3 (1.8%)</td><td>152 (93.2%)</td></tr><tr><td>Malignancies</td><td>3 (1.8%)</td><td>149 (91.4%)</td></tr><tr><td>Sufficient hepatitis B immunisation</td><td>153 (93.9%)</td><td>9 (5.5%)</td></tr><tr><td>Ever received BCG (tuberculosis) immunisation</td><td>128 (78.5%)</td><td>31 (19.0%)</td></tr><tr><td>Smoking</td><td>17 (10.4%)</td><td>145 (89.0%)</td></tr><tr><td>Cut-resistant gloves available at workplace</td><td>99 (60.7%)</td><td>60 (36.8%)</td></tr><tr><td>Regular personal use of cut-resistant gloves at dissections/autopsies</td><td>39 (23.9%)</td><td>108 (66.3%)</td></tr><tr><td>Extraction of air in the dissection room considered sufficient</td><td>94 (57.7%)</td><td>66 (40.5%)</td></tr></table>
a8dd9ca21cebccbb1c9f3642fc8a95e33a972dffe40c5f20b6d7e0bf6cfa8cb2.png
simple
<table><tr><td>Method Label</td><td>Method Description</td><td>Library used within R statistical software</td><td>Number of iterations</td></tr><tr><td>CC</td><td>Complete case analysis: Analyses only cases with complete data for all covariates</td><td></td><td>-</td></tr><tr><td>SI</td><td>Single imputation performed using PMM</td><td>'<i>pmm</i>' function in 'mice'</td><td>20</td></tr><tr><td>MI-NORM</td><td>Multiple imputation (MI) using data augmentation approach [31] with a multivariate normal assumption for all variables</td><td>'norm' [41]</td><td>100</td></tr><tr><td>MI-MIX</td><td>MI using data augmentation approach using a general location model</td><td>'mix' [42]</td><td>100</td></tr><tr><td>MI-MIX-no truncating</td><td>MI using data augmentation approach using a general location model, but imputed values are not truncated to within plausible range</td><td>'mix' [42]</td><td>100</td></tr><tr><td>MI-MICE</td><td>MI using regression switching imputation [9]. Linear model are used for continuous covariates and logistic model for binary covariates and dummy variables for categorical covariates</td><td>'mice' [43]</td><td>20</td></tr><tr><td>MI-MICE-PMM</td><td>MI using MICE with PMM</td><td>'<i>pmm</i>' function in 'mice' [43]</td><td>20</td></tr><tr><td>MI-MICE-PMM-no transformation</td><td>MI using MICE with PMM without transforming the incomplete covariates</td><td>'<i>pmm</i>' function in 'mice' [43]</td><td>20</td></tr><tr><td>MI-Aregimpute</td><td>MI using flexible additive imputation models [20] with PMM</td><td>'<i>aregImpute</i>' function in 'Hmisc' [44]</td><td>1</td></tr></table>
<table><tr><td>Method Label</td><td>Method Description</td><td>Library used within R statistical software</td><td>Number of iterations</td></tr><tr><td>CC</td><td>Complete case analysis: Analyses only cases with complete data for all covariates</td><td></td><td>-</td></tr><tr><td>SI</td><td>Single imputation performed using PMM</td><td>'pmm' function in 'mice'</td><td>20</td></tr></table>
<table><tr><td>MI-NORM</td><td>Multiple imputation (MI) using data augmentation approach [31] with a multivariate normal assumption for all variables</td><td>'norm' [41]</td><td>100</td></tr><tr><td>MI-MIX</td><td>MI using data augmentation approach using a general location model</td><td>'mix' [42]</td><td>100</td></tr><tr><td>MI-MIX-no truncating</td><td>MI using data augmentation approach using a general location model, but imputed values are not truncated to within plausible range</td><td>'mix' [42]</td><td>100</td></tr><tr><td>MI-MICE</td><td>MI using regression switching imputation [9]. Linear model are used for continuous covariates and logistic model for binary covariates and dummy variables for categorical covariates</td><td>'mice' [43]</td><td>20</td></tr><tr><td>MI-MICE-PMM</td><td>MI using MICE with PMM</td><td>'pmm' function in 'mice' [43]</td><td>20</td></tr><tr><td>MI-MICE-PMM-no transformation</td><td>MI using MICE with PMM without transforming the incomplete covariates</td><td>'pmm' function in 'mice' [43]</td><td>20</td></tr><tr><td>MI-Aregimpute</td><td>MI using flexible additive imputation models [20] with PMM</td><td>'aregImpute' function in 'Hmisc' [44]</td><td>1</td></tr></table>
74c4216008f360e0cafe5770b3497d4b343537f94c6189aa159773f00a3e5bb9.png
simple
<table><tr><td>Case No.</td><td>Age(yrs)</td><td>FIGO score</td><td>AP</td><td>Interval time (mons)</td><td>Pretreatment serum &#946;-hCG level</td><td>Site of metastases</td><td>Chemotherapy</td><td>Cause of death</td></tr><tr><td>1</td><td>53</td><td>15</td><td>Abortion</td><td>180</td><td>99000.0</td><td>Lung/brain/kidney</td><td>Not done</td><td>Brain hemorrhage, respiratory failure</td></tr><tr><td>2</td><td>30</td><td>21</td><td>Abortion</td><td>10</td><td>906720.0</td><td>Lung/brain/liver/kidney</td><td>Not done</td><td>Septic shock</td></tr><tr><td>3</td><td>31</td><td>8</td><td>Mole</td><td>32</td><td>80.0</td><td>Lung/brain</td><td>5-FU*1d</td><td>Brain herniation</td></tr><tr><td>4</td><td>25</td><td>12</td><td>Mole</td><td>27</td><td>57380.0</td><td>Lung/brain</td><td>EMA*1</td><td>Brain herniation</td></tr><tr><td>5</td><td>32</td><td>12</td><td>Term</td><td>6</td><td>200000.0</td><td>Lung/brain/kidney</td><td>FAEV*2d</td><td>Respiratory failure, cardiac arrest</td></tr><tr><td>6</td><td>36</td><td>13</td><td>Mole</td><td>56</td><td>9306.0</td><td>Lung/brain/bladder</td><td>FAEV*1d</td><td>Multiple organ failure</td></tr><tr><td>7</td><td>26</td><td>15</td><td>Term</td><td>3</td><td>60436.5</td><td>Lung/brain</td><td>FAEV*3d</td><td>Brain stem hemorrhage</td></tr><tr><td>8<sup>a</sup></td><td>33</td><td>17</td><td>Mole</td><td>36</td><td>2400.0</td><td>Lung/brain</td><td>FAEV*4d</td><td>Brain herniation</td></tr></table>
<table><tr><td>Case No.</td><td>Age(yrs)</td><td>FIGO score</td><td>AP</td><td>Interval time (mons)</td><td>Pretreatment serum β-hCG level</td></tr><tr><td>1</td><td>53</td><td>15</td><td>Abortion</td><td>180</td><td>99000.0</td></tr><tr><td>2</td><td>30</td><td>21</td><td>Abortion</td><td>10</td><td>906720.0</td></tr><tr><td>3</td><td>31</td><td>8</td><td>Mole</td><td>32</td><td>80.0</td></tr><tr><td>4</td><td>25</td><td>12</td><td>Mole</td><td>27</td><td>57380.0</td></tr><tr><td>5</td><td>32</td><td>12</td><td>Term</td><td>6</td><td>200000.0</td></tr><tr><td>6</td><td>36</td><td>13</td><td>Mole</td><td>56</td><td>9306.0</td></tr><tr><td>7</td><td>26</td><td>15</td><td>Term</td><td>3</td><td>60436.5</td></tr><tr><td>8a</td><td>33</td><td>17</td><td>Mole</td><td>36</td><td>2400.0</td></tr></table>
<table><tr><td>Site of metastases</td><td>Chemotherapy</td><td>Cause of death</td></tr><tr><td>Lung/brain/kidney</td><td>Not done</td><td>Brain hemorrhage, respiratory failure</td></tr><tr><td>Lung/brain/liver/kidney</td><td>Not done</td><td>Septic shock</td></tr><tr><td>Lung/brain</td><td>5-FU*1d</td><td>Brain herniation</td></tr><tr><td>Lung/brain</td><td>EMA*1</td><td>Brain herniation</td></tr><tr><td>Lung/brain/kidney</td><td>FAEV*2d</td><td>Respiratory failure, cardiac arrest</td></tr><tr><td>Lung/brain/bladder</td><td>FAEV*1d</td><td>Multiple organ failure</td></tr><tr><td>Lung/brain</td><td>FAEV*3d</td><td>Brain stem hemorrhage</td></tr><tr><td>Lung/brain</td><td>FAEV*4d</td><td>Brain herniation</td></tr></table>
52c058b55cf7c34f33340fec7030b4d9688c7244376dc96309fb1119638ebaf1.png
complex
<table><tr><td>Characteristics</td><td colspan="2">Antenatal care utilization (&lt; 4 times and &#8805; 4 times)</td></tr><tr><td> </td><td>BivariateOR (95% CI)</td><td>MultivariateOR (95% CI)</td></tr><tr><td>Education</td><td> </td><td> </td></tr><tr><td>Illiterate</td><td>1</td><td>1</td></tr><tr><td>Informal education</td><td>1.54 (1.22&#8211;1.95)*</td><td>1.39 (1.10-1.77)*</td></tr><tr><td>Primary school</td><td>1.81 (1.34&#8211;2.45)*</td><td>1.38 (1.01-1.90)*</td></tr><tr><td>Secondary school</td><td>2.85 (2.12&#8211;3.78)*</td><td>1.94 (1.43-2.63)*</td></tr><tr><td>Intermediate and above</td><td>3.49 (2.35&#8211;5.17)*</td><td>2.41 (1.55-3.75)*</td></tr><tr><td>Occupation</td><td> </td><td> </td></tr><tr><td>Agriculture</td><td>1</td><td>1</td></tr><tr><td>Service</td><td>1.63 (0.99-2.68)</td><td>1.05 (0.61-1.80)</td></tr><tr><td>Business</td><td>1.95 (0.92-4.15)</td><td>1.34 (0.61-2.93)</td></tr><tr><td>Wage laborer</td><td>1.33 (0.63-2.83)</td><td>1.36 (0.63-2.94)</td></tr><tr><td>Housewife</td><td>1.69 (1.31-2.17)*</td><td>1.44 (1.10-1.89)*</td></tr><tr><td>Other</td><td>1.09 (0.58-2.07)</td><td>0.73 (0.37-1.42)</td></tr><tr><td>Wealth quintile</td><td> </td><td> </td></tr><tr><td>Lowest</td><td>1</td><td>1</td></tr><tr><td>Second</td><td>0.91 (0.69&#8211;1.19)</td><td>1.01 (0.76-1.33)</td></tr><tr><td>Middle</td><td>0.95 (0.71&#8211;1.26)</td><td>0.95 (0.70-1.28)</td></tr><tr><td>Fourth</td><td>1.44 (1.10&#8211;1.90)*</td><td>1.25 (0.93-1.67)</td></tr><tr><td>Highest</td><td>1.72 (1.30&#8211;2.27)*</td><td>1.38 (1.02-1.86)*</td></tr><tr><td colspan="3">Knowledge of danger signs</td></tr><tr><td>No</td><td>1</td><td>1</td></tr><tr><td>Yes</td><td>1.99 (1.67&#8211;2.38)*</td><td>1.71 (1.41-2.07)*</td></tr><tr><td colspan="3">Distance to health facility</td></tr><tr><td>&gt; 30 min</td><td>1</td><td>1</td></tr><tr><td>&#8804; 30 min</td><td>1.69 (1.39-2.05)*</td><td>1.44 (1.18-1.77)*</td></tr></table>
<table><tr><td>Characteristics</td><td colspan="2">Antenatal care utilization (< 4 times and ≥ 4 times)</td></tr><tr><td></td><td>BivariateOR (95% CI)</td><td>MultivariateOR (95% CI)</td></tr><tr><td>Education</td><td></td><td></td></tr><tr><td>Illiterate</td><td>1</td><td>1</td></tr><tr><td>Informal education</td><td>1.54 (1.22–1.95)*</td><td>1.39 (1.10-1.77)*</td></tr><tr><td>Primary school</td><td>1.81 (1.34–2.45)*</td><td>1.38 (1.01-1.90)*</td></tr><tr><td>Secondary school</td><td>2.85 (2.12–3.78)*</td><td>1.94 (1.43-2.63)*</td></tr><tr><td>Intermediate and above</td><td>3.49 (2.35–5.17)*</td><td>2.41 (1.55-3.75)*</td></tr><tr><td>Occupation</td><td></td><td></td></tr><tr><td>Agriculture</td><td>1</td><td>1</td></tr><tr><td>Service</td><td>1.63 (0.99-2.68)</td><td>1.05 (0.61-1.80)</td></tr><tr><td>Business</td><td>1.95 (0.92-4.15)</td><td>1.34 (0.61-2.93)</td></tr><tr><td>Wage laborer</td><td>1.33 (0.63-2.83)</td><td>1.36 (0.63-2.94)</td></tr><tr><td>Housewife</td><td>1.69 (1.31-2.17)*</td><td>1.44 (1.10-1.89)*</td></tr><tr><td>Other</td><td>1.09 (0.58-2.07)</td><td>0.73 (0.37-1.42)</td></tr><tr><td>Wealth quintile</td><td></td><td></td></tr><tr><td>Lowest</td><td>1</td><td>1</td></tr><tr><td>Second</td><td>0.91 (0.69–1.19)</td><td>1.01 (0.76-1.33)</td></tr><tr><td>Middle</td><td>0.95 (0.71–1.26)</td><td>0.95 (0.70-1.28)</td></tr><tr><td>Fourth</td><td>1.44 (1.10–1.90)*</td><td>1.25 (0.93-1.67)</td></tr><tr><td>Highest</td><td>1.72 (1.30–2.27)*</td><td>1.38 (1.02-1.86)*</td></tr><tr><td colspan="3">Knowledge of danger signs</td></tr><tr><td>No</td><td>1</td><td>1</td></tr><tr><td>Yes</td><td>1.99 (1.67–2.38)*</td><td>1.71 (1.41-2.07)*</td></tr></table>
<table><tr><td>Characteristics</td><td colspan="2">Antenatal care utilization (< 4 times and ≥ 4 times)</td></tr><tr><td></td><td>BivariateOR (95% CI)</td><td>MultivariateOR (95% CI)</td></tr><tr><td colspan="3">Distance to health facility</td></tr><tr><td>> 30 min</td><td>1</td><td>1</td></tr><tr><td>≤ 30 min</td><td>1.69 (1.39-2.05)*</td><td>1.44 (1.18-1.77)*</td></tr></table>
7e1855cc3d23779a41a0ec72a82983ccd4112614e35f51876ef1115337ac1f73.png
simple
<table><tr><td>Organism</td><td>BlastX threshold</td><td>Matches against 454 unigenes</td><td>Matches against Sanger unigenes</td></tr><tr><td><i>Arabidopsis </i>(31,921)</td><td>1e-5</td><td>14250 (45%)</td><td>10154 (32%)</td></tr><tr><td></td><td>1e-10</td><td>12347 (39%)</td><td>9561 (30%)</td></tr><tr><td></td><td>1e-20</td><td>9077 (28%)</td><td>8410 (26%)</td></tr><tr><td><i>Arabidopsis </i>with transcript evidence (22,032)</td><td>1e-5</td><td>12790 (58%)</td><td>9542 (43%)</td></tr><tr><td></td><td>1e-10</td><td>11265 (51%)</td><td>9029 (41%)</td></tr><tr><td></td><td>1e-20</td><td>8489 (39%)</td><td>8003 (36%)</td></tr><tr><td><i>Populus </i>(45,555)</td><td>1e-5</td><td>17724 (39%)</td><td>11580 (25%)</td></tr><tr><td></td><td>1e-10</td><td>15383 (34%)</td><td>10962 (24%)</td></tr><tr><td></td><td>1e-20</td><td>11190 (25%)</td><td>9701 (21%)</td></tr><tr><td><i>Oryza </i>(66,710)</td><td>1e-5</td><td>14510 (22%)</td><td>9893 (15%)</td></tr><tr><td></td><td>1e-10</td><td>12139 (18%)</td><td>9193 (14%)</td></tr><tr><td></td><td>1e-20</td><td>8393 (13%)</td><td>7834 (12%)</td></tr></table>
<table><tr><td>Organism</td><td>BlastX threshold</td></tr><tr><td>Arabidopsis (31,921)</td><td>1e-5</td></tr><tr><td></td><td>1e-10</td></tr><tr><td></td><td>1e-20</td></tr><tr><td>Arabidopsis with transcript evidence (22,032)</td><td>1e-5</td></tr><tr><td></td><td>1e-10</td></tr><tr><td></td><td>1e-20</td></tr><tr><td>Populus (45,555)</td><td>1e-5</td></tr><tr><td></td><td>1e-10</td></tr><tr><td></td><td>1e-20</td></tr><tr><td>Oryza (66,710)</td><td>1e-5</td></tr><tr><td></td><td>1e-10</td></tr><tr><td></td><td>1e-20</td></tr></table>
<table><tr><td>Matches against 454 unigenes</td><td>Matches against Sanger unigenes</td></tr><tr><td>14250 (45%)</td><td>10154 (32%)</td></tr><tr><td>12347 (39%)</td><td>9561 (30%)</td></tr><tr><td>9077 (28%)</td><td>8410 (26%)</td></tr><tr><td>12790 (58%)</td><td>9542 (43%)</td></tr><tr><td>11265 (51%)</td><td>9029 (41%)</td></tr><tr><td>8489 (39%)</td><td>8003 (36%)</td></tr><tr><td>17724 (39%)</td><td>11580 (25%)</td></tr><tr><td>15383 (34%)</td><td>10962 (24%)</td></tr><tr><td>11190 (25%)</td><td>9701 (21%)</td></tr><tr><td>14510 (22%)</td><td>9893 (15%)</td></tr><tr><td>12139 (18%)</td><td>9193 (14%)</td></tr><tr><td>8393 (13%)</td><td>7834 (12%)</td></tr></table>
737c9398bd5825a4458d22d7b4d593d1e69a37b7599cf779eebea314610153de.png
simple
<table><tr><td>DATA CATEGORY</td><td>DATA</td></tr><tr><td>Counter IDIN</td><td>37&#8211;95</td></tr><tr><td>Station </td><td>95</td></tr><tr><td>County</td><td>37</td></tr><tr><td>City</td><td>35</td></tr><tr><td>Route</td><td>65</td></tr><tr><td>Mile point</td><td>250.08</td></tr><tr><td>AADT 2009</td><td>115,150</td></tr><tr><td>AADT 2008 </td><td>113,900</td></tr><tr><td>AADT 2007 </td><td>118,520</td></tr><tr><td>AADT 2006 </td><td>117,930</td></tr><tr><td>AADT 2005 </td><td>117,800</td></tr><tr><td>AADT 2004 </td><td>115,060</td></tr><tr><td>AADT 2003 </td><td>113,300</td></tr><tr><td>AADT 2002 </td><td>109,720</td></tr><tr><td>AADT 2001 </td><td>110,210</td></tr><tr><td>K </td><td>10</td></tr><tr><td>D </td><td>65</td></tr><tr><td>TDHV </td><td>8</td></tr><tr><td>TADT </td><td>11</td></tr><tr><td>Heavy </td><td>70</td></tr><tr><td>Functional Class </td><td>11</td></tr></table>
<table><tr><td>DATA CATEGORY</td></tr><tr><td>Counter IDIN</td></tr><tr><td>Station</td></tr><tr><td>County</td></tr><tr><td>City</td></tr><tr><td>Route</td></tr><tr><td>Mile point</td></tr><tr><td>AADT 2009</td></tr><tr><td>AADT 2008</td></tr><tr><td>AADT 2007</td></tr><tr><td>AADT 2006</td></tr><tr><td>AADT 2005</td></tr><tr><td>AADT 2004</td></tr><tr><td>AADT 2003</td></tr><tr><td>AADT 2002</td></tr><tr><td>AADT 2001</td></tr><tr><td>K</td></tr><tr><td>D</td></tr><tr><td>TDHV</td></tr><tr><td>TADT</td></tr><tr><td>Heavy</td></tr><tr><td>Functional Class</td></tr></table>
<table><tr><td>DATA</td></tr><tr><td>37–95</td></tr><tr><td>95</td></tr><tr><td>37</td></tr><tr><td>35</td></tr><tr><td>65</td></tr><tr><td>250.08</td></tr><tr><td>115,150</td></tr><tr><td>113,900</td></tr><tr><td>118,520</td></tr><tr><td>117,930</td></tr><tr><td>117,800</td></tr><tr><td>115,060</td></tr><tr><td>113,300</td></tr><tr><td>109,720</td></tr><tr><td>110,210</td></tr><tr><td>10</td></tr><tr><td>65</td></tr><tr><td>8</td></tr><tr><td>11</td></tr><tr><td>70</td></tr><tr><td>11</td></tr></table>
a41359585e5c2096a03621a445e8ce4bbeacd266c020567fe4d6ceb8c557161c.png
complex
<table><tr><td colspan="2">Clinical features</td></tr><tr><td>Number of patients</td><td>13</td></tr><tr><td>Women/men</td><td>7/6</td></tr><tr><td>Age (years), mean &#177; SD</td><td>52.02 &#177; 19.01</td></tr><tr><td colspan="2"><i>Triggering factor</i></td></tr><tr><td> AOSD flare, number (%)</td><td>13 (100)</td></tr><tr><td> Lymphoma, number (%)</td><td>0</td></tr><tr><td> Infectious disease, number (%)</td><td>0</td></tr><tr><td colspan="2"><i>Laboratory features</i></td></tr><tr><td> WBC (10<sup>3</sup>/mL), mean &#177; SD</td><td>3.28 &#177; 1.36</td></tr><tr><td> RBC (10<sup>3</sup>/mL), mean &#177; SD</td><td>3.31 &#177; 0.69</td></tr><tr><td> HB (gr/dL), mean &#177; SD</td><td>9.19 &#177; 2.05</td></tr><tr><td> PLT (10<sup>3</sup>/mL), mean &#177; SD</td><td>55.52 &#177; 46.54</td></tr><tr><td> Serum Ferritin (ng/mL), mean &#177; SD</td><td>4362.15 &#177; 7569.70</td></tr><tr><td> ESR (mm/hour), mean &#177; SD</td><td>71.23 &#177; 30.19</td></tr><tr><td> CRP (mg/L), mean &#177; SD</td><td>74.76 &#177; 46.92</td></tr><tr><td> Triglycerides (mg/dL), mean &#177; SD</td><td>183.12 &#177; 69.33</td></tr><tr><td> ASAT (IU/L), mean &#177; SD</td><td>74.59 &#177; 41.89</td></tr><tr><td> ALAT (IU/L), mean &#177; SD</td><td>129.98 &#177; 91.21</td></tr><tr><td colspan="2"><i>Treatments</i></td></tr><tr><td> High dosage steroid pulses, number (%)</td><td>13 (100)</td></tr><tr><td> Immunosuppressive drugs, number (%)</td><td>7 (53.84)</td></tr><tr><td> Cyclosporine A, number (%)</td><td>5 (38.46)</td></tr><tr><td> Methotrexate, number (%)</td><td>2 (15.38)</td></tr><tr><td> Etoposide</td><td>0</td></tr><tr><td> Biologic drugs</td><td>2 (15.38)</td></tr><tr><td>Deaths, number (%)</td><td>10 (76.92)</td></tr><tr><td>Number of relapses in MAS-survivors patients, mean &#177; SD</td><td>2.66 &#177; 1.69</td></tr></table>
<table><tr><td colspan="2">Clinical features</td></tr><tr><td>Number of patients</td><td>13</td></tr><tr><td>Women/men</td><td>7/6</td></tr><tr><td>Age (years), mean ± SD</td><td>52.02 ± 19.01</td></tr><tr><td colspan="2">Triggering factor</td></tr><tr><td>AOSD flare, number (%)</td><td>13 (100)</td></tr><tr><td>Lymphoma, number (%)</td><td>0</td></tr><tr><td>Infectious disease, number (%)</td><td>0</td></tr><tr><td colspan="2">Laboratory features</td></tr><tr><td>WBC (103/mL), mean ± SD</td><td>3.28 ± 1.36</td></tr><tr><td>RBC (103/mL),</td><td>3.31 ± 0</td></tr></table>
<table><tr><td> mean ± SD</td><td>.69</td></tr><tr><td>HB (gr/dL), mean ± SD</td><td>9.19 ± 2.05</td></tr><tr><td>PLT (103/mL), mean ± SD</td><td>55.52 ± 46.54</td></tr><tr><td>Serum Ferritin (ng/mL), mean ± SD</td><td>4362.15 ± 7569.70</td></tr><tr><td>ESR (mm/hour), mean ± SD</td><td>71.23 ± 30.19</td></tr><tr><td>CRP (mg/L), mean ± SD</td><td>74.76 ± 46.92</td></tr><tr><td>Triglycerides (mg/dL), mean ± SD</td><td>183.12 ± 69.33</td></tr><tr><td>ASAT (IU/L), mean ± SD</td><td>74.59 ± 41.89</td></tr><tr><td>ALAT (IU/L), mean ± SD</td><td>129.98 ± 91.21</td></tr><tr><td colspan="2">Treatments</td></tr><tr><td>High dosage steroid pulses, number (%)</td><td>13 (100)</td></tr><tr><td>Immunosuppressive drugs, number (%)</td><td>7 (53.84)</td></tr><tr><td>Cyclosporine A, number (%)</td><td>5 (38.46)</td></tr><tr><td>Methotrexate, number (%)</td><td>2 (15.38)</td></tr><tr><td>Etoposide</td><td>0</td></tr><tr><td>Biologic drugs</td><td>2 (15.38)</td></tr><tr><td>Deaths, number (%)</td><td>10 (76.92)</td></tr><tr><td>Number of relapses in MAS-survivors patients, mean ± SD</td><td>2.66 ± 1.69</td></tr></table>
eb959ed92aafe77c4198b5bb09be6b388317a1b7800b9d901a3f826d1c131169.png
complex
<table><tr><td>Section</td><td colspan="2">Conventional<sup>1</sup></td><td colspan="2">Enzymatic</td></tr><tr><td></td><td>%</td><td>(US$ &#215; 100)</td><td>%</td><td>(US$ &#215; 100)</td></tr><tr><td>Grain handling</td><td>8.2</td><td>6,500</td><td>8.7</td><td>6,500</td></tr><tr><td>Steeping (or pretreatment)</td><td>22.3</td><td>17,700</td><td>10.7</td><td>8,000</td></tr><tr><td>Enzymatic treatment</td><td>0</td><td>0</td><td>4.9</td><td>3,700</td></tr><tr><td>Germ separation</td><td>13.5</td><td>10,700</td><td>14.4</td><td>10,800</td></tr><tr><td>Fiber separation</td><td>23.7</td><td>18,800</td><td>25.9</td><td>19,400</td></tr><tr><td>Gluten separation</td><td>27.1</td><td>21,500</td><td>30.0</td><td>22,500</td></tr><tr><td>Starch washing</td><td>5.2</td><td>4,100</td><td>5.5</td><td>4,100</td></tr><tr><td>TOTAL</td><td>100.0</td><td>79,300</td><td>100.0</td><td>75,000</td></tr></table>
<table><tr><td>Section</td><td colspan="2">Conventional1</td><td colspan="2">Enzymatic</td></tr><tr><td></td><td>%</td><td>(US$ × 100)</td><td>%</td><td>(US$ × 100)</td></tr><tr><td>Grain handling</td><td>8.2</td><td>6,500</td><td>8.7</td><td>6,500</td></tr><tr><td>Steeping (or pretreatment)</td><td>22.3</td><td>17,700</td><td>10.7</td><td>8,000</td></tr></table>
<table><tr><td>Section</td><td colspan="2">Conventional1</td><td colspan="2">Enzymatic</td></tr><tr><td></td><td>%</td><td>(US$ × 100)</td><td>%</td><td>(US$ × 100)</td></tr><tr><td>Enzymatic treatment</td><td>0</td><td>0</td><td>4.9</td><td>3,700</td></tr><tr><td>Germ separation</td><td>13.5</td><td>10,700</td><td>14.4</td><td>10,800</td></tr><tr><td>Fiber separation</td><td>23.7</td><td>18,800</td><td>25.9</td><td>19,400</td></tr><tr><td>Gluten separation</td><td>27.1</td><td>21,500</td><td>30.0</td><td>22,500</td></tr><tr><td>Starch washing</td><td>5.2</td><td>4,100</td><td>5.5</td><td>4,100</td></tr><tr><td>TOTAL</td><td>100.0</td><td>79,300</td><td>100.0</td><td>75,000</td></tr></table>
8c062e8c447611cf3611127e1271b679558944be47ce8f1ccbfea561fafaaeaa.png
simple
<table><tr><td>Domain</td><td>Scale/items</td><td>Parent-report</td><td>Self-report</td></tr><tr><td>Sexual socialization</td><td>Friendship skills of child</td><td>5 items</td><td>5 items</td></tr><tr><td></td><td>Social acceptance by peers</td><td>3 items</td><td>6 items</td></tr><tr><td></td><td>Romantic ability of child</td><td>-</td><td>3 items</td></tr><tr><td></td><td>Openness about intimacy</td><td>4 items</td><td>3 items</td></tr><tr><td></td><td>Adequate dealing with boundaries</td><td>8 items</td><td>-</td></tr><tr><td>Sexual selfhood</td><td>Bodily perception</td><td>3 items</td><td>6 items</td></tr><tr><td></td><td>Self-esteem</td><td>-</td><td>12 items</td></tr><tr><td></td><td>Perceived social competence</td><td>-</td><td>12 items</td></tr><tr><td></td><td>Sexual knowledge of the child according to parent</td><td>9 items</td><td>-</td></tr><tr><td>Sexual behavior</td><td>Separate items on age or context appropriate behaviors, intimate experiences including age of onset and sexual orientation</td><td>33 items</td><td>41 items</td></tr></table>
<table><tr><td>Domain</td><td>Scale/items</td><td>Parent-report</td><td>Self-report</td></tr><tr><td>Sexual socialization</td><td>Friendship skills of child</td><td>5 items</td><td>5 items</td></tr><tr><td></td><td>Social acceptance by peers</td><td>3 items</td><td>6 items</td></tr><tr><td></td><td>Romantic ability of child</td><td>-</td><td>3 items</td></tr><tr><td></td><td>Openness about intimacy</td><td>4 items</td><td>3 items</td></tr><tr><td></td><td>Adequate dealing with boundaries</td><td>8 items</td><td>-</td></tr><tr><td>Sexual selfhood</td><td>Bodily perception</td><td>3 items</td><td>6 items</td></tr><tr><td></td><td>Self-esteem</td><td>-</td><td>12 items</td></tr></table>
<table><tr><td></td><td>Perceived social competence</td><td>-</td><td>12 items</td></tr><tr><td></td><td>Sexual knowledge of the child according to parent</td><td>9 items</td><td>-</td></tr><tr><td>Sexual behavior</td><td>Separate items on age or context appropriate behaviors, intimate experiences including age of onset and sexual orientation</td><td>33 items</td><td>41 items</td></tr></table>
a6b65d57cfed481d78e5a2d4bb4d059394613bbd479c5404cab3690756e09f49.png
complex
<table><tr><td></td><td colspan="2">Moderately/severely thin</td><td colspan="2">Mildly thin</td><td colspan="2">Overweight</td><td colspan="2">Obese</td></tr><tr><td>IMD decile</td><td>% (n)</td><td>RRR (95 % CI)</td><td>% (n)</td><td>RRR (95 % CI)</td><td>% (n)</td><td>RRR (95 % CI)</td><td>% (n)</td><td>RRR (95 % CI)</td></tr><tr><td colspan="9">Girls</td></tr><tr><td>Most advantaged</td><td>0.71 (855)</td><td>-</td><td>4.14 (4 998)</td><td>-</td><td>14.45 (17 426)</td><td>-</td><td>2.95 (3 563)</td><td>-</td></tr><tr><td>2</td><td>0.76 (868)</td><td>1.08 (0.98, 1.19)</td><td>4.01 (4 606)</td><td>0.98 (0.94, 1.02)</td><td>15.09 (17 334)</td><td>1.06 (1.04, 1.08)</td><td>3.36 (3 980)</td><td>1.19 (1.14, 1.25)</td></tr><tr><td>3</td><td>0.74 (812)</td><td>1.07 (0.97, 1.17)</td><td>4.01 (4 426)</td><td>0.99 (0.95, 1.03)</td><td>15.46 (17 055)</td><td>1.09 (1.07, 1.12)</td><td>3.84 (4 236)</td><td>1.33 (1.27, 1.39)</td></tr><tr><td>4</td><td>0.75 (805)</td><td>1.10 (1.00, 1.21)</td><td>4.02 (4 315)</td><td>1.00 (0.96, 1.05)</td><td>15.97 (17 138)</td><td>1.14 (1.11, 1.17)</td><td>4.04 (4 334)</td><td>1.41 (1.35, 1.48)</td></tr><tr><td>5</td><td>0.79 (876)</td><td>1.17 (1.07, 1.29)</td><td>4.0 (4 408)</td><td>1.01 (0.97, 1.05)</td><td>16.12 (17 761)</td><td>1.16 (1.14, 1.19)</td><td>4.53 (4 990)</td><td>1.60 (1.53, 1.67)</td></tr><tr><td>6</td><td>0.86 (991)</td><td>1.28 (1.17, 1.41)</td><td>4.10 (4 739)</td><td>1.05 (1.00, 1.09)</td><td>16.53 (19 121)</td><td>1.21 (1.19, 1.24)</td><td>5.00 (5 784)</td><td>1.79 (1.72, 1.87)</td></tr><tr><td>7</td><td>0.89 (1 089)</td><td>1.37 (1.25, 1.50)</td><td>4.41 (5 374)</td><td>1.15 (1.11, 1.20)</td><td>17.06 (20 768)</td><td>1.28 (1.25, 1.31)</td><td>5.60 (6 816)</td><td>2.05 (1.96, 2.13)</td></tr><tr><td>8</td><td>1.02 (1 370)</td><td>1.57 (1.44, 1.71)</td><td>4.5 (6 042)</td><td>1.18 (1.14, 1.23)</td><td>16.77 (22 529)</td><td>1.27 (1.25, 1.30)</td><td>6.11 (18 210)</td><td>2.25 (2.16, 2.34)</td></tr><tr><td>9</td><td>1.06 (1 605)</td><td>1.67 (1.53, 1.81)</td><td>4.8 (7 254)</td><td>1.28 (1.24, 1.33)</td><td>17.25 (26 091)</td><td>1.34 (1.31, 1.37)</td><td>6.77 (10 238)</td><td>2.54 (2.44, 2.64)</td></tr><tr><td>Least advantaged</td><td>1.14 (2 009)</td><td>1.80 (1.66, 1.95)</td><td>4.73 (8 317)</td><td>1.27 (1.23, 1.32)</td><td>17.36 (30 561)</td><td>1.36 (1.34, 1.39)</td><td>7.18 (12 630)</td><td>2.71 (2.61, 2.82)</td></tr><tr><td>Total n</td><td>11 280</td><td></td><td>54 479</td><td></td><td>205 784</td><td></td><td>64 781</td><td></td></tr><tr><td colspan="9">Boys</td></tr><tr><td>Most advantaged</td><td>0.65 (828)</td><td>-</td><td>4.88 (6 183)</td><td>-</td><td>9.97 (12 618)</td><td>-</td><td>2.03 (2 573)</td><td>-</td></tr><tr><td>2</td><td>0.68 (822)</td><td>1.05 (0.96, 1.16)</td><td>4.64 (5 608)</td><td>0.96 (0.93, 1.00)</td><td>10.71 (12 932)</td><td>1.08 (1.06, 1.11)</td><td>2.42 (2 920)</td><td>1.20 (1.14, 1.27)</td></tr><tr><td>3</td><td>0.67 (775)</td><td>1.05 (0.95, 1.16)</td><td>4.59 (5 295)</td><td>0.96 (0.92, 1.00)</td><td>11.22 (12 958)</td><td>1.14 (1.11, 1.17)</td><td>2.63 (3 033)</td><td>1.32 (1.25, 1.39)</td></tr><tr><td>4</td><td>0.75 (839)</td><td>1.18 (1.07, 1.30)</td><td>4.77 (5 352)</td><td>1.01 (0.97, 1.05)</td><td>11.61 (13 036)</td><td>1.20 (1.17, 1.23)</td><td>2.89 (3 243)</td><td>1.47 (1.39, 1.55)</td></tr><tr><td>5</td><td>0.78 (911)</td><td>1.25 (1.14, 1.38)</td><td>4.77 (5 544)</td><td>1.02 (0.98, 1.06)</td><td>11.93 (13 863)</td><td>1.25 (1.22, 1.28)</td><td>3.23 (3 748)</td><td>1.65 (1.57, 1.74)</td></tr><tr><td>6</td><td>0.84 (1 026)</td><td>1.37 (1.25, 1.50)</td><td>5.01 (6 088)</td><td>1.08 (1.05, 1.12)</td><td>12.30 (14 947)</td><td>1.31 (1.28, 1.34)</td><td>3.74 (4 539)</td><td>1.94 (1.85, 2.04)</td></tr><tr><td>7</td><td>0.91 (1 153)</td><td>1.49 (1.36, 1.63)</td><td>4.98 (6 328)</td><td>1.09 (1.05, 1.13)</td><td>12.82 (16 285)</td><td>1.38 (1.35, 1.41)</td><td>4.08 (5 188)</td><td>2.15 (2.05, 2.25)</td></tr><tr><td>8</td><td>1.03 (1 443)</td><td>1.71 (1.56, 1.86)</td><td>5.16 (7 242)</td><td>1.14 (1.10, 1.18)</td><td>13.02 (18 286)</td><td>1.43 (1.40, 1.47)</td><td>4.54 (6 384)</td><td>2.42 (2.31, 2.54)</td></tr><tr><td>9</td><td>1.11 (1 765)</td><td>1.87 (1.72, 2.04)</td><td>5.36 (8 504)</td><td>1.21 (1.17, 1.25)</td><td>13.33 (21 170)</td><td>1.49 (1.46,1.53)</td><td>5.08 (8 066)</td><td>2.75 (2.62, 2.87)</td></tr><tr><td>Least advantaged</td><td>1.16 (2 125)</td><td>1.97 (1.81, 2.13)</td><td>5.49 (10 062)</td><td>1.25 (1.21, 1.29)</td><td>13.63 (24 989)</td><td>1.54 (1.51,1.58)</td><td>5.33 (9 769)</td><td>2.91 (2.78, 3.04)</td></tr><tr><td>Total n</td><td>11 687</td><td></td><td>66 206</td><td></td><td>161 084</td><td></td><td>49 463</td><td></td></tr></table>
<table><tr><td></td><td colspan="2">Moderately/severely thin</td><td colspan="2">Mildly thin</td><td colspan="2">Overweight</td><td colspan="2">Obese</td></tr><tr><td>IMD decile</td><td>% (n)</td><td>RRR (95 % CI)</td><td>% (n)</td><td>RRR (95 % CI)</td><td>% (n)</td><td>RRR (95 % CI)</td><td>% (n)</td><td>RRR (95 % CI)</td></tr><tr><td colspan="9">Girls</td></tr><tr><td>Most advantaged</td><td>0.71 (855)</td><td>-</td><td>4.14 (4 998)</td><td>-</td><td>14.45 (17 426)</td><td>-</td><td>2.95 (3 563)</td><td>-</td></tr><tr><td>2</td><td>0.76 (868)</td><td>1.08 (0.98, 1.19)</td><td>4.01 (4 606)</td><td>0.98 (0.94, 1.02)</td><td>15.09 (17 334)</td><td>1.06 (1.04, 1.08)</td><td>3.36 (3 980)</td><td>1.19 (1.14, 1.25)</td></tr><tr><td>3</td><td>0.74 (812)</td><td>1.07 (0.97, 1.17)</td><td>4.01 (4 426)</td><td>0.99 (0.95, 1.03)</td><td>15.46 (17 055)</td><td>1.09 (1.07, 1.12)</td><td>3.84 (4 236)</td><td>1.33 (1.27, 1.39)</td></tr><tr><td>4</td><td>0.75 (805)</td><td>1.10 (1.00, 1.21)</td><td>4.02 (4 315)</td><td>1.00 (0.96, 1.05)</td><td>15.97 (17 138)</td><td>1.14 (1.11, 1.17)</td><td>4.04 (4 334)</td><td>1.41 (1.35, 1.48)</td></tr><tr><td>5</td><td>0.79 (876)</td><td>1.17 (1.07, 1.29)</td><td>4.0 (4 408)</td><td>1.01 (0.97, 1.05)</td><td>16.12 (17 761)</td><td>1.16 (1.14, 1.19)</td><td>4.53 (4 990)</td><td>1.60 (1.53, 1.67)</td></tr><tr><td>6</td><td>0.86 (991)</td><td>1.28 (1.17, 1.41)</td><td>4.10 (4 739)</td><td>1.05 (1.00, 1.09)</td><td>16.53 (19 121)</td><td>1.21 (1.19, 1.24)</td><td>5.00 (5 784)</td><td>1.79 (1.72, 1.87)</td></tr><tr><td>7</td><td>0.89 (1 089)</td><td>1.37 (1.25, 1.50)</td><td>4.41 (5 374)</td><td>1.15 (1.11, 1.20)</td><td>17.06 (20 768)</td><td>1.28 (1.25, 1.31)</td><td>5.60 (6 816)</td><td>2.05 (1.96, 2.13)</td></tr><tr><td>8</td><td>1.02 (1 370)</td><td>1.57 (1.44, 1.71)</td><td>4.5 (6 042)</td><td>1.18 (1.14, 1.23)</td><td>16.77 (22 529)</td><td>1.27 (1.25, 1.30)</td><td>6.11 (18 210)</td><td>2.25 (2.16, 2.34)</td></tr><tr><td>9</td><td>1.06 (1 605)</td><td>1.67 (1.53, 1.81)</td><td>4.8 (7 254)</td><td>1.28 (1.24, 1.33)</td><td>17.25 (26 091)</td><td>1.34 (1.31, 1.37)</td><td>6.77 (10 238)</td><td>2.54 (2.44, 2.64)</td></tr><tr><td>Least advantaged</td><td>1.14 (2 009)</td><td>1.80 (1.66, 1.95)</td><td>4.73 (8 317)</td><td>1.27 (1.23, 1.32)</td><td>17.36 (30 561)</td><td>1.36 (1.34, 1.39)</td><td>7.18 (12 630)</td><td>2.71 (2.61, 2.82)</td></tr><tr><td>Total n</td><td>11 280</td><td></td><td>54 479</td><td></td><td>205 784</td><td></td><td>64 781</td><td></td></tr><tr><td colspan="9">Boys</td></tr><tr><td>Most advantaged</td><td>0.65 (828)</td><td>-</td><td>4.88 (6 183)</td><td>-</td><td>9.97 (12 618)</td><td>-</td><td>2.03 (2 573)</td><td>-</td></tr></table>
<table><tr><td>2</td><td>0.68 (822)</td><td>1.05 (0.96, 1.16)</td><td>4.64 (5 608)</td><td>0.96 (0.93, 1.00)</td><td>10.71 (12 932)</td><td>1.08 (1.06, 1.11)</td><td>2.42 (2 920)</td><td>1.20 (1.14, 1.27)</td></tr><tr><td>3</td><td>0.67 (775)</td><td>1.05 (0.95, 1.16)</td><td>4.59 (5 295)</td><td>0.96 (0.92, 1.00)</td><td>11.22 (12 958)</td><td>1.14 (1.11, 1.17)</td><td>2.63 (3 033)</td><td>1.32 (1.25, 1.39)</td></tr><tr><td>4</td><td>0.75 (839)</td><td>1.18 (1.07, 1.30)</td><td>4.77 (5 352)</td><td>1.01 (0.97, 1.05)</td><td>11.61 (13 036)</td><td>1.20 (1.17, 1.23)</td><td>2.89 (3 243)</td><td>1.47 (1.39, 1.55)</td></tr><tr><td>5</td><td>0.78 (911)</td><td>1.25 (1.14, 1.38)</td><td>4.77 (5 544)</td><td>1.02 (0.98, 1.06)</td><td>11.93 (13 863)</td><td>1.25 (1.22, 1.28)</td><td>3.23 (3 748)</td><td>1.65 (1.57, 1.74)</td></tr><tr><td>6</td><td>0.84 (1 026)</td><td>1.37 (1.25, 1.50)</td><td>5.01 (6 088)</td><td>1.08 (1.05, 1.12)</td><td>12.30 (14 947)</td><td>1.31 (1.28, 1.34)</td><td>3.74 (4 539)</td><td>1.94 (1.85, 2.04)</td></tr><tr><td>7</td><td>0.91 (1 153)</td><td>1.49 (1.36, 1.63)</td><td>4.98 (6 328)</td><td>1.09 (1.05, 1.13)</td><td>12.82 (16 285)</td><td>1.38 (1.35, 1.41)</td><td>4.08 (5 188)</td><td>2.15 (2.05, 2.25)</td></tr><tr><td>8</td><td>1.03 (1 443)</td><td>1.71 (1.56, 1.86)</td><td>5.16 (7 242)</td><td>1.14 (1.10, 1.18)</td><td>13.02 (18 286)</td><td>1.43 (1.40, 1.47)</td><td>4.54 (6 384)</td><td>2.42 (2.31, 2.54)</td></tr><tr><td>9</td><td>1.11 (1 765)</td><td>1.87 (1.72, 2.04)</td><td>5.36 (8 504)</td><td>1.21 (1.17, 1.25)</td><td>13.33 (21 170)</td><td>1.49 (1.46,1.53)</td><td>5.08 (8 066)</td><td>2.75 (2.62, 2.87)</td></tr><tr><td>Least advantaged</td><td>1.16 (2 125)</td><td>1.97 (1.81, 2.13)</td><td>5.49 (10 062)</td><td>1.25 (1.21, 1.29)</td><td>13.63 (24 989)</td><td>1.54 (1.51,1.58)</td><td>5.33 (9 769)</td><td>2.91 (2.78, 3.04)</td></tr><tr><td>Total n</td><td>11 687</td><td></td><td>66 206</td><td></td><td>161 084</td><td></td><td>49 463</td><td></td></tr></table>
7206c24f79c539be2c134bf7f9b51a7c0526679e5dc04c74976af8c6374df310.png
simple
<table><tr><td>Species</td><td>Ratio Gavage/i.p.</td><td>Mean Ratio</td></tr><tr><td><i>G. pacificus</i></td><td>&gt;800, &gt;1000, &gt;340</td><td>&gt;713</td></tr><tr><td><i>G. honu</i></td><td>395, 500</td><td>448</td></tr><tr><td><i>G. australes</i></td><td>54, 108, 80, 94, 126, 79, 100</td><td>92</td></tr><tr><td><i>G. cheloniae</i></td><td>369, 170</td><td>270</td></tr><tr><td><i>G. carpenteri</i></td><td>&gt;16</td><td>-</td></tr><tr><td><i>F. paulensis</i></td><td>&gt;63</td><td>-</td></tr><tr><td><i>G. polynesiensis</i></td><td>1.7</td><td>-</td></tr></table>
<table><tr><td>Species</td><td>Ratio Gavage/i.p.</td><td>Mean Ratio</td></tr><tr><td>G. pacificus</td><td>>800, >1000, >340</td><td>>713</td></tr><tr><td>G. honu</td><td>395, 500</td><td>448</td></tr></table>
<table><tr><td>G. australes</td><td>54, 108, 80, 94, 126, 79, 100</td><td>92</td></tr><tr><td>G. cheloniae</td><td>369, 170</td><td>270</td></tr><tr><td>G. carpenteri</td><td>>16</td><td>-</td></tr><tr><td>F. paulensis</td><td>>63</td><td>-</td></tr><tr><td>G. polynesiensis</td><td>1.7</td><td>-</td></tr></table>
fb5d82c6cbf925c57c7eef899ac515f89bae45cb6622120e44c803277761d6ea.png
simple
<table><tr><td>Up-regulated miRNAs</td><td>Down-regulated miRNAs</td></tr><tr><td>mmu-miR-2137</td><td>mmu-miR-1199-3p</td></tr><tr><td>mmu-miR-5131</td><td>mmu-miR-218-5p</td></tr><tr><td>mmu-miR-680</td><td>mmu-miR-7a-5p</td></tr><tr><td>mmu-miR-5130</td><td>mmu-miR-374c-5p</td></tr><tr><td>mmu-miR-144</td><td>mmu-miR-449c-5p</td></tr><tr><td>mmu-miR-486</td><td>mmu-miR-450a-2-3p</td></tr><tr><td>mmu-miR-711</td><td>mmu-miR-696</td></tr><tr><td>mmu-miR-449a</td><td></td></tr><tr><td>mmu-miR-193</td><td></td></tr><tr><td>mmu-miR-34c-5p</td><td></td></tr><tr><td>mmu-miR-2861</td><td></td></tr><tr><td>mmu-miR-211-3p</td><td></td></tr><tr><td>mmu-miR-763</td><td></td></tr><tr><td>mmu-miR-128-2-5p</td><td></td></tr><tr><td>mmu-miR-542-5p</td><td></td></tr><tr><td>mmu-miR-3473</td><td></td></tr><tr><td>mmu-miR-511-3p</td><td></td></tr><tr><td>mmu-miR-34c-5p</td><td></td></tr><tr><td>mmu-miR-143-5p</td><td></td></tr><tr><td>mmu-miR-5115</td><td></td></tr></table>
<table><tr><td>Up-regulated miRNAs</td><td>Down-regulated miRNAs</td></tr><tr><td>mmu-miR-2137</td><td>mmu-miR-1199-3p</td></tr><tr><td>mmu-miR-5131</td><td>mmu-miR-218-5p</td></tr><tr><td>mmu-miR-680</td><td>mmu-miR-7a-5p</td></tr><tr><td>mmu-miR-5130</td><td>mmu-miR-374c-5p</td></tr></table>
<table><tr><td>Up-regulated miRNAs</td><td>Down-regulated miRNAs</td></tr><tr><td>mmu-miR-144</td><td>mmu-miR-449c-5p</td></tr><tr><td>mmu-miR-486</td><td>mmu-miR-450a-2-3p</td></tr><tr><td>mmu-miR-711</td><td>mmu-miR-696</td></tr><tr><td>mmu-miR-449a</td><td></td></tr><tr><td>mmu-miR-193</td><td></td></tr><tr><td>mmu-miR-34c-5p</td><td></td></tr><tr><td>mmu-miR-2861</td><td></td></tr><tr><td>mmu-miR-211-3p</td><td></td></tr><tr><td>mmu-miR-763</td><td></td></tr><tr><td>mmu-miR-128-2-5p</td><td></td></tr><tr><td>mmu-miR-542-5p</td><td></td></tr><tr><td>mmu-miR-3473</td><td></td></tr><tr><td>mmu-miR-511-3p</td><td></td></tr><tr><td>mmu-miR-34c-5p</td><td></td></tr><tr><td>mmu-miR-143-5p</td><td></td></tr><tr><td>mmu-miR-5115</td><td></td></tr></table>
387ded1e614fce03bf996c326e9af77523c2e99c9898cc423d1e456735239ad6.png
complex
<table><tr><td colspan="2">Data source</td><td colspan="3">Exhaustive search</td><td colspan="4">KL1LR</td></tr><tr><td></td><td></td><td colspan="2"># of GO terms (# in union)</td><td>AUC</td><td colspan="2"># of GO terms (# in union)</td><td>AUC</td><td>NCG</td></tr><tr><td>Protein-protein interactions</td><td>OPHID</td><td>192</td><td></td><td>0.82</td><td>201</td><td></td><td>0.89</td><td>83</td></tr><tr><td>Protein domain</td><td>Interpro</td><td>522</td><td>(697)</td><td>0.87</td><td>408</td><td>(518)</td><td>0.89</td><td>266</td></tr><tr><td></td><td>Pfam</td><td>600</td><td></td><td>0.86</td><td>311</td><td></td><td>0.89</td><td>210</td></tr><tr><td>Phenotype</td><td>MGI</td><td>213</td><td></td><td>0.87</td><td>346</td><td></td><td>0.90</td><td>129</td></tr><tr><td>Phylogenetic profile</td><td>BioMart</td><td>33</td><td>(95)</td><td>0.83</td><td>59</td><td>(166)</td><td>0.88</td><td>4</td></tr><tr><td></td><td>Inparanoid</td><td>70</td><td></td><td>0.84</td><td>124</td><td></td><td>0.88</td><td>22</td></tr><tr><td>Disease</td><td>OMIM</td><td>41</td><td></td><td>0.85</td><td>32</td><td></td><td>0.88</td><td>3</td></tr><tr><td>Gene expression</td><td>Zhang <i>et al.</i></td><td>28</td><td></td><td>0.81</td><td>147</td><td></td><td>0.90</td><td>10</td></tr><tr><td></td><td>Su <i>et al.</i></td><td>21</td><td>(55)</td><td>0.82</td><td>158</td><td>(309)</td><td>0.89</td><td>8</td></tr><tr><td></td><td>Sage <i>et al.</i></td><td>16</td><td></td><td>0.83</td><td>113</td><td></td><td>0.90</td><td>7</td></tr></table>
<table><tr><td colspan="2">Data source</td><td colspan="3">Exhaustive search</td><td colspan="4">KL1LR</td></tr><tr><td></td><td></td><td colspan="2"># of GO terms (# in union)</td><td>AUC</td><td colspan="2"># of GO terms (# in union)</td><td>AUC</td><td>NCG</td></tr><tr><td>Protein-protein interactions</td><td>OPHID</td><td>192</td><td></td><td>0.82</td><td>201</td><td></td><td>0.89</td><td>83</td></tr></table>
<table><tr><td>Protein domain</td><td>Interpro</td><td>522</td><td>(697)</td><td>0.87</td><td>408</td><td>(518)</td><td>0.89</td><td>266</td></tr><tr><td></td><td>Pfam</td><td>600</td><td></td><td>0.86</td><td>311</td><td></td><td>0.89</td><td>210</td></tr><tr><td>Phenotype</td><td>MGI</td><td>213</td><td></td><td>0.87</td><td>346</td><td></td><td>0.90</td><td>129</td></tr><tr><td>Phylogenetic profile</td><td>BioMart</td><td>33</td><td>(95)</td><td>0.83</td><td>59</td><td>(166)</td><td>0.88</td><td>4</td></tr><tr><td></td><td>Inparanoid</td><td>70</td><td></td><td>0.84</td><td>124</td><td></td><td>0.88</td><td>22</td></tr><tr><td>Disease</td><td>OMIM</td><td>41</td><td></td><td>0.85</td><td>32</td><td></td><td>0.88</td><td>3</td></tr><tr><td>Gene expression</td><td>Zhang et al.</td><td>28</td><td></td><td>0.81</td><td>147</td><td></td><td>0.90</td><td>10</td></tr><tr><td></td><td>Su et al.</td><td>21</td><td>(55)</td><td>0.82</td><td>158</td><td>(309)</td><td>0.89</td><td>8</td></tr><tr><td></td><td>Sage et al.</td><td>16</td><td></td><td>0.83</td><td>113</td><td></td><td>0.90</td><td>7</td></tr></table>
f95ee00effdfc2670e1f8e4d440056df0a2cc1c6cfdd9f8207a871a30eaffd11.png
complex
<table><tr><td rowspan="2"> Criterion</td><td colspan="2">Score</td></tr><tr><td>No</td><td>Yes</td></tr><tr><td>Tortuous vessels</td><td>0</td><td>1</td></tr><tr><td>Large vessels</td><td>0</td><td>1</td></tr><tr><td>Leakage</td><td>0</td><td>1</td></tr><tr><td>Defective flux</td><td>0</td><td>1</td></tr></table>
<table><tr><td rowspan="2">Criterion</td><td colspan="2">Score</td></tr><tr><td>No</td><td>Yes</td></tr><tr><td>Tortuous vessels</td><td>0</td><td>1</td></tr><tr><td>Large vessels</td><td>0</td><td>1</td></tr></table>
<table><tr><td>Leakage</td><td>0</td><td>1</td></tr><tr><td>Defective flux</td><td>0</td><td>1</td></tr></table>
a836372f29ba4f94e367d5d219f5c23a48f776bf6d553346fcef3bb0942f9374.png
simple
<table><tr><td>BMI classes</td><td>Mean</td><td>95% C.I</td><td>N</td></tr><tr><td>Normal Weight</td><td>21.7</td><td>20.8&#8211;22.6</td><td>84</td></tr><tr><td>Overweight</td><td>19.1</td><td>18.3&#8211;19.8</td><td>123</td></tr><tr><td>Obese Class I</td><td>18.2</td><td>17.3&#8211;19.1</td><td>77</td></tr><tr><td>Obese Class II</td><td>17.4</td><td>16.3&#8211;18.7</td><td>37</td></tr><tr><td>Obese Class III</td><td>17.0</td><td>15.9&#8211;18.1</td><td>59</td></tr></table>
<table><tr><td></td><td>Mean</td><td></td><td>N</td></tr></table>
<table><tr><td>BMI classes</td><td></td><td>95% C.I</td><td></td></tr><tr><td>Normal Weight</td><td>21.7</td><td>20.8–22.6</td><td>84</td></tr><tr><td>Overweight</td><td>19.1</td><td>18.3–19.8</td><td>123</td></tr><tr><td>Obese Class I</td><td>18.2</td><td>17.3–19.1</td><td>77</td></tr><tr><td>Obese Class II</td><td>17.4</td><td>16.3–18.7</td><td>37</td></tr><tr><td>Obese Class III</td><td>17.0</td><td>15.9–18.1</td><td>59</td></tr></table>
bbb2766af5760cf46c509963ae453f66512aa59aeb7c880158aa97e3ae53843b.png
simple
<table><tr><td></td><td>January</td><td>February</td><td>March</td><td>April</td><td>May</td><td>June</td><td>July</td><td>August</td><td>September</td><td>October</td><td>November</td><td>December</td><td>Total</td></tr><tr><td>Girls</td><td>7057</td><td>6897</td><td>7724</td><td>7414</td><td>7726</td><td>7303</td><td>7600</td><td>7544</td><td>7243</td><td>7078</td><td>6337</td><td>6552</td><td>86475</td></tr><tr><td>Boys</td><td>7280</td><td>7023</td><td>7781</td><td>7750</td><td>8184</td><td>7480</td><td>8021</td><td>7739</td><td>7624</td><td>7199</td><td>6567</td><td>6637</td><td>89285</td></tr><tr><td>Total</td><td>14337</td><td>13920</td><td>15505</td><td>15164</td><td>15910</td><td>14783</td><td>15621</td><td>15283</td><td>14867</td><td>14277</td><td>12904</td><td>13189</td><td>175760</td></tr></table>
<table><tr><td></td><td>J</td><td>Febru</td><td></td><td>A</td><td>Ma</td><td></td><td>Ju</td><td>Augu</td><td></td><td></td><td>Novembe</td><td>D</td><td>T</td></tr></table>
<table><tr><td></td><td>anuary</td><td>ary</td><td>March</td><td>pril</td><td>y</td><td>June</td><td>ly</td><td>st</td><td>September</td><td>October</td><td>r</td><td>ecember</td><td>otal</td></tr><tr><td>Girls</td><td>7057</td><td>6897</td><td>7724</td><td>7414</td><td>7726</td><td>7303</td><td>7600</td><td>7544</td><td>7243</td><td>7078</td><td>6337</td><td>6552</td><td>86475</td></tr><tr><td>Boys</td><td>7280</td><td>7023</td><td>7781</td><td>7750</td><td>8184</td><td>7480</td><td>8021</td><td>7739</td><td>7624</td><td>7199</td><td>6567</td><td>6637</td><td>89285</td></tr><tr><td>Total</td><td>14337</td><td>13920</td><td>15505</td><td>15164</td><td>15910</td><td>14783</td><td>15621</td><td>15283</td><td>14867</td><td>14277</td><td>12904</td><td>13189</td><td>175760</td></tr></table>
4dde64cab867c1bdcf95dcb274d7b66e6cf927716ae654b73df8647a359b7dc3.png
complex
<table><tr><td rowspan="2"> </td><td>Patients with IBS</td><td>Healthy controls</td><td rowspan="2"><i>p</i> value</td></tr><tr><td>(<i>n</i> = 89)</td><td>(<i>n</i> = 13)</td></tr><tr><td>Age in years, mean &#177; SD</td><td>45.7 &#177; 12.9</td><td>43.3 &#177; 8.6</td><td>0.595</td></tr><tr><td>Sex, male/female</td><td>47/42</td><td>9/4</td><td>0.266</td></tr><tr><td>BMI, kg/m<sup>2</sup></td><td>22.1 &#177; 5.8</td><td>24.5 &#177; 2.9</td><td>0.245</td></tr><tr><td>Anxiety, mean &#177; SD</td><td>5.17 &#177; 3.16</td><td>2.77 &#177; 1.64</td><td>0.009</td></tr><tr><td>Depression, mean &#177; SD</td><td>5.52 &#177; 3.30</td><td>3.54 &#177; 2.50</td><td>0.041</td></tr><tr><td>LES</td><td>40.0 (11.0&#8211;75.0)</td><td>8.0 (0.0&#8211;35.0)</td><td>&lt;0.001</td></tr></table>
<table><tr><td rowspan="2"></td><td>Patients with IBS</td></tr><tr><td>(n = 89)</td></tr><tr><td>Age in years, mean ± SD</td><td>45.7 ± 12.9</td></tr><tr><td>Sex, male/female</td><td>47/42</td></tr><tr><td>BMI, kg/m2</td><td>22.1 ± 5.8</td></tr><tr><td>Anxiety, mean ± SD</td><td>5.17 ± 3.16</td></tr><tr><td>Depression, mean ± SD</td><td>5.52 ± 3.30</td></tr><tr><td>LES</td><td>40.0 (11.0–75.0)</td></tr></table>
<table><tr><td>Healthy controls</td><td rowspan="2">p value</td></tr><tr><td>(n = 13)</td></tr><tr><td>43.3 ± 8.6</td><td>0.595</td></tr><tr><td>9/4</td><td>0.266</td></tr><tr><td>24.5 ± 2.9</td><td>0.245</td></tr><tr><td>2.77 ± 1.64</td><td>0.009</td></tr><tr><td>3.54 ± 2.50</td><td>0.041</td></tr><tr><td>8.0 (0.0–35.0)</td><td><0.001</td></tr></table>
c7478d290c95b5a04ef89c20d47b6eaa3b63f2e4781ea670a60afe0c99e23cbe.png
simple
<table><tr><td>Variables</td><td>Overall survival(RR, 95% CI)</td><td><i>p</i></td><td>Disease-specific survival(RR, 95% CI))</td><td><i>p</i></td><td>Disease-free survival(RR, 95% CI)</td><td><i>p</i></td><td>Loco-regional control(RR, 95% CI)</td><td><i>p</i></td><td>Distant metastasis-free survival(RR, 95% CI)</td><td><i>p</i></td></tr><tr><td>T1-2 vs. T3-4</td><td>1.29, 0.56-2.98</td><td>0.56</td><td>1.42, 0.41-4.86</td><td>0.58</td><td>0.85, 0.34-2.16</td><td>0.73</td><td>1.44, 0.27-7.64</td><td>0.67</td><td>1.00, 0.36-2.81</td><td>1.00</td></tr><tr><td>N0-2 vs. N3</td><td>2.47, 0.48-12.71</td><td>0.28</td><td>1.86, 0.15-23.26</td><td>0.63</td><td>2.85, 0.53-15.18</td><td>0.22</td><td>39.06, 1.55-983.27</td><td>0.03</td><td>2.77, 0.54-14.07</td><td>0.22</td></tr><tr><td>Cranial nerve involvement</td><td>0.71, 0.26-1.95</td><td>0.51</td><td>0.73, 0.17-3.13</td><td>0.67</td><td>0.65, 0.18-2.28</td><td>0.50</td><td>0.11, 0.006-2.10</td><td>0.14</td><td>0.95, 0.26-3.46</td><td>0.94</td></tr><tr><td>Supraclavicular nodes</td><td>0.74, 0.15-3.74</td><td>0.71</td><td>0.78, 0.06-9.59</td><td>0.85</td><td>0.45, 0.08-2.50</td><td>0.36</td><td>0.02, 0.001-0.87</td><td>0.04</td><td>0.68, 0.13-3.43</td><td>0.64</td></tr><tr><td>GTVprn (13 ml)</td><td>2.92, 1.22-6.98</td><td>0.02</td><td>4.10, 1.06-15.97</td><td>0.04</td><td>4.81, 1.73-13.36</td><td>&lt; 0.01</td><td>16.83, 1.48-190.78</td><td>0.02</td><td>2.50, 0.84-7.43</td><td>0.10</td></tr></table>
<table><tr><td>Variables</td><td>Overall survival(RR, 95% CI)</td><td>p</td><td>Disease-specific survival(RR, 95% CI))</td><td>p</td><td>Disease-free survival(RR, 95% CI)</td><td>p</td><td>Loco-regional control(RR, 95% CI)</td><td>p</td><td>Distant metastasis-free survival(RR, 95% CI)</td><td>p</td></tr><tr><td>T1-2 vs. T3-4</td><td>1.29, 0.56-2.98</td><td>0.56</td><td>1.42, 0.41-4.86</td><td>0.58</td><td>0.85, 0.34-2.16</td><td>0.73</td><td>1.44, 0.27-7.64</td><td>0.67</td><td>1.00, 0.36-2.81</td><td>1.00</td></tr><tr><td>N0-2 vs. N3</td><td>2.47, 0.48-12.71</td><td>0.28</td><td>1.86, 0.15-23.26</td><td>0.63</td><td>2.85, 0.53-15.18</td><td>0.22</td><td>39.06, 1.55-983.27</td><td>0.03</td><td>2.77, 0.54-14.07</td><td>0.22</td></tr><tr><td>Cranial nerve involvement</td><td>0.71, 0.26-1.95</td><td>0.51</td><td>0.73, 0.17-3.13</td><td>0.67</td><td>0.65, 0.18-2.28</td><td>0.50</td><td>0.11, 0.006-2.10</td><td>0.14</td><td>0.95, 0.26-3.46</td><td>0.94</td></tr><tr><td>Supraclavicular nodes</td><td>0.74, 0.15-3.74</td><td>0.71</td><td>0.78, 0.06-9.59</td><td>0.85</td><td>0.45, 0.08-2.50</td><td>0.36</td><td>0.02, 0.001-0.87</td><td>0.04</td><td>0.68, 0.13-3.43</td><td>0.64</td></tr></table>
<table><tr><td>Variables</td><td>Overall survival(RR, 95% CI)</td><td>p</td><td>Disease-specific survival(RR, 95% CI))</td><td>p</td><td>Disease-free survival(RR, 95% CI)</td><td>p</td><td>Loco-regional control(RR, 95% CI)</td><td>p</td><td>Distant metastasis-free survival(RR, 95% CI)</td><td>p</td></tr><tr><td>GTVprn (13 ml)</td><td>2.92, 1.22-6.98</td><td>0.02</td><td>4.10, 1.06-15.97</td><td>0.04</td><td>4.81, 1.73-13.36</td><td>< 0.01</td><td>16.83, 1.48-190.78</td><td>0.02</td><td>2.50, 0.84-7.43</td><td>0.10</td></tr></table>
09c6c243eb6e428c47cc335c0355ba6194c9bbd0eb3266e3ccf70bc449663056.png
complex
<table><tr><td>Characteristics</td><td><i>n</i></td><td><i>P</i>-value<sup>a</sup><sup>,</sup><sup>b</sup></td><td>Hazard ratio<sup>a</sup><sup>,</sup><sup>b</sup></td><td>95% CI<sup>a</sup><sup>,</sup><sup>b</sup></td></tr><tr><td colspan="5">Age</td></tr><tr><td>&lt; 20</td><td>18 (82%)</td><td></td><td></td><td></td></tr><tr><td>&gt; 20</td><td>4 (18%)</td><td>0.06</td><td>0.16</td><td>2.3 &#215; 10<sup>&#8722;10</sup>&#8211;1.3</td></tr><tr><td>Median</td><td>13</td><td></td><td></td><td></td></tr><tr><td colspan="5">Gender</td></tr><tr><td>Male</td><td>15 (68%)</td><td rowspan="2">0.05</td><td rowspan="2">0.20</td><td rowspan="2">1.9 &#215; 10<sup>&#8722;10</sup>&#8211;1.2</td></tr><tr><td>Female</td><td>7 (32%)</td></tr><tr><td colspan="5">Tumor volume (cm<sup>3</sup>)</td></tr><tr><td>Median</td><td>1,476</td><td rowspan="2">0.40</td><td rowspan="2">0.48</td><td rowspan="2">0.04&#8211;3.0</td></tr><tr><td>Range</td><td>85&#8211;10,590</td></tr><tr><td colspan="5">Tumor surface (cm<sup>2</sup>)</td></tr><tr><td>Median</td><td>19.2</td><td rowspan="2">0.43</td><td rowspan="2">0.50</td><td rowspan="2">0.02&#8211;3.3</td></tr><tr><td>Range</td><td>3.2&#8211;57.7</td></tr><tr><td colspan="5">Pattern on MRI</td></tr><tr><td>Concentric</td><td>19 (86%)</td><td rowspan="2">0.72</td><td rowspan="2">0.47</td><td rowspan="2">0.10&#8211;2.1</td></tr><tr><td>Longitudinal</td><td>3 (14%)</td></tr><tr><td colspan="5">Histologic response</td></tr><tr><td>Good</td><td>12 (54%)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Poor</td><td>10 (46%)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td colspan="5">Pathologic subtype</td></tr><tr><td>Osteoblastic</td><td>10 (46%)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Chondroblastic</td><td>6 (27%)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Fibroblastic</td><td>4 (18%)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Other</td><td>2 (9%)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td colspan="5">Location</td></tr><tr><td>Distal femur</td><td>22 (100%)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td colspan="5">Metastatic disease</td></tr><tr><td>No</td><td>22 (100%)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr></table>
<table><tr><td>Characteristics</td></tr><tr><td>Age</td></tr><tr><td>< 20</td></tr><tr><td>> 20</td></tr><tr><td>Median</td></tr><tr><td>Gender</td></tr><tr><td>Male</td></tr><tr><td>Female</td></tr><tr><td>Tumor volume (cm3)</td></tr><tr><td>Median</td></tr><tr><td>Range</td></tr><tr><td>Tumor surface (cm2)</td></tr><tr><td>Median</td></tr><tr><td>Range</td></tr><tr><td>Pattern on MRI</td></tr><tr><td>Concentric</td></tr><tr><td>Longitudinal</td></tr><tr><td>Histologic response</td></tr><tr><td>Good</td></tr><tr><td>Poor</td></tr><tr><td>Pathologic subtype</td></tr><tr><td>Osteoblastic</td></tr><tr><td>Chondroblastic</td></tr><tr><td>Fibroblastic</td></tr><tr><td>Other</td></tr><tr><td>Location</td></tr><tr><td>Distal femur</td></tr><tr><td>Metastatic disease</td></tr><tr><td>No</td></tr></table>
<table><tr><td>n</td><td>P-valuea,b</td><td>Hazard ratioa,b</td><td>95% CIa,b</td></tr><tr><td colspan="4">Age</td></tr><tr><td>18 (82%)</td><td></td><td></td><td></td></tr><tr><td>4 (18%)</td><td>0.06</td><td>0.16</td><td>2.3 × 10−10–1.3</td></tr><tr><td>13</td><td></td><td></td><td></td></tr><tr><td colspan="4">Gender</td></tr><tr><td>15 (68%)</td><td rowspan="2">0.05</td><td rowspan="2">0.20</td><td rowspan="2">1.9 × 10−10–1.2</td></tr><tr><td>7 (32%)</td></tr><tr><td colspan="4">Tumor volume (cm3)</td></tr><tr><td>1,476</td><td rowspan="2">0.40</td><td rowspan="2">0.48</td><td rowspan="2">0.04–3.0</td></tr><tr><td>85–10,590</td></tr><tr><td colspan="4">Tumor surface (cm2)</td></tr><tr><td>19.2</td><td rowspan="2">0.43</td><td rowspan="2">0.50</td><td rowspan="2">0.02–3.3</td></tr><tr><td>3.2–57.7</td></tr><tr><td colspan="4">Pattern on MRI</td></tr><tr><td>19 (86%)</td><td rowspan="2">0.72</td><td rowspan="2">0.47</td><td rowspan="2">0.10–2.1</td></tr><tr><td>3 (14%)</td></tr><tr><td colspan="4">Histologic response</td></tr><tr><td>12 (54%)</td><td>–</td><td>–</td><td>–</td></tr><tr><td>10 (46%)</td><td>–</td><td>–</td><td>–</td></tr><tr><td colspan="4">Pathologic subtype</td></tr><tr><td>10 (46%)</td><td>–</td><td>–</td><td>–</td></tr><tr><td>6 (27%)</td><td>–</td><td>–</td><td>–</td></tr><tr><td>4 (18%)</td><td>–</td><td>–</td><td>–</td></tr><tr><td>2 (9%)</td><td>–</td><td>–</td><td>–</td></tr><tr><td colspan="4">Location</td></tr><tr><td>22 (100%)</td><td>–</td><td>–</td><td>–</td></tr><tr><td colspan="4">Metastatic disease</td></tr><tr><td>22 (100%)</td><td>–</td><td>–</td><td>–</td></tr></table>
98f89ff9aa0f2e589d9d6f8a52f1016f3fb1bf7a7d79c08cfc9698ce6a861a09.png
simple
<table><tr><td>Date</td><td>Advance</td><td>Applications</td></tr><tr><td>1670s</td><td>Microscope invented by Leeuwenhoek</td><td>Visualize bacteria, protozoa</td></tr><tr><td>1850s</td><td>Puerperal fever identified as infectious and interventions implemented by Semmelweis [23]</td><td>Hospital infection control motivated by growing understanding of microbial etiology</td></tr><tr><td>1864</td><td>Cholera transmission by water proven by Snow</td><td>Risk factor (mode of transmission) and prevention measure for specific infectious syndrome</td></tr><tr><td>1890s</td><td>Proof of parasitic origin (Grassi) and mosquito transmission (Ross) of malaria</td><td>Vector control</td></tr><tr><td>1890s</td><td>Identification of microbial etiologies for tuberculosis, anthrax, and so on; Koch&#8217;s postulates</td><td>Targeted diagnostics, therapeutics, and move from syndromic diagnosis to pathogen identification</td></tr><tr><td>1900-1930s</td><td>Discovery of filterable animal viruses [24]</td><td>Influenza etiology settled (previously thought bacterial) [25]</td></tr><tr><td>1910s-1950s</td><td>Phenotypic subspecies taxonomy: serotyping [26,27], phage typing [28]</td><td>Association of particular types with prognosis [27,29], drug resistance</td></tr><tr><td>1944</td><td>Discovery of DNA as the genetic material [30]</td><td>Basis for genotyping tools for molecular epidemiology</td></tr><tr><td>1970</td><td>Restriction enzymes [31]</td><td>Basis for restriction fragment length polymorphism approaches, including pulsed field gel electrophoresis</td></tr><tr><td>1975-1985</td><td>Sanger DNA sequencing [32], PCR [33]</td><td>Basis for variable number tandem repeat (VNTR) and multilocus sequence typing (MLST) approaches to characterize microbes and their genetic relatedness</td></tr><tr><td>2000s-now</td><td>High-throughput rapid sequencing technologies</td><td>Microbial genome sequencing</td></tr></table>
<table><tr><td>Date</td><td>Advance</td><td>Applications</td></tr><tr><td>1670s</td><td>Microscope invented by Leeuwenhoek</td><td>Visualize bacteria, protozoa</td></tr><tr><td>1850s</td><td>Puerperal fever identified as infectious and interventions implemented by Semmelweis [23]</td><td>Hospital infection control motivated by growing understanding of microbial etiology</td></tr><tr><td>1864</td><td>Cholera transmission by water proven by Snow</td><td>Risk factor (mode of transmission) and prevention measure for specific infectious syndrome</td></tr><tr><td>1890s</td><td>Proof of parasitic origin (Grassi) and mosquito transmission (Ross) of malaria</td><td>Vector control</td></tr></table>
<table><tr><td>1890s</td><td>Identification of microbial etiologies for tuberculosis, anthrax, and so on; Koch’s postulates</td><td>Targeted diagnostics, therapeutics, and move from syndromic diagnosis to pathogen identification</td></tr><tr><td>1900-1930s</td><td>Discovery of filterable animal viruses [24]</td><td>Influenza etiology settled (previously thought bacterial) [25]</td></tr><tr><td>1910s-1950s</td><td>Phenotypic subspecies taxonomy: serotyping [26,27], phage typing [28]</td><td>Association of particular types with prognosis [27,29], drug resistance</td></tr><tr><td>1944</td><td>Discovery of DNA as the genetic material [30]</td><td>Basis for genotyping tools for molecular epidemiology</td></tr><tr><td>1970</td><td>Restriction enzymes [31]</td><td>Basis for restriction fragment length polymorphism approaches, including pulsed field gel electrophoresis</td></tr><tr><td>1975-1985</td><td>Sanger DNA sequencing [32], PCR [33]</td><td>Basis for variable number tandem repeat (VNTR) and multilocus sequence typing (MLST) approaches to characterize microbes and their genetic relatedness</td></tr><tr><td>2000s-now</td><td>High-throughput rapid sequencing technologies</td><td>Microbial genome sequencing</td></tr></table>
ce92307b438370f5580bc5b6826c71a604f88fa1790883916fd53135bbf9332b.png
simple
<table><tr><td>Conditions</td><td>Biological Process</td><td>FDRp-value</td><td>Molecular Function</td><td>FDRp-value</td></tr><tr><td>Control</td><td>response to abiotic or biotic stimulus</td><td>2.8e-19</td><td>transcription factor activity</td><td>3.4e-04</td></tr><tr><td></td><td>response to stress</td><td>1.6e-13</td><td>other enzyme activity</td><td>2.1e-03</td></tr><tr><td></td><td>other biological processes</td><td>7.7e-10</td><td>other molecular functions</td><td>4.5e-02</td></tr><tr><td>Cold</td><td>response to stress</td><td>4.9e-08</td><td>transcription factor activity</td><td>1.7e-07</td></tr><tr><td></td><td>other biological processes</td><td>1.3e-07</td><td>receptor binding or activity</td><td>3.8e-03</td></tr><tr><td></td><td>response to abiotic or biotic stimulus</td><td>8.1e-06</td><td>kinase activity</td><td>2.9e-02</td></tr><tr><td></td><td>transcription</td><td>3.3e-04</td><td></td><td></td></tr><tr><td></td><td>signal transduction</td><td>3.2e-03</td><td></td><td></td></tr><tr><td>Genotoxic</td><td>response to abiotic or biotic stimulus</td><td>2.9e-20</td><td>kinase activity</td><td>7.6e-06</td></tr><tr><td></td><td>response to stress</td><td>3.8e-16</td><td>transcription factor activity</td><td>8.9e-04</td></tr><tr><td></td><td>other biological processes</td><td>1.8e-11</td><td>transferase activity</td><td>1.7e-03</td></tr><tr><td></td><td>signal transduction</td><td>7.3e-03</td><td>transporter activity</td><td>1.4e-02</td></tr><tr><td>Osmotic</td><td>response to stress</td><td>1.4e-16</td><td>transferase activity</td><td>7.0e-04</td></tr><tr><td></td><td>response to abiotic or biotic stimulus</td><td>1.4e-14</td><td>kinase activity</td><td>1.4e-03</td></tr><tr><td></td><td>other biological processes</td><td>1.3e-08</td><td>transcription factor activity</td><td>1.3e-02</td></tr><tr><td></td><td>signal transduction</td><td>1.3e-02</td><td>other molecular functions</td><td>4.3e-02</td></tr><tr><td>Salt</td><td>response to abiotic or biotic stimulus</td><td>3.0e-12</td><td>structural molecule activity</td><td>1.1e-13</td></tr><tr><td></td><td>response to stress</td><td>6.0e-07</td><td>transferase activity</td><td>2.3e-03</td></tr><tr><td></td><td>other biological processes</td><td>3.3e-03</td><td>other enzyme activity</td><td>2.4e-02</td></tr><tr><td>UV-B</td><td>response to abiotic or biotic stimulus</td><td>3.1e-12</td><td>transferase activity</td><td>1.3e-02</td></tr><tr><td></td><td>response to stress</td><td>2.3e-11</td><td>kinase activity</td><td>1.4e-02</td></tr><tr><td></td><td>other biological processes</td><td>1.6e-08</td><td></td><td></td></tr><tr><td>Wounding</td><td>response to abiotic or biotic stimulus</td><td>1.4e-17</td><td>other enzyme activity</td><td>6.3e-06</td></tr><tr><td></td><td>response to stress</td><td>1.0e-15</td><td>transferase activity</td><td>2.1e-03</td></tr><tr><td></td><td>other biological processes</td><td>1.1e-10</td><td>transcription factor activity</td><td>2.1e-03</td></tr><tr><td></td><td>other metabolic processes</td><td>4.7e-02</td><td>hydrolase activity</td><td>1.2e-02</td></tr><tr><td></td><td></td><td></td><td>transporter activity</td><td>4.1e-02</td></tr><tr><td>Drought</td><td>response to abiotic or biotic stimulus</td><td>2.8e-19</td><td>structural molecule activity</td><td>7.9e-18</td></tr><tr><td></td><td>response to stress</td><td>6.0e-19</td><td>transferase activity</td><td>6.7e-05</td></tr><tr><td></td><td>other biological processes</td><td>6.4e-10</td><td>other enzyme activity</td><td>3.8e-04</td></tr><tr><td></td><td>other metabolic processes</td><td>1.8e-02</td><td></td><td></td></tr><tr><td>Heat</td><td>other biological processes</td><td>7.0e-12</td><td>transferase activity</td><td>9.3e-04</td></tr><tr><td></td><td>response to abiotic or biotic stimulus</td><td>7.7e-10</td><td>other enzyme activity</td><td>2.1e-03</td></tr><tr><td></td><td>response to stress</td><td>3.4e-08</td><td>hydrolase activity</td><td>3.1e-02</td></tr><tr><td></td><td>electron transport or energy pathways</td><td>9.5e-03</td><td></td><td></td></tr><tr><td>Oxidative</td><td>response to abiotic or biotic stimulus</td><td>7.3e-17</td><td>transcription factor activity</td><td>2.2e-03</td></tr><tr><td></td><td>other biological processes</td><td>6.5e-14</td><td>other enzyme activity</td><td>5.7e-03</td></tr><tr><td></td><td>response to stress</td><td>7.7e-10</td><td>kinase activity</td><td>1.4e-02</td></tr><tr><td></td><td></td><td></td><td>transferase activity</td><td>1.6e-02</td></tr></table>
<table><tr><td>Conditions</td><td>Biological Process</td><td>FDRp-value</td><td>Molecular Function</td><td>FDRp-value</td></tr><tr><td>Control</td><td>response to abiotic or biotic stimulus</td><td>2.8e-19</td><td>transcription factor activity</td><td>3.4e-04</td></tr><tr><td></td><td>response to stress</td><td>1.6e-13</td><td>other enzyme activity</td><td>2.1e-03</td></tr><tr><td></td><td>other biological processes</td><td>7.7e-10</td><td>other molecular functions</td><td>4.5e-02</td></tr><tr><td>Cold</td><td>response to stress</td><td>4.9e-08</td><td>transcription factor activity</td><td>1.7e-07</td></tr><tr><td></td><td>other biological processes</td><td>1.3e-07</td><td>receptor binding or activity</td><td>3.8e-03</td></tr><tr><td></td><td>response to abiotic or biotic stimulus</td><td>8.1e-06</td><td>kinase activity</td><td>2.9e-02</td></tr><tr><td></td><td>transcription</td><td>3.3e-04</td><td></td><td></td></tr><tr><td></td><td>signal transduction</td><td>3.2e-03</td><td></td><td></td></tr><tr><td>Genotoxic</td><td>response to abiotic or biotic stimulus</td><td>2.9e-20</td><td>kinase activity</td><td>7.6e-06</td></tr><tr><td></td><td>response to stress</td><td>3.8e-16</td><td>transcription factor activity</td><td>8.9e-04</td></tr><tr><td></td><td>other biological processes</td><td>1.8e-11</td><td>transferase activity</td><td>1.7e-03</td></tr><tr><td></td><td>signal transduction</td><td>7.3e-03</td><td>transporter activity</td><td>1.4e-02</td></tr><tr><td>Osmotic</td><td>response to stress</td><td>1.4e-16</td><td>transferase activity</td><td>7.0e-04</td></tr><tr><td></td><td>response to abiotic or biotic stimulus</td><td>1.4e-14</td><td>kinase activity</td><td>1.4e-03</td></tr><tr><td></td><td>other biological processes</td><td>1.3e-08</td><td>transcription factor activity</td><td>1.3e-02</td></tr><tr><td></td><td>signal transduction</td><td>1.3e-02</td><td>other molecular functions</td><td>4.3e-02</td></tr><tr><td>Salt</td><td>response to abiotic or biotic stimulus</td><td>3.0e-12</td><td>structural molecule activity</td><td>1.1e-13</td></tr></table>
<table><tr><td>Conditions</td><td>Biological Process</td><td>FDRp-value</td><td>Molecular Function</td><td>FDRp-value</td></tr><tr><td></td><td>response to stress</td><td>6.0e-07</td><td>transferase activity</td><td>2.3e-03</td></tr><tr><td></td><td>other biological processes</td><td>3.3e-03</td><td>other enzyme activity</td><td>2.4e-02</td></tr><tr><td>UV-B</td><td>response to abiotic or biotic stimulus</td><td>3.1e-12</td><td>transferase activity</td><td>1.3e-02</td></tr><tr><td></td><td>response to stress</td><td>2.3e-11</td><td>kinase activity</td><td>1.4e-02</td></tr><tr><td></td><td>other biological processes</td><td>1.6e-08</td><td></td><td></td></tr><tr><td>Wounding</td><td>response to abiotic or biotic stimulus</td><td>1.4e-17</td><td>other enzyme activity</td><td>6.3e-06</td></tr><tr><td></td><td>response to stress</td><td>1.0e-15</td><td>transferase activity</td><td>2.1e-03</td></tr><tr><td></td><td>other biological processes</td><td>1.1e-10</td><td>transcription factor activity</td><td>2.1e-03</td></tr><tr><td></td><td>other metabolic processes</td><td>4.7e-02</td><td>hydrolase activity</td><td>1.2e-02</td></tr><tr><td></td><td></td><td></td><td>transporter activity</td><td>4.1e-02</td></tr><tr><td>Drought</td><td>response to abiotic or biotic stimulus</td><td>2.8e-19</td><td>structural molecule activity</td><td>7.9e-18</td></tr><tr><td></td><td>response to stress</td><td>6.0e-19</td><td>transferase activity</td><td>6.7e-05</td></tr><tr><td></td><td>other biological processes</td><td>6.4e-10</td><td>other enzyme activity</td><td>3.8e-04</td></tr><tr><td></td><td>other metabolic processes</td><td>1.8e-02</td><td></td><td></td></tr><tr><td>Heat</td><td>other biological processes</td><td>7.0e-12</td><td>transferase activity</td><td>9.3e-04</td></tr><tr><td></td><td>response to abiotic or biotic stimulus</td><td>7.7e-10</td><td>other enzyme activity</td><td>2.1e-03</td></tr><tr><td></td><td>response to stress</td><td>3.4e-08</td><td>hydrolase activity</td><td>3.1e-02</td></tr><tr><td></td><td>electron transport or energy pathways</td><td>9.5e-03</td><td></td><td></td></tr><tr><td>Oxidative</td><td>response to abiotic or biotic stimulus</td><td>7.3e-17</td><td>transcription factor activity</td><td>2.2e-03</td></tr><tr><td></td><td>other biological processes</td><td>6.5e-14</td><td>other enzyme activity</td><td>5.7e-03</td></tr><tr><td></td><td>response to stress</td><td>7.7e-10</td><td>kinase activity</td><td>1.4e-02</td></tr><tr><td></td><td></td><td></td><td>transferase activity</td><td>1.6e-02</td></tr></table>
a4989750a2dda864ebc579c8a78a9f8eb511dd6b111feef8d30d2802d4c56556.png
complex
<table><tr><td rowspan="2"></td><td>Did not require ICU(<i>n</i> = 249)</td><td>Required ICU (severe)(<i>n</i> = 18)</td><td rowspan="2"><i>P</i>b value</td></tr><tr><td>N (%)</td><td>N (%)</td></tr><tr><td>Any medical risk factor a</td><td>115 (46.2)</td><td>11 (61.1)</td><td>.22</td></tr><tr><td>Influenza B strain</td><td>47 (19.0)</td><td>7 (38.9)</td><td>.04</td></tr><tr><td>Iron&#8208;deficient anaemia</td><td>21 (8.4)</td><td>5 (27.8)</td><td>.01</td></tr><tr><td>Food allergy</td><td>6 (2.4)</td><td>2 (11.1)</td><td>.09</td></tr><tr><td>Proportion less than 2 y of age </td><td>150 (60.2)</td><td>14 (77.8)</td><td>.14</td></tr><tr><td>Antiviral prescribed</td><td>34 (13.7)</td><td>2 (11.8)</td><td>.82</td></tr><tr><td>Antibiotic prescribed</td><td>121 (48.8)</td><td>9 (52.9)</td><td>.74</td></tr><tr><td>Co&#8208;infection identified</td><td>99 (39.8)</td><td>8 (47.1)</td><td>.55</td></tr></table>
<table><tr><td rowspan="2"></td><td>Did not require ICU(n = 249)</td><td>Required ICU (severe)(n = 18)</td><td rowspan="2">Pb value</td></tr><tr><td>N (%)</td><td>N (%)</td></tr><tr><td>Any medical risk factor a</td><td>115 (46.2)</td><td>11 (61.1)</td><td>.22</td></tr><tr><td>Influenza B strain</td><td>47 (19.0)</td><td>7 (38.9)</td><td>.04</td></tr><tr><td>Iron‐deficient anaemia</td><td>21 (8.4)</td><td>5 (27.8)</td><td>.01</td></tr><tr><td>Food allergy</td><td>6 (2.4)</td><td>2 (11.1)</td><td>.09</td></tr></table>
<table><tr><td rowspan="2"></td><td>Did not require ICU(n = 249)</td><td>Required ICU (severe)(n = 18)</td><td rowspan="2">Pb value</td></tr><tr><td>N (%)</td><td>N (%)</td></tr><tr><td>Proportion less than 2 y of age</td><td>150 (60.2)</td><td>14 (77.8)</td><td>.14</td></tr><tr><td>Antiviral prescribed</td><td>34 (13.7)</td><td>2 (11.8)</td><td>.82</td></tr><tr><td>Antibiotic prescribed</td><td>121 (48.8)</td><td>9 (52.9)</td><td>.74</td></tr><tr><td>Co‐infection identified</td><td>99 (39.8)</td><td>8 (47.1)</td><td>.55</td></tr></table>
08fd2a0cad135e41181b932b258fa6759b00db0e909dd311a6b95bb73ba038ce.png
complex
<table><tr><td>Baseline characteristics</td><td></td><td>Missed scheduled appointments (%)</td><td>RR</td><td>95 % CI</td><td><i>p</i> (value)</td></tr><tr><td rowspan="2">Sex</td><td>Female</td><td>4/153 (2.6)</td><td>1</td><td></td><td></td></tr><tr><td>Male</td><td>33/304 (10.9)</td><td>4.2</td><td>1.5&#8211;11.5</td><td>0.004</td></tr><tr><td>Age (years)</td><td>&lt;25</td><td>5/82 (6.1)</td><td>1</td><td></td><td></td></tr><tr><td></td><td>25&#8211;64</td><td>31/360 (8.6)</td><td>1.4</td><td>0.6&#8211;3.5</td><td>0.21</td></tr><tr><td></td><td>&#8805;65</td><td>1/15 (6.7)</td><td>1.1</td><td>0.1&#8211;8.7</td><td>1</td></tr><tr><td>HIV-Status</td><td>Negative</td><td>34/346 (9.8)</td><td>1</td><td></td><td></td></tr><tr><td></td><td>Positive</td><td>3/108 (2.8)</td><td>0.3</td><td>0.1&#8211;0.9</td><td>0.03</td></tr><tr><td></td><td>Unknown</td><td>0/3 (0)</td><td>-</td><td></td><td>-</td></tr><tr><td>Type of TB</td><td>New SS+</td><td>36/410 (9.8)</td><td>1</td><td></td><td></td></tr><tr><td></td><td>Retreatment</td><td>1/47 (4.3)</td><td>0.2</td><td>0.03&#8211;1.7</td><td>0.16</td></tr><tr><td>Place of treatment</td><td>CNHP-P</td><td>21/259 (8.1)</td><td>1</td><td></td><td></td></tr><tr><td></td><td>DOT clinic</td><td>16/198 (8.1)</td><td>1.0</td><td>0.5&#8211;1.9</td><td>0.99</td></tr></table>
<table><tr><td>Baseline characteristics</td><td></td></tr><tr><td rowspan="2">Sex</td><td>Female</td></tr><tr><td>Male</td></tr><tr><td>Age (years)</td><td><25</td></tr><tr><td></td><td>25–64</td></tr><tr><td></td><td>≥65</td></tr><tr><td>HIV-Status</td><td>Negative</td></tr><tr><td></td><td>Positive</td></tr><tr><td></td><td>Unknown</td></tr><tr><td>Type of TB</td><td>New SS+</td></tr><tr><td></td><td>Retreatment</td></tr><tr><td>Place of treatment</td><td>CNHP-P</td></tr><tr><td></td><td>DOT clinic</td></tr></table>
<table><tr><td>Missed scheduled appointments (%)</td><td>RR</td><td>95 % CI</td><td>p (value)</td></tr><tr><td>4/153 (2.6)</td><td>1</td><td></td><td></td></tr><tr><td>33/304 (10.9)</td><td>4.2</td><td>1.5–11.5</td><td>0.004</td></tr><tr><td>5/82 (6.1)</td><td>1</td><td></td><td></td></tr><tr><td>31/360 (8.6)</td><td>1.4</td><td>0.6–3.5</td><td>0.21</td></tr><tr><td>1/15 (6.7)</td><td>1.1</td><td>0.1–8.7</td><td>1</td></tr><tr><td>34/346 (9.8)</td><td>1</td><td></td><td></td></tr><tr><td>3/108 (2.8)</td><td>0.3</td><td>0.1–0.9</td><td>0.03</td></tr><tr><td>0/3 (0)</td><td>-</td><td></td><td>-</td></tr><tr><td>36/410 (9.8)</td><td>1</td><td></td><td></td></tr><tr><td>1/47 (4.3)</td><td>0.2</td><td>0.03–1.7</td><td>0.16</td></tr><tr><td>21/259 (8.1)</td><td>1</td><td></td><td></td></tr><tr><td>16/198 (8.1)</td><td>1.0</td><td>0.5–1.9</td><td>0.99</td></tr></table>
46921367575651aa16bd7a894dcbc987c9e708e3d8318f88a0d3895202c0189a.png
complex
<table><tr><td>Explanatory variable</td><td>Coefficient &#177; Standar Error</td><td><i>P</i></td></tr><tr><td colspan="3">Body Fat at follow-up equation, kg</td></tr><tr><td> Leisure time physical activity at follow-up, METs/wk</td><td>&#8722;0.215 &#177; 0.091</td><td>0.019</td></tr><tr><td> Calorie Intake at follow-up, 100 kcal</td><td>0.328 &#177; 0.142</td><td>0.021</td></tr><tr><td> Age at follow-up</td><td>0.115 &#177; 0.036</td><td>0.001</td></tr><tr><td> Height at follow-up</td><td>0.520 &#177; 0.092</td><td>&lt; 0.001</td></tr><tr><td> Constant</td><td>28.399 &#177; 0.425</td><td>&lt; 0.001</td></tr><tr><td colspan="3">Leisure time physical activity at follow-up equation, METs/wk</td></tr><tr><td> Body fat at follow-up, kg</td><td>1.059 &#177; 0.456</td><td>0.020</td></tr><tr><td> Depression score at follow-up, CES-D*</td><td>&#8722;0.191 &#177; 0.095</td><td>0.045</td></tr><tr><td> Age at follow-up</td><td>&#8722;0.025 &#177; 0.071</td><td>0.722</td></tr><tr><td> Constant</td><td>&#8722;30.038 &#177; 12.750</td><td>0.018</td></tr><tr><td colspan="3">Calorie Intake at follow-up equation, 100 kcal</td></tr><tr><td> Body fat at follow-up, kg</td><td>&#8722;0.341 &#177; 0.183</td><td>0.063</td></tr><tr><td> Depression score at follow-up, CES-D*</td><td>0.188 &#177; 0.048</td><td>&lt; 0.001</td></tr><tr><td> Age at follow-up</td><td>&#8722;0.067 &#177; 0.035</td><td>0.057</td></tr><tr><td> Constant</td><td>9.630 &#177; 5.285</td><td>0.068</td></tr><tr><td colspan="3">Error Covariances</td></tr><tr><td> Calorie intake with physical activity</td><td>&#8722;26.882 &#177; 20.302</td><td>0.185</td></tr></table>
<table><tr><td>Explanatory variable</td><td>Coefficient ± Standar Error</td></tr><tr><td colspan="2">Body Fat at follow-up equation, kg</td></tr><tr><td>Leisure time physical activity at follow-up, METs/wk</td><td>−0.215 ± 0.091</td></tr><tr><td>Calorie Intake at follow-up, 100 kcal</td><td>0.328 ± 0.142</td></tr><tr><td>Age at follow-up</td><td>0.115 ± 0.036</td></tr><tr><td>Height at follow-up</td><td>0.520 ± 0.092</td></tr><tr><td>Constant</td><td>28.399 ± 0.425</td></tr><tr><td colspan="2">Leisure time physical activity at follow-up equation, METs/wk</td></tr><tr><td>Body fat at follow-up, kg</td><td>1.059 ± 0.456</td></tr><tr><td>Depression score at follow-up, CES-D*</td><td>−0.191 ± 0.095</td></tr><tr><td>Age at follow-up</td><td>−0.025 ± 0.071</td></tr><tr><td>Constant</td><td>−30.038 ± 12.750</td></tr><tr><td colspan="2">Calorie Intake at follow-up equation, 100 kcal</td></tr><tr><td>Body fat at follow-up, kg</td><td>−0.341 ± 0.183</td></tr><tr><td>Depression score at follow-up, CES-D*</td><td>0.188 ± 0.048</td></tr><tr><td>Age at follow-up</td><td>−0.067 ± 0.035</td></tr><tr><td>Constant</td><td>9.630 ± 5.285</td></tr><tr><td colspan="2">Error Covariances</td></tr><tr><td>Calorie intake with physical activity</td><td>−26.882 ± 20.302</td></tr></table>
<table><tr><td>P</td></tr><tr><td>Body Fat at follow-up equation, kg</td></tr><tr><td>0.019</td></tr><tr><td>0.021</td></tr><tr><td>0.001</td></tr><tr><td>< 0.001</td></tr><tr><td>< 0.001</td></tr><tr><td>Leisure time physical activity at follow-up equation, METs/wk</td></tr><tr><td>0.020</td></tr><tr><td>0.045</td></tr><tr><td>0.722</td></tr><tr><td>0.018</td></tr><tr><td>Calorie Intake at follow-up equation, 100 kcal</td></tr><tr><td>0.063</td></tr><tr><td>< 0.001</td></tr><tr><td>0.057</td></tr><tr><td>0.068</td></tr><tr><td>Error Covariances</td></tr><tr><td>0.185</td></tr></table>
885348360a75b1e94d40f18dee9595953e38215d7904c2fb978d4aebf0d64977.png
complex
<table><tr><td>Brain regions</td><td> </td><td>Voxels</td><td><i>X</i> (MNI)</td><td><i>Y</i> (MNI)</td><td><i>Z</i> (MNI)</td><td><i>T</i> value</td></tr><tr><td>High BrAC group &lt; control</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td rowspan="2"> Superior frontal gyrus</td><td>R</td><td>750</td><td>15</td><td>21</td><td>57</td><td>&#8722;4.6134</td></tr><tr><td>R</td><td>39</td><td>12</td><td>39</td><td>&#8722;24</td><td>&#8722;3.7952</td></tr><tr><td> Inferior frontal gyrus</td><td>R </td><td>37</td><td>54</td><td>21</td><td>18</td><td>&#8722;4.4388</td></tr><tr><td> Hippocampal gyrus</td><td>R</td><td>39</td><td>18</td><td>&#8722;6</td><td>&#8722;33</td><td>&#8722;4.6794</td></tr><tr><td> Inferior temporal gyrus</td><td>R</td><td>30</td><td>33</td><td>9</td><td>&#8722;45</td><td>&#8722;4.2946</td></tr><tr><td>High BrAC group &gt; control</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td rowspan="2"> Middle frontal gyrus</td><td>L</td><td>100</td><td>&#8722;27</td><td>45</td><td>3</td><td>4.7207</td></tr><tr><td>R</td><td>42</td><td>12</td><td>&#8722;21</td><td>60</td><td>6.4199</td></tr><tr><td> Basal ganglia</td><td>L</td><td>468</td><td>&#8722;27</td><td>12</td><td>&#8722;3</td><td>5.7696</td></tr><tr><td> Cerebellum </td><td>R</td><td>114</td><td>9</td><td>48</td><td>&#8722;24</td><td>6.8909</td></tr><tr><td> Internal capsule</td><td>R</td><td>39</td><td>9</td><td>0</td><td>6</td><td>3.9489</td></tr></table>
<table><tr><td>Brain regions</td><td></td><td>Voxels</td><td>X (MNI)</td><td>Y (MNI)</td><td>Z (MNI)</td><td>T value</td></tr><tr><td>High BrAC group < control</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Superior frontal gyrus</td><td>R</td><td>750</td><td>15</td><td>21</td><td>57</td><td>−4.6134</td></tr></table>
<table><tr><td>Superior frontal gyrus</td><td>R</td><td>39</td><td>12</td><td>39</td><td>−24</td><td>−3.7952</td></tr><tr><td>Inferior frontal gyrus</td><td>R</td><td>37</td><td>54</td><td>21</td><td>18</td><td>−4.4388</td></tr><tr><td>Hippocampal gyrus</td><td>R</td><td>39</td><td>18</td><td>−6</td><td>−33</td><td>−4.6794</td></tr><tr><td>Inferior temporal gyrus</td><td>R</td><td>30</td><td>33</td><td>9</td><td>−45</td><td>−4.2946</td></tr><tr><td>High BrAC group > control</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan="2">Middle frontal gyrus</td><td>L</td><td>100</td><td>−27</td><td>45</td><td>3</td><td>4.7207</td></tr><tr><td>R</td><td>42</td><td>12</td><td>−21</td><td>60</td><td>6.4199</td></tr><tr><td>Basal ganglia</td><td>L</td><td>468</td><td>−27</td><td>12</td><td>−3</td><td>5.7696</td></tr><tr><td>Cerebellum</td><td>R</td><td>114</td><td>9</td><td>48</td><td>−24</td><td>6.8909</td></tr><tr><td>Internal capsule</td><td>R</td><td>39</td><td>9</td><td>0</td><td>6</td><td>3.9489</td></tr></table>
27ced2db3f8c24ec1cca5d270792e966d17fd60d5c7f282a69ea16680adb4462.png
simple
<table><tr><td>Gene</td><td>Acc. No</td><td>Primer sequence (5&#8242; to 3&#8242;)</td></tr><tr><td><i>Pparg</i> (mouse)</td><td>NM_001127330</td><td>F: GACCACTCGCATTCCTTT</td></tr><tr><td> </td><td> </td><td>R: CCACAGACTCGGCACTCA</td></tr><tr><td><i>Fabp4</i> (mouse)</td><td>NM_024406</td><td>F: AAATCACCGCAGACGACA</td></tr><tr><td> </td><td> </td><td>R: CACATTCCACCACCAGCT</td></tr><tr><td><i>Runx2</i> (mouse)</td><td>NM_001146038</td><td>F: ACTTCCTGTGCTCCGTGCTG</td></tr><tr><td> </td><td> </td><td>R: TCGTTGAACCTGGCTACTTGG</td></tr><tr><td><i>Osterix</i> (mouse)</td><td>NM_130458</td><td>F: ACCAGGTCCAGGCAACAC</td></tr><tr><td> </td><td> </td><td>R: GCAAAGTCAGATGGGTAAGTAG</td></tr><tr><td><i>Tmem64</i> (mouse)</td><td>NM_181401</td><td>F: AGGAAGCGGCCTGAAGGT</td></tr><tr><td> </td><td> </td><td>R: GAAGGAAGAGCCACTGGGAT</td></tr><tr><td><i>&#946;-actin</i> (mouse)</td><td>NM_007393</td><td>F: CTGTCCCTGTATGCCTCTG</td></tr><tr><td> </td><td> </td><td>R: TGATGTCACGCACGATTT</td></tr></table>
<table><tr><td>Gene</td><td>Acc. No</td></tr><tr><td>Pparg (mouse)</td><td>NM_001127330</td></tr><tr><td></td><td></td></tr><tr><td>Fabp4 (mouse)</td><td>NM_024406</td></tr><tr><td></td><td></td></tr><tr><td>Runx2 (mouse)</td><td>NM_001146038</td></tr><tr><td></td><td></td></tr><tr><td>Osterix (mouse)</td><td>NM_130458</td></tr><tr><td></td><td></td></tr><tr><td>Tmem64 (mouse)</td><td>NM_181401</td></tr><tr><td></td><td></td></tr><tr><td>β-actin (mouse)</td><td>NM_007393</td></tr><tr><td></td><td></td></tr></table>
<table><tr><td>Primer sequence (5′ to 3′)</td></tr><tr><td>F: GACCACTCGCATTCCTTT</td></tr><tr><td>R: CCACAGACTCGGCACTCA</td></tr><tr><td>F: AAATCACCGCAGACGACA</td></tr><tr><td>R: CACATTCCACCACCAGCT</td></tr><tr><td>F: ACTTCCTGTGCTCCGTGCTG</td></tr><tr><td>R: TCGTTGAACCTGGCTACTTGG</td></tr><tr><td>F: ACCAGGTCCAGGCAACAC</td></tr><tr><td>R: GCAAAGTCAGATGGGTAAGTAG</td></tr><tr><td>F: AGGAAGCGGCCTGAAGGT</td></tr><tr><td>R: GAAGGAAGAGCCACTGGGAT</td></tr><tr><td>F: CTGTCCCTGTATGCCTCTG</td></tr><tr><td>R: TGATGTCACGCACGATTT</td></tr></table>
fe6c4929fda8844b175be8fa59cbd75836ecb1604876ba88bf149578c97da2a2.png
complex
<table><tr><td rowspan="3">Dataset</td><td colspan="6">Sum of Weights</td></tr><tr><td colspan="3">Deterministic Model</td><td colspan="3">Stochastic Model</td></tr><tr><td>Before Failure</td><td>After Failure</td><td>W-GAP</td><td>Before Failure</td><td>After Failure</td><td>W-GAP</td></tr><tr><td>Dataset_1</td><td>37.6</td><td>33</td><td>12.2%</td><td>36.3</td><td>36.3</td><td>0.0%</td></tr><tr><td>Dataset_2</td><td>35.9</td><td>31.6</td><td>12.0%</td><td>35.3</td><td>33.8</td><td>4.2%</td></tr><tr><td>Dataset_3</td><td>35.9</td><td>26.4</td><td>26.5%</td><td>32.9</td><td>32.9</td><td>0.0%</td></tr><tr><td>Dataset_4</td><td>33.1</td><td>23.6</td><td>28.7%</td><td>32.1</td><td>26.9</td><td>16.2%</td></tr><tr><td>Dataset_5</td><td>27.7</td><td>21.7</td><td>21.7%</td><td>26.5</td><td>21.9</td><td>17.4%</td></tr><tr><td>Dataset_6</td><td>34.6</td><td>30.4</td><td>12.1%</td><td>33.9</td><td>33.9</td><td>0.0%</td></tr><tr><td>Dataset_7</td><td>32.2</td><td>31.1</td><td>3.4%</td><td>31.4</td><td>31.4</td><td>0.0%</td></tr><tr><td>Dataset_8</td><td>34</td><td>25.8</td><td>24.1%</td><td>32.5</td><td>30.9</td><td>4.9%</td></tr><tr><td>Dataset_9</td><td>34.5</td><td>26.9</td><td>22.0%</td><td>32.4</td><td>32.4</td><td>0.0%</td></tr><tr><td>Dataset_10</td><td>29.4</td><td>26.1</td><td>11.2%</td><td>28.3</td><td>28.3</td><td>0.0%</td></tr><tr><td>Average</td><td>33.5</td><td>27.7</td><td>17.4%</td><td>32.2</td><td>30.9</td><td>4.0%</td></tr></table>
<table><tr><td rowspan="3">Dataset</td><td colspan="6">Sum of Weights</td></tr><tr><td colspan="3">Deterministic Model</td><td colspan="3">Stochastic Model</td></tr><tr><td>Before Failure</td><td>After Failure</td><td>W-GAP</td><td>Before Failure</td><td>After Failure</td><td>W-GAP</td></tr><tr><td>Dataset_1</td><td>37.6</td><td>33</td><td>12.2%</td><td>36.3</td><td>36.3</td><td>0.0%</td></tr><tr><td>Dataset_2</td><td>35.9</td><td>31.6</td><td>12.0%</td><td>35.3</td><td>33.8</td><td>4.2%</td></tr><tr><td>Dataset_3</td><td>35.9</td><td>26.4</td><td>26.5%</td><td>32.9</td><td>32.9</td><td>0.0%</td></tr><tr><td>Dataset_4</td><td>33.1</td><td>23.6</td><td>28.7%</td><td>32.1</td><td>26.9</td><td>16.2%</td></tr><tr><td>Dataset_5</td><td>27.7</td><td>21.7</td><td>21.7%</td><td>26.5</td><td>21.9</td><td>17.4%</td></tr><tr><td>Dataset_6</td><td>34.6</td><td>30.4</td><td>12.1%</td><td>33.9</td><td>33.9</td><td>0.0%</td></tr><tr><td>Dataset_7</td><td>32.2</td><td>31.1</td><td>3.4%</td><td>31.4</td><td>31.4</td><td>0.0%</td></tr></table>
<table><tr><td>Dataset_8</td><td>34</td><td>25.8</td><td>24.1%</td><td>32.5</td><td>30.9</td><td>4.9%</td></tr><tr><td>Dataset_9</td><td>34.5</td><td>26.9</td><td>22.0%</td><td>32.4</td><td>32.4</td><td>0.0%</td></tr><tr><td>Dataset_10</td><td>29.4</td><td>26.1</td><td>11.2%</td><td>28.3</td><td>28.3</td><td>0.0%</td></tr><tr><td>Average</td><td>33.5</td><td>27.7</td><td>17.4%</td><td>32.2</td><td>30.9</td><td>4.0%</td></tr></table>
4039b2734334d5809c8645d80c30fbf0f70321b27a284f2e6e8ec880bb8d0864.png
complex
<table><tr><td></td><td colspan="2">Girls</td><td>Boys</td></tr><tr><td>Goodness-of-fit statistics</td><td>1-factor model</td><td>2- factor model</td><td>1-factor model</td></tr><tr><td>&#967;<sup>2</sup></td><td>8.13</td><td>4.41</td><td>4.44</td></tr><tr><td>df</td><td>5</td><td>4</td><td>5</td></tr><tr><td>p</td><td>.15</td><td>.35</td><td>.49</td></tr><tr><td>RMSEA</td><td>.028</td><td>.018</td><td>.00</td></tr><tr><td>CFI</td><td>.98</td><td>.99</td><td>1.00</td></tr><tr><td>TLI</td><td>.97</td><td>.98</td><td>1.02</td></tr><tr><td>r</td><td></td><td>.61</td><td></td></tr></table>
<table><tr><td></td><td colspan="2">Girls</td><td>Boys</td></tr></table>
<table><tr><td>Goodness-of-fit statistics</td><td>1-factor model</td><td>2- factor model</td><td>1-factor model</td></tr><tr><td>χ2</td><td>8.13</td><td>4.41</td><td>4.44</td></tr><tr><td>df</td><td>5</td><td>4</td><td>5</td></tr><tr><td>p</td><td>.15</td><td>.35</td><td>.49</td></tr><tr><td>RMSEA</td><td>.028</td><td>.018</td><td>.00</td></tr><tr><td>CFI</td><td>.98</td><td>.99</td><td>1.00</td></tr><tr><td>TLI</td><td>.97</td><td>.98</td><td>1.02</td></tr><tr><td>r</td><td></td><td>.61</td><td></td></tr></table>
e15065c932c2541de2dd9d1deca51c3101d72e57d22cdd6d178cddb2ff53eb52.png
complex
<table><tr><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td>First outbreak (October 2013)</td><td></td><td>Second outbreak (July 2014)</td><td></td></tr><tr><td colspan="2">Water temperature: 23 &#176;C</td><td colspan="2">Water temperature: 26 &#176;C</td></tr><tr><td>Cage</td><td>Date stocked</td><td>Age at stocking (months)</td><td>Average weight at first outbreak (g)</td><td>Cumulative mortality (%)</td><td>Average weight at second outbreak (g)</td><td>Cumulative mortality (%)</td></tr><tr><td>1</td><td>April 2012</td><td>2</td><td>323</td><td>4,82</td><td>336</td><td>4,86</td></tr><tr><td>2</td><td>April 2012</td><td>2</td><td>319</td><td>5,30</td><td>440</td><td>5,3</td></tr><tr><td>3</td><td>July 2012</td><td>5</td><td>292</td><td>4,76</td><td>441</td><td>4,76</td></tr><tr><td>4</td><td>April 2013</td><td>2</td><td>84</td><td>2,23</td><td>274</td><td>2,23</td></tr></table>
<table><tr><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td>First outbreak (October 2013)</td><td></td><td>Second outbreak (July 2014)</td></tr><tr><td colspan="2">Water temperature: 23 °C</td><td>Water temperature: 26 °C</td></tr><tr><td>Cage</td><td>Date stocked</td><td>Age at stocking (months)</td><td>Average weight at first outbreak (g)</td><td>Cumulative mortality (%)</td><td>Average weight at second outbreak (g)</td></tr><tr><td>1</td><td>April 2012</td><td>2</td><td>323</td><td>4,82</td><td>336</td></tr><tr><td>2</td><td>April 2012</td><td>2</td><td>319</td><td>5,30</td><td>440</td></tr><tr><td>3</td><td>July 2012</td><td>5</td><td>292</td><td>4,76</td><td>441</td></tr><tr><td>4</td><td>April 2013</td><td>2</td><td>84</td><td>2,23</td><td>274</td></tr></table>
<table><tr><td></td></tr><tr><td>Water temperature: 26 °C</td></tr><tr><td>Cumulative mortality (%)</td></tr><tr><td>4,86</td></tr><tr><td>5,3</td></tr><tr><td>4,76</td></tr><tr><td>2,23</td></tr></table>
5c8b632deefe62dfe146ff9e84e0987afc0f144c8cee28a658430018792cc9ed.png
complex
<table><tr><td>Treatment</td><td colspan="2">Days from transplant to initial bolting (d)</td><td colspan="2">Days from transplant to 50% bolting (d)</td><td colspan="2">Bolting rate by 30 April (%)</td></tr><tr><td> </td><td>2011</td><td>2012</td><td>2011</td><td>2012</td><td>2011</td><td>2012</td></tr><tr><td>Grand mean</td><td>128.4</td><td>139.7</td><td>140.5</td><td>-</td><td>39.7</td><td>16.0</td></tr><tr><td>Cultivars</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>JinGuan</td><td>110.9c<sup>a</sup></td><td>118.6c</td><td>125.8c</td><td>-</td><td>53.9a</td><td>26.7a</td></tr><tr><td>XiaHei</td><td>145.2a</td><td>158.9a</td><td>-a</td><td>-</td><td>29.3c</td><td>5.9c</td></tr><tr><td>YeFu</td><td>129.1b</td><td>141.6b</td><td>130.8b</td><td>-</td><td>36.0b</td><td>15.5b</td></tr><tr><td>Sowing date</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>08.20</td><td>118.0c</td><td>124.2c</td><td>119.8c</td><td>-</td><td>64.5a</td><td>30.1a</td></tr><tr><td>09.09</td><td>125.6b</td><td>141.9b</td><td>136.8b</td><td>-</td><td>39.7b</td><td>12.6b</td></tr><tr><td>09.29</td><td>141.7a</td><td>152.9a</td><td>-a</td><td>-</td><td>15.0c</td><td>5.4c</td></tr><tr><td>Transplant location</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Open field</td><td>155.0a</td><td>151.9a</td><td>-a</td><td>-</td><td>9.3c</td><td>5.6c</td></tr><tr><td>Cold shed</td><td>123.7b</td><td>138.4b</td><td>132.8b</td><td>-</td><td>44.7b</td><td>16.0b</td></tr><tr><td>Plastic tunnel</td><td>106.6c</td><td>128.7c</td><td>123.8c</td><td>-</td><td>65.2a</td><td>26.4a</td></tr><tr><td>F-test</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Cultivar (C)</td><td>***</td><td>***</td><td>***</td><td>NS</td><td>***</td><td>***</td></tr><tr><td>Sowing date (D)</td><td>***</td><td>***</td><td>***</td><td>NS</td><td>***</td><td>***</td></tr><tr><td>Transplant location (L)</td><td>***</td><td>***</td><td>***</td><td>NS</td><td>**</td><td>***</td></tr><tr><td>C*D</td><td>***</td><td>***</td><td>*</td><td>NS</td><td>***</td><td>***</td></tr><tr><td>C*L</td><td>***</td><td>***</td><td>NS</td><td>NS</td><td>*</td><td>***</td></tr><tr><td>D*L</td><td>***</td><td>***</td><td>**</td><td>NS</td><td>***</td><td>***</td></tr><tr><td>C*D*L</td><td>***</td><td>***</td><td>NS</td><td>NS</td><td>***</td><td>***</td></tr></table>
<table><tr><td>Treatment</td><td colspan="2">Days from transplant to initial bolting (d)</td><td colspan="2">Days from transplant to 50% bolting (d)</td><td colspan="2">Bolting rate by 30 April (%)</td></tr><tr><td></td><td>2011</td><td>2012</td><td>2011</td><td>2012</td><td>2011</td><td>2012</td></tr><tr><td>Grand mean</td><td>128.4</td><td>139.7</td><td>140.5</td><td>-</td><td>39.7</td><td>16.0</td></tr></table>
<table><tr><td>Treatment</td><td colspan="2">Days from transplant to initial bolting (d)</td><td colspan="2">Days from transplant to 50% bolting (d)</td><td colspan="2">Bolting rate by 30 April (%)</td></tr><tr><td></td><td>2011</td><td>2012</td><td>2011</td><td>2012</td><td>2011</td><td>2012</td></tr><tr><td>Cultivars</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>JinGuan</td><td>110.9ca</td><td>118.6c</td><td>125.8c</td><td>-</td><td>53.9a</td><td>26.7a</td></tr><tr><td>XiaHei</td><td>145.2a</td><td>158.9a</td><td>-a</td><td>-</td><td>29.3c</td><td>5.9c</td></tr><tr><td>YeFu</td><td>129.1b</td><td>141.6b</td><td>130.8b</td><td>-</td><td>36.0b</td><td>15.5b</td></tr><tr><td>Sowing date</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>08.20</td><td>118.0c</td><td>124.2c</td><td>119.8c</td><td>-</td><td>64.5a</td><td>30.1a</td></tr><tr><td>09.09</td><td>125.6b</td><td>141.9b</td><td>136.8b</td><td>-</td><td>39.7b</td><td>12.6b</td></tr><tr><td>09.29</td><td>141.7a</td><td>152.9a</td><td>-a</td><td>-</td><td>15.0c</td><td>5.4c</td></tr><tr><td>Transplant location</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Open field</td><td>155.0a</td><td>151.9a</td><td>-a</td><td>-</td><td>9.3c</td><td>5.6c</td></tr><tr><td>Cold shed</td><td>123.7b</td><td>138.4b</td><td>132.8b</td><td>-</td><td>44.7b</td><td>16.0b</td></tr><tr><td>Plastic tunnel</td><td>106.6c</td><td>128.7c</td><td>123.8c</td><td>-</td><td>65.2a</td><td>26.4a</td></tr><tr><td>F-test</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Cultivar (C)</td><td>***</td><td>***</td><td>***</td><td>NS</td><td>***</td><td>***</td></tr><tr><td>Sowing date (D)</td><td>***</td><td>***</td><td>***</td><td>NS</td><td>***</td><td>***</td></tr><tr><td>Transplant location (L)</td><td>***</td><td>***</td><td>***</td><td>NS</td><td>**</td><td>***</td></tr><tr><td>C*D</td><td>***</td><td>***</td><td>*</td><td>NS</td><td>***</td><td>***</td></tr><tr><td>C*L</td><td>***</td><td>***</td><td>NS</td><td>NS</td><td>*</td><td>***</td></tr><tr><td>D*L</td><td>***</td><td>***</td><td>**</td><td>NS</td><td>***</td><td>***</td></tr><tr><td>C*D*L</td><td>***</td><td>***</td><td>NS</td><td>NS</td><td>***</td><td>***</td></tr></table>
090c8168b7e69df332f615d544c57fa69508654b1bacf50189c61c3233081086.png
complex
<table><tr><td rowspan="2">Brain region</td><td>BA</td><td>Cluster sizes</td><td>t-value</td><td>P value</td><td colspan="3">Peak MNI coodinate</td></tr><tr><td colspan="2">(voxels)</td><td colspan="2">(Corr.)</td><td>X</td><td>Y</td><td>Z</td></tr><tr><td>R medial prefrontal cortex</td><td>8</td><td>12</td><td>6.02</td><td>&lt;.05</td><td>9</td><td>27</td><td>57</td></tr><tr><td>R middle frontal gyrus</td><td>9</td><td>211</td><td>10.87</td><td>&lt;.05</td><td>3</td><td>48</td><td>21</td></tr><tr><td>L middle temporal gyrus</td><td>21</td><td>14</td><td>&#8722;5.49</td><td>&lt;.05</td><td>&#8722;66</td><td>&#8722;54</td><td>3</td></tr><tr><td>R superior temporal gyrus</td><td>38</td><td>12</td><td>&#8722;5.59</td><td>&lt;.05</td><td>54</td><td>12</td><td>&#8722;18</td></tr><tr><td>L primary somatosensory cortex</td><td>2</td><td>19</td><td>&#8722;3.88</td><td>&lt;.05</td><td>&#8722;60</td><td>&#8722;21</td><td>42</td></tr><tr><td>R inferior parietal lobule</td><td>40</td><td>10</td><td>&#8722;10.94</td><td>&lt;.05</td><td>66</td><td>&#8722;36</td><td>21</td></tr><tr><td>L parahippocampal gyrus</td><td>&#8213;</td><td>11</td><td>&#8722;5.62</td><td>&lt;.05</td><td>&#8722;9</td><td>&#8722;3</td><td>&#8722;21</td></tr><tr><td>R parahippocampal gyrus</td><td>35</td><td>29</td><td>9.51</td><td>&lt;.05</td><td>30</td><td>&#8722;6</td><td>&#8722;21</td></tr><tr><td>L anterior cingulate cortex</td><td>32</td><td>12</td><td>&#8722;4.74</td><td>&lt;.05</td><td>&#8722;6</td><td>21</td><td>39</td></tr><tr><td>R precuneus</td><td>7</td><td>14</td><td>4.70</td><td>&lt;.05</td><td>18</td><td>&#8722;66</td><td>33</td></tr><tr><td>R insula</td><td>13</td><td>10</td><td>5.47</td><td>&lt;.05</td><td>39</td><td>0</td><td>18</td></tr><tr><td>R cerebellar tonsil</td><td>&#8213;</td><td>13</td><td>5.30</td><td>&lt;.05</td><td>9</td><td>&#8722;60</td><td>&#8722;48</td></tr></table>
<table><tr><td rowspan="2">Brain region</td></tr><tr></tr><tr><td>R medial prefrontal cortex</td></tr><tr><td>R middle frontal gyrus</td></tr><tr><td>L middle temporal gyrus</td></tr><tr><td>R superior temporal gyrus</td></tr><tr><td>L primary somatosensory cortex</td></tr><tr><td>R inferior parietal lobule</td></tr><tr><td>L parahippocampal gyrus</td></tr><tr><td>R parahippocampal gyrus</td></tr><tr><td>L anterior cingulate cortex</td></tr><tr><td>R precuneus</td></tr><tr><td>R insula</td></tr><tr><td>R cerebellar tonsil</td></tr></table>
<table><tr><td>BA</td><td>Cluster sizes</td><td>t-value</td><td>P value</td><td colspan="3">Peak MNI coodinate</td></tr><tr><td colspan="2">(voxels)</td><td colspan="2">(Corr.)</td><td>X</td><td>Y</td><td>Z</td></tr><tr><td>8</td><td>12</td><td>6.02</td><td><.05</td><td>9</td><td>27</td><td>57</td></tr><tr><td>9</td><td>211</td><td>10.87</td><td><.05</td><td>3</td><td>48</td><td>21</td></tr><tr><td>21</td><td>14</td><td>−5.49</td><td><.05</td><td>−66</td><td>−54</td><td>3</td></tr><tr><td>38</td><td>12</td><td>−5.59</td><td><.05</td><td>54</td><td>12</td><td>−18</td></tr><tr><td>2</td><td>19</td><td>−3.88</td><td><.05</td><td>−60</td><td>−21</td><td>42</td></tr><tr><td>40</td><td>10</td><td>−10.94</td><td><.05</td><td>66</td><td>−36</td><td>21</td></tr><tr><td>―</td><td>11</td><td>−5.62</td><td><.05</td><td>−9</td><td>−3</td><td>−21</td></tr><tr><td>35</td><td>29</td><td>9.51</td><td><.05</td><td>30</td><td>−6</td><td>−21</td></tr><tr><td>32</td><td>12</td><td>−4.74</td><td><.05</td><td>−6</td><td>21</td><td>39</td></tr><tr><td>7</td><td>14</td><td>4.70</td><td><.05</td><td>18</td><td>−66</td><td>33</td></tr><tr><td>13</td><td>10</td><td>5.47</td><td><.05</td><td>39</td><td>0</td><td>18</td></tr><tr><td>―</td><td>13</td><td>5.30</td><td><.05</td><td>9</td><td>−60</td><td>−48</td></tr></table>
4b1d8a4cbf03c98390d4d4ec431f86aa43fb09f9e644a0d77d7a8792550999d8.png
complex
<table><tr><td>Category</td><td>Treatment adherence barriers</td></tr><tr><td rowspan="2">Stigma related factors</td><td>&#9642; Fear of disclosure of child&#8217;s status to the teachers and family members by parents</td></tr><tr><td>&#9642; Segregation by teachers and other children</td></tr><tr><td rowspan="4">Lack of supportive environment at home</td><td>&#9642; Inadequate support from parents</td></tr><tr><td>&#10146; Parents move to farming areas without one to follow up on child&#8217;s treatment schedule</td></tr><tr><td>&#10146; Men do not provide enough treatment adherence support</td></tr><tr><td>&#10146; Extended family members do not provide support</td></tr><tr><td>Lack of supportive environment from school</td><td>&#9642; Teachers do not provide adequate support to children on ART</td></tr><tr><td rowspan="3">Health service delivery factors</td><td>&#9642; Lack of child friendly counseling services</td></tr><tr><td>&#9642; Inconvenient treatment schedule</td></tr><tr><td>&#9642; Longevity of treatment</td></tr><tr><td rowspan="2">Patient factor</td><td>&#9642; Forgetfulness</td></tr><tr><td>&#9642; Feeling better</td></tr></table>
<table><tr><td>Category</td><td>Treatment adherence barriers</td></tr><tr><td rowspan="2">Stigma related factors</td><td>▪ Fear of disclosure of child’s status to the teachers and family members by parents</td></tr><tr><td>▪ Segregation by teachers and other children</td></tr><tr><td>Lack of s</td><td>▪ Inadequate support from pare</td></tr></table>
<table><tr><td rowspan="4">upportive environment at home</td><td>nts</td></tr><tr><td>➢ Parents move to farming areas without one to follow up on child’s treatment schedule</td></tr><tr><td>➢ Men do not provide enough treatment adherence support</td></tr><tr><td>➢ Extended family members do not provide support</td></tr><tr><td>Lack of supportive environment from school</td><td>▪ Teachers do not provide adequate support to children on ART</td></tr><tr><td rowspan="3">Health service delivery factors</td><td>▪ Lack of child friendly counseling services</td></tr><tr><td>▪ Inconvenient treatment schedule</td></tr><tr><td>▪ Longevity of treatment</td></tr><tr><td rowspan="2">Patient factor</td><td>▪ Forgetfulness</td></tr><tr><td>▪ Feeling better</td></tr></table>
8d0225008b7b48603909bccc03608dd06a86821a010fa8703d4395ef8970876b.png
complex
<table><tr><td rowspan="2"></td><td>Factor</td></tr><tr><td>1</td></tr><tr><td>Me siento cansado y desanimado cuando me levanto por las man&#771;anas</td><td>0.612</td></tr><tr><td>Mis mu&#769;sculos esta&#769;n tensos y doloridos</td><td>0.650</td></tr><tr><td>Tengo ataques de pa&#769;nico</td><td>0.388</td></tr><tr><td>Rechino los dientes o aprieto la mandi&#769;bula</td><td>0.342</td></tr><tr><td>Tengo problemas de diarrea o estren&#771;imiento</td><td>0.400</td></tr><tr><td>Necesito ayuda pare realizar mis actividades diarias</td><td>0.476</td></tr><tr><td>Soy sensible a la luz brillante</td><td>0.440</td></tr><tr><td>Me canso fa&#769;cilmente cuando estoy fi&#769;sicamente activo</td><td>0.724</td></tr><tr><td>Siento dolor en todo mi cuerpo</td><td>0.582</td></tr><tr><td>Tengo dolores de cabeza</td><td>416</td></tr><tr><td>Tengo molestia en mi vejiga o sensacio&#769;n de quemazo&#769;n al orinar</td><td>0.294</td></tr><tr><td>No duermo bien</td><td>0.504</td></tr><tr><td>Tengo dificultad para concentrarme</td><td>0.436</td></tr><tr><td>Tengo problemas en la piel como resequedad, picor o sarpullido</td><td>0.299</td></tr><tr><td>El estre&#769;s hace que mis si&#769;ntomas fi&#769;sicos empeoren</td><td>0.587</td></tr><tr><td>Me siento triste o deprimido</td><td>0.621</td></tr><tr><td>Me siento con poca energi&#769;a</td><td>0.718</td></tr><tr><td>Tengo tensio&#769;n muscular en mi cuello y hombros</td><td>0.555</td></tr><tr><td>Tengo dolor en mi mandi&#769;bula</td><td>0.426</td></tr><tr><td>Algunos olores, como perfumes, me hacen sentir na&#769;useas.</td><td>0.269</td></tr><tr><td>Tengo que orinar frecuentemente</td><td>0.276</td></tr><tr><td>Mis piernas se sienten inco&#769;modas e inquietas cuando intento dormir por la noche</td><td>0.476</td></tr><tr><td>Tengo dificultad para recordar cosas</td><td>0.482</td></tr><tr><td>Sufri&#769; algu&#769;n trauma cuando era nin&#771;o (a)</td><td>0.120</td></tr><tr><td>Tengo dolor en mi zona pe&#769;lvica</td><td>0.289</td></tr></table>
<table><tr><td rowspan="2"></td><td>Factor</td></tr><tr><td>1</td></tr><tr><td>Me siento cansado y desanimado cuando me levanto por las mañanas</td><td>0.612</td></tr><tr><td>Mis músculos están tensos y doloridos</td><td>0.650</td></tr><tr><td>Tengo ataques de pánico</td><td>0.388</td></tr><tr><td>Rechino los dientes o aprieto la mandíbula</td><td>0.342</td></tr><tr><td>Tengo problemas de diarrea o estreñimiento</td><td>0.400</td></tr><tr><td>Necesito ayuda pare realizar mis actividades diarias</td><td>0.476</td></tr><tr><td>Soy sensible a la luz brillante</td><td>0.440</td></tr><tr><td>Me canso fácilmente cuando estoy físicamente activo</td><td>0.724</td></tr><tr><td>Siento dolor en todo mi cuerpo</td><td>0.582</td></tr><tr><td>Tengo dolores de cabeza</td><td>416</td></tr><tr><td>Tengo molestia en mi vejiga o sensación de quemazón al orinar</td><td>0.294</td></tr><tr><td>No duermo bien</td><td>0.504</td></tr></table>
<table><tr><td rowspan="2"></td><td>Factor</td></tr><tr><td>1</td></tr><tr><td>Tengo dificultad para concentrarme</td><td>0.436</td></tr><tr><td>Tengo problemas en la piel como resequedad, picor o sarpullido</td><td>0.299</td></tr><tr><td>El estrés hace que mis síntomas físicos empeoren</td><td>0.587</td></tr><tr><td>Me siento triste o deprimido</td><td>0.621</td></tr><tr><td>Me siento con poca energía</td><td>0.718</td></tr><tr><td>Tengo tensión muscular en mi cuello y hombros</td><td>0.555</td></tr><tr><td>Tengo dolor en mi mandíbula</td><td>0.426</td></tr><tr><td>Algunos olores, como perfumes, me hacen sentir náuseas.</td><td>0.269</td></tr><tr><td>Tengo que orinar frecuentemente</td><td>0.276</td></tr><tr><td>Mis piernas se sienten incómodas e inquietas cuando intento dormir por la noche</td><td>0.476</td></tr><tr><td>Tengo dificultad para recordar cosas</td><td>0.482</td></tr><tr><td>Sufrí algún trauma cuando era niño (a)</td><td>0.120</td></tr><tr><td>Tengo dolor en mi zona pélvica</td><td>0.289</td></tr></table>
5b785a269eb49f6dad43714f4c71fb9af31f0eb1ca0f916bddfbd4614dc30dc1.png
complex
<table><tr><td rowspan="2">Symbol</td><td colspan="2">2 Days <i>vs.</i> Ctr</td><td colspan="2">4 Days <i>vs.</i> Ctr</td><td colspan="2">7 Days <i>vs.</i> Ctr</td></tr><tr><td><i>P</i>-Value</td><td>Fold Change</td><td><i>P</i>-Value</td><td>Fold Change</td><td><i>P</i>-Value</td><td>Fold Change</td></tr><tr><td>ANKRD50</td><td>2.82 &#215; 10<sup>&#8722;2</sup></td><td>&#8722;1.323</td><td>2.32 &#215; 10<sup>&#8722;6</sup></td><td>&#8722;2.191</td><td>2.35 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;1.749</td></tr><tr><td>ANKRD36B </td><td>4.65 &#215; 10<sup>&#8722;3</sup></td><td>&#8722;2.292</td><td>1.85 &#215; 10<sup>&#8722;3</sup></td><td>&#8722;2.546</td><td>9.24 &#215; 10<sup>&#8722;3</sup></td><td>&#8722;1.979</td></tr><tr><td>C9orf3</td><td>7.91 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;3.622</td><td>5.04 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;3.860</td><td>6.56 &#215; 10<sup>&#8722;2</sup></td><td>&#8722;1.938</td></tr><tr><td>CCDC88C</td><td>1.82 &#215; 10<sup>&#8722;1</sup></td><td>&#8722;1.363</td><td>1.51 &#215; 10<sup>&#8722;1</sup></td><td>&#8722;1.398</td><td>6.70 &#215; 10<sup>&#8722;3</sup></td><td>&#8722;2.041</td></tr><tr><td>CYP24A1</td><td>9.28 &#215; 10<sup>&#8722;1</sup></td><td>&#8722;1.027</td><td>8.44 &#215; 10<sup>&#8722;1</sup></td><td>&#8722;1.060</td><td>3.32 &#215; 10<sup>&#8722;2</sup></td><td>&#8722;2.011</td></tr><tr><td>DGKH</td><td>3.48 &#215; 10<sup>&#8722;5</sup></td><td>&#8722;1.619</td><td>8.80 &#215; 10<sup>&#8722;8</sup></td><td>&#8722;2.114</td><td>2.51 &#215; 10<sup>&#8722;5</sup></td><td>&#8722;1.681</td></tr><tr><td>DHFR</td><td>3.77 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;1.779</td><td>6.90 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;1.717</td><td>3.10 &#215; 10<sup>&#8722;5</sup></td><td>&#8722;2.139</td></tr><tr><td>FAP</td><td>2.07 &#215; 10<sup>&#8722;1</sup></td><td>&#8722;1.562</td><td>4.72 &#215; 10<sup>&#8722;1</sup></td><td>&#8722;1.284</td><td>3.01 &#215; 10<sup>&#8722;2</sup></td><td>&#8722;2.314</td></tr><tr><td>GTF2B</td><td>2.33 &#215; 10<sup>&#8722;2</sup></td><td>&#8722;1.580</td><td>6.39 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;2.131</td><td>1.37 &#215; 10<sup>&#8722;3</sup></td><td>&#8722;2.072</td></tr><tr><td>HDCA1</td><td>8.97 &#215; 10<sup>&#8722;1</sup></td><td>&#8722;1.015</td><td>2.43 &#215; 10<sup>&#8722;1</sup></td><td>&#8722;1.147</td><td>1.11 &#215; 10<sup>&#8722;2</sup></td><td>&#8722;3.399</td></tr><tr><td>HAS2</td><td>6.50 &#215; 10<sup>&#8722;2</sup></td><td>&#8722;1.375</td><td>7.49 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;1.920</td><td>8.18 &#215; 10<sup>&#8722;5</sup></td><td>&#8722;2.342</td></tr><tr><td>LIF</td><td>4.97 &#215; 10<sup>&#8722;2</sup></td><td>&#8722;1.906</td><td>2.85 &#215; 10<sup>&#8722;1</sup></td><td>&#8722;1.403</td><td>1.23 &#215; 10<sup>&#8722;2</sup></td><td>&#8722;2.440</td></tr><tr><td>LRRN1</td><td>2.41 &#215; 10<sup>&#8722;1</sup></td><td>&#8722;1.422</td><td>1.78 &#215; 10<sup>&#8722;1</sup></td><td>&#8722;1.501</td><td>1.71 &#215; 10<sup>&#8722;2</sup></td><td>&#8722;2.217</td></tr><tr><td>mir-21</td><td>5.77 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;2.677</td><td>6.96 &#215; 10<sup>&#8722;5</sup></td><td>&#8722;3.347</td><td>7.02 &#215; 10<sup>&#8722;3</sup></td><td>&#8722;2.131</td></tr><tr><td>MPLKIP</td><td>2.86 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;1.829</td><td>1.59 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;1.983</td><td>4.89 &#215; 10<sup>&#8722;6</sup></td><td>&#8722;2.618</td></tr><tr><td>NPIPL3 </td><td>3.40 &#215; 10<sup>&#8722;3</sup></td><td>&#8722;2.249</td><td>2.27 &#215; 10<sup>&#8722;3</sup></td><td>&#8722;2.348</td><td>5.88 &#215; 10<sup>&#8722;2</sup></td><td>&#8722;1.398</td></tr><tr><td>NRG1</td><td>1.57 &#215; 10<sup>&#8722;3</sup></td><td>&#8722;1.666</td><td>4.65 &#215; 10<sup>&#8722;5</sup></td><td>&#8722;2.067</td><td>1.12 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;2.022</td></tr><tr><td>PLA2G7</td><td>6.14 &#215; 10<sup>&#8722;1</sup></td><td>&#8722;1.062</td><td>3.73 &#215; 10<sup>&#8722;2</sup></td><td>&#8722;1.299</td><td>1.61 &#215; 10<sup>&#8722;5</sup></td><td>&#8722;2.018</td></tr><tr><td>PSD3</td><td>1.43 &#215; 10<sup>&#8722;1</sup></td><td>&#8722;1.141</td><td>1.78 &#215; 10<sup>&#8722;5</sup></td><td>&#8722;2.162</td><td>9.70 &#215; 10<sup>&#8722;5</sup></td><td>&#8722;2.012</td></tr><tr><td>RNF152</td><td>4.83 &#215; 10<sup>&#8722;1</sup></td><td>&#8722;1.118</td><td>1.16 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;2.119</td><td>6.23 &#215; 10<sup>&#8722;2</sup></td><td>&#8722;1.381</td></tr><tr><td>SESN3</td><td>6.85 &#215; 10<sup>&#8722;2</sup></td><td>&#8722;1.206</td><td>5.50 &#215; 10<sup>&#8722;7</sup></td><td>&#8722;2.044</td><td>6.02 &#215; 10<sup>&#8722;5</sup></td><td>&#8722;1.684</td></tr><tr><td>SLC7A11</td><td>1.55 &#215; 10<sup>&#8722;1</sup></td><td>&#8722;1.279</td><td>3.03 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;2.078</td><td>1.02 &#215; 10<sup>&#8722;3</sup></td><td>&#8722;1.963</td></tr><tr><td>SMAD2</td><td>4.59 &#215; 10<sup>&#8722;3</sup></td><td>&#8722;1.526</td><td>9.51 &#215; 10<sup>&#8722;6</sup></td><td>&#8722;2.195</td><td>2.76 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;1.848</td></tr><tr><td>SMG1</td><td>1.43 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;2.030</td><td>2.45 &#215; 10<sup>&#8722;5</sup></td><td>&#8722;2.503</td><td>4.67 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;1.395</td></tr><tr><td>TAF1D</td><td>7.99 &#215; 10<sup>&#8722;3</sup></td><td>&#8722;1.961</td><td>2.85 &#215; 10<sup>&#8722;3</sup></td><td>&#8722;2.177</td><td>2.71 &#215; 10<sup>&#8722;2</sup></td><td>&#8722;1.770</td></tr><tr><td>TRA2A</td><td>1.38 &#215; 10<sup>&#8722;3</sup></td><td>&#8722;2.456</td><td>3.45 &#215; 10<sup>&#8722;3</sup></td><td>&#8722;2.229</td><td>6.73 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;1.357</td></tr></table>
<table><tr><td rowspan="2">Symbol</td><td colspan="2">2 Days vs. Ctr</td><td colspan="2">4 Days vs. Ctr</td><td colspan="2">7 Days vs. Ctr</td></tr><tr><td>P-Value</td><td>Fold Change</td><td>P-Value</td><td>Fold Change</td><td>P-Value</td><td>Fold Change</td></tr><tr><td>ANKRD50</td><td>2.82 × 10−2</td><td>−1.323</td><td>2.32 × 10−6</td><td>−2.191</td><td>2.35 × 10−4</td><td>−1.749</td></tr><tr><td>ANKRD36B</td><td>4.65 × 10−3</td><td>−2.292</td><td>1.85 × 10−3</td><td>−2.546</td><td>9.24 × 10−3</td><td>−1.979</td></tr><tr><td>C9orf3</td><td>7.91 × 10−4</td><td>−3.622</td><td>5.04 × 10−4</td><td>−3.860</td><td>6.56 × 10−2</td><td>−1.938</td></tr></table>
<table><tr><td>CCDC88C</td><td>1.82 × 10−1</td><td>−1.363</td><td>1.51 × 10−1</td><td>−1.398</td><td>6.70 × 10−3</td><td>−2.041</td></tr><tr><td>CYP24A1</td><td>9.28 × 10−1</td><td>−1.027</td><td>8.44 × 10−1</td><td>−1.060</td><td>3.32 × 10−2</td><td>−2.011</td></tr><tr><td>DGKH</td><td>3.48 × 10−5</td><td>−1.619</td><td>8.80 × 10−8</td><td>−2.114</td><td>2.51 × 10−5</td><td>−1.681</td></tr><tr><td>DHFR</td><td>3.77 × 10−4</td><td>−1.779</td><td>6.90 × 10−4</td><td>−1.717</td><td>3.10 × 10−5</td><td>−2.139</td></tr><tr><td>FAP</td><td>2.07 × 10−1</td><td>−1.562</td><td>4.72 × 10−1</td><td>−1.284</td><td>3.01 × 10−2</td><td>−2.314</td></tr><tr><td>GTF2B</td><td>2.33 × 10−2</td><td>−1.580</td><td>6.39 × 10−4</td><td>−2.131</td><td>1.37 × 10−3</td><td>−2.072</td></tr><tr><td>HDCA1</td><td>8.97 × 10−1</td><td>−1.015</td><td>2.43 × 10−1</td><td>−1.147</td><td>1.11 × 10−2</td><td>−3.399</td></tr><tr><td>HAS2</td><td>6.50 × 10−2</td><td>−1.375</td><td>7.49 × 10−4</td><td>−1.920</td><td>8.18 × 10−5</td><td>−2.342</td></tr><tr><td>LIF</td><td>4.97 × 10−2</td><td>−1.906</td><td>2.85 × 10−1</td><td>−1.403</td><td>1.23 × 10−2</td><td>−2.440</td></tr><tr><td>LRRN1</td><td>2.41 × 10−1</td><td>−1.422</td><td>1.78 × 10−1</td><td>−1.501</td><td>1.71 × 10−2</td><td>−2.217</td></tr><tr><td>mir-21</td><td>5.77 × 10−4</td><td>−2.677</td><td>6.96 × 10−5</td><td>−3.347</td><td>7.02 × 10−3</td><td>−2.131</td></tr><tr><td>MPLKIP</td><td>2.86 × 10−4</td><td>−1.829</td><td>1.59 × 10−4</td><td>−1.983</td><td>4.89 × 10−6</td><td>−2.618</td></tr><tr><td>NPIPL3</td><td>3.40 × 10−3</td><td>−2.249</td><td>2.27 × 10−3</td><td>−2.348</td><td>5.88 × 10−2</td><td>−1.398</td></tr><tr><td>NRG1</td><td>1.57 × 10−3</td><td>−1.666</td><td>4.65 × 10−5</td><td>−2.067</td><td>1.12 × 10−4</td><td>−2.022</td></tr><tr><td>PLA2G7</td><td>6.14 × 10−1</td><td>−1.062</td><td>3.73 × 10−2</td><td>−1.299</td><td>1.61 × 10−5</td><td>−2.018</td></tr><tr><td>PSD3</td><td>1.43 × 10−1</td><td>−1.141</td><td>1.78 × 10−5</td><td>−2.162</td><td>9.70 × 10−5</td><td>−2.012</td></tr><tr><td>RNF152</td><td>4.83 × 10−1</td><td>−1.118</td><td>1.16 × 10−4</td><td>−2.119</td><td>6.23 × 10−2</td><td>−1.381</td></tr><tr><td>SESN3</td><td>6.85 × 10−2</td><td>−1.206</td><td>5.50 × 10−7</td><td>−2.044</td><td>6.02 × 10−5</td><td>−1.684</td></tr><tr><td>SLC7A11</td><td>1.55 × 10−1</td><td>−1.279</td><td>3.03 × 10−4</td><td>−2.078</td><td>1.02 × 10−3</td><td>−1.963</td></tr><tr><td>SMAD2</td><td>4.59 × 10−3</td><td>−1.526</td><td>9.51 × 10−6</td><td>−2.195</td><td>2.76 × 10−4</td><td>−1.848</td></tr><tr><td>SMG1</td><td>1.43 × 10−4</td><td>−2.030</td><td>2.45 × 10−5</td><td>−2.503</td><td>4.67 × 10−4</td><td>−1.395</td></tr><tr><td>TAF1D</td><td>7.99 × 10−3</td><td>−1.961</td><td>2.85 × 10−3</td><td>−2.177</td><td>2.71 × 10−2</td><td>−1.770</td></tr><tr><td>TRA2A</td><td>1.38 × 10−3</td><td>−2.456</td><td>3.45 × 10−3</td><td>−2.229</td><td>6.73 × 10−4</td><td>−1.357</td></tr></table>
4be53f7b3e3c6ef7e6203e7bd900ee7482f20c6399a5f4d14024e2d81fe662cc.png
simple
<table><tr><td>Patient Safety Culture Composite</td><td>Definition: The extent to which....</td><td>Number of Survey Items</td></tr><tr><td>1. Communication openness</td><td>Staff will freely speak up if they see something that may negatively affect patient care, and feel free to question those with more authority</td><td>3</td></tr><tr><td>2. Feedback &amp; communication about error</td><td>Staff are informed about errors that happen, given feedback about changes put into place based on event reports, and discuss ways to prevent errors</td><td>3</td></tr><tr><td>3. Frequency of events reported</td><td>Mistakes of the following types are reported:1) mistakes caught and corrected before affecting the patient, 2) mistakes with no potential to harm the patient, and 3) mistakes that could harm the patient, but do not</td><td>3</td></tr><tr><td>4. Handoffs &amp; transitions</td><td>Important patient care information is transferred across hospital units and during shift changes</td><td>4</td></tr><tr><td>5. Management support for patient safety</td><td>Hospital management provides a work climate that promotes patient safety and shows that patient safety is a top priority</td><td>3</td></tr><tr><td>6. Nonpunitive response to error</td><td>Staff feel that their mistakes are not held against them, and mistakes are not kept in their personnel file</td><td>3</td></tr><tr><td>7. Organizational learning--Continuous improvement</td><td>Mistakes have led to positive changes and changes are evaluated for their effectiveness</td><td>3</td></tr><tr><td>8. Overall perceptions of patient safety</td><td>Procedures and systems are good at preventing errors and there is a lack of patient safety problems</td><td>4</td></tr><tr><td>9. Staffing</td><td>There are enough staff to handle the workload and work hours are appropriate to provide the best care for patients</td><td>4</td></tr><tr><td>10. Supervisor/manager expectations and actions promoting safety</td><td>Supervisors/managers consider staff suggestions for improving patient safety, praise staff for following patient safety procedures, and do not overlook patient safety problems</td><td>4</td></tr><tr><td>11. Teamwork across units</td><td>Hospital units cooperate and coordinate with one another to provide the best care for patients</td><td>4</td></tr><tr><td>12. Teamwork within units</td><td>Staff support one another, treat each other with respect, and work together as a team</td><td>4</td></tr></table>
<table><tr><td>Patient Safety Culture Composite</td><td>Definition: The extent to which....</td><td>Number of Survey Items</td></tr><tr><td>1. Communication openness</td><td>Staff will freely speak up if they see something that may negatively affect patient care, and feel free to question those with more authority</td><td>3</td></tr><tr><td>2. Feedback & communication about error</td><td>Staff are informed about errors that happen, given feedback about changes put into place based on event reports, and discuss ways to prevent errors</td><td>3</td></tr><tr><td>3. Frequency of events reported</td><td>Mistakes of the following types are reported:1) mistakes caught and corrected before affecting the patient, 2) mistakes with no potential to harm the patient, and 3) mistakes that could harm the patient, but do not</td><td>3</td></tr><tr><td>4. Handoffs & transitions</td><td>Important patient care information is transferred across hospital units and during shift changes</td><td>4</td></tr><tr><td>5. Management support for patient safety</td><td>Hospital management provides a work climate that promotes patient safety and shows that patient safety is a top priority</td><td>3</td></tr></table>
<table><tr><td>6. Nonpunitive response to error</td><td>Staff feel that their mistakes are not held against them, and mistakes are not kept in their personnel file</td><td>3</td></tr><tr><td>7. Organizational learning--Continuous improvement</td><td>Mistakes have led to positive changes and changes are evaluated for their effectiveness</td><td>3</td></tr><tr><td>8. Overall perceptions of patient safety</td><td>Procedures and systems are good at preventing errors and there is a lack of patient safety problems</td><td>4</td></tr><tr><td>9. Staffing</td><td>There are enough staff to handle the workload and work hours are appropriate to provide the best care for patients</td><td>4</td></tr><tr><td>10. Supervisor/manager expectations and actions promoting safety</td><td>Supervisors/managers consider staff suggestions for improving patient safety, praise staff for following patient safety procedures, and do not overlook patient safety problems</td><td>4</td></tr><tr><td>11. Teamwork across units</td><td>Hospital units cooperate and coordinate with one another to provide the best care for patients</td><td>4</td></tr><tr><td>12. Teamwork within units</td><td>Staff support one another, treat each other with respect, and work together as a team</td><td>4</td></tr></table>
4a4be3ef8497afcb7ebc9291452ac4b1ac01fe1fe30c459f9b92f23bf05757d8.png
simple
<table><tr><td>Oligonucleotide</td><td>Sequence</td></tr><tr><td>NUCKS F (forward)</td><td>5'-AATTCACAGGAAGATAGTGAGG-3'</td></tr><tr><td>NUCKS R (reverse)</td><td>5'-TCACTGTAG CCTTTAGTCTGGG-3'</td></tr><tr><td>GAPDH forward</td><td>5'-ATGGGGAAGGTGAAGGTCGGAGTC-3'</td></tr><tr><td>GAPDH reverse</td><td>5'-GAACATGGGGGCGTCAGCAGAG-3'</td></tr><tr><td>NUCKS Fq (forward, real-time PCR)</td><td>5'-TCTGATGATGCAGATGAAGATTA-3'</td></tr><tr><td>NUCKS Rq (reverse, real-time PCR)</td><td>5'-CTGCTGAGTGAGAATCATCC-3'</td></tr><tr><td>NUCKS FL probe</td><td>5'-TCTTGGTCTTCACATCTTTGTCTTCT-FL-3'</td></tr><tr><td>NUCKS LC probe</td><td>5'-LC640-AGTCCTCACTATCTTCCTGTGAATTCTTT-3'</td></tr></table>
<table><tr><td>Oligonucleotide</td><td>Sequence</td></tr><tr><td>NUCKS F (forward)</td><td>5'-AATTCACAGGAAGATAGTGAGG-3'</td></tr><tr><td>NUCKS R (reverse)</td><td>5'-TCACTGTAG CCTTTAGTCTGGG-3'</td></tr><tr><td>GAPDH forward</td><td>5'-ATGGGGAAGGTGAAGGTCGGAGTC-3'</td></tr></table>
<table><tr><td>GAPDH reverse</td><td>5'-GAACATGGGGGCGTCAGCAGAG-3'</td></tr><tr><td>NUCKS Fq (forward, real-time PCR)</td><td>5'-TCTGATGATGCAGATGAAGATTA-3'</td></tr><tr><td>NUCKS Rq (reverse, real-time PCR)</td><td>5'-CTGCTGAGTGAGAATCATCC-3'</td></tr><tr><td>NUCKS FL probe</td><td>5'-TCTTGGTCTTCACATCTTTGTCTTCT-FL-3'</td></tr><tr><td>NUCKS LC probe</td><td>5'-LC640-AGTCCTCACTATCTTCCTGTGAATTCTTT-3'</td></tr></table>
cc8735b169ca4cda682511a99d58758ee793e20b241737be165e5c7f975290ac.png
complex
<table><tr><td rowspan="2">Characteristics of the partner at the first sexual relation</td><td colspan="2">Sex (%)</td></tr><tr><td>Women</td><td>Men</td></tr><tr><td>Type of relationship</td><td></td><td></td></tr><tr><td><i>Namorado </i>(steady boyfriend/girlfriend)</td><td>86</td><td>45</td></tr><tr><td>Husband/wife/living together</td><td>4</td><td>1</td></tr><tr><td>Eventual partner</td><td>9</td><td>48</td></tr><tr><td>Prostitute</td><td>&#8212;</td><td>5 </td></tr><tr><td>Was it also the partner's first sexual relation?</td><td></td><td></td></tr><tr><td>Yes</td><td>14</td><td>37</td></tr><tr><td>No</td><td>83</td><td>57</td></tr><tr><td>Do not know</td><td>3</td><td>6</td></tr><tr><td>Age difference between the interviewee and the partner</td><td></td><td></td></tr><tr><td>The partner is younger</td><td>2</td><td>10</td></tr><tr><td>Same age (&#177;1 year)</td><td>24</td><td>52</td></tr><tr><td>The partner is older (2&#8211;4 years)</td><td>36</td><td>24</td></tr><tr><td>The partner is much older (5 years and more)</td><td>38</td><td>15</td></tr><tr><td>The partner was in school</td><td></td><td></td></tr><tr><td>Yes</td><td>50</td><td>76</td></tr><tr><td>No</td><td>50</td><td>24</td></tr></table>
<table><tr><td rowspan="2">Characteristics of the partner at the first sexual relation</td><td colspan="2">Sex (%)</td></tr><tr><td>Women</td><td>Men</td></tr><tr><td>Type of relationship</td><td></td><td></td></tr><tr><td>Namorado (steady boyfriend/girlfriend)</td><td>86</td><td>45</td></tr><tr><td>Husband/wife/living together</td><td>4</td><td>1</td></tr><tr><td>Eventual partner</td><td>9</td><td>48</td></tr><tr><td>Prostitute</td><td>—</td><td>5</td></tr><tr><td>Was it also the partner's first sexual relation?</td><td></td><td></td></tr><tr><td>Yes</td><td>14</td><td>37</td></tr><tr><td>No</td><td>83</td><td>57</td></tr><tr><td>Do not know</td><td>3</td><td>6</td></tr><tr><td>Age difference between the interviewee and the partner</td><td></td><td></td></tr><tr><td>The partner is younger</td><td>2</td><td>10</td></tr><tr><td>Same age (±1 year)</td><td>24</td><td>52</td></tr><tr><td>The partner is older (2–4 years)</td><td>36</td><td>24</td></tr><tr><td>The partner is much older (5 years and more)</td><td>38</td><td>15</td></tr><tr><td>The partner was in school</td><td></td><td></td></tr></table>
<table><tr><td rowspan="2">Characteristics of the partner at the first sexual relation</td><td colspan="2">Sex (%)</td></tr><tr><td>Women</td><td>Men</td></tr><tr><td>Yes</td><td>50</td><td>76</td></tr><tr><td>No</td><td>50</td><td>24</td></tr></table>
43053b2f8580b32dc4c9c9290987e1b6ed7bed4bc4458fd7f096c873ce314a7c.png
complex
<table><tr><td rowspan="2">Type of Patient/Specimen Type</td><td colspan="2">2011</td><td colspan="2">2012</td><td colspan="2">2013</td><td colspan="2">2014</td></tr><tr><td>%</td><td><i>n</i><sup>1</sup></td><td>%</td><td><i>n</i><sup>1</sup></td><td>%</td><td><i>n</i><sup>1</sup></td><td>%</td><td><i>n</i><sup>1</sup></td></tr><tr><td>Inpatients</td><td>88.5</td><td>96</td><td>81.0</td><td>126</td><td>86.1</td><td>216</td><td>90.7</td><td>140</td></tr><tr><td>Respiratory samples</td><td>39.0</td><td>95 <sup>2</sup></td><td>39.7</td><td>126</td><td>61.1</td><td>216</td><td>47.1</td><td>140</td></tr></table>
<table><tr><td rowspan="2">Type of Patient/Specimen Type</td><td colspan="2">2011</td><td colspan="2">2012</td><td colspan="2">2013</td></tr><tr><td>%</td><td>n1</td><td>%</td><td>n1</td><td>%</td><td>n1</td></tr><tr><td>Inpatients</td><td>88.5</td><td>96</td><td>81.0</td><td>126</td><td>86.1</td><td>216</td></tr><tr><td>Respiratory samples</td><td>39.0</td><td>95 2</td><td>39.7</td><td>126</td><td>61.1</td><td>216</td></tr></table>
<table><tr><td colspan="2">2014</td></tr><tr><td>%</td><td>n1</td></tr><tr><td>90.7</td><td>140</td></tr><tr><td>47.1</td><td>140</td></tr></table>
24bc14970a39984765c577d7f062bfd25683ea96c0bcdfac870522601351509e.png
simple
<table><tr><td>Demographic</td><td>Number (%)</td></tr><tr><td>Gender</td><td> </td></tr><tr><td>Male</td><td>64 (43.2)</td></tr><tr><td>Female</td><td>84 (56.8)</td></tr><tr><td>Marital status</td><td> </td></tr><tr><td>Single</td><td>57 (38.5)</td></tr><tr><td>Married</td><td>44 (29.7)</td></tr><tr><td>Widowed</td><td>10 (6.8)</td></tr><tr><td>Divorced</td><td>36 (24.3)</td></tr><tr><td>Unknown</td><td>1 (0.7)</td></tr><tr><td>Educational level</td><td> </td></tr><tr><td>None</td><td>6 (4.1)</td></tr><tr><td>Primary</td><td>45 (30.4)</td></tr><tr><td>Secondary</td><td>83 (56.1)</td></tr><tr><td>University/post graduate</td><td>13 (8.8)</td></tr><tr><td>Unknown</td><td>1 (0.7)</td></tr><tr><td>Diagnosis</td><td> </td></tr><tr><td>Schizophrenia</td><td>53 (35.8)</td></tr><tr><td>Paranoid Schizophrenia</td><td>35 (23.6)</td></tr><tr><td>Delusional disorder</td><td>10 (6.8)</td></tr><tr><td>Bipolar affective disorder (BPAD)</td><td>15 (10.1)</td></tr><tr><td>Psychotic depression</td><td>23 (15.5)</td></tr><tr><td>Other (i.e. schizoaffective disorder; non-specified psychosis)</td><td>10 (6.8)</td></tr><tr><td>Unknown</td><td>2 (1.4)</td></tr><tr><td>Employment status</td><td> </td></tr><tr><td>Unemployed</td><td>68 (45.9)</td></tr><tr><td>Employed</td><td>39 (26.3)</td></tr><tr><td>Homemaker</td><td>35 (23.6)</td></tr><tr><td>Retired/other</td><td>5 (3.4)</td></tr><tr><td>Unknown</td><td>1 (0.7)</td></tr></table>
<table><tr><td>Demographic</td><td>Number (%)</td></tr><tr><td>Gender</td><td></td></tr><tr><td>Male</td><td>64 (43.2)</td></tr><tr><td>Female</td><td>84 (56.8)</td></tr><tr><td>Marital status</td><td></td></tr><tr><td>Single</td><td>57 (38.5)</td></tr><tr><td>Married</td><td>44 (29.7)</td></tr><tr><td>Widowed</td><td>10 (6.8)</td></tr><tr><td>Divorced</td><td>36 (24.3)</td></tr><tr><td>Unknown</td><td>1 (0.7)</td></tr><tr><td>Educational level</td><td></td></tr><tr><td>None</td><td>6 (4.1)</td></tr><tr><td>Primary</td><td>45 (30.4)</td></tr><tr><td>Secondary</td><td>83 (56.1)</td></tr><tr><td>University/post graduate</td><td>13 (8.8)</td></tr><tr><td>Unknown</td><td>1 (0.7)</td></tr><tr><td>Diagnosis</td><td></td></tr><tr><td>Schizophrenia</td><td>53 (35.8)</td></tr><tr><td>Paranoid Schizophrenia</td><td>35 (23.6)</td></tr><tr><td>Delusional disorder</td><td>10 (6.8)</td></tr><tr><td>Bipolar affective disorder (BPAD)</td><td>15 (10.1)</td></tr><tr><td>Psychotic depression</td><td>23 (15.5)</td></tr><tr><td>Other (i.e. schizoaffective disorder; non-specified psychosis)</td><td>10 (6.8)</td></tr><tr><td>Unknown</td><td>2 (1.4)</td></tr></table>
<table><tr><td>Employment status</td><td></td></tr><tr><td>Unemployed</td><td>68 (45.9)</td></tr><tr><td>Employed</td><td>39 (26.3)</td></tr><tr><td>Homemaker</td><td>35 (23.6)</td></tr><tr><td>Retired/other</td><td>5 (3.4)</td></tr><tr><td>Unknown</td><td>1 (0.7)</td></tr></table>
b9b18391a1f1573dc62bdee1caafcc5f72e4ac42329269d0c7b1c799d89c2311.png
complex
<table><tr><td rowspan="3">Indices of clinical burden of Sickle Cell Disease</td><td colspan="2">Children</td></tr><tr><td><i>n</i></td><td>%</td></tr><tr><td>Duration of care since diagnosis</td><td></td><td></td></tr><tr><td>&#8804; 6 months</td><td>22</td><td>9.8</td></tr><tr><td>&gt; 6 months</td><td>203</td><td>90.2</td></tr><tr><td>Previous hospitalisation (range = 0&#8211;24)</td><td></td><td></td></tr><tr><td>No hospitalisation</td><td>16</td><td>7.1</td></tr><tr><td>Once</td><td>32</td><td>14.2</td></tr><tr><td>Twice</td><td>85</td><td>37.8</td></tr><tr><td>&gt; twice</td><td>92</td><td>40.9</td></tr><tr><td>Previous blood transfusion (range = 0&#8211;10)</td><td></td><td></td></tr><tr><td>None</td><td>67</td><td>29.8</td></tr><tr><td>Once</td><td>53</td><td>23.6</td></tr><tr><td>Twice</td><td>70</td><td>31.1</td></tr><tr><td>&gt; twice</td><td>35</td><td>15.6</td></tr><tr><td>Significant bone pain episodes</td><td></td><td></td></tr><tr><td>None</td><td>13</td><td>5.8</td></tr><tr><td>One</td><td>41</td><td>18.2</td></tr><tr><td>Twice</td><td>25</td><td>11.1</td></tr><tr><td>&gt; twice</td><td>146</td><td>64.9</td></tr></table>
<table><tr><td rowspan="3">Indices of clinical burden of Sickle Cell Disease</td><td colspan="2">Children</td></tr><tr><td>n</td><td>%</td></tr><tr><td colspan="2"></td></tr><tr><td>Duration of care since diagnosis</td><td></td><td></td></tr><tr><td>≤ 6 months</td><td>22</td><td>9.8</td></tr><tr><td>> 6 months</td><td>203</td><td>90.2</td></tr><tr><td>Previous hospitalisation (range = 0–24)</td><td></td><td></td></tr><tr><td>No hospitalisation</td><td>16</td><td>7.1</td></tr><tr><td>Once</td><td>32</td><td>14.2</td></tr></table>
<table><tr><td rowspan="3">Indices of clinical burden of Sickle Cell Disease</td><td colspan="2">Children</td></tr><tr><td>n</td><td>%</td></tr><tr><td colspan="2"></td></tr><tr><td>Twice</td><td>85</td><td>37.8</td></tr><tr><td>> twice</td><td>92</td><td>40.9</td></tr><tr><td>Previous blood transfusion (range = 0–10)</td><td></td><td></td></tr><tr><td>None</td><td>67</td><td>29.8</td></tr><tr><td>Once</td><td>53</td><td>23.6</td></tr><tr><td>Twice</td><td>70</td><td>31.1</td></tr><tr><td>> twice</td><td>35</td><td>15.6</td></tr><tr><td>Significant bone pain episodes</td><td></td><td></td></tr><tr><td>None</td><td>13</td><td>5.8</td></tr><tr><td>One</td><td>41</td><td>18.2</td></tr><tr><td>Twice</td><td>25</td><td>11.1</td></tr><tr><td>> twice</td><td>146</td><td>64.9</td></tr></table>
fe808ab93885c8fdf0c8ea34b46410eb52531abebc40a073c9473d7ed1c6f5b1.png
simple
<table><tr><td></td><td>(A) 176 drug products</td><td>(B) 45 drug products</td><td>(C) 162 drug products</td></tr><tr><td>Therapeutic group</td><td></td><td></td><td></td></tr><tr><td> A&#8212;alimentary tract and metabolism</td><td>18</td><td>8</td><td>17</td></tr><tr><td> B&#8212;blood and blood-forming organs</td><td>9</td><td>3</td><td>8</td></tr><tr><td> C&#8212;cardiovascular system</td><td>20</td><td>3</td><td>20</td></tr><tr><td> D&#8212;dermatologicals</td><td>6</td><td>3</td><td>5</td></tr><tr><td> G&#8212;genitourinary system and sex hormones</td><td>13</td><td>1</td><td>13</td></tr><tr><td> H&#8212;systemic hormonal preparations, excluding sex hormones and insulins</td><td>7</td><td>1</td><td>6</td></tr><tr><td> J&#8212;anti-infectives for systemic use</td><td>25</td><td>5</td><td>23</td></tr><tr><td> L&#8212;anti-neoplastic and immunomodulating agents</td><td>10</td><td>3</td><td>10</td></tr><tr><td> M&#8212;musculoskeletal system</td><td>6</td><td>3</td><td>6</td></tr><tr><td> N&#8212;nervous system</td><td>24</td><td>8</td><td>23</td></tr><tr><td> P&#8212;anti-parasitic products, insecticides, and repellents</td><td>2</td><td>0</td><td>1</td></tr><tr><td> R&#8212;respiratory system</td><td>15</td><td>4</td><td>10</td></tr><tr><td> S&#8212;sensory organs</td><td>6</td><td>1</td><td>6</td></tr><tr><td> V&#8212;various</td><td>15</td><td>2</td><td>14</td></tr><tr><td>Re-examination dates</td><td></td><td></td><td></td></tr><tr><td> January 2009 to December 2009</td><td>45</td><td>6</td><td>42</td></tr><tr><td> January 2010 to December 2010</td><td>44</td><td>13</td><td>42</td></tr><tr><td> January 2011 to December 2011</td><td>30</td><td>9</td><td>27</td></tr><tr><td> January 2012 to December 2012</td><td>21</td><td>5</td><td>20</td></tr><tr><td> January 2013 to December 2013</td><td>19</td><td>8</td><td>16</td></tr><tr><td> January 2014 to December 2014</td><td>17</td><td>4</td><td>15</td></tr></table>
<table><tr><td></td><td>(A) 176 drug products</td><td>(B) 45 drug products</td><td>(C) 162 drug products</td></tr><tr><td>Therapeutic group</td><td></td><td></td><td></td></tr><tr><td>A—alimentary tract and metabolism</td><td>18</td><td>8</td><td>17</td></tr><tr><td>B—blood and blood-forming organs</td><td>9</td><td>3</td><td>8</td></tr><tr><td>C—cardiovascular system</td><td>20</td><td>3</td><td>20</td></tr><tr><td>D—dermatologicals</td><td>6</td><td>3</td><td>5</td></tr><tr><td>G—genitourinary system and sex hormones</td><td>13</td><td>1</td><td>13</td></tr><tr><td>H—systemic hormonal preparations, excluding sex hormones and insulins</td><td>7</td><td>1</td><td>6</td></tr><tr><td>J—anti-infectives for systemic use</td><td>25</td><td>5</td><td>23</td></tr><tr><td>L—anti-neoplastic and immunomodulating agents</td><td>10</td><td>3</td><td>10</td></tr><tr><td>M—musculoskeletal system</td><td>6</td><td>3</td><td>6</td></tr><tr><td>N—nervous system</td><td>24</td><td>8</td><td>23</td></tr><tr><td>P—anti-parasitic products, insecticides, and repellents</td><td>2</td><td>0</td><td>1</td></tr><tr><td>R—respiratory system</td><td>15</td><td>4</td><td>10</td></tr><tr><td>S—sensory organs</td><td>6</td><td>1</td><td>6</td></tr><tr><td>V—various</td><td>15</td><td>2</td><td>14</td></tr></table>
<table><tr><td>Re-examination dates</td><td></td><td></td><td></td></tr><tr><td>January 2009 to December 2009</td><td>45</td><td>6</td><td>42</td></tr><tr><td>January 2010 to December 2010</td><td>44</td><td>13</td><td>42</td></tr><tr><td>January 2011 to December 2011</td><td>30</td><td>9</td><td>27</td></tr><tr><td>January 2012 to December 2012</td><td>21</td><td>5</td><td>20</td></tr><tr><td>January 2013 to December 2013</td><td>19</td><td>8</td><td>16</td></tr><tr><td>January 2014 to December 2014</td><td>17</td><td>4</td><td>15</td></tr></table>
2e8b6f5db011f0db8c537b5d5af6f39d50108ea06ec69d99db499a644877cf38.png
simple
<table><tr><td>Variables</td><td>Mean&#177;SD</td></tr><tr><td>BMI (Kg/m<sup>2</sup>)</td><td>43.40 &#177; 20.20</td></tr><tr><td>Post-Load PG (mg/dL)</td><td>80.00&#177;15.80</td></tr><tr><td>SBP (mmHg)</td><td>127.60 &#177; 26.70</td></tr><tr><td>DBP (mmHg)</td><td>80.00 &#177; 15.80</td></tr><tr><td>FPG (mg/dL)</td><td>93.40 &#177; 19.80</td></tr><tr><td>Waist Circumference (CM)</td><td>182.84 &#177; 101.10</td></tr></table>
<table><tr><td>Variables</td></tr><tr><td>BMI (Kg/m2)</td></tr><tr><td>Post-Load PG (mg/dL)</td></tr><tr><td>SBP (mmHg)</td></tr><tr><td>DBP (mmHg)</td></tr><tr><td>FPG (mg/dL)</td></tr><tr><td>Waist Circumference (CM)</td></tr></table>
<table><tr><td>Mean±SD</td></tr><tr><td>43.40 ± 20.20</td></tr><tr><td>80.00±15.80</td></tr><tr><td>127.60 ± 26.70</td></tr><tr><td>80.00 ± 15.80</td></tr><tr><td>93.40 ± 19.80</td></tr><tr><td>182.84 ± 101.10</td></tr></table>
3f804b6eaef6a1c4ffbf1c578e4f6c57959d13b54076512babceeb45eb5d4ae3.png
simple
<table><tr><td>Indication for surgery</td><td>Frequency</td><td>Percentage</td></tr><tr><td>Bleeding duodenal ulcers not responding to either medical or endoscopic treatment</td><td>5</td><td>26.3</td></tr><tr><td>Gastric malignancy</td><td>6</td><td>31.6</td></tr><tr><td>Gastrointestinal stroma tumour</td><td>8</td><td>42.1</td></tr></table>
<table><tr><td>Indication for surgery</td><td>Frequency</td></tr><tr><td>Bleeding duodenal ulcers not responding to either medical or endoscopic treatment</td><td>5</td></tr><tr><td>Gastric malignancy</td><td>6</td></tr><tr><td>Gastrointestinal stroma tumour</td><td>8</td></tr></table>
<table><tr><td>Percentage</td></tr><tr><td>26.3</td></tr><tr><td>31.6</td></tr><tr><td>42.1</td></tr></table>
77ee500d0e90417bece89b36b8cb9cf247b2b8c20e5b863f4d4535ab1888d7c6.png
complex
<table><tr><td></td><td colspan="4">Survey I (<i>n</i> = 2200)</td><td colspan="4">Survey II (<i>n</i> = 2203)</td></tr><tr><td></td><td colspan="2">VL</td><td colspan="2">H</td><td colspan="2">VL</td><td colspan="2">H</td></tr><tr><td></td><td>OR</td><td>95 % CI</td><td>OR</td><td>95 % CI</td><td>OR</td><td>95 % CI</td><td>OR</td><td>95 % CI</td></tr><tr><td>Parent characteristics</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Mother&#8217;s education</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>College Grad</td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td></tr><tr><td>Some college</td><td>1.30</td><td>.96/1.76</td><td>1.35</td><td>.99/1.85</td><td>1.09</td><td>.80/1.49</td><td>1.06</td><td>.77/1.44</td></tr><tr><td>HS Grad</td><td>.73</td><td>.51/1.03</td><td>1.37</td><td>1.19/1.88</td><td>.83</td><td>.58/1.18</td><td>1.50</td><td>1.10/2.04</td></tr><tr><td>Less than HS</td><td>.46</td><td>.21/1.00</td><td>2.27</td><td>1.37/3.75</td><td>.44</td><td>.19/1.03</td><td>1.96</td><td>1.69/3.14</td></tr><tr><td> Parent smokes</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td></tr><tr><td>Yes</td><td>.76</td><td>.57/1.03</td><td>2.10</td><td>1.62/2.73</td><td>.77</td><td>.56/1.06</td><td>2.08</td><td>1.59/2.70</td></tr><tr><td>Family engagement</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> No. of days eat together</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>&lt;3</td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td></tr><tr><td>3&#8211;5</td><td>1.16</td><td>.84/1.61</td><td>.51</td><td>.38/.67</td><td>1.10</td><td>.79/1.53</td><td>.54</td><td>.41/.73</td></tr><tr><td>6&gt;</td><td>1.54</td><td>1.12/2.11</td><td>.48</td><td>.35/.65</td><td>1.17</td><td>.85/1.62</td><td>.49</td><td>.36/.66</td></tr><tr><td> No. times do things for fun</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>&lt;2</td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td></tr><tr><td>2&#8211;4</td><td>.79</td><td>.60/1.03</td><td>.73</td><td>.55/.96</td><td>1.18</td><td>.89/1.57</td><td>.52</td><td>.41/.67</td></tr><tr><td>5&gt;</td><td>1.07</td><td>.74/1.56</td><td>.77</td><td>.51/.98</td><td>1.51</td><td>1.05/2.17</td><td>.36</td><td>.23/.55</td></tr><tr><td>Parent monitoring</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> No. of four best friends parents know well</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>0&#8211;1</td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td></tr><tr><td>2&#8211;3</td><td>.87</td><td>.59/1.26</td><td>.67</td><td>.48/.94</td><td>.84</td><td>.57/1.25</td><td>.82</td><td>.59/1.18</td></tr><tr><td>4</td><td>1.38</td><td>.95/1.99</td><td>.49</td><td>.35/.70</td><td>1.24</td><td>.85/1.81</td><td>.53</td><td>.37/.77</td></tr><tr><td> No. four best friend&#8217;s parents parents know well</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>0&#8211;1</td><td>______</td><td></td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td></tr><tr><td>2&#8211;3</td><td>1.44</td><td>1.06/1.96</td><td>.60</td><td>.46/.77</td><td>1.07</td><td>.78/1.45</td><td>.62</td><td>.49/.82</td></tr><tr><td>4</td><td>1.87</td><td>1.33/2.65</td><td>.31</td><td>.21/.46</td><td>1.37</td><td>.98/1.91</td><td>.43</td><td>.31/.81</td></tr><tr><td> Your parents tell on friend smoking</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td></tr><tr><td>Not sure</td><td>1.36</td><td>.78/2.36</td><td>.49</td><td>.34/.70</td><td>1.27</td><td>.64/2.53</td><td>.47</td><td>.29/.77</td></tr><tr><td>Yes</td><td>2.03</td><td>1.24/3.30</td><td>.22</td><td>.16/.31</td><td>1.89</td><td>1.30/2.97</td><td>.28</td><td>.21/.37</td></tr><tr><td> Friend&#8217;s parents tell on you smoking</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td></tr><tr><td>Not sure</td><td>1.13</td><td>.61/2.09</td><td>.49</td><td>.34/.70</td><td>1.02</td><td>.46/2.22</td><td>.49</td><td>.21/.82</td></tr><tr><td>Yes</td><td>1.51</td><td>.86/2.65</td><td>.22</td><td>.16/.31</td><td>1.56</td><td>.93/2.64</td><td>.22</td><td>.16/.30</td></tr></table>
<table><tr><td></td><td colspan="4">Survey I (n = 2200)</td><td colspan="4">Survey II (n = 2203)</td></tr><tr><td></td><td colspan="2">VL</td><td colspan="2">H</td><td colspan="2">VL</td><td colspan="2">H</td></tr><tr><td></td><td>OR</td><td>95 % CI</td><td>OR</td><td>95 % CI</td><td>OR</td><td>95 % CI</td><td>OR</td><td>95 % CI</td></tr><tr><td>Parent characteristics</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Mother’s education</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>College Grad</td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td></tr><tr><td>Some college</td><td>1.30</td><td>.96/1.76</td><td>1.35</td><td>.99/1.85</td><td>1.09</td><td>.80/1.49</td><td>1.06</td><td>.77/1.44</td></tr><tr><td>HS Grad</td><td>.73</td><td>.51/1.03</td><td>1.37</td><td>1.19/1.88</td><td>.83</td><td>.58/1.18</td><td>1.50</td><td>1.10/2.04</td></tr><tr><td>Less than HS</td><td>.46</td><td>.21/1.00</td><td>2.27</td><td>1.37/3.75</td><td>.44</td><td>.19/1.03</td><td>1.96</td><td>1.69/3.14</td></tr></table>
<table><tr><td>Parent smokes</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td></tr><tr><td>Yes</td><td>.76</td><td>.57/1.03</td><td>2.10</td><td>1.62/2.73</td><td>.77</td><td>.56/1.06</td><td>2.08</td><td>1.59/2.70</td></tr><tr><td>Family engagement</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>No. of days eat together</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><3</td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td></tr><tr><td>3–5</td><td>1.16</td><td>.84/1.61</td><td>.51</td><td>.38/.67</td><td>1.10</td><td>.79/1.53</td><td>.54</td><td>.41/.73</td></tr><tr><td>6></td><td>1.54</td><td>1.12/2.11</td><td>.48</td><td>.35/.65</td><td>1.17</td><td>.85/1.62</td><td>.49</td><td>.36/.66</td></tr><tr><td>No. times do things for fun</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><2</td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td></tr><tr><td>2–4</td><td>.79</td><td>.60/1.03</td><td>.73</td><td>.55/.96</td><td>1.18</td><td>.89/1.57</td><td>.52</td><td>.41/.67</td></tr><tr><td>5></td><td>1.07</td><td>.74/1.56</td><td>.77</td><td>.51/.98</td><td>1.51</td><td>1.05/2.17</td><td>.36</td><td>.23/.55</td></tr><tr><td>Parent monitoring</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>No. of four best friends parents know well</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>0–1</td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td></tr><tr><td>2–3</td><td>.87</td><td>.59/1.26</td><td>.67</td><td>.48/.94</td><td>.84</td><td>.57/1.25</td><td>.82</td><td>.59/1.18</td></tr><tr><td>4</td><td>1.38</td><td>.95/1.99</td><td>.49</td><td>.35/.70</td><td>1.24</td><td>.85/1.81</td><td>.53</td><td>.37/.77</td></tr><tr><td>No. four best friend’s parents parents know well</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>0–1</td><td>______</td><td></td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td></tr><tr><td>2–3</td><td>1.44</td><td>1.06/1.96</td><td>.60</td><td>.46/.77</td><td>1.07</td><td>.78/1.45</td><td>.62</td><td>.49/.82</td></tr><tr><td>4</td><td>1.87</td><td>1.33/2.65</td><td>.31</td><td>.21/.46</td><td>1.37</td><td>.98/1.91</td><td>.43</td><td>.31/.81</td></tr><tr><td>Your parents tell on friend smoking</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td></tr><tr><td>Not sure</td><td>1.36</td><td>.78/2.36</td><td>.49</td><td>.34/.70</td><td>1.27</td><td>.64/2.53</td><td>.47</td><td>.29/.77</td></tr><tr><td>Yes</td><td>2.03</td><td>1.24/3.30</td><td>.22</td><td>.16/.31</td><td>1.89</td><td>1.30/2.97</td><td>.28</td><td>.21/.37</td></tr><tr><td>Friend’s parents tell on you smoking</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td></tr><tr><td>Not sure</td><td>1.13</td><td>.61/2.09</td><td>.49</td><td>.34/.70</td><td>1.02</td><td>.46/2.22</td><td>.49</td><td>.21/.82</td></tr><tr><td>Yes</td><td>1.51</td><td>.86/2.65</td><td>.22</td><td>.16/.31</td><td>1.56</td><td>.93/2.64</td><td>.22</td><td>.16/.30</td></tr></table>
c0336e1c0d2ddebd5f78d8bb57fee92b9d9096924286bb943a5654dd5efa806d.png
simple
<table><tr><td>Subfamily</td><td>Gene identification</td><td></td><td>Domain organisation</td><td>Amino acids</td></tr><tr><td>ABCB</td><td></td><td></td><td></td><td></td></tr><tr><td> ABCB1</td><td>PFE1150w</td><td>PfMDR1</td><td>(MSD-NBD)<sub>2</sub></td><td>1419</td></tr><tr><td> ABCB2</td><td>PF14_0455</td><td>PfMDR2</td><td>MSD-NBD</td><td>1024</td></tr><tr><td> ABCB3</td><td>PF11_0466</td><td></td><td>MSD-NBD</td><td>872</td></tr><tr><td> ABCB4</td><td>PFC0125w</td><td></td><td>MSD-NBD</td><td>1365</td></tr><tr><td> ABCB5</td><td>PF13_0218</td><td></td><td>MSD-NBD</td><td>925</td></tr><tr><td> ABCB6</td><td>PF13_0271</td><td></td><td>MSD-NBD</td><td>1049</td></tr><tr><td> ABCB7</td><td>PFL0495c</td><td></td><td>MSD-NBD</td><td>855</td></tr><tr><td>ABCC</td><td></td><td></td><td></td><td></td></tr><tr><td> ABCC1</td><td>PFA0590w</td><td>PfMRP1</td><td>(MSD-NBD)<sub>2</sub></td><td>1822</td></tr><tr><td> ABCC2</td><td>PFL1410c</td><td>PfMRP2</td><td>(MSD-NBD)<sub>2</sub></td><td>2108</td></tr><tr><td>ABCE</td><td></td><td></td><td></td><td></td></tr><tr><td> ABCE1</td><td>MAL13 P1.344</td><td></td><td>(NBD)<sub>2</sub></td><td>619</td></tr><tr><td>ABCF</td><td></td><td></td><td></td><td></td></tr><tr><td> ABCF1</td><td>PF11_0225</td><td></td><td>(NBD)<sub>2</sub></td><td>815</td></tr><tr><td> ABCF2</td><td>pfGCN20PF08_0078</td><td></td><td>(NBD)<sub>2</sub></td><td>1419</td></tr><tr><td>ABCG</td><td></td><td></td><td></td><td></td></tr><tr><td> ABCG1</td><td>PF14_0244</td><td></td><td>NBD-MSD</td><td>660</td></tr><tr><td>ABCI</td><td></td><td></td><td></td><td></td></tr><tr><td> ABCI1</td><td>PF14_0133</td><td></td><td>NBD</td><td>347</td></tr><tr><td> ABCI2</td><td>PF14_0321</td><td></td><td>NBD</td><td>171</td></tr><tr><td> ABCI3</td><td>PFC0875w</td><td></td><td>MSD-NBD-MSD</td><td>3133</td></tr></table>
<table><tr><td>Subfamily</td><td>Gene identification</td><td></td><td>Domain organisation</td><td>Amino acids</td></tr><tr><td>ABCB</td><td></td><td></td><td></td><td></td></tr><tr><td>ABCB1</td><td>PFE1150w</td><td>PfMDR1</td><td>(MSD-NBD)2</td><td>1419</td></tr><tr><td>ABCB2</td><td>PF14_0455</td><td>PfMDR2</td><td>MSD-NBD</td><td>1024</td></tr><tr><td>ABCB3</td><td>PF11_0466</td><td></td><td>MSD-NBD</td><td>872</td></tr><tr><td>ABCB4</td><td>PFC0125w</td><td></td><td>MSD-NBD</td><td>1365</td></tr><tr><td>ABCB5</td><td>PF13_0218</td><td></td><td>MSD-NBD</td><td>925</td></tr><tr><td>ABCB6</td><td>PF13_0271</td><td></td><td>MSD-NBD</td><td>1049</td></tr><tr><td>ABCB7</td><td>PFL0495c</td><td></td><td>MSD-NBD</td><td>855</td></tr><tr><td>ABCC</td><td></td><td></td><td></td><td></td></tr><tr><td>ABCC1</td><td>PFA0590w</td><td>PfMRP1</td><td>(MSD-NBD)2</td><td>1822</td></tr><tr><td>ABCC2</td><td>PFL1410c</td><td>PfMRP2</td><td>(MSD-NBD)2</td><td>2108</td></tr><tr><td>ABCE</td><td></td><td></td><td></td><td></td></tr><tr><td>ABCE1</td><td>MAL13 P1.344</td><td></td><td>(NBD)2</td><td>619</td></tr><tr><td>ABCF</td><td></td><td></td><td></td><td></td></tr><tr><td>ABCF1</td><td>PF11_0225</td><td></td><td>(NBD)2</td><td>815</td></tr><tr><td>ABCF2</td><td>pfGCN20PF08_0078</td><td></td><td>(NBD)2</td><td>1419</td></tr><tr><td>ABCG</td><td></td><td></td><td></td><td></td></tr><tr><td>ABCG1</td><td>PF14_0244</td><td></td><td>NBD-MSD</td><td>660</td></tr></table>
<table><tr><td>ABCI</td><td></td><td></td><td></td><td></td></tr><tr><td>ABCI1</td><td>PF14_0133</td><td></td><td>NBD</td><td>347</td></tr><tr><td>ABCI2</td><td>PF14_0321</td><td></td><td>NBD</td><td>171</td></tr><tr><td>ABCI3</td><td>PFC0875w</td><td></td><td>MSD-NBD-MSD</td><td>3133</td></tr></table>
2881fab5c060ab899e3eb7f7d7407d7b5532ebfc39a4f0daecae8c4599288656.png
complex
<table><tr><td></td><td colspan="3">Climate model</td></tr><tr><td>Time period</td><td>Median</td><td>Minimal</td><td>Maximal</td></tr><tr><td>1986&#8211;2005</td><td>20.7 (27.4)</td><td></td><td></td></tr><tr><td>2026&#8211;2045</td><td>22.9 (30.0)</td><td>21.6 (28.9)</td><td>22.9 (30.2)</td></tr><tr><td>2081&#8211;2100</td><td>26.1 (35.1)</td><td>24.6 (32.4)</td><td>28.5 (37.7)</td></tr></table>
<table><tr><td></td><td colspan="3">Climate model</td></tr></table>
<table><tr><td>Time period</td><td>Median</td><td>Minimal</td><td>Maximal</td></tr><tr><td>1986–2005</td><td>20.7 (27.4)</td><td></td><td></td></tr><tr><td>2026–2045</td><td>22.9 (30.0)</td><td>21.6 (28.9)</td><td>22.9 (30.2)</td></tr><tr><td>2081–2100</td><td>26.1 (35.1)</td><td>24.6 (32.4)</td><td>28.5 (37.7)</td></tr></table>
8490452076a40dbcbf9cd27587d474139423e3235d473eb2f714956d5eb8bdea.png
complex
<table><tr><td>Patient</td><td>Gene</td><td>Varianta</td><td>Patient cancer historyb</td></tr><tr><td colspan="4"><i>Discovered cancer gene mutations (163 disease-gene panel)</i>c</td></tr><tr><td>BRCA1.60</td><td>CHEK2</td><td>c.573+1G&gt;A</td><td>Breast-47, 49</td></tr><tr><td>BRCA1.61</td><td>ATM</td><td>p.Glu2290&#8270;</td><td>Unaffected-24</td></tr><tr><td>BRCA2.7</td><td>RAD50</td><td>c.3G&gt;A</td><td>Breast-49</td></tr><tr><td>BRCA2.13</td><td>ATM</td><td>p.Glu1978&#8270;</td><td>Breast-28, 39, 55; Skin-49</td></tr><tr><td>BRCA2.65</td><td>CDKN2B</td><td>p.Glu35&#8270;</td><td>Melanoma-50</td></tr><tr><td>BRCA2.93</td><td>CHEK2</td><td>p.Gln20&#8270;</td><td>Breast-37, 61; Ovarian-56</td></tr><tr><td colspan="4">&#8232;&#8232;</td></tr><tr><td colspan="4"><i>Discovered cancer gene mutations (ClinVar)</i><sup>c</sup></td></tr><tr><td>BRCA1.48</td><td>ERCC3</td><td>p.Arg109&#8270;</td><td>Breast-39; Skin-61, 66</td></tr><tr><td>BRCA1.73</td><td>DLEC1</td><td>c.2436-2A&gt;G</td><td>Breast-32</td></tr><tr><td>BRCA1.74</td><td>FANCC</td><td>p.Arg548&#8270;</td><td>Breast-42, 53, 55</td></tr></table>
<table><tr><td>Patient</td><td>Gene</td></tr><tr><td colspan="2">Discovered cancer gene mutations (163 disease-gene panel)c</td></tr><tr><td>BRCA1.60</td><td>CHEK2</td></tr><tr><td>BRCA1.61</td><td>ATM</td></tr><tr><td>BRCA2.7</td><td>RAD50</td></tr><tr><td>BRCA2.13</td><td>ATM</td></tr><tr><td>BRCA2.65</td><td>CDKN2B</td></tr><tr><td>BRCA2.93</td><td>CHEK2</td></tr><tr><td colspan="2"></td></tr><tr><td colspan="2">Discovered cancer gene mutations (ClinVar)c</td></tr><tr><td>BRCA1.48</td><td>ERCC3</td></tr><tr><td>BRCA1.73</td><td>DLEC1</td></tr><tr><td>BRCA1.74</td><td>FANCC</td></tr></table>
<table><tr><td>Varianta</td><td>Patient cancer historyb</td></tr><tr><td colspan="2">Discovered cancer gene mutations (163 disease-gene panel)c</td></tr><tr><td>c.573+1G>A</td><td>Breast-47, 49</td></tr><tr><td>p.Glu2290⁎</td><td>Unaffected-24</td></tr><tr><td>c.3G>A</td><td>Breast-49</td></tr><tr><td>p.Glu1978⁎</td><td>Breast-28, 39, 55; Skin-49</td></tr><tr><td>p.Glu35⁎</td><td>Melanoma-50</td></tr><tr><td>p.Gln20⁎</td><td>Breast-37, 61; Ovarian-56</td></tr><tr><td colspan="2"></td></tr><tr><td colspan="2">Discovered cancer gene mutations (ClinVar)c</td></tr><tr><td>p.Arg109⁎</td><td>Breast-39; Skin-61, 66</td></tr><tr><td>c.2436-2A>G</td><td>Breast-32</td></tr><tr><td>p.Arg548⁎</td><td>Breast-42, 53, 55</td></tr></table>
94afe6212d82708cc1cb4d94161c9e0e565ab31c0941b1ea31443428a65bb1c4.png
complex
<table><tr><td>DPC*</td><td>Type</td><td colspan="3">Pathological findings&#8224;</td></tr><tr><td></td><td></td><td>Lung</td><td>Inguinal Lymph Nodes</td><td>Heart</td></tr><tr><td>14</td><td>I</td><td>Moderate focal/multifocal bronchointerstitial pneumonia (3/3)</td><td>Lymphadenopathy (3/3)</td><td>Mild multifocal perivascular lymphohistiocytic myocarditis (1/3)</td></tr><tr><td></td><td>II</td><td>Moderate diffuse/multifocal bronchointerstitial pneumonia (2/3)</td><td>Lymphadenopathy (3/3)</td><td>Mild multifocal perivascular lymphohistiocytic myocarditis. (3/3)</td></tr><tr><td></td><td>Control</td><td>No lesions (2/2)</td><td>No lesions (2/2)</td><td>No lesions (2/2)</td></tr><tr><td>21</td><td>I</td><td>Moderate diffuse interstitial pneumonia (2/2), moderate peribronchiolar and perivascular lymphohistiocytic cuffing (2/2)</td><td>Lymphadenopathy (2/2)</td><td>Mild multifocal perivascular lymphohistiocytic myocarditis (1/2)</td></tr><tr><td></td><td>II</td><td>Mild to moderate diffuse interstitial pneumonia (2/2), severe peribronchiolar and perivascular lymphohistiocytic cuffing (1/2)</td><td>Lymphadenopathy (2/2)</td><td>Very mild multifocal perivascular lymphohistiocytic myocarditis (1/2)</td></tr><tr><td></td><td>Control</td><td>No lesions (1/1)</td><td>No lesions (1/1)</td><td>No lesions (1/1)</td></tr></table>
<table><tr><td>DPC*</td><td></td><td colspan="3">Patholo</td></tr></table>
<table><tr><td></td><td>Type</td><td colspan="3">gical findings†</td></tr><tr><td></td><td></td><td>Lung</td><td>Inguinal Lymph Nodes</td><td>Heart</td></tr><tr><td>14</td><td>I</td><td>Moderate focal/multifocal bronchointerstitial pneumonia (3/3)</td><td>Lymphadenopathy (3/3)</td><td>Mild multifocal perivascular lymphohistiocytic myocarditis (1/3)</td></tr><tr><td></td><td>II</td><td>Moderate diffuse/multifocal bronchointerstitial pneumonia (2/3)</td><td>Lymphadenopathy (3/3)</td><td>Mild multifocal perivascular lymphohistiocytic myocarditis. (3/3)</td></tr><tr><td></td><td>Control</td><td>No lesions (2/2)</td><td>No lesions (2/2)</td><td>No lesions (2/2)</td></tr><tr><td>21</td><td>I</td><td>Moderate diffuse interstitial pneumonia (2/2), moderate peribronchiolar and perivascular lymphohistiocytic cuffing (2/2)</td><td>Lymphadenopathy (2/2)</td><td>Mild multifocal perivascular lymphohistiocytic myocarditis (1/2)</td></tr><tr><td></td><td>II</td><td>Mild to moderate diffuse interstitial pneumonia (2/2), severe peribronchiolar and perivascular lymphohistiocytic cuffing (1/2)</td><td>Lymphadenopathy (2/2)</td><td>Very mild multifocal perivascular lymphohistiocytic myocarditis (1/2)</td></tr><tr><td></td><td>Control</td><td>No lesions (1/1)</td><td>No lesions (1/1)</td><td>No lesions (1/1)</td></tr></table>
d87c27328353c713d2c7e9469ece0c74cfeb74f52f5d80ff715ee2467756aa80.png
complex
<table><tr><td rowspan="2" colspan="2"> </td><td colspan="2">Believes PPM has exposed him/her to hazardous chemicals</td><td colspan="2">Felt he/she was coughing, breathless or wheezing due to something in the air</td><td colspan="2">Believes the industry will affect children born in the future in the community</td><td colspan="2">Believes the industry will expose him/her to hazards if it opens in the future</td><td colspan="2">Worries about getting health problems in the future because of a polluted environment</td></tr><tr><td>OR</td><td>95% CI</td><td>OR</td><td>95% CI</td><td>OR</td><td>95% CI</td><td>OR</td><td>95% CI</td><td>OR</td><td>95% CI</td></tr><tr><td rowspan="4">Demographic</td><td>Distance from PPM</td><td>2.747*</td><td>1.199-6.295</td><td>1.039<sup>&#8225;</sup></td><td>0.560-1927</td><td>1.132<sup>&#8225;</sup></td><td>0.502-2.554</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Presence of a child in the HH</td><td>34.769*</td><td>1.390-869.96</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Respondent completed HS</td><td>3.105*</td><td>1.394-6.918</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>2.553*</td><td>1.086-6.004</td></tr><tr><td>Employment Status</td><td> </td><td> </td><td> </td><td> </td><td>0.434<sup>&#8225;</sup></td><td>0.188-1.004</td><td>0.383*</td><td>0.167-0.879</td><td>0.365*</td><td>0.150-0.886</td></tr><tr><td rowspan="2">HH health Indicators</td><td>Perception of health</td><td>0.527<sup>&#8225;</sup></td><td>0.239-1.162</td><td>0.479*</td><td>0.261-0.878</td><td>0.299*</td><td>0.135-0.660</td><td>0.237**</td><td>0.108-0.517</td><td>0.332*</td><td>0.149-0.738</td></tr><tr><td>Somebody in the HH has one of the conditions (heart, respiratory or skin disease)</td><td>1.788<sup>&#8225;</sup></td><td>0.755-4.237</td><td>1.980*</td><td>1.031-3.802</td><td>2.192<sup>&#8225;</sup></td><td>0.963-4.990</td><td> </td><td> </td><td>2.594*</td><td>1.096-6.143</td></tr><tr><td rowspan="2">Respiratory symptoms</td><td>Coughed phlegm daily for &#8805; 2 months, 2 yrs in a row</td><td> </td><td> </td><td>2.907*</td><td>1.127-7.498</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Had an attack of whistling or noisy sound in the chest when breathing</td><td> </td><td> </td><td>2.881*</td><td>1.402-5.920</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td rowspan="2">Role of Industrial plant</td><td>Family depended on industry</td><td> </td><td> </td><td> </td><td> </td><td>2.287*</td><td>1.001-5.228</td><td>2.792*</td><td>1.234-6.319</td><td> </td><td> </td></tr><tr><td>Community benefited from industry</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>2.289*</td><td>0.997-5.257</td></tr><tr><td rowspan="2">Environmental awareness/knowledge</td><td>Ever actively looked for environmental health information</td><td> </td><td> </td><td>1.883*</td><td>1.002-3.537</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Willing to participate in environmental campaigns</td><td> </td><td> </td><td>2.297<sup>&#8225;</sup></td><td>0.713-7.396</td><td>2.985*</td><td>1.031-8.645</td><td> </td><td> </td><td>3.127*</td><td>1.100-8.888</td></tr><tr><td rowspan="2">Main Information source</td><td>Friends/relatives</td><td>2.553*</td><td>1.198-5.438</td><td> </td><td> </td><td>0.411*</td><td>0.180-0.937</td><td>0.451*</td><td>0.207-0.981</td><td> </td><td> </td></tr><tr><td>Church/Community leaders</td><td> </td><td> </td><td> </td><td> </td><td>3.148*</td><td>1.303-7.602</td><td>2.368*</td><td>1.090-5.147</td><td>2.447*</td><td>1.089-5.499</td></tr><tr><td>Omnibus Tests of Model Coefficients</td><td>Model (Sig.)</td><td colspan="2">&lt;0.001</td><td colspan="2">&lt;0.001</td><td colspan="2">&lt;0.001</td><td colspan="2">&lt;0.001</td><td colspan="2">&lt;0.001</td></tr><tr><td>Correctly predicted observations on average</td><td> </td><td colspan="2">85.6%</td><td colspan="2">79.7%</td><td colspan="2">84.6%</td><td colspan="2">86%</td><td colspan="2">84.4%</td></tr></table>
<table><tr><td rowspan="2" colspan="2"></td><td colspan="2">Believes PPM has exposed him/her to hazardous chemicals</td><td colspan="2">Felt he/she was coughing, breathless or wheezing due to something in the air</td><td colspan="2">Believes the industry will affect children born in the future in the community</td><td colspan="2">Believes the industry will expose him/her to hazards if it opens in the future</td><td colspan="2">Worries about getting health problems in the future because of a polluted environment</td></tr><tr><td>OR</td><td>95% CI</td><td>OR</td><td>95% CI</td><td>OR</td><td>95% CI</td><td>OR</td><td>95% CI</td><td>OR</td><td>95% CI</td></tr><tr><td rowspan="4">Demographic</td><td>Distance from PPM</td><td>2.747*</td><td>1.199-6.295</td><td>1.039‡</td><td>0.560-1927</td><td>1.132‡</td><td>0.502-2.554</td><td></td><td></td><td></td><td></td></tr><tr><td>Presence of a child in the HH</td><td>34.769*</td><td>1.390-869.96</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Respondent completed HS</td><td>3.105*</td><td>1.394-6.918</td><td></td><td></td><td></td><td></td><td></td><td></td><td>2.553*</td><td>1.086-6.004</td></tr><tr><td>Employment Status</td><td></td><td></td><td></td><td></td><td>0.434‡</td><td>0.188-1.004</td><td>0.383*</td><td>0.167-0.879</td><td>0.365*</td><td>0.150-0.886</td></tr><tr><td rowspan="2">HH health Indicators</td><td>Perception of health</td><td>0.527‡</td><td>0.239-1.162</td><td>0.479*</td><td>0.261-0.878</td><td>0.299*</td><td>0.135-0.660</td><td>0.237**</td><td>0.108-0.517</td><td>0.332*</td><td>0.149-0.738</td></tr><tr><td>Somebody in the HH has one of the conditions (heart, respiratory or skin disease)</td><td>1.788‡</td><td>0.755-4.237</td><td>1.980*</td><td>1.031-3.802</td><td>2.192‡</td><td>0.963-4.990</td><td></td><td></td><td>2.594*</td><td>1.096-6.143</td></tr><tr><td rowspan="2">Respiratory symptoms</td><td>Coughed phlegm daily for ≥ 2 months, 2 yrs in a row</td><td></td><td></td><td>2.907*</td><td>1.127-7.498</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Had an attack of whistling or noisy sound in the chest when breathing</td><td></td><td></td><td>2.881*</td><td>1.402-5.920</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan="2">Role of Industrial plant</td><td>Family depended on industry</td><td></td><td></td><td></td><td></td><td>2.287*</td><td>1.001-5.228</td><td>2.792*</td><td>1.234-6.319</td><td></td><td></td></tr><tr><td>Community benefited from industry</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>2.289*</td><td>0.997-5.257</td></tr><tr><td>Environmental awareness/knowledge</td><td>Ever actively looked for environmental health information</td><td></td><td></td><td>1.883*</td><td>1.002-3.537</td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
<table><tr><td>Environmental awareness/knowledge</td><td>Willing to participate in environmental campaigns</td><td></td><td></td><td>2.297‡</td><td>0.713-7.396</td><td>2.985*</td><td>1.031-8.645</td><td></td><td></td><td>3.127*</td><td>1.100-8.888</td></tr><tr><td rowspan="2">Main Information source</td><td>Friends/relatives</td><td>2.553*</td><td>1.198-5.438</td><td></td><td></td><td>0.411*</td><td>0.180-0.937</td><td>0.451*</td><td>0.207-0.981</td><td></td><td></td></tr><tr><td>Church/Community leaders</td><td></td><td></td><td></td><td></td><td>3.148*</td><td>1.303-7.602</td><td>2.368*</td><td>1.090-5.147</td><td>2.447*</td><td>1.089-5.499</td></tr><tr><td>Omnibus Tests of Model Coefficients</td><td>Model (Sig.)</td><td colspan="2"><0.001</td><td colspan="2"><0.001</td><td colspan="2"><0.001</td><td colspan="2"><0.001</td><td colspan="2"><0.001</td></tr><tr><td>Correctly predicted observations on average</td><td></td><td colspan="2">85.6%</td><td colspan="2">79.7%</td><td colspan="2">84.6%</td><td colspan="2">86%</td><td colspan="2">84.4%</td></tr></table>
58a2debeb215df21f123557f4b0e882ee0c55a6cefbb5eecfc6449db6dd18bf9.png
simple
<table><tr><td>Hemi</td><td>Region</td><td><i>&#223;</i></td><td>SE</td><td><i>p</i>-value (uncorrected)</td><td>FDR-corrected <i>p</i>-value</td></tr><tr><td>R</td><td>Nucleus accumbens</td><td>&#8722;0.23</td><td>0.058</td><td>0.000077</td><td>0.0055</td></tr><tr><td>L</td><td>Inferior parietal cortex</td><td>&#8722;0.38</td><td>0.10</td><td>0.00014</td><td>0.0055</td></tr><tr><td>R</td><td>Superior parietal cortex</td><td>&#8722;0.42</td><td>0.12</td><td>0.00056</td><td>0.011</td></tr><tr><td>R</td><td>Caudate nucleus</td><td>&#8722;0.28</td><td>0.081</td><td>0.00064</td><td>0.011</td></tr><tr><td>L</td><td>Putamen</td><td>&#8722;0.24</td><td>0.071</td><td>0.00068</td><td>0.011</td></tr><tr><td>L</td><td>Caudate nucleus</td><td>&#8722;0.23</td><td>0.071</td><td>0.0011</td><td>0.014</td></tr><tr><td>R</td><td>Amygdala</td><td>&#8722;0.21</td><td>0.064</td><td>0.0012</td><td>0.014</td></tr><tr><td><i>L</i></td><td><i>Supramarginal gyrus</i></td><td>&#8722;<i>0.26</i></td><td><i>0.098</i></td><td><i>0.0076</i></td><td><i>0.076</i></td></tr><tr><td><i>R</i></td><td><i>Supramarginal gyrus</i></td><td>&#8722;<i>0.27</i></td><td><i>0.10</i></td><td><i>0.0090</i></td><td><i>0.076</i></td></tr></table>
<table><tr><td>Hemi</td><td>Region</td><td>ß</td><td>SE</td><td>p-value (uncorrected)</td><td>FDR-corrected p-value</td></tr><tr><td>R</td><td>Nucleus accumbens</td><td>−0.23</td><td>0.058</td><td>0.000077</td><td>0.0055</td></tr><tr><td>L</td><td>Inferior parietal cortex</td><td>−0.38</td><td>0.10</td><td>0.00014</td><td>0.0055</td></tr><tr><td>R</td><td>Superior parietal cortex</td><td>−0.42</td><td>0.12</td><td>0.00056</td><td>0.011</td></tr></table>
<table><tr><td>R</td><td>Caudate nucleus</td><td>−0.28</td><td>0.081</td><td>0.00064</td><td>0.011</td></tr><tr><td>L</td><td>Putamen</td><td>−0.24</td><td>0.071</td><td>0.00068</td><td>0.011</td></tr><tr><td>L</td><td>Caudate nucleus</td><td>−0.23</td><td>0.071</td><td>0.0011</td><td>0.014</td></tr><tr><td>R</td><td>Amygdala</td><td>−0.21</td><td>0.064</td><td>0.0012</td><td>0.014</td></tr><tr><td>L</td><td>Supramarginal gyrus</td><td>−0.26</td><td>0.098</td><td>0.0076</td><td>0.076</td></tr><tr><td>R</td><td>Supramarginal gyrus</td><td>−0.27</td><td>0.10</td><td>0.0090</td><td>0.076</td></tr></table>
502b78ffce5b5a8d913937dd1ffa177486235eeb756660c97b33df049a0d3a5b.png
complex
<table><tr><td>Outcome</td><td>General anaesthesia</td><td>Neuraxial anaesthesia</td><td>Combination</td></tr><tr><td rowspan="2">Major VTE and VTE-related mortality</td><td>4.2%*</td><td>3.1%*</td><td>3.1%</td></tr><tr><td>(73/1731)</td><td>(101/3305)</td><td>(35/1147)</td></tr><tr><td>MBE</td><td>1.2%</td><td>1.4%</td><td>1.2%</td></tr><tr><td> </td><td>(27/2311)</td><td>(59/4212)</td><td>(19/1539)</td></tr><tr><td>MBE/CRBE</td><td>4.9%</td><td>5.6%</td><td>5.7%</td></tr><tr><td> </td><td>(114/2311)</td><td>(237/4212)</td><td>(88/1539)</td></tr></table>
<table><tr><td>Outcome</td><td>General anaesthesia</td></tr><tr><td rowspan="2">Major VTE and VTE-related mortality</td><td>4.2%*</td></tr><tr><td>(73/1731)</td></tr><tr><td>MBE</td><td>1.2%</td></tr><tr><td></td><td>(27/2311)</td></tr><tr><td>MBE/CRBE</td><td>4.9%</td></tr><tr><td></td><td>(114/2311)</td></tr></table>
<table><tr><td>Neuraxial anaesthesia</td><td>Combination</td></tr><tr><td>3.1%*</td><td>3.1%</td></tr><tr><td>(101/3305)</td><td>(35/1147)</td></tr><tr><td>1.4%</td><td>1.2%</td></tr><tr><td>(59/4212)</td><td>(19/1539)</td></tr><tr><td>5.6%</td><td>5.7%</td></tr><tr><td>(237/4212)</td><td>(88/1539)</td></tr></table>
8196dc74ed4cf5380cf6514e4c78d449dd2bd132459eedc62f2c8b67021ab63e.png
complex
<table><tr><td rowspan="2"><i>R<sub>FB</sub></i></td><td rowspan="2">Mineral Filler Quantity(g)</td><td colspan="3">Mineral Filler A <i>V<sub>g</sub></i> = 0.26</td><td colspan="3">Mineral Filler B <i>V<sub>g</sub></i> = 0.11</td><td colspan="3">Mineral Filler C <i>V<sub>g</sub></i> = 0.19</td><td colspan="3">Mineral Filler D <i>V<sub>g</sub></i> = 0.32</td></tr><tr><td>S(g)</td><td>F(g)</td><td>S/F</td><td>S(g)</td><td>F(g)</td><td>S/F</td><td>S(g)</td><td>F(g)</td><td>S/F</td><td>S(g)</td><td>F(g)</td><td>S/F</td></tr><tr><td>0.6</td><td>60</td><td>18.72</td><td>81.28</td><td>0.23</td><td>7.92</td><td>92.08</td><td>0.09</td><td>13.68</td><td>86.32</td><td>0.16</td><td>23.04</td><td>76.96</td><td>0.30</td></tr><tr><td>0.8</td><td>80</td><td>24.96</td><td>75.04</td><td>0.33</td><td>10.56</td><td>89.44</td><td>0.12</td><td>18.24</td><td>81.76</td><td>0.22</td><td>30.72</td><td>69.28</td><td>0.44</td></tr><tr><td>1</td><td>100</td><td>31.2</td><td>68.8</td><td>0.45</td><td>13.2</td><td>86.8</td><td>0.15</td><td>22.8</td><td>77.2</td><td>0.30</td><td>38.40</td><td>61.60</td><td>0.62</td></tr><tr><td>1.2</td><td>120</td><td>37.44</td><td>62.56</td><td>0.60</td><td>15.84</td><td>84.16</td><td>0.19</td><td>27.36</td><td>72.64</td><td>0.38</td><td>46.08</td><td>53.92</td><td>0.85</td></tr><tr><td>1.5</td><td>150</td><td>46.8</td><td>53.2</td><td>0.88</td><td>19.8</td><td>80.20</td><td>0.25</td><td>34.20</td><td>65.80</td><td>0.52</td><td>57.60</td><td>42.40</td><td>1.36</td></tr></table>
<table><tr><td rowspan="2">RFB</td><td rowspan="2">Mineral Filler Quantity(g)</td><td colspan="3">Mineral Filler A Vg = 0.26</td><td colspan="3">Mineral Filler B Vg = 0.11</td><td colspan="3">Mineral Filler C Vg = 0.19</td><td colspan="3">Mineral Filler D Vg = 0.32</td></tr><tr><td>S(g)</td><td>F(g)</td><td>S/F</td><td>S(g)</td><td>F(g)</td><td>S/F</td><td>S(g)</td><td>F(g)</td><td>S/F</td><td>S(g)</td><td>F(g)</td><td>S/F</td></tr><tr><td>0.6</td><td>60</td><td>18.72</td><td>81.28</td><td>0.23</td><td>7.92</td><td>92.08</td><td>0.09</td><td>13.68</td><td>86.32</td><td>0.16</td><td>23.04</td><td>76.96</td><td>0.30</td></tr><tr><td>0.8</td><td>80</td><td>24.96</td><td>75.04</td><td>0.33</td><td>10.56</td><td>89.44</td><td>0.12</td><td>18.24</td><td>81.76</td><td>0.22</td><td>30.72</td><td>69.28</td><td>0.44</td></tr><tr><td>1</td><td>100</td><td>31.2</td><td>68.8</td><td>0.45</td><td>13.2</td><td>86.8</td><td>0.15</td><td>22.8</td><td>77.2</td><td>0.30</td><td>38.40</td><td>61.60</td><td>0.62</td></tr><tr><td>1.2</td><td>120</td><td>37.44</td><td>62.56</td><td>0.60</td><td>15.84</td><td>84.16</td><td>0.19</td><td>27.36</td><td>72.64</td><td>0.38</td><td>46.08</td><td>53.92</td><td>0.85</td></tr><tr><td>1.</td><td></td><td>4</td><td>53</td><td></td><td>19.8</td><td>80</td><td>0.25</td><td>34.2</td><td>65.8</td><td>0</td><td></td><td></td><td>1.</td></tr></table>
<table><tr><td rowspan="2">RFB</td><td rowspan="2">Mineral Filler Quantity(g)</td><td colspan="3">Mineral Filler A Vg = 0.26</td><td>Mineral Filler B Vg = 0.11</td><td colspan="3">Mineral Filler C Vg = 0.19</td><td colspan="3">Mineral Filler D Vg = 0.32</td></tr><tr><td>S(g)</td><td>F(g)</td><td>S/F</td><td>F(g)</td><td>S(g)</td><td>F(g)</td><td>S/F</td><td>S(g)</td><td>F(g)</td><td>S/F</td></tr><tr><td>5</td><td>150</td><td>6.8</td><td>.2</td><td>0.88</td><td>.20</td><td>0</td><td>0</td><td>.52</td><td>57.60</td><td>42.40</td><td>36</td></tr></table>
729e33bd92994207fafcbcd59c3805ea7058131095800d9e65f7bc0ce72af3db.png
simple
<table><tr><td></td><td>Sanger technology</td><td>454 FLX technology</td><td>Sanger + 454 FLX</td></tr><tr><td>Total number of reads</td><td>14,120</td><td>789,105</td><td>-</td></tr><tr><td>Average length of read (bases)</td><td>780</td><td>218</td><td>-</td></tr><tr><td>Total number of reads in the assembly</td><td>12,032</td><td>466,737</td><td>478,769</td></tr><tr><td>Total number of contigs</td><td>2,120</td><td>22,203</td><td>18,690</td></tr><tr><td>Total number of singlets</td><td>4,775</td><td>25,604</td><td>-</td></tr><tr><td>Number of unique sequences</td><td>6,895</td><td>47,807</td><td>-</td></tr><tr><td>Average/Largest contig size</td><td>995/3,560</td><td>1132/4,762</td><td>1180/4,762</td></tr></table>
<table><tr><td></td><td>Sanger technology</td><td>454 FLX technology</td><td>Sanger + 454 FLX</td></tr></table>
<table><tr><td>Total number of reads</td><td>14,120</td><td>789,105</td><td>-</td></tr><tr><td>Average length of read (bases)</td><td>780</td><td>218</td><td>-</td></tr><tr><td>Total number of reads in the assembly</td><td>12,032</td><td>466,737</td><td>478,769</td></tr><tr><td>Total number of contigs</td><td>2,120</td><td>22,203</td><td>18,690</td></tr><tr><td>Total number of singlets</td><td>4,775</td><td>25,604</td><td>-</td></tr><tr><td>Number of unique sequences</td><td>6,895</td><td>47,807</td><td>-</td></tr><tr><td>Average/Largest contig size</td><td>995/3,560</td><td>1132/4,762</td><td>1180/4,762</td></tr></table>
b07295b39cbff853bb64eb20332203ca4078e909fd4eeedbe866099cc1385f51.png
complex
<table><tr><td> </td><td> </td><td>Sal</td><td>VH</td><td>SS</td><td>ES5</td><td>ES10</td></tr><tr><td rowspan="2">F0</td><td>Area</td><td>160.3 &#177; 23.6</td><td>164.5 &#177; 13.6</td><td>165.3 &#177; 12.5</td><td>160 &#177; 12.1</td><td>166.5 &#177; 26.5</td></tr><tr><td>WCI</td><td>00.0 &#177; 00.0</td><td>00.0 &#177; 00.0</td><td>00.0 &#177; 00.0</td><td>00.0 &#177; 00.0</td><td>00.0 &#177; 00.0</td></tr><tr><td rowspan="2">F1</td><td>Area</td><td>115.4 &#177; 15.9</td><td>113.1 &#177; 13.9</td><td>109.6 &#177; 12.1</td><td>95.5 &#177; 11.3<sup><i>&#8727;</i></sup></td><td>76.8 &#177; 16.06<sup><i>&#8727;</i></sup></td></tr><tr><td>WCI</td><td>31.9 &#177; 17.4</td><td>39.7 &#177; 11.5</td><td>37.7 &#177; 13.1</td><td>32.4 &#177; 11.7</td><td>50.5 &#177; 12.6</td></tr><tr><td rowspan="2">F2</td><td>Area</td><td>30.0 &#177; 11.3</td><td>25.2 &#177; 12.9</td><td>35.3 &#177; 10.4</td><td>15.9 &#177; 8.8<sup><i>&#8727;</i></sup></td><td>16.8 &#177; 8.1<sup><i>&#8727;</i></sup></td></tr><tr><td>WCI</td><td>84.7 &#177; 9.3</td><td>88.3 &#177; 7.9</td><td>81.3 &#177; 9.1</td><td>89.1 &#177; 6.05</td><td>89.9 &#177; 5.5</td></tr><tr><td rowspan="2">F3</td><td>Area</td><td>10.4 &#177; 3.4</td><td>9.1 &#177; 4.1</td><td>8.18 &#177; 3.6</td><td>2.8 &#177; 1.7<sup><i>&#8727;</i></sup></td><td>3.2 &#177; 1.5<sup><i>&#8727;</i></sup></td></tr><tr><td>WCI</td><td>94.3 &#177; 5.3</td><td>94.0 &#177; 5.3</td><td>94.9 &#177; 2.6</td><td>98.0 &#177; 1.2</td><td>96.7 &#177; 2.4</td></tr></table>
<table><tr><td></td><td></td><td>Sal</td><td>VH</td><td>SS</td><td>ES5</td><td>ES10</td></tr><tr><td rowspan="2">F0</td><td>Area</td><td>160.3 ± 23.6</td><td>164.5 ± 13.6</td><td>165.3 ± 12.5</td><td>160 ± 12.1</td><td>166.5 ± 26.5</td></tr><tr><td>WCI</td><td>00.0 ± 00.0</td><td>00.0 ± 00.0</td><td>00.0 ± 00.0</td><td>00.0 ± 00.0</td><td>00.0 ± 00.0</td></tr><tr><td rowspan="2">F1</td><td>Area</td><td>115.4 ± 15.9</td><td>113.1 ± 13.9</td><td>109.6 ± 12.1</td><td>95.5 ± 11.3∗</td><td>76.8 ± 16.06∗</td></tr><tr><td>W</td><td>31.9 ± 17</td><td>39.7 ± 1</td><td>37.</td><td>32.4 </td><td>50.5 ± </td></tr></table>
<table><tr><td></td><td></td><td>Sal</td><td>VH</td><td>SS</td><td>ES5</td><td>ES10</td></tr><tr><td></td><td>CI</td><td>.4</td><td>1.5</td><td>7 ± 13.1</td><td>± 11.7</td><td>12.6</td></tr><tr><td rowspan="2">F2</td><td>Area</td><td>30.0 ± 11.3</td><td>25.2 ± 12.9</td><td>35.3 ± 10.4</td><td>15.9 ± 8.8∗</td><td>16.8 ± 8.1∗</td></tr><tr><td>WCI</td><td>84.7 ± 9.3</td><td>88.3 ± 7.9</td><td>81.3 ± 9.1</td><td>89.1 ± 6.05</td><td>89.9 ± 5.5</td></tr><tr><td rowspan="2">F3</td><td>Area</td><td>10.4 ± 3.4</td><td>9.1 ± 4.1</td><td>8.18 ± 3.6</td><td>2.8 ± 1.7∗</td><td>3.2 ± 1.5∗</td></tr><tr><td>WCI</td><td>94.3 ± 5.3</td><td>94.0 ± 5.3</td><td>94.9 ± 2.6</td><td>98.0 ± 1.2</td><td>96.7 ± 2.4</td></tr></table>